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Abstract 
 
This thesis covers two broad areas of work under the general theme of the 
synthesis of bioactive and/or synthetically useful compounds based on natural 
products or deriving from the chiral pool. 
 
Chapters one, two and three focus on the 
marine secondary metabolite peloruside A (1), 
which has been shown to stabilise microtubules 
during mitosis and hence cause apoptosis (cell 
death) in a similar manner to the very 
successful anticancer drug Taxol®. A synthetic 
program with the aim of devising a total 
synthesis was initiated at Victoria University of 
Wellington after peloruside A’s discovery in 1999. Four synthetic disconnects 
were identified in the retrosynthetic analysis of peloruside A: to give the C-1 to 
C-2 fragment; the C-3 to C-7 fragment; the C-8 to C-11 fragments; and the C-12 
to C-24 fragment. The C-7 to C-8 bond was to be formed via an asymmetric 
aldol reaction to give the pyranose ring fragment (highlighted in blue). In this 
thesis, the synthesis of the C-3 to C-7 fragment is described. Aldol reactions with 
the C-8 to C-11 ketone have been investigated, and subsequent progress towards 
the assembly of the pyranose ring fragment is presented. 
 
  Chapters four, five, six and seven describe the preparation of selected 
synthetically and biologically useful derivatives of the commercially available 
inositols, quebrachitol (L-chiro-inositol-2-methyl ether) and myo-inositol. The 
butane di-acetal (BDA) derivatives 293, 300, and 301 (as well as acetylated and 
methylated derivatives thereof) were prepared during work directed towards the 
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 iii 
synthesis of the inositol core of a phosphatidylinositol manno-oligosaccharide 
(PIM-6) isolated from Mycobacterium bovis and M. smegmatis. Quebrachitol 
derivatives 305, 306 and 307 were prepared and subsequently tested against myo-
inositol (the optimal competitor) in biological uptake assays of the 
microorganisms, Candida albicans and Leishmania donovani. For both 
microorganisms, the mono- and di-O-methylated L-chiro-inositol derivatives 307 
and 305, as well as quebrachitol, gave significant inhibition results, with P values 
from P < 0.001 to P < 0.05 for paired-sample t-test analyses, i.e. 99.9% to 95% 
confidence for significant inhibition, respectively. The benzoylated derivative 
306 did not induce any inhibition of myo-inositol uptake. 
 
Myo-inositol is the most abundant of the inositols in 
nature and is readily available. However, as it is a meso 
compound, one of the key challenges in the use of myo-
inositol as a synthetic precursor is an efficient resolution 
method. The formation of myo-inositol camphanylidene 
acetal 269a is one successful solution, and work done in an 
attempt to better understand the selectivity of the reaction is reported here. Also, 
process development work was done to adapt the preparation so that it was 
suitable for scale-up, and a subsequent large scale synthesis of the acetal was 
undertaken. Previously unpublished X-ray crystal structures were obtained for 
269a and for two of the diastereomeric impurities of the reaction. 
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Chapter One 
 
Peloruside A: an Antimitotic Natural Product 
 
  
 
This chapter introduces the marine natural product peloruside A,1 1 
(figure 1.1), as a potential player in the fight against cancer. A brief introduction 
to the diseases collectively known as cancer and the treatments currently 
available will be given. Peloruside A is a potential chemotherapeutic agent which 
causes programmed cell death (apoptosis) through stabilisation of microtubules 
in the cell cytoskeleton. Hence, an overview of the cell cycle and the importance 
of microtubules will be given, to explain the biochemistry of peloruside A, and 
of other natural products that have also been 
found to interfere with microtubule 
dynamics. The retrosynthetic plan for 
peloruside A that is the basis of the work 
described in chapters two and three will then 
be described. Finally, a summary will be 
given of the relevant work published by other 
groups working towards a total synthesis of 
peloruside A since the initial reports of its 
biochemical potential, in 2000.  
 
 
1.1 Introduction 
 
In New Zealand, approximately one quarter of all human deaths are 
caused by cancer. There were a total of 16,790 new cancer registrations in 1999 
alone, and 7,647 cancer-related deaths in that year.2 Most of those deaths (95.1% 
in 2000) were of people aged 45 or over,3 but cancer affects people of all ages. 
Although it is estimated that about one of every three people who get cancer in 
New Zealand are cured, New Zealand’s mortality rate due to cancer (298.3 per 
100,000 population in 1999)2 is still high by international standards. The most 
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Figure 1.1. The marine 
natural product, peloruside A. 
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common cancer in New Zealand males is prostate cancer, while cancer of the 
lung is their leading cause of cancer-related death. For New Zealand females, 
breast cancer has the highest incidence (28%) and is the biggest killer (18% of 
female cancer deaths in 1999).2 Other common cancers for both sexes are large 
bowel cancer and melanoma.  
 
The history of cancer diagnosis and treatment 
 
Although cancer is sometimes thought of as a ‘modern day’ disease, its 
diagnosis and treatment has a long history.2 Evidence of cancer has been found in 
Egyptian mummies from ca. 3000 BC, and papyruses dated at ca. 1600 BC 
describe cancer treatments. These included cutting out the tumour with a knife or 
red hot irons, the treatment of stomach cancer with boiled barley and dates, and 
the treatment of uterine cancer with the application of a concoction of fresh dates 
and pig’s brains. Mummies of pre-Columbian Incas of Peru have also been found 
that show evidence of cancer. 
 
The Greek ‘father of medicine’ Hippocrates (ca. 300 BC), named a range 
of lumps, bumps and tumours as carcinos or carcinoma. It was believed that the 
carcinoma had spreading roots – like the legs of a crab, and they were believed to 
be caused by too much ‘black bile’ in the body. The Greeks and the Romans (ca. 
50 AD) both found that tumours could sometimes be successfully removed by 
surgery and cauterisation, but also that surgery could aggravate the tumour’s 
spread. Through the next 1000 years, a wide variety of remedies were used – 
caustic pastes (often containing arsenic), blood-letting, dietary modifications, 
herbs, powder of crab, and other charms and potions – but little further progress 
was made in the understanding of cancer until ca. 1500 AD. Around that date, 
the practise of autopsy became more widespread, with a concomitant 
understanding of internal cancers. By the mid-1600’s, medical technology was 
rapidly improving. Microscopes were invented, and major advances made in the 
understanding of circulation, cells, and the lymphatic system. The 1700’s 
heralded the first identification of causes for some cancers, such as snuff being 
related to cancer in the nose, and soot to cancer in chimney sweeps. From 1840 – 
1900 AD, hundreds more carcinogenic materials were identified. Improved 
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diagnosis methods and pathology techniques were matched by continual 
improvement in surgery, with crucial discoveries made in the anaesthetics and 
antibiotics areas. In 1895, X-rays were discovered, and radium was isolated in 
1898. This led to the development in the early 1900’s of radiotherapy as a viable 
cancer treatment. This is still one of the major weapons in the fight against 
cancer. Chemotherapy began to emerge as a treatment from about 1945 onwards, 
after observations during the Second World War that soldiers who were exposed 
to sulphur mustard suffered from lower white blood cell counts. This led to the 
use of nitrogen mustard (a similar but less toxic agent) to treat patients with high 
white blood cell counts (lymphoid leukaemia) and lymphomas.  
 
 
1.2 Cancer treatment  
 
It is now widely understood that cancer is, in fact, not one but many 
different diseases. What all have in common is that the normal growth of the 
body’s cells has become disrupted, resulting in out-of control cell division, and 
often (but not necessarily), resultant growth of a cell mass or tumour. Once a 
tumour is established, it is possible for abnormal cells to break away and travel 
through the blood or lymph system to form secondary tumours (also called 
metastases) elsewhere in the body. The many different cancer types fall into 
three main categories:2 
• Carcinomas, cancers that occur in the lining of the body’s external and 
internal surfaces, e.g. the skin, mouth, bowel. 
• Sarcomas, which form in the body’s tissues, e.g. muscles and bones. 
• Leukaemias and lymphomas – the cancers of the bone marrow and lymph 
glands (often do not produce tumours – ‘regional’ cancers).  
 
The treatment of all these types of cancer involves medical procedures to 
destroy, modify, control or remove the cancer tissue. The primary goal is to 
remove all traces of abnormal cells and prevent recurrence of the cancer, but in 
some cases, treatment becomes the prevention of spreading, or finally palliative 
treatment – to relieve symptoms if all reasonable curative methods have been 
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exhausted. Peloruside A is a potential chemotherapeutic agent, which specifically 
acts on tubulin,4,5,6 and therefore this area will be elaborated in the next section. 
However, a brief overview of the cancer treatments that are in use today7 is given 
in the following paragraphs. 
 
Surgery, radiation therapy and chemotherapy are the three main avenues 
of attack in cancer treatment. In fact, it is uncommon for a cancer to be treated by 
one method alone. Combination therapy can achieve a greater likelihood of cure, 
and also help minimise the damage to healthy organs and tissues. For example, 
surgery is often followed up with radiation therapy and/or chemotherapy to 
remove any remaining traces of cancer cells. Or, chemotherapy can be used to 
shrink a tumour, making it easier to surgically remove. Some chemotherapy 
drugs can make certain cancer cells more susceptible to radiation.  
 
Surgery is the oldest form of cancer treatment, and the techniques and 
methods used today are extremely varied and advanced. Curative cancer surgery 
attempts to completely remove localised tumours, or reduce the size of a tumour 
to increase the effectiveness of follow-up radiation or chemotherapy. Surgery 
may also be done as a diagnostic procedure, to relieve pain or to repair 
deformities caused by curative surgery (e.g., breast reconstruction surgery 
following a mastectomy). In radiation therapy treatment, X-rays, gamma rays, 
and other sources of radiation are used to kill cancer cells by breaking up 
molecules and causing reactions that damage living cells – sometimes they are 
immediately destroyed, sometimes they are damaged (eg DNA damage) and the 
cell’s ability to divide is affected. Modern technology can produce high-energy 
beams of radiation with great accuracy – thereby minimising the exposure of 
healthy tissue to the damaging rays. Two types of treatment are used – external 
beam radiation (teletherapy) and internal therapy (brachytherapy), where a 
radioactive source is placed inside the body close to the tumour. Chemotherapy 
is a systemic method of cancer treatment. This means that the drugs will reach 
most parts of the body, and therefore chemotherapy is very useful where cancer 
has already spread, or for tumours that cannot be reached surgically. The drugs 
may be administered orally, by injection into muscle or under the skin, into a 
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vein, or sometimes into the spinal fluid.  For some cancers, such as Hodgkin’s 
disease, leukaemia, and testicular cancer, chemotherapy alone can effect a cure.  
 
There are also a number of newer techniques available, as well as a host 
of ‘alternatives’ to conventional therapies (eg, acupuncture, prayer, etc). Cancers 
in tissues that require hormones to develop, such as breast and prostate, may 
respond to hormonal therapy – the administration or withdrawal of hormones, or 
interference with hormone function. Rarely used on their own, hormone 
treatments are often used to prevent or delay recurrence of a cancer after 
treatment with other methods. Biological therapy is a relatively new approach 
for cancer treatment. Also known as immunotherapy, the aim is to stimulate the 
body’s immune system to fight the abnormal cancerous cells.  
 
 
1.3 Antimitotic chemotherapeutic agents 
 
Tubulin and the cell cycle 
 
In order to understand the mode of action of the antimitotic class of 
compounds that peloruside A belongs to, an understanding of the eukaryotic cell 
cycle, and the role that tubulin plays in the cell is required.  
 
The cell cycle (shown in figure 1.2 overleaf) is the series of changes a 
cell goes through from the time it is first formed until its division into two 
daughter cells in the process called mitosis. Hence, mitosis (also known as the 
M-phase of the cell cycle) is both the beginning and end of the cycle. Mitosis is 
followed by the G-1 (Gap 1), S and G-2 (Gap 2) phases. These are collectively 
known as the interphase, and in healthy tissues, the duration of the three is 
relatively constant in different tissues. Chromosome replication happens during 
the S-phase of the interphase, in readiness for the process of mitosis, which will 
be discussed in more detail shortly. 
 
Microtubules constitute one of the major components of the cytoskeleton 
– the transparent web of filamentatious protein networks that dynamically 
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organise the interior of eukaryotic cells. They are involved in many essential cell 
processes, providing both structural and transport functions.8,9 They rigidify the 
cell, and they translocate vesicles, organelles, and chromosomes (through special 
attachment proteins).8 In conjunction with other proteins, they can form more 
complex structures such as cilia and flagella, which aid cell movement.  
   
 
Figure 1.2. Schematic diagram of the cell cycle, including the inhibition of 
mitosis by Taxol® and the epothilones.8  
 
Microtubules are also a major component of the mitotic spindle, and 
hence play a crucial role in mitosis. During mitosis, the cell undergoes dramatic 
structural change as it passes through the steps prophase, metaphase, anaphase, 
and teleophase. As the prophase begins, the cytoskeletal microtubule network 
‘melts’ at the centre, and two dipolar spindle-shaped networks originating from 
two centrosomes at opposite ends of the cell are formed. The chromosomes then 
align along the spindles (metaphase). During anaphase, the chromosomes move 
to two opposite ends of the cell, literally pulled toward the two poles by the 
shortening of microtubules. Each of the newly emerging daughter cells has 
received a complete set of genes, and the final cell division can then occur. 
During mitosis, the rate at which microtubules grow and disassemble increases 
by 20- to 100- fold relative to the rate during the interphase. These enhanced 
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microtubule dynamics make the cell susceptible to agents that can interact with 
tubulin and suppress microtubule dynamics. In particular, the metaphase to 
anaphase transition is very sensitive to such compounds, for example Taxol® 
and the epothilones (figure 1.2).  
 
The structural subunit of the microtubule is the  tubulin heterodimer, 
itself composed of two tubulin monomers (figure 1.3). The  and  tubulins share 
40% amino acid sequence identity,10 and their compact structures are basically 
identical; comprising a 
core of two -sheets 
surrounded by -
helices.10 In the 
presence of Mg2+, 
guanosine triphosphate 
(GTP) and 
microtubule-associated 
proteins (MAPs), a 
nucleation process 
takes place in which 
the preformed 
heterodimers assemble 
to form microtubules.11 
Linear polymers called protofilaments form first, and when thirteen of these have 
aligned they self-assemble to form microtubules approximately 24 nm in 
diameter, and up to several m in length.8 The microtubule may be elongated (or 
disassembled) from both ends, although the two ends are not identical. Labelled 
the (+) and (-) ends, the (+) end tends to grow faster. Although the half-life of 
tubulin is nearly 24 hours at 37 °C, the half-life of any given microtubule may be 
only about 10 minutes. This reflects the constant state of flux that microtubules 
exhibit to meet the needs of the cell. Regulatory processes within the cell control 
the growth rate of the microtubules, exerted by adding (for growth) or 
hydrolysing (for shrinkage) GTP on the ends of the microtubule.8,11 
 
     Figure 1.3. Microtubule formation from  and  tubulin.8 
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Natural products as antimitotic agents 
 
There are two broad categories of antimitotic compounds. The first of 
these contains compounds that, at appropriate concentrations, inhibit the 
formation of spindle microtubules, diverting tubulin into other types of 
aggregates.8,12(b)  They can also cause existing microtubules to depolymerise.8,12(b) 
The well-established chemotherapeutic agents colchicine,13 podophyllotoxin,14 
vinblastine,12 and vincristine12 (figure 1.4) belong to this group. It also includes 
compounds such as rhizoxin,15 the bacterial metabolite RPR112378,16 (figure 
1.4) and a number of other natural products. These compounds have been found 
to interact with tubulin in a variety of ways. For example, colchicine first binds 
to free tubulin and the formed complexes are then incorporated into 
microtubules,12(b) while vinblastine binds with high affinity to the ends of already 
formed microtubules.12  
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Figure 1.4. Selected compounds that promote tubulin depolymerisation. 
 
The most successful clinically used tubulin binding agent however, has 
the opposite effect on microtubule dynamics. The diterpene Taxol® (paclitaxel, 
figure 1.5 overleaf) was isolated from extracts of the Pacific Yew tree in 1971,17 
and developed as a drug by Bristol-Meyers Squibb in the 1990’s. Taxol® is 
currently available in over 60 countries. The semi-synthetic derivative taxotere 
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(docetaxel), developed by Rhone-Poulenc Rorer,18 has more recently also been 
approved for clinical use. Both drugs are indicated primarily for the treatment of 
solid tumours such as those commonly found in cases of breast and ovarian 
cancer, and Taxol® still holds a major market share in that area. 
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Figure 1.5. Selected compounds that promote tubulin polymerisation and 
microtubule stabilisation. 
 
Unlike the tubulin-destabilising drugs that preceded it, Taxol® had the 
unique effect of stabilising microtubules. It was found to promote both the 
formation of abnormal mitotic spindles and mitotic arrest, and thereby initiate 
apoptosis.19 Induction of apoptosis is generally associated with G2/M arrest, with 
cells accumulating at that stage of the cell cycle and cell death occurring as a 
direct result of the abnormal spindle growth and suppression of microtubule 
dynamics.20 It has also been shown that in some instances the cell may pass 
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through the M phase and arrest at the G1 stage;21 the mechanism by which this 
happens remains unclear.  
 
Taxol® and its relatives were, for more than fifteen years, the only 
known compounds to exhibit this mode of action. They have been joined more 
recently however, by a number of new compounds. The epothilones A and B 
(figure 1.5) were discovered by a German group in the late 1980’s.22 They were 
isolated from culture extracts of a strain of the cellulose-degrading 
myxobacterium Sorangium cellulosum, first found in soil collected from the 
banks of the Zambezi River in southern Africa. Scientists at Merck also, 
independently, isolated the compounds,23 and subsequently included them in a 
high-throughput screening program to discover Taxol®-like tubulin 
polymerisation agents. Their only hit, among tens of thousands of compounds, 
were the epothilones A and B. Significantly, they were shown to compete with 
Taxol® for the same binding site,23,24 and gave rise to microscopic pictures of 
stabilised microtubules and damaged cells essentially identical to those obtained 
with Taxol®.23 Furthermore, epothilones A and B were shown to be more potent 
killers of tumour cells in a number of cell lines, particularly in some multiple-
drug resistant ones.23,24 Epothilone B was identified as being too toxic for use as 
an anticancer drug, but aza-epothilone B (the lactam analogue) is currently in 
phase II clinical trials.25 
 
A computer-assisted structure analysis indicated that (+)-discodermolide 
(figure 1.5), isolated from the sponge Discodermia dissoluta,26 should act as an 
antimitotic compound.27 This prediction was confirmed, with discodermolide-
treated cells accumulating at the G2/M phase. Marked rearrangement of the 
microtubule cytoskeleton, including extensive microtubule bundling, was 
observed in discodermolide-treated breast cancer cells, and discodermolide was 
shown to be ten-fold more active at inducing microtubule rearrangement or 
assembly than Taxol®.27 More recently, eleutherobin,28 sarcodictyin A,29 and 
laulimalide30 (figure 1.5) have been added to the list of cytotoxic tubulin-
stabilising natural compounds. 
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1.4 Peloruside A 
 
 Peloruside A was isolated by West and Northcote1 in 1999, from samples 
of the marine sponge Mycale hentschelli collected in Pelorus Sound on the north 
coast of the South Island of New Zealand. Sponges of the Mycale genus are a 
rich source of bioactive secondary metabolites, and M. hentschelli had already 
yielded the antiviral and antitumour agents mycalamide A and B and the 
immunosuppressant pateamine (figure 1.6). The mycalamides were originally 
isolated from samples collected in Otago Harbour on the southeast coast of the 
South Island,31,32 while pateamine was first identified in samples from Thompson 
Sound on the southwest coast of the same.33 Interestingly, no mycalamides were 
detected in the Thompson Sound samples, but the sponges growing in Pelorus 
Sound contained mycalamide A, pateamine and peloruside A. 
 
  The isolation of peloruside A involved methanolic extraction of a 170 g 
(wet weight) sample of the sponge and subsequent fractionation on polymeric 
reverse-phase chromatographic material. NMR-guided separation was used to 
isolate 3.0 mg of peloruside A, 10.6 mg of mycalamide A and 11.7 mg of 
pateamine (figure 1.6). In the first report, the relative structure of peloruside A 
was elucidated through a variety of high-field NMR experiments.1 The structure 
shown in figure 1.1 ((+)-1) is the natural enantiomer, although the opposite 
enantiomer was shown in the first publication. It was not until de Brabander’s 
group published the total synthesis of (-)-1,34 and it was shown to have a negative 
optical rotation (the opposite sign to that reported for the dextrorotatory natural 
isolate) that the absolute stereochemistry of peloruside A was known. 
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Figure 1.6. Structures of mycalamides A and B, and of pateamine. 
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Biochemistry of Peloruside A 
 
 Peloruside A has shown effects remarkably similar to those of paclitaxel 
in cell lines and with purified tubulin.4 After two-day exposures to either 
peloruside A or paclitaxel at 100 nM concentration, human lung adenocarcinoma 
H441 cells showed multiple micronuclei, which increased upon longer 
exposures. Microtubule fibre bundles and multiple asters (the centres of the 
spindles formed during metaphase), and large ‘rod-like’ fibres were observed to 
form. These observations are consistent with those seen for other microtubule-
stabilising agents, including discodermolide and the epothilones.  
 
Treatment of the H441 cell line with 1 M peloruside A or paclitaxel 
induced partial cell cycle arrest at the G2/M phase; peloruside A having a 
somewhat less marked effect than paclitaxel. However, Western blot analysis of 
another cellular assay, following the shift from depolymerised to polymerised 
tubulin, indicated that peloruside A could be slightly more efficient than 
paclitaxel at inducing microtubule polymerisation. At 100 nM concentration of 
peloruside A, the conversion was essentially complete approximately 30 minutes 
after addition, and for paclitaxel at the same concentration, at approximately 
35 minutes after addition.4   
 
With purified tubulin (free of GTP or microtubule-associated proteins), 
peloruside A induced polymerisation at 10 M concentration. Long, straight 
microtubules analogous to those formed with paclitaxel were seen to form at 
37 °C. Only sparse microtubules were observed in the absence of the drug.4   
 
The cytotoxicity of peloruside A has been tested in a number of cell lines, 
including the H441 cell line (as discussed above), the myeloid leukaemic cell 
line HL-60, the nontransformed murine myeloid cell line 32D, and 32D cells 
transformed with ras and bcr/abl oncogenes. The toxicities were comparable to 
those of other microtubule stabilising agents, with IC50 values ranging from 4 nM 
to 15 nM. Interestingly, the sodium borohydride reduction product of peloruside 
A, 2 (figure 1.7, overleaf) is 30-fold less cytotoxic than peloruside A.5 
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Compound 2 did not cause significant 
microtubule polymerisation in cell assays 
where peloruside A itself did.  
 
The unique structure and properties of 
peloruside A may convey benefits over the 
widely used chemotherapeutic agent 
paclitaxel. Paclitaxel is lipophilic (has low 
aqueous solubility), and therefore is 
administered to the patient dissolved in 
polyoxyethylated castor oil (Cremophor EL). 
This substance contributes to paclitaxel’s undesirable side effects, including 
hypersensitivity reactions. Moreover, paclitaxel’s hydrophobicity contributes to 
the development of multiple-drug resistance (MDR), a phenotype that cells can 
develop which results in the efflux of a broad range of organic compounds 
(including paclitaxel) from the cell. This phenotype has generally been 
associated with over-expression of the P-glycoprotein efflux pump (P-gp),35 but 
also occurs as a result of mutation of the paclitaxel binding site on -tubulin.36 
Whichever mechanism is the cause, the effect is that cancers become resistant to 
paclitaxel. It is therefore important to identify drugs that have similar 
pharmacological properties to paclitaxel, but which are active in the MDR cell 
lines, and also which do not induce the MDR phenotype to develop in the first 
place. Peloruside A is considerably less lipophilic than paclitaxel, which suggests 
it should be both easier to administer, and active in MDR cell lines.4 Indeed, it 
has been shown that peloruside A is less susceptible than paclitaxel to MDR 
arising from overexpression of the P-gp pump.6 Peloruside A’s action was 
furthermore not affected at all in cell lines with mutations that affect the taxoid 
binding site on -tubulin.6 These observations were similar to those obtained for 
laulimalide, which had been shown to bind to a different site to paclitaxel.30 It 
was also found that laulimalide can displace peloruside A bound to microtubules, 
and hence it was concluded that they may compete for the same or overlapping 
binding sites.6 The binding properties of peloruside A (and laulimalide) are 
therefore distinctly different from other microtubule stabilising agents such as 
paclitaxel, the epothilones and discodermolide. Importantly, this suggests that 
Figure 1.7. The NaBH4 
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they may become very useful chemotherapeutic agents against tumour cells that 
have developed the MDR phenotype. 
 
 
1.5 Strategy for the Synthesis of Peloruside A 
 
The retrosynthetic analysis of peloruside A that formed the basis of the 
work described in this thesis is presented in scheme 1.1. Three disconnections 
were envisioned to give three main building blocks: the pyranose ring fragment 
3, the side chain and remainder of the macrocycle fragment 4, and the two-
carbon fragment 5 as commercially available benzyloxy acetic acid.  
 
3
Aldol reaction
OHO
OMe
HO
OO
BnO OR
O
OBn
OHOMe
5
OHBnO
O
4
HO
O
OH
6
O
OR
OR
(S)-8
Macrolactonisation
Aldol
HO
O
O
O
OCH3
HO
OCH3
HO
HO
OH
H3CO
BnO
OBn
O
7
(-)-1
Peloruside A
+
1
2
11
15
12
6
3
2
1
5
21
17
24
20
12
24
311
38
11 7
+
+
15
Aldol
8
7
Hemiacetal
formation
5
59
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Scheme 1.1. Retrosynthetic analysis of peloruside A. 
 
The key C-3 to C-11i pyranose ring fragment was further disconnected to 
give 7 and 8; a diastereoselective aldol reaction between a suitably protected 
aldehyde 8 and an enolate formed from the gem-dimethyl ketone fragment 7 was 
                                                
i
 Throughout chapters one, two and three, the numbering of fragments relates to the numbering of 
peloruside A itself (rather than the IUPAC numbering of individual fragments).  
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planned. The preparation of 8ii and the assembly of the C-3 to C-11 fragment fall 
within the scope of this thesis. For completeness, however, progress that has 
been made towards the synthesis of all of the fragments will be outlined here in 
this introductory chapter, along with strategies for assembly of the building 
blocks and final elaboration to give peloruside A. 
 
Synthesis of the C-3 to C-11 fragment  
 
The C-3 to C-11 fragment was to be synthesised by an aldol reaction 
between 7 (C-8 to C-11) and a version of synthon 8 (C-3 to C-7), such as 13, 
containing TES and TBDPS protecting groups. The latter is available via the 
synthesis shown in scheme 1.2. The starting aldehyde 10 is prepared from 
commercially available 1,3-propane diol (9) via monosilylation and Swern 
oxidation. Either enantiomer of alcohol 12 is then available from the well-
established asymmetric allyl boration procedure developed by Brown and co-
workers.37 Use of (+)-B-allyldiisopinocampheylborane (prepared from (-)--
pinene)38,39 yields the alcohol with the R- configuration, and use of the reagent 
prepared from (+)--pinene yields the alcohol with the S- configuration.40 The 
resulting alcohol is then protected with a protecting group such as TES, and then 
cleavage of the double bond via ozonolysis followed by a reductive workup, 
yields the aldehyde.40 
 
HO OH O OTBDPS
(-)-11
)2B
9 10
 (S)-12
(S)-13
OTBDPS
OH
O OTBDPS
OTES
1) TBDPSCl
2) Swern oxidation
1) TESCl
2) Ozonolysis
(-)-11 =
 
 
Scheme 1.2. Synthesis of aldehyde 13 via asymmetric allyl boration procedure. 
                                                
ii
 Both (R)-8 and (S)-8 were prepared during the course of this PhD. When the stereochemistry of 
peloruside A was established by De Brabander et al.,34 it was shown to be opposite to that shown 
in scheme 1.1. Hence the synthetic strategy changed accordingly. 
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An alternative and more versatile preparation of analogues of 8 was also 
proposed, starting with a suitably protected derivative of 3-hydroxypropionitrile 
such as 14 (scheme 1.3). A Grignard reaction with allylmagnesium chloride 
would yield the intermediate imine 15. This could then be hydrolysed to give the 
ketone 16, followed by asymmetric reduction,41,42,43 protection, and ozonolysis to 
yield the desired aldehyde.  
CN MgCl
14 THF
N
OTBDPS
MgCl
NH2
OTBDPS
H+
H2O
O
OTES
OTBDPS
O
OTBDPS
.
1) Asymmetric
reduction
2) TESCl
3) O3 then DMS
15
16
(S)-13
17
TBDPSO
Scheme 1.3. Grignard reaction synthesis of 13. 
 
Alternatively, the intermediate 15 could be converted to the amine 17,37 
or 17 could be prepared by addition of chirally modified allylboron reagent 
directly to 14,44 allowing entry into a nitrogen-containing analogue of peloruside 
A. The amine would need to be protected while the rest of the ring system was 
installed (scheme 1.4). It was envisioned that, upon deprotection to give 19, the 
amine would cyclise onto the ketone at C-9 to form an imine, which would be 
reduced to give 20, a nitrogen-containing analogue of fragment 3. 
 
BnO
OBn
O
O
NHR
OTBDPS
7
(S)-18
20
19
H
N
H
OMe
HO
OTBDPS
HO
BnO
OTBDPS
O
OBn
NH2OMe
+
3
1138
11
7 1) Aldol reaction
2) Methylation
3) Deprotection
    of amine
H2, Pd/C
11
3Further elaboration 
at C-3 and C-11
Scheme 1.4. Nitrogen containing ring fragment. 
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There are a number of other potential synthetic routes to suitable 
analogues of fragment 8. Malonaldehyde bis(dimethyl acetal) (21) was proposed 
early on as a potentially useful starting material (scheme 1.5). The mixed acetal 
22 could be prepared and one aldehyde group then selectively deprotected,45 
ready for either a Grignard reaction46 or the boron-mediated allylation described 
above.  
MeO OMe
MeO OMe HCl, CH2Cl2
MeO O
MeO O
MgCl O
TESO O
O
1) H+
2)
3) TESCl
4) O3 then DMS
21 22 23
HO OH
 
Scheme 1.5. Initially proposed route from malonaldehyde bis(dimethyl acetal). 
 
The nitrile 14 could also be used in a Blaise reaction47 with ethyl 
bromoacetate and zinc dust, followed by asymmetric reduction, protection and 
reduction of the ester to give the desired aldehyde 13 (scheme 1.6). 
 
TBDPSO CN
O
OTES
TBDPSO14
13Br
OEt
O
THF, Zn dust
OEt
O O
TBDPSO 24
1) Asymmetric
    reduction
2) TESCl
3) Reduction
 
Scheme 1.6. Proposed synthesis of 13 via a Blaise reaction. 
 
The synthesis of the C-8 to C-11 ketone48 7 started from the 
commercially available pantolactone, 25 (scheme 1.7). Protection of 25 was 
followed by reductive ring opening to give the diol, 26. The two primary 
hydroxyl groups were then converted to their benzyl ethers. Subsequent 
liberation and oxidation of the hydroxyl group at C-9 yields the ketone fragment 
7 as required. The use of benzyl ethers was preferred due to literature precedent 
for the formation of benzyloxy enolates,49 and the ease with which they can be 
selectively removed fitted well within the overall synthetic plan.   
O OH
O
HO OH
OR
25 26
7
BnO OBn
O
a) Protect
b) LAH
1) NaH, BnBr
2) Remove R
3) Oxidise
99
 
Scheme 1.7. Synthesis of the C-8 to C-11 ketone, 7. 
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In order to obtain the desired stereochemical relationship between the 
methoxyl and hydroxyl substituents at C-7 and C-8 of peloruside A, the 
formation of an anti aldol product is required from the aldol reaction between 7 
and 8. If the classic Zimmerman-Traxler (cyclic six-membered transition state) 
model for the aldol50 reaction is invoked, the E enolate of 7 was required to 
achieve this aim. It was anticipated that the use of LDA would provide the Z 
enolate of 7, minimising the steric interaction between the gem-dimethyl groups 
and the OBn substituent at C-8 (figure 1.8). However, use of the more sterically 
hindered base LiTMP may, due to increased 1,3-diaxial interaction, force the 
OBn substituent to adopt an equatorial position as the enolate is formed, hence 
providing the E enolate.51  
O
BnO OBn
O
BnO OBn
LiTMP
O
H
NLi
BnO
OBn
H
O
H
NLi
BnO
H
BnO
O
BnO OBn
H
Li
O
HBnO
Li
OBn
E enolate of 7
Z enolate of 7
LDA
Gauche interactions minimised
1,3-diaxial interactions minimised
7
7
 
Scheme 1.8. Postulated formation of E and Z enolates of ketone 7. 
 
Alternatively, Mukaiyama-type aldol reactions have been shown, since 
their introduction in the 1970’s,52 to be widely useful. Trimethylsilyl enol ethers 
of ketones similar to 7 have been shown to give anti aldol products upon reaction 
with various aldehydes, for example in equation 1, scheme 1.9 where the Lewis 
acid BF3.OEt2 gave excellent yield and diastereoselectivities.53 In the same 
publication, TiCl4 was also used, to give similar diastereoselectivities but slightly 
lower yields (53% and 65% for R=Ph and R=iPr). Another example where TiCl4 
was used as the Lewis acid is shown in equation 2, scheme 1.9.54  
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TMSO
THF
OTMS
O OH
R
Ph
OOH
O OH
R
Ph
OOH
BF3.Et2O, RCHO
+
R=Ph, 95% yield, >95:5 anti:syn
R=iPr, 84% yield, >95:5 anti:syn
+
PhCHO, TiCl4,
CH2Cl2, -78 oC
63% yield, >97:3 anti:syn
Equation 1
Equation 2
anti syn
anti syn
 
Scheme 1.9. Formation of anti aldol products with ketones similar to 7. 
 
Once an E enolate of 7 has been formed, the next challenge will be to 
control the facial selectivity of the attack on the approaching aldehyde, 13. It has 
been reported that useful chelation control can be achieved using lithium 
enolates,55 such as the LiTMP discussed above. In this case, it is anticipated that 
the lithium enolate will chelate to the aldehyde moiety, coordinating to both the 
aldehyde oxygen and the OTES substituent. In the transition state 27 (depicted in 
scheme 1.10), both the gem-dimethyl substituent of 7 and the alkyl chain of the 
aldehyde fragment adopt equatorial positions. Because the stereochemistry at C-5 
(OTES substituent) is fixed, and because of the crowded nature of the transition 
state, only one conformation is favourable and attack at the ‘re’ face of the 
aldehyde is preferred. Hence, the anticipated anti aldol product 28 also has the 
correct 1,3-anti relationship between C-5 and C-7. 
 
BnO
OBn
O Li
(S)-13
O
OTES
OTBDPS
28
OTES
OTBDPSBnO
O OH
OBn
E enolate of 7 27
BnO
BnO
O Li O OTBDPS
TES
O
29
OMeO
OMe
BnO
OTBDPS
BnO
8
7
3
8
11
7
1) Methylation
2) MeOH, pTsOH
78
 
Scheme 1.10. Chelation control of the aldehyde attack to form 28.  
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Should establishing a stereoselective aldol reaction prove unsuccessful, 
an alternative approach to setting the stereochemistry around the ring has also 
been proposed (scheme 1.11). In this case, the aldol product 28 would have 
undefined stereochemistry at C-7 and C-8. After methylation and cyclisation of 
this molecule to give acetal 29, the benzyl protecting groups would be removed 
and the resulting hydroxyl groups then oxidised. The methoxy at C-7 can then be 
epimerised, using for example sodium methoxide in methanol, to the more 
thermodynamically favourable equatorial conformation (30).56 Elaboration at 
C-11 could then proceed, and at a later stage in the synthesis, the ketone at C-8 
would be selectively reduced with a reducing agent such as NaBH434 to give the 
axial hydroxyl group. 
 
BnO
O
OBn
7
(S)-13
O
OTES
OTBDPS
O
OTBDPS
OBnOMeBnO
MeO
29
28
30
O
OTBDPS
OOMeO
MeO
OTES
OTBDPSBnO
O OH
OBn
1) Methylation
2) H+, MeOH
2 syn diastereomers 
     in a 1:1 mixture
2)
1) LiTMP
1) H2, Pd/C
2) Oxidation
3) NaOMe
Either elaboration at C-11,
or protection at C-11 and 
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Scheme 1.11. Alternative route to pyranose ring with correct stereochemistry. 
 
Synthesis of the C-12 to C-24 fragment 
 
A successful strategy for the synthesis of the C-12 to C-24 fragment 4 has 
been developed by Dr. Bridget Stocker,48,57 albeit without the ethyl group in 
place (scheme 1.12). Cyclic compound 36 is equivalent to 39, a protected 
analogue of the desired fragment 4, however the silyl protecting group was found 
to be crucial to the subsequent aldol reaction to form the C-11 to C-12 bond with 
good stereoselectivity, and hence will not be removed until later in the synthesis. 
Although the ethyl group at C-23 had not yet been introduced, the use of (S)-2-
ethyl-3-butenol (38) in place of 3-butenol in step (a), scheme 1.12 would allow 
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access to the requisite fragment 39 (equivalent to 36). Both (R)- and (S)-2-ethyl-
3-butenol are available in one step using a Zr-catalysed ethyl-magnesation of 2,5-
dihydrofuran.58  
Cl
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Scheme 1.12. Synthesis of C-12 to C-24 fragment, and coupling to a model for 
the C-3 to C-11 fragment. Reagents: (a) 3-butenol, Et3N, CH2Cl2, reflux; (b) 
acetone, DMSO, 20% L-proline, RT, overnight; (c) Et3N, CH2Cl2, 0 °C - RT; (d) 
10 mol% 40, CH2Cl2; (e) (-)-Ipc2BCl, Et2O, Et3N, 0 °C then pivaldehyde, -78 °C 
3 h, and -20 °C, 10 h. 
 
Aldol reaction studies were undertaken48,57 using pivaldehyde as a model 
for the C-3 to C-11 fragment in reactions with 36 (scheme 1.12). In order to set 
the desired stereochemistry at C-11, a 1,5-anti relationship is required between 
C-11 and C-15. Interaction between the enolate and the remote phenyl-silyl 
substituents was found to provide the desired 1,5-anti induction. A number of 
boron reagents were employed successfully, with the (-)-Ipc2BCl mediated aldol 
reaction giving the best yield for the compounds shown in scheme 1.12. The 
model aldol reaction between 36 and pivaldehyde proceeded to yield 37 in 94% 
yield and >99:1 ratio of 1,5-anti:1,5-syn aldol products.    
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Introduction of the C-1 to C-2 fragment 
 
The C-1 to C-2 fragment is available commercially as benzyloxyacetic 
acid. It is proposed that a diastereoselective aldol reaction (scheme 1.13) between 
41 and the enolate of a derivative of the benzyloxyacetic acid (5a), will give the 
desired -facial selectivity. Based on literature precedent, the use of a chiral 
auxiliary (X) such as Evan’s oxazolidinone59 should afford the desired 
selectivity. Methylation of the resulting alcohol (to give 42) and deprotection of 
the primary benzyl group using triphenylmethyl tetrafluoroborate60 followed by 
Swern oxidation61 will give the C-1 to C-11 fragment 43, ready to undergo the 
aldol reaction with the C-12 to C-24 fragment as discussed above.  
 
OMeO
OMe
BnO
OTBDPS
BnO
OMeO
OMe
O
BnO
BnO
X
OBn
OM
5a
OMeO
OMe
BnO
OMe
OBn
O
XOOMeO
OMe
BnO
OMe
OBn
O
XBnO
42
41
43
1
2
6
3
6
1
1)
2) Methylation
1) TBAF
2) Swern oxidation
1) Ph3C+BF4-
2) Swern oxidation
29
Scheme 1.13. Introduction of the C-1 to C-2 fragment. 
 
Final assembly and macrolactonisation strategy 
 
The final assembly strategy is depicted in scheme 1.14. First, an 
asymmetric aldol reaction as developed by Dr. Stocker between 39 and 43 will 
set the 1,5-anti relationship between C-11 and C-15. At this point the complete 
carbon skeleton of peloruside A is in place. Then, an Evans-Tischenko 
reduction62 of 44 with samarium iodide in propanal will set the final undefined 
stereocentre at C-13, and protect the C-11 hydroxyl group as the propanoyl ester. 
Methylation of the resulting hydroxyl group and subsequent deprotection of the 
bis-silyl ether, gives intermediate 45. In order to ensure that the final 
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macrolactonisation is selective for the 16-membered macrocycle, the primary 
hydroxyl group at C-24 will be protected. Deprotection of the propanoyl ester 
and hydrolysis of the chiral auxiliary ‘X’ to form the intermediate 46, will be 
required before the final macrolactonisation, which will be attempted under 
Yamaguchi esterification conditions.63 It is possible that the 12-membered 
macrocycle will also form, and depending on the result of this reaction, the C-11 
hydroxyl group may need to be suitably reprotected before macrolactonisation 
(the propanoyl ester group would not be suitable as the conditions for its removal 
might also cleave the ester in the macrocycle). Finally, removal of the remaining 
protecting groups will reveal the target molecule, peloruside A ((-)1). 
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Scheme 1.14. Final assembly and macrolactonisation strategy. 
 
 The synthetic strategy described above is convergent and seems efficient 
and flexible. There are many points where modifications could be made to 
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overcome the inevitable problems that will be encountered during the synthesis. 
Due to its convergent nature, it also provides ample opportunity for analogue 
synthesis in the future. Although the total synthesis was not achieved during the 
course of this PhD, it is hoped that this synthetic plan will eventually contribute 
to a successful total synthesis and, perhaps even more significantly, to a fruitful 
analogue search.   
 
 
1.6 Peloruside A in the Synthetic Organic Chemistry Literature 
 
The clinical potential of peloruside A, as well as the synthetic challenges 
inherent in the structure, have made it an appealing target for a number of 
organic chemistry groups around the world. In this section, the reported synthesis 
and partial syntheses that have appeared to date will be discussed. 
 
The first partial synthesis of peloruside A was reported in 2003 by 
Paterson, Di Francesco and Kühn from Cambridge University.64 Their 
retrosynthetic strategy is shown in scheme 1.15; three major disconnections were 
identified to give three synthetic target fragments of similar complexity: C-12 to 
C-24, C-7 to C-11, and C-1 to C-6. The asymmetric syntheses of all three 
fragments were reported, along with boron-mediated aldol reaction studies 
directed towards the assembly of the complete carbon skeleton. They envisioned 
assembly of a fully protected complete carbon skeleton followed by macro-
lactonisation, and finally deprotection which would induce hemiacetal formation 
and hence yield peloruside A. 
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HOOH
MeO OPMB
TIPSO
O
O OHO
OTBS
PMP
PMBO OMe
TBSO
O
(-)-1
1
6
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+
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6
7
11
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15
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24
Scheme 1.15. Paterson, Di Francesco and Kühn’s retrosynthesis. 
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Paterson’s synthesis of fragment 47 (C-1 to C-6) commenced with methyl 
acetoacetate 50, affording the desired 47 after 11 steps. Sharpless asymmetric 
dihydroxylation was used to install the desired stereochemistry at C-2 and C-3; 
with an extensive screening of ligands carried out to optimise the yield and ee of 
the reaction. Using AD-mix- containing (DHQ)2PHAL, 54% ee was obtained; 
using the ligand (DHQ)2PYR, 84% ee was obtained. With 47 in hand, it was 
found that a Cy2BCl mediated aldol reaction between 47 and the model substrate 
isobutyraldehyde resulted in the desired 1,5-anti relationship between C-7 and 
C-3, albeit with a moderate diastereomeric ratio of 3:1.  
 
OMe
O O
PMBO OMe
TBSO
O
OPMB
MeO OMe
PMBO OMe
TBSO
O OH
53
OPMB
MeO
MeO
OH
OH
1
6
(DHQ)2PYR, K2CO3,
K3Fe(CN)6, K2OsO4,
MeSO2NH2, 
t-BuOH/H2O, 4 oC
Cy2BCl, Et3N,
Et2O, -78 oC
i-PrCHO, 61%
3:1 anti:syn
52
5150
47
Scheme 1.16. Synthesis of fragment 47 and model aldol reaction. 
 
The synthesis of the C-7 to C-11 fragment 48 (scheme 1.17) was 
achieved in eight steps from neopentylglycol (54). Horner-Wadsworth-Emmons 
homologation and Sharpless asymmetric dihydroxylation (this time using 
(DHQ)PHN ligand to achieve 95% yield and 96% ee for this step) were followed 
by an oxidative cyclisation step in which two PMP acetals, 56 and 57 were 
formed. Fortuitously, it was found that the crude product mixture could be 
subjected to equilibrating conditions (CSA, CH2Cl2) to afford solely the more 
thermodynamically stable 57. Silylation and DIBAL reduction gave the required 
fragment 48. Subsequent Dess-Martin oxidation gave the aldehyde 58, and with 
that fragment in hand, further model aldol reaction studies were conducted, also 
directed towards the formation of the C-6 to C-7 bond as above. Low 
diastereoselectivities, and even excess of the undesired product 60, were 
observed with a range of boron-mediated aldol reactions, with only (+)-Ipc2BCl 
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resulting in a reasonable excess of the desired diastereomer 59. However, it was 
anticipated that the analogous aldol reaction with fragment 47 should result in a 
higher selectivity than was observed with the model substrate, acetone.  
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Scheme 1.17. Synthesis of 48 and model aldol reaction with acetone.   
 
Finally, Paterson’s synthesis of the C-12 to C-24 fragment 49 (scheme 
1.18) commenced with the (S)-lactate derived ketone, 60. The stereochemistry of 
the ethyl side chain was introduced (with 92:8 dr) by a Cy2BCl mediated aldol 
reaction with formaldehyde to give 61. This was followed by silyl ether 
formation, reduction, benzoate hydrolysis and glycol cleavage using Pb(OAc)4 to 
give an aldehyde. This aldehyde was subjected to the Still-Gennari variation of 
Horner-Wadsworth-Emmons coupling to give exclusively the desired (Z)-enoate 
62. Then, after conversion to 63, another boron-mediated aldol reaction was 
 
 
OBz
O
O OTIPS
OH O
HO OBz
O
49
OTIPS
O
R
63 R=H
62 R=OMe
Cy2BCl, Me2NEt,
Et2O, HCHO, -78 oC
64
60 61
(-)-Ipc2BCl, Et3N, 
Et2O, -78 oC, 65%
15
 
Scheme 1.18. Synthesis of the C-12 to C-24 fragment according to Paterson. 
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conducted. Using (-)-Ipc2BCl, 64 was formed, setting the requisite stereo-
chemistry at C-15 (a 83:17 dr was obtained). The resulting hydroxyl group was 
converted to a PMB ether to give the desired fragment 49. 
  
The similarity between fragment 49 and the C-12 to C-24 fragment 4 
proposed in this thesis is noteworthy. Paterson’s fragment is synthesised in ten 
linear steps with an overall yield of 18%; the equivalent fragment 4 (albeit 
without the ethyl group present) has been synthesised in four linear steps with an 
overall yield of 33%.  
 
Aldol reactions of fragment 49, directed towards the formation of the 
C-11 to C-12 bond, were carried out using model substrate 65 (scheme 1.19). As 
expected (based on previous work by Paterson’s group) the reaction with 
Cy2BCl/NEt3 resulted in excellent levels of remote 1,5-anti induction to give 66 
in 88% yield (>95:5 dr), thereby setting the correct stereochemistry at C-11. This 
induction relied upon the presence of the PMB group at the  position in 65. 
Again, this strategy is comparable to the one proposed in this thesis, in which the 
cyclic silyl tether is responsible for the 1,5-anti induction (refer section 1.5).    
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Scheme 1.19. Model aldol reaction and subsequent Evans-Tishchenko reduction. 
 
Paterson’s publication also reported a successful SmI2-catalysed Evans-
Tishchenko reduction of compound 66 to give 67 (scheme 1.19), effectively 
providing the C-9 to C-24 subunit of peloruside A. This provides further 
precedence for the analogous reduction proposed in this thesis. No follow-up 
publication has yet appeared from Paterson’s group reporting the successful 
assembly of the three reported fragments to give unnatural peloruside A. 
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Shortly thereafter, Liao, Wu, and De Brabander published the first and to 
date onlyiii reported total synthesis of (unnatural) peloruside A.34 Hence, they 
were also able to document the absolute configuration of the dextrorotatory 
natural isolate, which is the opposite to the one originally published by Northcote 
and co-workers. De Brabander’s approach to the macrolide was significantly 
different to the previously published fragment synthesis, with two major 
synthetic disconnects identified (scheme 1.20). The overall yield of the 
somewhat linear synthetic strategy was less than 2%. The elegant synthesis was 
notable for the successful use of minimally protected advanced intermediates, 
and an interesting configuration-dependent mechanistic switch, which was 
observed during the final Mitsunobu macrolactonisation. 
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Scheme 1.20. De Brabander’s retrosynthetic analysis of peloruside A. 
 
The synthesis of the fragment 68a, the C-14 to C-24 fragment with a TBS 
protecting group, began with the Zr-catalysed ethyl-magnesation of 2,5-
dihydrofuran 70,58 the same procedure as was proposed in this thesis. This was 
followed by acylation with methacryloyl chloride and ring-closing olefin 
metathesis to give 71. Treatment of the lactone with methyllithium and then 
silylation gave fragment 68a in ca. 17% overall yield.  
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Scheme 1.21. Synthesis of fragment 68a. 
                                                
iii
 Although this statement was true at the time of submission, Taylor and Jin published an 
elegant, convergent total synthesis of (+) peloruside A prior to the thesis examination; Jin, M.; 
Taylor, R. E. Org. Lett. 2005, 7, 1303-1305.  
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Synthesis of the second, substantially more complex C-1 to C-13 
fragment 69a began with alcohol 72 (scheme 1.22), which was protected and 
then dihydroxylated with catalytic OsO4. The diol was then subjected to 
Pb(OAc)4-assisted cleavage to yield the aldehyde 73, which when treated with 
(Z)-alkoxyallylborane 74 at low temperature, produced the desired homoallylic 
alcohol 75, setting the desired stereochemistry at C-2 and C-3. A further 5-step 
sequence (methylation, removal of PMB, oxidation, an aldol reaction with the 
lithium enolate derived from 78, and oxidation) gave 76, which upon stirring in 
an acidic toluene solution was transformed into the dihydropyranone 77.   
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Scheme 1.22. Synthesis of the key intermediate 77. 
 
Intermediate 77 was thus the key starting point for setting the crucial 
stereochemistry around the ring. Luche reduction at C-7, followed by hydroxyl-
directed epoxidation and in-situ methanolysis, gave the glycoside 79 in 72% 
yield from 77 (scheme 1.23). Further, the hydroxyl groups were protected, then 
the double bond oxidatively transformed to a carboxylic acid and treated with 
diazomethane, forming the methyl ester. Debenzylation and oxidation followed 
to give aldehyde 80, ready for the introduction of the final two-carbon unit. 
Although the sterically crowded 80 proved resistant to nucleophilic addition, 
formation of a single diastereomer 81 was achieved with allyldiethyborane. 
 
Numerous difficulties were encountered when 81 was protected at the 
C-11 alcohol and then further advanced through the synthesis. Therefore it was  
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Scheme 1.23. De Brabander’s assembly of the complete carbon skeleton.  
 
decided to attempt the assembly of peloruside A without further protection at 
C-11. Dihydroxylation and subsequent Pb(OAc)4-assisted cleavage again gave 
the aldehyde 69a (a specifically protected analogue of 69), which was coupled 
with the enolborinate derived from 68a, in 87% yield, as a separable mixture of 
C-13 epimers in a 2:1 ratio. This rather modest selectivity was welcomed in light 
of the difficulties experienced previously, and at this point the complete carbon 
skeleton of peloruside A was in place. 
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Scheme 1.24. Final transformations in de Brabander’s total synthesis of (-)-1.  
 
Methylation of the resulting hydroxyl group was accompanied by 
unexpected hydrolysis at C-9 to yield a hemiacetal. This was not reprotected, but 
carried through the next transformations: asymmetric reduction at C-15 using 
H3B.SMe2 and either (S)- or (R)-B-Me-oxazaborolidine, followed by liberation of 
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the carboxylic acid, to give either enantiomer of 83 (scheme 1.24), and then 
Mitsunobu-type macrolactonisation. Remarkably, it was found that the same 
lactone was produced, regardless of the stereochemistry at C-15. It was 
speculated that the geometric constraints of the macrocycle directed the 
mechanism of the reaction, so that the cyclisation occurred via either an 
acyloxyphosphonium intermediate (with retention of configuration) or via the 
more familiar alkoxyphosphonium intermediate (with inversion).    
 
Shortly thereafter, two separate papers by Ghosh and Kim appeared 
reporting the partial syntheses of the C-1 to C-965 and the C-10 to C-2466 
fragments of peloruside A. Their retrosynthesis is shown in scheme 1.25. 
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Scheme 1.25. Ghosh and Kim’s retrosynthesis.  
 
 The synthesis of the C-1 to C-9 fragment 84 (scheme 1.26) commenced 
with the ,-unsaturated ester 86 (available from literature procedures) which 
was converted to aldehyde 87 via a six-step process including a Sharpless 
asymmetric dihydroxylation. This was then converted to allyl alcohol 88 via 
either the asymmetric allylation procedure developed by Brown and co-workers, 
or by a procedure involving treatment of the aldehyde 87 with allylmagnesium 
bromide, then oxidation and subsequent asymmetric reduction using LAH in the 
presence of LiI. The latter route gave the desired alcohol diastereoselectively 
(91:1 ratio) in 87% yield. The selectivity of this reduction was rationalised by a 
chelation-controlled transition state model in which lithium chelates to the ketone 
oxygen and attack is to the less hindered face of the carbonyl (89, scheme 1.26). 
The alcohol 88 is then esterified with acryloyl chloride and subjected to ring-
closing metathesis to provide the lactone 90. The lactone was converted to the 
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open-chain moleculeiv by saponification before Sharpless asymmetric 
dihydroxylation was employed to set the desired stereochemistry at C-7 and C-8. 
The resultant 91 is suitable for reaction with the C-10 to C-24 fragment, but was 
also further elaborated to give 84, which allowed NOESY experiments to 
confirm that the desired stereochemistry had been achieved.  
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Scheme 1.26. Ghosh and Kim’s synthesis of the C-1 to C-9 fragment of 
peloruside A. Reagents and conditions: a) allylB((-)-Ipc)2), THF, -78 °C, 3 h 
(71%); b) allylMgBr, Et2O, 0 °C, 1 h (74%); c) Dess-Martin periodinane, 
NaHCO3, CH2Cl2, 23 °C, 2 h; d) LAH, LiI, Et2O, -78 °C, 30 min (87%); 
e) nBu4N+F-, THF, 23 °C, 3 h; f) Me2C(OMe)2, PPTS (cat.) Me2CO, 23 °C, 24 h 
(63% over 2 steps).   
 
 Their synthesis of the C-10 to C-24 segment 85 (scheme 1.27) began with 
the asymmetric alkylation of chiral imide 92 with benzyloxymethyl chloride 
(Evan’s procedure). A five-step sequence including a Horner-Wadsworth-
Emmons reaction (giving the tri-substituted Z-olefin in >99:1 selectivity) gave 
the aldehyde 93, which was subjected to Brown’s asymmetric allylboration with 
CH2=CHCH2B[(+)Ipc]2 to set the desired stereochemistry at C-15. Then, 
esterification and ring-closing methathesis using Grubb’s first generation catalyst 
gave the lactone 94. The correct stereochemistry was then introduced at C-13 by 
                                                
iv
 Dihydroxylation of 90 did not proceed even under forcing conditions. 
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formation of a single epoxide by nucleophilic epoxidation with alkaline hydrogen 
peroxide, and subsequent treatment with diphenyldiselenide and sodium 
borohydride in 2-propanol. Hydroxylactone 95 was formed in quantitative yield, 
and the hydroxyl group protected with TBDPSCl. Direct opening of the lactone 
with isopropyl magnesium chloride proved elusive, and hence the final 
transformations were effected by reaction with N,O-dimethylhydroxylamine 
hydrochloride in the presence of trimethylaluminium in CH2Cl2, followed by 
protection with MEMCl to furnish the Weinreb amide 96. Treatment of 96 with 
excess isopropyl magnesium chloride gave 85, the C-10 to C-24 fragment of 
peloruside A.  
 
Scheme 1.27. Ghosh and Kim’s synthesis of the C-10 to C-24 fragment. 
 
The next partial synthesis to be reported was of the C-8 to C-24 fragment 
101 (scheme 1.28), by Taylor and Jin.67 This was the first report of a synthesis of 
a fragment of peloruside A with the natural stereochemistry. Their synthesis 
began in a very similar fashion to that of Ghosh and Kim for the C-10 to C-24 
fragment above, starting with the oxazolidinone 92. A stereoselective alkylation 
with BOMCl in the presence of TiCl4, a Still-Gennari olefination (providing 
exclusively the desired Z-trisubstituted alkene), and Brown’s asymmetric 
allylation (setting the desired stereochemistry at C-15) were the key features of 
the nine-step approach to the intermediate 97.   
 
The 1,3-syn relationship between C-15 and C-13 was then established 
using an iodine-induced carbonate cyclisation reaction. After BOC-protection of  
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Scheme 1.28. Taylor and Jin’s partial synthesis of the C-8 to C-24 fragment of 
peloruside A. Reagents and conditions: a) Boc-ON, 91%; b) NIS, CH3CN, 92%; 
c) K2CO3, MeOH, 86%; d) TBDMSCl, imidazole, 92%; e) 1,3-dithiane, nBuLi, 
85%; f) KOtBu, MeI, 78%; g) MeI, CH3CN/H2O, 90%; h) 102, BF3.OEt2, 
CH2Cl2, -78 °C, 91%. 
 
97, treatment with N-iodosuccinimide was found to regioselectively form the six-
membered carbonate 98 in excellent yield. Treatment with basic methanol and 
protection gave the syn-epoxy ether 99, and the epoxide was then opened with 
the lithium anion of dithiane. After methylation, the hydrolysis of the dithiane 
gave aldehyde 100. Finally, the gem-dimethyl portion of peloruside A was 
introduced by Mukaiyama aldol reaction of 100 with 102 in the presence of 
boron trifluoride etherate. Although an achiral Lewis acid was used, the reaction 
proceeded in a diastereomeric ratio of 8:1, providing as the major product the 
anti aldol product 101, representing the C-8 to C-24 fragment of peloruside A.  
 
 Taylor and Jin also noted the structural and conformational similarities 
between peloruside A and the epothilones, derived from NMR and computer 
modelling analysis. The possibility that peloruside A and the epothilones may 
have overlapping pharmacophores was noted, although this has since been 
demonstrated to not be the case.6 
 
A unique, chiral pool approach to the C-1 to C-11 segment of (-)-1 
(unnatural peloruside A) has been published by Gurjar et al.68 The overall 
retrosynthetic analysis is presented in scheme 1.29, with the key C-11 to C-12 
disconnect being the same as that proposed in this thesis. However, Gurjar et al. 
 35 
envisage a Mukaiyama aldol reaction between 103 and 104 as the key 
transformation to form this bond. They used D-glucose as a starting material for 
the reported synthesis of the C-1 to C-11 segment 105, with the stereogenic 
centres at C-5, C-3 and C-2 of peloruside A to be derived from the glucose. 
Dihydroxylation of the key intermediate lactone 107 (itself derived from a ring-
closing metathesis of 108) provides the correct stereochemistry at C-7 and C-8.  
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Scheme 1.29. Gurjar et al.’s retrosynthetic analysis of peloruside A . 
 
Thereupon followed a paper by Liu and Zhou69 reporting a stereoselective 
synthesis of ‘the backbone of the core’ of natural peloruside A. A convergent 
retrosynthetic plan was presented (scheme 1.30 overleaf), with disconnects 
between C-10 and C-11, and a previously unproposed disconnect between C-16 
and C-17. In their paper, the synthesis of fragments 113 and 114 were presented. 
Their successful coupling to give 112, representing the carbon skeleton of the 
macrocycle of peloruside A, was also reported.  
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Scheme 1.30. Liu and Zhou’s retrosynthesis. 
 
Both 113 and 114 were derived from L-glyceraldehyde acetonide 115. 
The synthesis of fragment 113 (scheme 1.31) began with a substrate-controlled 
stereoselective allylation with diallyl zinc to give 116, followed by Mitsunobu 
inversion of the free hydroxyl group. A further nine-step sequence, including a 
second stereoselective allylation reaction using Brown’s B-allyldiisopino-
campheyl borane reagent, gave the aldehydic fragment 113.   
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OBz OMe
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85:15 dr
9 steps
115 116
Scheme 1.31. Synthesis of fragment 113.  
 
The synthesis of fragment 114 started with the common intermediate 116 
(scheme 1.32). In this case, the stereochemistry of the alcohol was retained. 
Methylation and Johnson-Lemieux oxidation (with cat. OsO4 and NaIO4 in THF-
H2O) gave the aldehyde 117, ready for allylation, again with Brown’s B-
allyldiisopinocampheyl borane reagent. A series of protecting group 
manipulations and another Johnson-Lemieux oxidation gave aldehyde 118. To 
this was added Z-alkoxyallylborane generated in-situ from 121, and the resultant 
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alcohol methylated to give 119. Finally, after removal of the TBDPS group and 
oxidation to give the aldehyde, the isopropyl group was introduced. Use of 
isopropyl Grignard reagents was not successful, but it was found that treatment 
of the aldehyde with freshly prepared isopropyllithium, followed by oxidation 
with Dess-Martin periodonane gave the desired product 114 in satisfactory yield 
of 70%. 
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Scheme 1.32. Synthesis of fragment 114 and LDA coupling to 113. Reagents 
and conditions: a) 121, sBuLi, THF, -78 °C, 40 min then (-)-Ipc2BOMe, -78 °C, 
1.5 h, then aldehyde 118, -78 °C, 3.5 h, 75%; b) MeI, NaH, THF, RT, 85%; 
c) LDA, THF, -78 °C, then aldehyde 113, THF, -78 °C to -40 °C, 74:26 dr, 60%. 
 
The final coupling of 113 and 114 proved to be troublesome. No 
satisfactory reaction was obtained under BF3.Et2O or TiCl4 – promoted 
Mukaiyama aldol conditions (although the TMS enol ether of 114 was readily 
prepared). Aldol reaction with TiCl4/iPrNEt2, and a range of boron-mediated 
aldol reactions were also unsuccessful, as was reaction with LiHMDS. The 
sterically hindered nature of the ketone, next to the isopropyl group, was 
suggested as the cause of these problems. Fortunately, LDA-induced aldol 
reaction provided the desired product 112 in 74:26 dr in 60% yield. 
 
Finally, Pagenkopf et al. have reported recently an elegant synthesis of 
the C-1 to C-12 portion of natural peloruside A.70 Their retrosynthetic analysis of 
the molecule is shown in scheme 1.33. As can be seen, the disconnections are 
similar to those proposed in this thesis. Three key fragments are identified, with 
two aldol reactions required for the final assembly of the carbon skeleton; a 
methyl ketone aldol reaction to form the C-12 to C-13 bond (not discussed in the 
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publication) and an -hydroxy ketone aldol reaction to form the C-7 to C-8 bond, 
which is reported. 
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Scheme 1.33. Pagenkopf et al.’s retrosynthesis of peloruside A. 
 
The synthesis of 128, a suitably protected analogue of the C-1 to C-7 
subunit 125, notably began with commercially available triacetyl D-glucal 126 
(scheme 1.34). The glucal was converted to the known pyranoside 127 via a five-
step sequence involving reaction with methanol and catalytic Ph3P.HBr (to give 
the 2-deoxypyranoside), acetate cleavage, benzylidene acetal formation, 
methylation, and selective primary benzylidene ether cleavage under Hanessian-
Hullar radical bromination conditions. Allylation of 127 afforded one 
diastereomer exclusively, then dihydroxylation and oxidative cleavage with 
NaIO4 gave the aldehyde 128. This preparation has been carried out on 50 g of 
triacetal D-glucal to yield 31 g of 128, in a very respectable overall yield of 46%. 
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Scheme 1.34. Synthesis of the C-1 to C-7 fragment, 128. 
 
To allow study of the C-7 to C-8 bond forming aldol reactions, an 
analogue of 124 was prepared. Hence, 131 was synthesised in 69% overall yield 
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by addition of an allylic stannane generated in-situ from Barbier-type reaction of 
129 with SnCl2.2H2O and benzyloxy acetaldehyde 130 (scheme 1.35). 
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Scheme 1.35. Synthesis of an analogue of the C-8 to C-12 fragment. 
 
With the two fragments in hand, extensive screening of aldol reaction 
conditions to discover means for accessing all four possible diastereomeric 
products were carried out. It was reported that the best method for obtaining the 
desired 2,3-anti-3,5-anti product 132 was a Mukaiyama aldol reaction promoted 
by BF3.OEt2 (scheme 1.36). Optimised conditions were found to be adding 1.1 
equivalents of BF3.OEt2 to a –20 °C solution of 131a and 128 in CH2Cl2, 
warming the reaction to 0 °C and maintaining that temperature for 2 h. Under 
these conditions, an 85% yield of the 2,3-anti-3,5-anti and the 2,3-anti-3,5-syn 
aldol productsv in a 3.5 to 1 ratio; this modest ratio was considered satisfactory in 
view of the complex and challenging nature of the problem. 
 
The synthesis continued with methylation and then reduction of the alkyl 
bromide by zinc-copper couple. Spontaneous -elimination of the alkyl zinc 
generated in-situ (Vasella ring cleavage) provided the acyclic 133. It was hoped 
that cyclisation to form the hemiketal 134 (or the corresponding methyl ketal) 
could be induced at this point (scheme 1.36), however obtaining 134 proved 
elusive. Hence, the open chain molecule with the ketone intact was advanced 
further; TBDMS protection, cleavage of both alkenes by ozonolysis, and then 
immediate oxidation of the aldehyde (at C-1) to the carboxylic acid, followed by 
esterification, gave the methyl ester 135. 
 
                                                
v
 The stereochemistry was assigned based on NOE analysis of cyclic di-tert-butylsilylene ether 
derivatives prepared at a later stage in the synthesis, and on comparison of coupling constants and 
literature precedence with tert-butyl ethyl ketones. 
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Scheme 1.36. Aldol reaction to form C-7 to C-8 bond and further elaboration. 
 
 
1.7 The eight retrosynthetic strategies – summary and final comment  
 
It is clear from the above survey that the total synthesis of peloruside A is 
far from a simple matter. Despite the fact that eight groups have published 
fragment syntheses since the structure of peloruside A was revealed in 1999, 
only the de Brabander group has achieved a total synthesis to date.vi Figure 1.8 
overleaf shows a brief summary of the disconnections proposed by seven of the 
eight groups (although Taylor and Jin published a synthesis of the C-8 to C-19 
region of peloruside A, they did not present an overall retrosynthetic analysis). 
The macrolactonisation between C-1 and C-15 is common to all groups, although 
de Brabander used an interesting Mitsunobu-type macrolactonisation while other 
groups propose the more traditional Yamaguchi macrolactonisation strategy. De 
Brabander’s strategy is among the more linear. The retrosynthesis of Gurjar et 
al., although apparently also quite linear, represents an elegant approach starting 
with a substrate from the chiral pool, D-glucose. Unfortunately, this strategy will 
                                                
vi
 NB: A total synthesis of natural peloruside A has since appeared - see footnote iii, page 28.  
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yield the (-) peloruside A, and L-glucose, which would yield the natural product, 
is considerably more expensive. Pagenkopf et al. also use D-glucose as a starting 
material, while Liu and Zhou use L-glyceraldehyde. Paterson et al., Pagenkopf et 
al. and Hoberg et al. propose more convergent syntheses.   
 
 
Figure 1.8. Summary of the retrosynthetic strategies adopted by various groups. 
 
The assembly of the pyranose ring with the correct stereochemistry in the 
sterically crowded C-7 to C-11 region appears to be one of the greatest 
challenges of this structure. The greatest variation in approach also occurs in this 
region, although the C-11 to C-12 disconnection was also common to three 
groups, including that of Hoberg et al. (the strategy presented in this thesis). No 
other published strategy has all of the same disconnections as that presented in 
this thesis, although there are some similarities as noted throughout this chapter, 
particularly with Paterson et al.’s strategy in the C-12 to C-24 region and with 
Pagenkopf et al.’s in the pyranose ring region. Overall, however, the different 
approaches to peloruside A can be said to be both creative and diverse.  
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Chapter Two 
 
Synthesis of the C-3 to C-7 Fragment of Peloruside A 
 
 
The retrosynthetic analysis of peloruside A presented 
in chapter one required the preparation of a protected variant 
of the C-3 to C-7 fragment 8.i Brown’s boron-mediated 
allylation procedure was used to prepare significant quantities of both 
enantiomers of the C-3 to C-7 fragment, but several other routes were also 
investigated, and these are discussed in this chapter. Significantly, the Grignard 
reaction route presented in section 2.1.2 was investigated as it gave the option of 
entry to a nitrogen-containing analogue of peloruside A. 
 
 
2.1 Racemic synthesis of the C-3 to C-7 fragment 
 
2.1.1 Strategy One 
 
Racemic syntheses were considered initially, to provide quantities of 
suitably protected 8 to begin the aldol reaction studies presented in chapter three. 
Initially, a route commencing with malonaldehyde bis(dimethyl acetal) 21 was 
proposed (scheme 2.1). Acid-catalysed conversion of 21 to malonaldehyde 
mixed bisacetal 22 with 1,3-propane diol has been reported.45 Subsequent 
selective acetal cleavage, allylation, protection and ozonolysis would yield 23 
(which constitutes a suitably protected variant of 8). If this route had been 
successful, a suitable chiral allylation procedure would have been investigated. 
 
However, it rapidly became clear that the formation of the mixed acetal 
22 was not as straightforward as had been indicated in the literature. A complex 
                                                
i
 As in chapter one and three, the numbering of fragments throughout this chapter relates to the 
numbering of peloruside A itself (rather than the IUPAC numbering of individual fragments).  
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mixture of products was obtained, which was extremely difficult to purify. This 
strategy was not pursued further. 
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Scheme 2.1. Route to the C-3 to C-7 fragment from 21. 
 
2.1.2 Strategy Two 
 
The plan for the second strategy for preparing a variant of 8 is shown in 
scheme 2.2 (scheme 2.5 shows the modified procedure adopted after optimisation 
of the reactions, with yields included). Initial protection of 3-hydroxypropio-
nitrile (136) with tert-butyldimethylsilyl (TBDMS) chloride to form the silyl 
ether 137 was planned, followed by a Grignard reaction of the nitrile46 with 
commercially available allyl magnesium chloride,ii and acid hydrolysis to give 
ketone 138. Subsequent reduction, protection and ozonolysis would give the 
target precursor 141.  
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Scheme 2.2. Planned Grignard reaction synthesis of C-3 to C-11 fragment. 
 
The initial protection proceeded well with TBDMSCl and imidazole in 
DMF, to give 137 in 97% yield. The subsequent Grignard reaction, however, 
proved to be extremely troublesome. When the reaction was run in diethyl ether 
overnight at ambient temperature and the resulting iminium magnesium salt 
(scheme 2.3) hydrolysed with dilute sulphuric acid, TLC analysis of the crude 
                                                
ii
 Allylmagnesium chloride, 2 M in Et2O, purchased from Aldrich Chemical Company. 
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product revealed a myriad of products along with the desired 138. A significant 
by-product was the conjugated isomer 143 (scheme 2.3), which was isolated. 
Aside from a large amount (often > 50%) of unreacted starting material, the other 
side products were not identified. Attempts to drive the reaction to completion by 
heating to reflux or extending the reaction times to several days did not 
significantly increase the amount of product, while seeming to cause more by-
product formation. Other modifications such as changing the order of addition, 
using a slow addition rate, and changing the ratio of allylmagnesium chloride to 
nitrile, gave little improvement in yield or quality of the product. Changing the 
reaction solvent from diethyl ether to THF did give moderate improvement in 
yield and reproducibility of the reaction but the typical yield for the Grignard 
reaction of 137 was still less than 35%. Careful flash column chromatography 
did, however, provide sufficient 138 to further the synthesis. 
137
MgCl
THF
N
OR
MgCl
H+
H2O
O
OR
O
OR
142 R=TBDMS
  15 R=TBDPS
138 R=TBDMS
  16 R=TBDPS
143 R=TBDMS
144 R=TBDPS
.
H+
 
Scheme 2.3. Hydrolysis and isomerization of the Grignard product. 
 
The isomerization to the more stable ,-unsaturated compounds (143 or 
144) shown in scheme 2.3 represents one of the key problems with this route. 
Unfortunately, the aqueous acid workup (that is required to hydrolyse the 
intermediate product to the ketone), also promotes this isomerization. Workup of 
142 with dilute aqueous sulphuric acid at ambient temperature for three hours, 
gave the isomer 143 as the major product. The internal double bond of 143/144 
was clearly differentiable from the terminal double bond in 138/16 in the 1H 
NMR spectrum. For compound 144, the two olefinic protons appear as doublets 
of quartets at 6.82 and 6.14 ppm (coupling to each other with a coupling constant 
J = 15.9, and both also coupling to the methyl group). Fortunately, it was found 
that by using a milder workup procedure, using cold (0 °C) dilute acetic acid, 
conversion of 138 to 143 could be minimised. Prompt purification of the crude 
product 138 was required after workup, to preclude the isomerization occurring 
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in the crude product, presumably catalysed by residual traces of acid. 
Fortunately, the subsequent reduction of the ketone (scheme 2.2) was found to be 
very robust. Semi-crude 138 can (and should) be rapidly carried through the 
reduction step to the stable alcohol 139. 
 
There have been reports in the literature that Cu(I) salts can facilitate the 
addition of Grignard reagents to nitriles. For example, the addition of tert-
butylmagnesium chloride to 4-methoxybenzonitrile, which proceeded in only 7% 
yield after 24 hours, was improved dramatically by the addition of 2 mol% of 
CuCl.71 The yield after only 1.5 hours was increased to 85%, and reported to be 
100% after 14 hours. The procedure was applied to the Grignard system 
described here, however in this case the yield and quality of the product were not 
improved. In fact, it appeared that the cleavage of the silyl ether present in 137 
(and in 14) was more marked under the Cu(I)-catalysed conditions. 
  
The most significant improvement to the Grignard procedure was 
obtained by changing the protecting group used to protect the hydroxyl moiety of 
136. The original TBDMS protecting group was somewhat labile under the 
forcing Grignard reaction conditions (particularly at elevated temperatures), and 
was also partially cleaved during the acidic workup. Replacing the TBDMS 
group with the significantly more stable TBDPS group alleviated these problems. 
The TBDPS group was sucessfully introduced72 using TBDPSCl and imidazole 
in DMF (scheme 2.4).iii A welcome consequence of this change was that the 
incorporation of UV-active functionality into the molecule made visualisation of 
the compounds on TLC much easier. The TBDPS-protected nitrile 14 could be 
heated to reflux in THF without significant cleavage of the silyl ether, during the 
Grignard reaction - with a consequent improvement in yield to 40% – 50% 
(scheme 2.5). The optimum reaction time was found to be approximately three 
hours; any longer and even the TBDPS group was cleaved. The best yield of 
53% was obtained upon a moderate scaleup of the reaction to 1.5 g scale. 
  
                                                
iii
 An alternative procedure73 using pyridine and DMAP was also attempted but found to be less 
satisfactory, requiring longer reaction times. 
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Other analogues of 137 were also prepared, in the hope that these would 
further improve the yield of the Grignard reaction (scheme 2.4). The tert-butyl 
ether 145, was introduced by treatment of 136 with tert-butyl-2,2,2-trichlor-
acetimidate.iv Although the desired product 145 was formed, it was in low yield 
(< 50%) and purification was not satisfactory. Also, the stability of the tert-butyl 
ether means that reasonably strongly acidic conditions are required for its 
removal,75(a) and hence it was not considered ideal for the orthogonal protection 
strategy.  
NC OTBDPS NC
OH
OMe
Cl
O
NH
Cl3C
NC O
145
136
O
NC O
O
146
AlCl3.6H2O
NC OPMB
73
OPMB
OH
OPMB
OTES
147
1) THF, MgBr
2) LiBH4, THF, 0 oC-RT
TESCl, DMF,
imidazole, 80%
Cyclohexane, 
BH3.THF,
80%
                THF, KOtBu, 40%
72, 30% over 
      2 steps
TBDPSCl, DMF,
imidazole, 90%
14
Scheme 2.4. Alternative protection reactions of 3-hydroxypropionitrile. 
 
The tetrahydropyranyl (THP) ether 146 was prepared in good yield of 
80%, by treatment of 136 with and 3,4-dihydro-2-H-pyran and AlCl3.6H2O.76 
Although 146 was shown to be stable to the Grignard reaction workup conditions 
for a prolonged period, the Grignard reaction of 146 did not give better results 
than with the silyl ether 137. The Cu(I)-catalysed Grignard reaction was also 
attempted, in the hope that the THP ether would be more stable to the conditions 
than the silyl ethers, but again, unsatisfactory results were obtained (low yield 
and quality of product). This was perhaps fortuitous, since the NMR spectra of 
the subsequent products would have been complicated due to the presence of the 
diastereotopic THP group. 
                                                
iv
 This reagent was prepared according to literature procedure74 by treatment of tert-butyl alcohol 
with KOtBu and trichloacetonitrile. 
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Finally, the para-methoxybenzyl (PMB) ether 147 was prepared.76(b) 
Initially, this was attempted with excess NaH as base, resulting in a polymeric 
brown mass. This was attributed to deprotonation of both the alcohol and the 
acidic proton - to the nitrile, resulting in polymerisation via attack of the 
carbanion on the nitrile group of a second molecule. Alternatively, attack of the 
alkoxide ion on the nitrile could also lead to polymerisation. With 0.95 
equivalents of KOtBu as the base, better results were obtained. Although the 
yield of 147 was still low at approximately 40% (this was partly attributed to 
poor quality reagent), the material was carried through to the Grignard reaction, 
run in THF at ambient temperature overnight. The product was not rigorously 
purified but carried through the reduction to 72, with a 30% yield over the two 
steps. This was comparable to the yields obtained with the TBDPS protected 
analogue, 14. Alcohol 72 was protected with TESCl and the resultant silyl ether 
73 used in the deprotection trial (discussed below). However, since PMB did not 
confer any great advantage over TBDPS and the initial protection step had been 
difficult, this approach was not pursued further.  
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Scheme 2.5. Racemic synthesis, final version. 
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The next step in the synthesis, reduction of the ketone to provide the 
alcohol 139 (or 12), was straightforward. Sodium borohydride and LAH could be 
used, with yields of 70% – 80%, but the best results were obtained with lithium 
borohydride at 0 °C for 30-40 minutes (scheme 2.5). This reagent was available 
in the laboratory as a solution in THF, which made it very easy to use, and clean 
product was obtained in high yield (97% for 139). As already mentioned, the 
reduction could be carried out on relatively impure starting material, and 
purification of the alcohol was fortunately much easier than purification of the 
ketone. The alcohols 139 and 12 were protected with triethyl silyl (TES) 
chloride, also in high yield, to provide 140 and 148 respectively (scheme 2.5), 
and then subjected to ozonolysis. 
 
Adventures with ozonolysis 
 
The final step of the synthesis was ozonolysis of the alkene 140 (or 148) 
and subsequent reductive workup with DMS. The first ozonolysis reaction, done 
on 140, used the ozoniser available at Industrial Research Limited (IRL). The 
yield from this reaction was only 54%, but there were high hopes that this could 
be easily improved, and an ozoniser was purchased by the research group at 
VUW – an Envirozone V.T-2A (produced and marketed by Ozone Technologies, 
Napier, N.Z.). Anticipating that 141 would soon be readily in hand for aldol 
studies, ozonolysis of 140 was embarked upon. Unexpectedly, the initial attempts 
using the new machine were extremely disappointing. Significant amount of both 
140 and 13 were destroyed in attempts to optimise the reaction conditions. 
 
The problems encountered were threefold. Firstly, the new ozoniser 
appeared to be tearing apart the molecules  – the TES group was certainly lost, 
and unexpectedly the TBDMS and TBDPS groups were also cleaved to some 
degree. Other degradation may also have been taking place. Starting material 148 
was found to be somewhat more robust to the conditions, but yields were still 
very poor (< 30%). After numerous experiments, it was realised that a very short 
burst of ozone from the new machine was sufficient to effect complete reaction 
 49 
of the alkene, and that prolonged reaction times led to the degradation. This was 
surprising, because ozonolyses are usually continued until either a blue solution 
is observed (indicating excess ozone in CH2Cl2 solution) or until a red indicator 
dye, Sudan III, decolourises (also indicating excess ozone present). In our case, if 
the ozone was allowed to flow until those observations were made, essentially 
complete degradation of the molecule was observed. In addition to reducing the 
time that the ozone was bubbled into the reaction, consultation with a technician 
from Ozone Technologies revealed that the ozoniser incorporated a preset 
function that turned off the ozone generation when the oxygen flow into the 
machine dropped below a certain level. This was reset so that a minimum flow 
rate could be used. The resultant reduction in the ‘aggressiveness’ of the ozone 
stream significantly improved the yield that could be obtained in the ozonolysis 
reaction. Careful experimentation with the lower flow rate led to the ability to 
predict the number of seconds of ozone flow required to convert a given amount 
of starting material 148 (up to ca. 400 mg).  
 
Secondly, the formation of a persistent side product was encountered. 
This product was first isolated from an ozonolysis of 149, prepared during the 
attempts to optimise the ozonolysis because it lacked the labile TES group. For 
example, when 185 mg of 149 was subjected to bubbling ozone for 70 seconds, 
50 mg of product 150 was obtained together with 117 mg of the by-product. 1H, 
13C and COSY NMR analysis of the by-product revealed it was similar in 
structure to the starting material, retaining both the TBDPS protecting groups and 
with the C-3 to C-6 portion of the molecule intact. After this, the analogous by-
product was also noted in reactions of 140 (the TES/TBDPS protected variant), 
and it was even identified in the 1H NMR of the crude product of the first 
reaction, which had been conducted using a different ozoniser. Varying the 
reaction time or workup time did not appear to affect whether the by-product was 
formed. However, it was found that the byproduct was not observed when PPh3 
was used in place of DMS. Hence, the use of DMS was abandoned and PPh3 was 
adopted for all ozonolysis workups. Together with the modified flows discussed 
above, this change allowed ozonolysis of up to ca. 250 mg of alkene with good 
results and yields routinely > 80%. However by the time that this level of control 
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was obtained, the enantioselective synthesis was being used (see the next 
section), so yields for ozonolysis of the racemic fragment are relatively low. 
  
The by-product was tentatively identified as being the intermediate 
ozonide, 152 (scheme 2.6). In the ozonolysis reaction, the intermediate 
molozonide (151) is produced by addition of ozone to the double bond. The 
molozonide then rearranges to form the ozonide (152), which is treated with 
DMS in a reductive workup to give the ketone. Ozonides are typically not very 
stable, but can be isolated. The fact that the by-product was only observed when 
DMS was used in the workup adds weight to the argument for the by-product 
being 152; DMS is volatile and may have been lost from the reaction mixture 
before all of the ozonide had reacted. Molecule 152 contains two stereogenic 
centres, and four diastereomers are therefore possible (as two enentiomeric pairs; 
1,3-syn or 1,3-anti between C-5 and C-7). In the 13C NMR spectrum of the by-
product, the signals are paired, suggesting two diastereomers are present. The 
ESMS spectrum of the by-products did not show a signal corresponding to 152a 
or 152b, but did show signals at m/z 509.2 and 633.3, respectively. These 
correspond to the carboxylic acids 153a and 153b (+Na+), which are likely 
degradation products of 152a and 152b.  
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Scheme 2.6. Ozonolysis of 149, showing the formation of by-product 152. 
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The third major problem was encountered when attempting to scale up 
the procedure. In every case, when an ozonolysis of greater than approximately 
300 mg of 148 was attempted, decreased yields and increased levels of by-
products were observed, or, if a shorter burst of ozone was used, incomplete 
conversion. Modifications such as adjusting the flow, increasing the dilution, or 
adjusting the time of the reaction did not alleviate the problems. An answer to 
this problem was not exhaustively pursued, partly because the ‘large’ scale 
destruction of the starting material was hindering progress in the subsequent 
aldol reaction studies, and partly because, at this stage, there was no need to form 
large amounts of 13. In any case, although it was found that the aldehyde could 
be stored for short periods (up to a week) under argon in the freezer, best results 
were always obtained in the aldol reactions when the aldehyde was freshly 
prepared, ideally on the same day as the aldol reaction. Hence, the preparation of 
large amounts of aldehyde at one time was not desirable. 
 
Deprotection trial 
 
At this point a short study was conducted to ensure that the TES group 
could be reliably removed without loss of the primary hydroxyl protecting group. 
This would be necessary at a later stage in the synthesis, and it was considered 
prudent to do this trial using the alkenes 140, 148 and 73 rather than the 
corresponding aldehydes, which were less readily available. The results of this 
trial are shown in table 2.1 (in which A is starting material, B is the desired 
product, and C is the unwanted diol 154). As expected, removal of TES group 
without cleavage of the TBDPS group77 (entries 4-7) or the PMB group76(c) 
(entries 8-10) was easy. Both were achieved in either THF-H2O or MeOH-H2O, 
with catalytic pTsOH. Removal of the TES group in preference to TBDMS was 
more difficult, with mixtures of products being obtained (entries 1-3). Although 
this trial was by no means exhaustive,v this did add weight to the decision to 
                                                
v
 A review has been published77 covering the selective deprotection of silyl ethers, in which the 
TBDPS group is described as one of the most stable silyl protecting groups available. For 
example, the half-life of hydrolysis of 1° TBDPS in 1% HCl/MeOH at 25 °C was reported to be 
225 min, while the half-life of the TBDMS ether under the same conditions was  1 min. 
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switch to using TBDPS rather than TBDMS as the group used to protect the 
primary hydroxyl moiety. 
  
Table 2.1. Selective deprotection of the TES group of 140, 148 and 73. 
RO
OTES
140 R=TBDMS
148 R=TBDPS
  73 R=PMB
139 R=TBDMS
  12 R=TBDPS
  72 R=PMB
RO
OH
HO
OH
154
++A
B
C
A
  
 
Entry    Substrate                        Conditions 
 
 
Ratio of 
products 
A:B:C 
1 140 THF-H2O 9:1, RT, 10 min, 5 mol % pTsOH 0 : 1 : 1 
2 140 MeOH-H2O 9:1, RT, 10 min, 5 mol % pTsOH 0 : 0 : 1 
3 140 MeCN-H2O 9:1, RT, 5 min, 5 mol % DDQ 0 : 1 : 1 
4 148 THF-H2O 9:1, 0 ºC, 5 min, 5 mol % pTsOH 1 : 4 : 0 
5 148 THF-H2O 9:1, RT, 40 min, 5 mol % pTsOH 0 : 1 : 0 
6 148 MeOH-H2O 9:1, 0 ºC, 5 min, 5 mol % pTsOH 1 : 20 :0 
7 148 MeOH-H2O 9:1, RT, 40 min, 5 mol % pTsOH 1 : 50 : 0 
8 73 THF-H2O 9:1, RT, 5 min, 5 mol % pTsOH 1 : 10 : 0 
9 73 MeOH-H2O 9:1, RT, 5 min, 5 mol % pTsOH 1 : 20 : 0 
10 73 MeOH-H2O 9:1, RT, 1.5 hr, 5 mol % pTsOH 1 : 50 : 0 
 
 
Summary 
   
The racemic synthesis of the C-3 to C-7 aldehyde (scheme 2.5) gave 141 
in a yield of 17% and 13 in 17% over five steps. Aside from the relatively low-
yielding Grignard reaction with a difficult purification, this route is straight-
forward and can provide useful quantities of the aldehyde from readily available, 
inexpensive starting materials. Work towards the key aldol reaction forming the 
C-7 to C-8 bond (described in chapter three) could now be initiated, while work 
on an enantioselective synthesis of the C-3 to C-7 aldehyde also began. 
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2.2 Enantioselective synthesis 
 
2.2.1 Strategy One 
 
The first strategy that was investigated for an enantiomerically selective 
synthesis of the C-3 to C-7 fragment was the inclusion of an asymmetric 
reduction of the ketone in the racemic synthesis described in section 2.1.2. A 
number of literature methods were investigated for this reduction, such as a 
reduction with ruthenium-BINAP complex and H2, as reported in the literature.43 
The use of L-N,N-di(benzoyl)cystine as a ligand with sodium borohydride as the 
reducing agent was also considered. The ligand was prepared41 and the reduction 
of 16 conducted42 according to literature procedures, to give 12 in moderate yield 
(ca. 40%). The enantiomeric excess of the product was not measured, chiral GC 
was unavailable at that time at VUW, and in any case, the low yield prompted 
investigation of other potential enantioselectve routes instead.  
 
2.2.2 Strategy two 
 
Although the potentially versatile nitrile-based route was not completely 
abandoned, the need to obtain quantities of the C-3 to C-7 aldehyde prompted a 
search for an enantioselective literature method to reliably prepare the aldehyde 
for use in aldol reaction studies.  
 
The addition of a zinc ester enolate (formed from ethyl bromoacetate and 
zinc metal), to the nitrile was considered. Such additions, to form -keto esters, 
were first reported by Blaise in 1901.47 This would yield the -keto ester 24, 
which could then be subjected to asymmetric reduction to give 156, followed by 
protection of the hydroxyl moiety, and finally reduction of the ester to the 
aldehyde 13 as shown in scheme 2.7. An advantage of using a Blaise reaction in 
this synthesis is that it is possible to isolate either the -keto ester 24 or the 
initially formed -amino-,-unsaturated ester 155. Therefore, as with the 
Grignard route, this approach would still allow access to the nitrogen-containing 
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analogues of peloruside A (as discussed in chapter one). This potentially useful 
reaction has not been widely applied in the literature, with problems of low yield, 
narrow scope and competing side reactions. A Blaise reaction has been employed 
to prepare the TBDMS (rather than TBDPS) protected analogue of 24.78 No yield 
was reported, but the route was described as ‘unsatisfactory’ by a group 
attempting to repeat the synthesis,79 who ultimately used an alternative route.  
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Scheme 2.7. Proposed route to key fragment 13 employing a Blaise reaction. 
 
A modified method for carrying out a Blaise reaction, published by 
Hannick and Kishi,80 reported substantially improved yields of -
monosubstituted -keto esters compared to previous literature results. The 
method differs from the usual Blaise reaction in that it employs THF as solvent, 
uses activated zinc dust, and the -bromoester is added over 30-60 minutes rather 
than in one portion. A sonochemical Blaise reaction has been reported81 to 
successfully prepare both -monosubstituted and -disubstituted -keto esters. 
Another variation, in which TMS-Cl was used as a catalyst, was reported by 
Johnson et al.82 The methods of Hannick and Kishi and of Johnson were both 
used in attempts to prepare 24 in the course of this work, but the reported 
improvements could not be reproduced. Unfortunately, low yields and product 
mixtures that were very difficult to purify were obtained, and hence the Blaise 
reaction route was subsequently abandoned. 
 
2.2.3 Strategy three 
 
There are a number of published methods for the asymmetric allylation of 
aldehydes such as 10. Since a large supply of the nitrile 14 was available, the 
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preparation of 10 was attempted via reduction of the nitrile using DIBAL-H. 
Although good results have been reported in the literature, this reaction could not 
be driven to completion, and efficient separation of 14 and 10 was difficult. An 
alternative preparation of 10 from 1,3-propane diol 9 by monoprotection with 
TBDPSCl and then a Swern oxidation (scheme 2.8) was found to be more facile. 
The low yield of 61% in the protection step was due to formation of significant 
amounts of the di-protected analogue. Allylation of 10 with TiF4-BINOL and 
TMS-allyl83 to give 157 (scheme 2.8) was briefly considered; however Brown’s 
boron mediated allylation procedure using B-allyldiisopinocampheylborane (11) 
was settled upon as the most suitable method in this case.  
HO OH
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OTBDPS
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OTMS
OTBDPS
O OTBDPS
TMS
Et2O, 51%
O
OR
OTBDPS
(S)-12
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OTBDPS
1) Imidazole, DMF
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          84%
TiF4-BINOL
CH2Cl2 Ipc2B
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OR TBDPSCl, DMF, base (S)-148 R=TES, 75%
(S)-158 R=MOM, 60%
(S)-159 R=TBDPS, 78%
  (S)-13 R=TES, 84%
(S)-160 R=MOM, 83%
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O3 then PPh3
9
(S)-157
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Scheme 2.8. Enantioselective synthesis of the C-3 to C-7 fragment. 
 
Preparation of the B-allyldiisopinocampheylborane reagent (11),38,39 
although a somewhat lengthy preparation that required rigorously dry conditions, 
was successfully carried out several times on 50 mmol scale during this work 
(scheme 2.9).vi The reagent was prepared from the commercially available and 
relatively stable borane-methyl sulfide complex and either (+)- or (-)--pinene 
(162) of 92% enantiomeric purity. Following hydroboration of the -pinene, the 
diisopinocampheylborane (163) is equilibrated in THF with 15% excess -pinene 
                                                
 
vi
 The experimental procedure for the preparation of B-allyldiisopinocampheylborane is described 
in chapter eight, being a slightly modified version of that published in the literature.38,39 
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at 0 °C for three days, during which time the major isomer is selectively 
incorporated into the reagent, to give an enantiomeric purity (percentage of one 
enantiomer incorporated in the reagent) in excess of 99%. This is followed by 
methanolysis of 163 to give 164, and subsequent reaction with allylmagnesium 
bromide at ambient temperature for one hour to yield the desired B-allyldiiso-
pinocampheylborane, 11. Salts were filtered out and solvents removed under 
argon, the reagent was then dissolved in dry diethyl ether and kept under argon in 
a Schlenk flask. It could be stored in this way for several weeks before use.  
 
 
H3B.SMe2 )2BH
)2B
)2BOMe
MgBr
92% ee
THF, 0 oC, 3 days
MeOH, 0 oC, 
1 h
-78 oC - 25 oC
then 25 oC, 1 h
99% ee
99% ee
(+)-162 163 164
(-)-11
   
Scheme 2.9. Preparation of (-)-B-allyldiisopinocampheylborane ((-)-11) from 
(+)--pinene ((+)-162). 
 
Both (+) and (-)--pinene were used to make the reagent during the 
course of this work, allowing selective access to either of the two enantiomers of 
the alcohol 12.vii Use of (+)-B-allyldiisopinocampheylborane (prepared from (-)-
-pinene) yields the alcohol with the R- configuration, and use of the reagent 
prepared from (+)--pinene yields the alcohol with the S- configuration (scheme 
2.8).40 The allylation reaction itself is straightforward, with the only real 
drawback being that the by-product from the reaction co-elutes with the product 
in flash column chromatography. Fortunately, alcohol 12 is very stable, and a 
crude purification of the product (by passing through a short plug of silica) was 
                                                
vii
 Both were prepared because when the total synthesis of peloruside A was published, and the 
stereochemistry of the natural isolate thereby revealed, it was demonstrated that the original 
synthetic plan would prepare the unnatural enantiomer. 
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sufficient to prevent degradation upon storage. Smaller amounts of 12 were 
purified by more careful flash column chromatography as they were required.  
 
The free hydroxyl group of 12 was initially protected with the triethyl 
silyl (TES) protecting group to give 148, as part of the orthogonal protection 
strategy described in the introductory chapter. The protection step proceeded 
readily in good yield, and the subsequent ozonolysis, once the problems 
described in the previous section had been ironed out, was also reasonably 
straightforward, proceeding with yields upwards of 85%. Hence, the chiral C-3 to 
C-7 aldehyde 13 was prepared in a total of five steps in an overall yield of 17% 
from propanediol (equivalent yields were obtained for the preparation of (R)-13 
and (S)-13) as shown in scheme 2.8.   
 
As is discussed in the next chapter, aldehyde 141 was susceptible to 
elimination in the subsequent aldol reaction with ketone 7. This observation led 
to the preparation of the potentially more stable MOM and TBDPS containing 
analogues, aldehydes 160 and 161 (in 13% and 15% overall yields respectively, 
scheme 2.8). Both the MOM and the TBDPS protection reactions were 
successful, and the subsequent ozonolyses of 158 and 159 proceeded in similar 
yields to the ozonolysis of the original TES-protected 148 (see scheme 2.8).  
 
The 1H NMR spectrum of 13 is shown in figure 2.1 (overleaf), with the 
1.5 – 2.2 ppm region of the spectra of 160 and 161 shown in the insets. The 
signals attributed to the methylene protons on C-4 ( to the protected primary 
hydroxyl group) appear in this region. Interestingly, as the size of the protecting 
group of the secondary hydroxyl at C-5 increases, the degree that the 
enantiotopic protons of the methylene moiety are split increases. This reflects the 
bulk of the TBDPS at O-3, which is so large that the molecule cannot freely 
rotate about the bonds between C-3 and C-5. This is further observed in the 
spectrum of 160, where the signal due to the methylene protons of the MOM 
group is also split, into two doublets at 4.67 and 4.61 ppm, coupling to each other 
with J = 7.1 Hz. Even this relatively small protecting group’s conformation is 
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Figure 2.1. 1H NMR spectrum of aldehyde 13, with (insets) portion of the 
1H NMR spectra of 160 and 161.  
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affected by the proximity of the large TBDPS protecting group. In the 13C NMR 
spectrum of 13, the two phenyl groups of the TBDPS group give two sets of 
signals, indicating that they are not equivalent. This is presumably because the 
TBDPS group cannot freely rotate. In the spectrum of 160, the two phenyl 
groups give rise to only one set of signals. The smaller MOM group present in 
160 allows the TBDPS to rotate more freely.   
 
 
2.3 Summary 
 
 Racemic variants of the C-3 to C-7 fragment 141, 150 and 13, containing 
different protecting groups, were successfully prepared from 
hydroxypropionitrile over five steps (protection, Grignard reaction, reduction, 
protection and ozonolysis) in an optimal overall yield of 31% for 13. All steps of 
this synthesis proceeded in excellent yield except the Grignard reaction step. 
There is still potential for elaborating this synthetic route by incorporating an 
asymmetric reduction, and hence providing a new and versatile route to 
enantiopure variants of the C-3 to C-7 fragment 8.  
 
Both enantiomers of the C-3 to C-7 fragment have also been prepared via 
literature methods from 1,3-propanediol, with an asymmetric allylation using 
(+)- or (-)-B-allyldiisopinocampheylborane as the key reaction setting the crucial 
stereochemistry at C-5. An overall yield of 17% for either enantiomer of the 
TES-protected fragment 13, and 15% for the analogous MOM-protected 
fragment 149 were obtained.  
 
Both the racemic and the chiral aldehydes described in this chapter were 
used in the aldol reaction studies discussed in chapter three.  
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Chapter Three 
 
Towards the C-3 to C-11 Pyranose Ring Fragment 
 
 
This chapter is an account of the work done towards the synthesis of the 
C-3 to C-11 fragment of peloruside A (figure 3.1). As described in chapter one, 
the synthetic plan was based on an aldol reactioni between the key fragments 7 
and 8. Hence the work described herein is largely concerned with aldol reactions 
of fragment 7, and of a variant thereof with MOM protecting groups, 188. The 
elaboration of the aldol products and the progress made towards the formation of 
the pyranose ring is described and finally a consideration of the future work 
required to complete the synthesis of peloruside A is presented. 
Figure 3.1. Peloruside A, with the retrosynthesis of the C-3 to C-11 fragment. 
 
 
3.1 Preparation of the C-8 to C-11 ketone, 7, on large scale 
 
A synthesis of the gem-dimethyl ketone fragment 7, developed by Dr. 
Bridget Stocker (scheme 3.1), is described in her PhD thesis.48 As significant 
quantities of 7 were required for the work described in this chapter, a scale-up of 
the synthesis shown in scheme 3.1 was undertaken. The experimental for this 
scaled up synthesis is presented in chapter eight, and a brief overview follows. 
                                                
i
 As in chapters one and two, the numbering of fragments throughout this chapter relates to the 
numbering of peloruside A itself (rather than the IUPAC numbering of individual fragments).  
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The allylation of racemic pantolactone 25 was undertaken on a 10 g scale, 
and a yield of 88% (equivalent to those obtained on smaller scale) was obtained. 
The subsequent reductive ring opening of 165 to give 166 incorporates what is 
undoubtedly the most troublesome part of this synthesis – a slow, difficult 
filtration of the reaction mixture through a celite/silica plug during the workup. 
This step proceeded in a yield of 74%, slightly lower than expected based on 
smaller scale experiments. This was attributed to poor product recovery (in the 
filtration) rather than incomplete conversion or formation of side products. The 
benzylation step initially did not go to completion. Inadequate washing of the 
NaH (done to remove the mineral oil that is 40% of the weight in the jar) and 
consequently not having enough NaH present was part of the reason for this, but 
did not entirely explain this result. Fortunately, resubmission of the mono-
benzylated material to the reaction conditions resulted in a total yield of 93% of 
167. The subsequent deprotection of the allyl protecting group was plagued by 
the fact that the catalyst, Pd(PPh3)4, had a limited shelf life once opened – often, 
more catalyst was required than the original experimental procedure called for, 
longer reaction times were required, and lower than expected yields were 
obtained. Finally, the oxidation proceeded smoothly to give 7 in a very good 
yield of 82%. The overall yield of 7 over the five steps, from 10 g of 
pantolactone, was 38%.  
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25 165 166
167 168 7
88% 74% 93%
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Scheme 3.1. Synthesis of gem-dimethyl ketone fragment 7. Reagents and 
conditions: a) KOtBu (1 eq), DMF-THF, 0 °C, 30 min; then allyl bromide, RT, 
14 h; b) LAH (1.5 eq), THF, reflux, 3 h; c) NaH (5 eq) DMF, 0°C, 30 min; then 
BnBr (2 eq), RT, 14 h; d) Pd(Ph3)4, para-toluenesulfinic acid, THF, RT, 6 h; 
e) PDC, AcOH, 3 Å molecular sieves, CH2Cl2, 3 h.   
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3.2 Model aldol reactions of the gem-dimethyl ketone fragment, 7 
 
Early on in the work done towards an asymmetric aldol reaction with 7, 
and particularly because of the difficulties experienced making variants of 
aldehyde 8, it was decided to perform some model aldol reactions. Benzaldehyde 
was chosen as a substrate to gain some understanding of the reactivity of the 
enolate of 7. Reactions were carried out with lithium 
enolates of 7; boron enolates of 7; and Mukaiyama aldol 
reactions of the trimethylsilyl enol ether of 7, 169 (the 
preparation of which is discussed in section 3.2.3). The 
results are summarised in table 3.1.  
   
Table 3.1. Results of aldol reactions of 7 and 169 with benzaldehyde. 
Entry Substrate Conditions Yield Syn-:anti- 
1 7 LDA 65% 14:1 
2 7 LiTMP 55% 13:1 
3 7 LDA then Ti(OiPr)4 59% 4:1 
4 7 BF3.OEt2 ** - 
5 169 BF3.OEt2 ** - 
6 7 Cy2BCl 42% 1:4 
7 7 ClB(Ipc)2 No reaction† - 
8 7 Cy2BOTf 60% >20:1 
9 169 TiCl4 33% 1:3 
10 169 Ti(OiPr)4 No reaction† - 
** A myriad of spots were observed in TLC analysis; degradation of starting materials was 
assumed and neither a meaningful yield nor a product ratio could be determined. 
†
 Even after overnight reaction at room temperature, only starting materials were recovered. 
 
3.2.1 Lithium enolates - LDA and LiTMP  
 
An aldol reaction between 7 and benzaldehyde can give two possible 
diastereomeric products, each present as a racemic pair of enantiomers (scheme 
3.2). At this stage, attention was focussed on achieving an anti aldol product in 
line with the retrosynthetic analysis presented in chapter one, so formation of an 
BnO OBn
O
TMS
H
169
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excess of one diastereomer (rather than one enantiomer) was the initial focus of 
this work.  
BnO
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OBn
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7
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2) PhCHO
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Scheme 3.2. Aldol reaction of 7 with benzaldehyde to give 170. 
 
The lithium enolate of 7 (formed using LDA) probably forms by way of a 
six-centred, lithium-chelated transition state as shown in scheme 1.8 (pg 18, 
chapter one).84 Due to the large steric bulk of the gem-dimethyl groups - to the 
carbonyl group, formation of the Z enolate is favoured53,54 (as discussed in 
chapter one) and its subsequent reaction, also via a six-membered transition state, 
gives the syn-aldol product as the major diastereomer. In the reaction of 7 with 
LDA and benzaldehyde, a yield of 65% was obtained, with a syn:anti product 
ratio of 14:1 (see table 3.1 above).ii  
 
The assignment of the aldol products 170 as syn- or anti- was supported 
by analysis of the coupling constants between Hb and Ha (see figure 3.2 on the 
following page). There is considerable literature precedence demonstrating that 
-hydroxy carbonyl compounds such as 170 exist in an intra-molecularly 
hydrogen-bonded chair conformation, and that the coupling constant between Ha 
and Hb (- and - to the carbonyl group, see figure 3.2) can hence be used to 
differentiate between the syn- and anti- diastereomers.85,86 The chair conformer 
that minimises axial interactions will dominate, and hence it is expected that 
Jab(anti-) > Jab(syn-).85 In this case, 170a (the syn- diastereomer) has Jab of 4.2 
Hz, consistent with the expected coupling for vicinal axial-equatorial protons in 
six-membered rings, while 170b (the anti- diastereomer) has Jab of 7.3 Hz, a 
considerably larger coupling constant consistent with the expected coupling for 
vicinal axial-axial protons. An interesting observation was made in the 1H NMR 
spectra of 170a and 170b. In some cases, the signal for proton Hb appeared as a 
doublet (coupling to Ha) while sometimes Hb was also coupled to Hc (the 
alcoholic proton) with a coupling constant J = 5.4 Hz, so that the signal due to Hc 
                                                
ii
 The syn:anti diastereomeric ratios were determined by inspection of the 1H NMR spectra. 
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at 3.22 ppm appeared as a doublet and the Hb signal as a doublet of doublets, 
appearing as a pseudo-triplet (see figure 3.3). This was attributed to the hydrogen 
bonding between Hc and the carbonyl oxygen (figure 3.2) locking the molecule 
into a conformation containing a six-membered ring and slowing down exchange 
of the hydroxyl proton Hc. 
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Figure 3.2. The four possible isomeric products, and chair conformations 
resulting from hydrogen-bonding. 
 
When lithium 2,2,6,6-tetramethylpiperidide (LiTMP) was used in place 
of LDA, an essentially equivalent syn:anti ratio of 13:1 was obtained, in a 
slightly lower total yield of 55% (table 3.1, entry 2). This indicates that the 1,3-
diaxial interactions between the dimethyl groups of the base and the OBn group 
of 7 were not large enough to force the OBn group to an equatorial position in 
the cyclic six-membered transition state during enolate formation as had been 
hoped (see scheme 1.8, page 18). The gem-dimethyl groups of 7, therefore, have 
a dominant effect on the arrangement of the transition state, their bulkiness 
precluding an equatorial orientation for the OBn group in the transition state and 
hence precluding the formation of an E enolate. In fact, it has been reported that 
in some cases the use of LiTMP in place of LDA can enhance the selectivity of 
aldol reactions to give higher syn:anti ratios of aldol products.87  
 
Titanium enolates may be formed by addition of titanium complexes to 
pre-formed lithium enolates.88(a) The addition of 1 mol equivalent of Ti(OiPr)4 to 
Li enolates (formed with LDA) and subsequent successful addition of the 
enolates to a variety of systems has been reported. When the titanium enolate of  
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Figure 3.3. 1HNMR spectrum of 170b with (inset) portions of the spectrum of 
170a with and without coupling to the hydroxyl proton. 
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7 was prepared according to the described procedure,89 and then reacted with 
benzaldehyde, a reasonably good 59% yield was obtained, with a syn:anti ratio of 
4:1. Although the reaction was tried using aldehyde (S)-160 (described below) 
these conditions were not pursued.  
 
3.2.2 Mukaiyama aldol reactions 
 
Given the attention that has been focussed on the development of 
asymmetric catalysts for aldol reactions using silyl enol ethers of ketones (the 
Mukaiyama aldol reaction),90,88(b) the trimethyl silyl enol ether 169 was prepared 
for aldol studies. The enolate of 7 was formed using LDA, and then trapped with 
TMSCl to give 169 (scheme 3.3), which was surprisingly stable and able to be 
purified by column chromatography. The reaction proceeded in excellent yield 
and with good Z/E selectivity (only one product could be detected by 1H NMR). 
The 1H NMR spectrum of this material showed a distinctive series of singlets – 
the alkene proton at 5.67, and the three methylene groups at 4.70, 4.51, and 3.26 
ppm. The stereochemistry of 169 was determined to be Z by NOE experiments. 
Positive NOE correlations were observed between the vinyl proton and the gem-
dimethyl groups (at 1.02 ppm), and between the vinyl proton and the methylene 
group at 4.70 ppm (scheme 3.3). This is consistent with the Z alkene geometry. A 
very weak interaction was also seen between the alkene and the methylene group 
- to the gem-dimethyl group, the signal for which appears significantly upfield 
of the benzyl methylene groups, at 3.26 ppm. No interaction was observed 
between the vinyl proton and the methyl groups of the trimethyl silyl moiety.    
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Scheme 3.3. Preparation and NOE analysis of trimethylsilyl enol ether 169. 
 
The Mukaiyama aldol reaction of 169 catalysed with titanium 
tetrachloride was initially attempted in THF. In this solvent, the mixture of 
 67 
benzaldehyde and Lewis acid resulted in a thick gelatinous precipitate. Changing 
the solvent to CH2Cl2 resulted in some improvement, with a mobile slurry being 
formed rather than a gelatinous precipitate. Under these modified conditions, a 
33% yield of aldol product was obtained and as had been hoped, the anti- aldol 
product was formed as the major product, in a ratio of 4:1 anti to syn.   
 
These observations are consistent with those of Heathcock et al.53 who 
obtained ‘preparatively useful’ ratios of the anti- diastereomers from the aldol 
reactions of the Z enol silane formed from ethyl tert-butyl ketone. In the reaction 
with benzaldehyde, using boron trifluoride etherate as catalyst, they obtained anti 
and syn aldol products in a 5:1 ratio. With titanium tetrachloride, the products 
were obtained in a ratio of 9:1. Their rationalisation of these observations was 
based on an analysis of the unfavourable dipole-dipole and steric interactions 
present in the staggered transition states of the Lewis acid mediated reaction.   
 
In the case of the titanium tetrachloride catalysed aldol reaction of 169 
with benzaldehyde, the staggered transition states shown in figure 3.4 are 
available. Of these, A3 and B3 are clearly disfavoured by two dipole-dipole 
interactions: between the oxygen atoms of the approaching aldehyde, and those 
of the silyl ether and of the benzyl ether of 169. Conformations A2 and B2 both 
involve an unfavourable electronic interaction between the oxygen of the  
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Figure 3.4. Model for the selectivity of the TiCl4 catalysed aldol reaction of 169. 
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aldehyde, and the oxygen of the benzyl ether, although B2 contains only two 
significant steric interactions (phenyl group - gem-dimethyls and aldehydic 
oxygen – OBn). Conformation B1 has three destabilising steric interactions. The 
most favourable of the available conformations appears to be A1, since although 
it incorporates two major steric interactions (Ph – OBn and aldehydic oxygen – 
gem-dimethyl groups), unfavourable electronic interactions are minimised. Thus, 
the reaction proceeds to give the anti- aldol product 170b.    
 
 The reaction of 169 using other Lewis acids was also attempted. Use of 
titanium tetraisopropoxide (Ti(OiPr)4) in place of TiCl4 (entry 10, table 3.1) gave 
no reaction, even after prolonged reaction times. In this system, the sterically 
hindered nature of the ketone seems to be a barrier to reaction, hence the lack of 
reaction with Ti(OiPr)4 could be due to the bulky nature of the -OiPr ligands. The 
Mukaiyama aldol reaction with boron trifluoride etherate was also attempted 
(entry 5, table 3.1).91 After addition of the catalyst TLC analysis of the reaction 
mixture quickly showed several different spots. After workup, the crude product 
was found to contain significant amounts of ketone 7 (i.e. decomposed starting 
material), benzaldehyde, and also suspected to contain BnOH (presumably from 
further decomposition of 7), and other unidentified spots. Use of this catalyst was 
not pursued further.  
 
3.2.3 Boron-mediated aldol reactions 
 
The use of enolborinates derived from reaction of ketones with 
organoborane derivatives (R2BX, X=leaving group, R=alkyl group) in the 
presence of a suitable tertiary amine and their use in aldol reactions was 
introduced by Mukaiyama, who introduced the dialkylboron triflates (R2BOTf) 
for this purpose.92,93 Dialkylboron chlorides, which are reported to be easier to 
prepare and handle,94(a),94(b) were developed by Brown, and have been found to 
be particularly useful for the generation of E enolates, although a range of factors 
influence enolate geometry.94,95 The R2BX reagents used during this work were 
prepared according to literature procedures for the synthesis of Cy2BCl,94(b) 
(Ipc)2BCl,94(b) and Cy2BOTf.94(d)  
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Treatment of a variety of ketones with Cy2BCl and Et3N selectively gives 
E- enolates.94 In the case of a boron-mediated aldol reaction between ketone 7 
and benzaldehyde, conducted using these reagents, the anti- aldol product 170b 
was isolated as the major product of the reaction. This may be attributed to 
activation of those - protons which are cis- to the Cl during the formation of the 
enolate.95 Conformation 171a would be favoured over 171b (scheme 3.4) 
because unfavourable dipole-dipole interactions are minimised. The small, 
unhindered base Et3N would deprotonate - to the ketone from 171a, hence 
forming the E-boron enolate 172. Upon reaction of enolate 172 with 
benzaldehyde through six-membered transition state 173 (with the phenyl group 
of benzaldehyde adopting an equatorial position as shown), the anti- aldol 
product 170b results.  
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Scheme 3.4. Formation of anti- aldol product (racemic) 170b with Cy2BCl. 
 
Interestingly, when the aldol reaction between 7 and benzaldehyde was 
attempted with (Ipc)2BCl reagent, no reaction was observed. This is likely to be 
due to steric factors, in that the Ipc ligands are much bulkier than the Cy ligands 
and it may be the case that the initial coordination of boron to the ketone 
(analogous to structure 171, scheme 3.4) may be sterically disfavoured. 
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Alternatively, the initial coordination may occur but the subsequent 
deprotonation be unfavourable due to steric hindrance.  
 
The boron dialkyl triflate reagents on the other hand, generally show a 
preference for forming Z-, rather than E-, enolates.95 Accordingly, when 7 was 
treated with Cy2BOTf and Et3N in dichloromethane the Z- boron enolate was 
formed, as evidenced by the subsequent treatment with benzaldehyde and 
isolation of the syn- aldol product 170a as the major product of that aldol 
reaction.  
 
 
3.3 Aldol reactions between ketone 7 and the C-3 to C-7 fragment  
 
The first attempts to perform an aldol reaction were between 7 and the 
racemic C-3 to C-11 fragments 140 and 13. The product of this reaction was 
presumed to be the 7,8-syn diastereomers shown in scheme 3.5; four 
diastereomers (two pairs of enantiomers) are possible because the 
stereochemistry at C-5 was not fixed. Although product was observed, and in one 
case, isolation of a small amount of a single (unidentified) diastereomer of the 
aldol product 28 was achieved,iii in general the results of these reactions were not 
good, with low yields and poor product recovery, particularly when aldehyde 140 
was used. Although in retrospect this was attributed to the inexperience of the 
author at the time, and particularly to lack of attention to rigorous purification of 
starting materials, it was noted that the TBDMS-containing 140 was significantly 
more susceptible to degradation than the TBDPS-containing 13. 
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Scheme 3.5. Initial aldol reactions between ketone 7 and racemic 140. 
                                                
iii
 It was later assumed that the other diastereomers had been inadvertently discarded after column 
chromatography due to inexperience of the author at the time. 
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With the knowledge gained, when chiral aldehydes (R)-13 and (S)-13 
were used in LDA aldol reactions with 7, better results were obtained. The 
enolate of 7 was prepared by adding 7 to freshly prepared LDA at –78 °C, 
stirring for 50 min at that temperature, and then adding the aldehyde and stirring 
for approximately 1 hour before quenching. Using these conditions, yields of up 
to 40% of the aldol product were obtained, although significant quantities of 
ketone 7 were also recovered in all cases. It was planned to confirm the 
stereochemistry of the aldol products by NMR analysis at a later stage when a 
locked ring system was present in the molecule, but based on the work described 
in the previous section, it was assumed that at this stage the product was a 
mixture of the two 7,8-syn diastereomers shown in scheme 3.6. With the 
stereochemistry at C-5 fixed, only two syn- diastereomers are available (present 
in a 1:1 ratio). However, it was found that aldol product 28 had an Rf very close 
to that of the gem-dimethyl ketone fragment 7, and separation of the 
diastereomers 28a and 28b proved to be very difficult. Further reactions were 
carried out with the mixed diastereomers, contaminated with small amounts of 7. 
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Scheme 3.6. Aldol reaction with fragment (S)-13.  
 
The reasons for the low yields observed in these aldol reactions were not 
entirely clear. After extending the reaction time at –78 °C to several hours, 
significant quantities of the starting material 7 were still observed by TLC 
analysis of the reaction mixture. Warming the reaction (to –40 °C, 0 C° or RT) 
also did not significantly increase the amount of aldol product that was formed.  
 
One of the reasons that was identified for the relatively low yields was 
elimination of aldehydes 140 and 13 under the aldol reaction conditions to give 
the conjugated by-product, 176 (scheme 3.7). This by-product was isolated from 
the reaction in 5 – 70% yields, depending on the reaction conditions used. Its 
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formation was particularly noted when reaction time was extended, or when the 
aldol reaction was warmed as described above. The formation of the by-product 
might be promoted by the chelation of the aldehyde (transition state 27, scheme 
1.10, page 19), withdrawing electron density from the OTES oxygen and thus 
promoting the elimination. Alternatively, an E1CB elimination could occur by 
abstraction of the -H of the aldehyde by the enolate, to give 177, followed by 
elimination of the OTES group to give conjugated molecule 176 (as shown in 
scheme 3.7) and reformation of ketone 7. The elimination also occurred if any 
aldehyde was left in the crude product after workup of the aldol reaction, unless 
purification was done immediately. 
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Scheme 3.7. Elimination of aldehyde 13 to give the conjugated by-product, 176.  
 
The problem of elimination from the starting material was somewhat 
alleviated by substituting the TES group by MOM, hence conducting the aldol 
reaction with aldehyde (S)-160 (scheme 3.8). The diastereomeric aldol products 
178a and 178b were prepared in 56% (combined) yield, when an excess of the 
enolate of 7 was used. With the MOM group, the aldehyde fragment was much 
more stable to the reaction conditions, and 160 could be recovered if the reaction 
was quenched at –78 °C. However, even with this improvement higher yields 
could not be obtained by extended reaction time or by warming the reaction to 
-40 °C or 0 °C (the elimination product was observed in this case only when the 
reaction was warmed). 
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 Having achieved satisfactory yields with the LDA aldol reaction 
conditions, the next challenge was to perform an aldol reaction that would give 
the anti- aldol product. The conditions described in section 3.2 that had been 
successfully employed to give anti- aldol products with the model substrate, 
were therefore attempted. Unfortunately, isolable amounts of aldol product were 
obtained from neither the Cy2BCl mediated aldol reaction, nor from an attempted 
Mukaiyama aldol reaction with TiCl4. In some cases small traces of what were 
presumed to be aldol products were detectable in the 1H NMR spectra of the 
crude product. However, despite trying a variety of conditions (longer reaction 
times or allowing the reactions to warm to –40 °C, 0 °C or RT), the major 
products of the reactions were always the ketone 7, and either the aldehyde (160 
or 13) or degradation products thereof.  
 
Finally, the aldol reaction using LDA and Ti(OiPr)4 as described in 
section 3.2 was attempted using 161 as the aldehyde. In the analysis of the crude 
product from the reaction, along with the usual unreacted starting materials and 
byproduct 176, was found the eliminated aldol product 179 (scheme 3.9). Again, 
this elimination was attributed to an E1CB mechanism similar to that shown in 
scheme 3.7, with abstraction of the -H of the ketone of the newly formed aldol 
product, and subsequent elimination of the hydroxyl group (possibly assisted by 
co-ordination of titanium) to give 179. 
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Scheme 3.9. Formation of eliminated aldol product 179 with Ti(OiPr)4. 
 
It was proposed that, if 179 could be reliably prepared, then nucleophilic 
1,4- Michael-type addition at C-7 of 179 with methoxide anion could be used to 
give product 180, essentially methylated aldol product.  Unfortunately the 
methoxide addition was not achieved, and this route was not pursued. 
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3.4 Elaboration of the LDA aldol products  
 
The subsequent steps in the planned synthesis of the pyranose ring were 
protection of the newly formed hydroxyl moiety of the anti- aldol product as the 
methyl ether, then deprotection at C-5 and subsequent cyclisation of the pyranose 
ring, which would be converted into an acetal such as 29 (scheme 1.10, page 19). 
In view of the difficulties experienced obtaining the anti- aldol product, it was 
decided to proceed with the largely syn- aldol product obtained from LDA 
reaction. Hence, a slightly modified synthetic plan (shown in scheme 3.10) was 
adopted, in which the methylation, deprotection-cyclisation and acetal formation 
steps are followed by cleavage of the benzyl ethers, oxidation and subsequent 
epimerisation of the methoxy substituent at C-7 to the thermodynamically 
favoured equatorial position. This would eventually be followed by reduction of 
the resultant C-8 ketone34 to the axial hydroxyl, giving the required 
stereochemistry around the pyranose ring. This strategy takes advantage of the 
locked pyranose ring system to ‘correct’ the stereochemistry around the ring. 
Although introducing extra steps, this strategy has the advantage that all the 
diastereomers formed in the aldol reaction can be carried through the synthesis, 
maximising the overall yield.  
 
Mixtue of 178a and 178b
OMOM
OTBDPSBnO
O OH
OBn
30
O
OTBDPS
OOMeO
MeO
29
O
OTBDPS
OBnOMeBnO
MeO
1) Methylation
2) Removal of MOM group
3) H+, MeOH
2 syn-diastereomers
1) Removal of Bn groups
2) Oxidation
3) Epimerisation, eg NaOMe
Either elaboration at C-11, or
protection C-11 and reduction at 
C-8 with large reducing agent
7 5
11
 
Scheme 3.10. Modified strategy for pyranose ring formation. 
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3.4.1 Initial cyclisation attempt and subsequent strategy modification 
 
Initially, to investigate the viability of the proposed cyclisation, the TES 
group of 28 was removed without first protecting at C-7. Hence, the aldol 
product 28 was stirred at 0 °C in MeOH with a catalytic amount of pTsOH, and 
the deprotected product 181 was isolated in 82% yield (scheme 3.11). However, 
it was clear from the 13C NMR spectrum that 181 was present as the open chain 
form, not, as had been hoped, as the pyranose ring (scheme 3.11). In the 13C 
NMR spectrum, the ketone carbon signal was clearly present at 213.4 ppm, and 
no signals were seen around 100-110 ppm where they would be expected for a 
cyclic acetal. The major HRMS (ESI) signal was found at 691.3453, which 
correlates to the mass calculated for 181 + Na+ (the cyclic acetal would have 
mass for 182 + Na+ of 705.3587). It was postulated that the benzyl groups present 
at O-8 and O-11 might be a steric hindrance to ring closing. This hypothesis has 
since been supported by literature reports indicating that the closed ring structure 
is elusive until the molecule is largely deprotected.34,70 
 
28
OTES
OTBDPSBnO
O OH
OBn
O OTBDPS
BnO
OH
BnO
MeO H
OH
OTBDPSBnO
O OH
OBn
182
181
MeOH, pTsOH
mixture of 2 syn- diastereomers
MeOH, pTsOH
 
Scheme 3.11. Product of deprotection of 28. 
 
Removal of both the benzyl groups and the TES group appeared to be 
necessary to effect cyclisation. This could be done with the unprotected aldol 
product 28 as shown in scheme 3.12, using a published method for the 
simultaneous deprotection of TES goups and benzyl groups in methanol with Pd 
on charcoal96 to liberate the hydroxyl groups present in the molecule, providing 
 76 
183 which would be in an equilibrium with the pyranose ring form (183a). The 
acetal 184 could then be formed with acidic methanol. 
 
Mixture of 28a and 28b
OTES
OTBDPSBnO
O OH
OBn
O
OTBDPS
HO
OH
HO
HO HOH
OTBDPS
HO
O OH
OH
183a183
Pd/C, H2, MeOH, H+
2 syn- diastereomers
MeOH, H+ O
OTBDPS
HO
OH
HO
MeO H
184
7
 
Scheme 3.12. Pd/C deprotection of TES and Bn groups of aldol product 28. 
 
However, the polyol 183 would be very polar and consequently difficult 
to handle, and it was considered prudent to return to the original strategy and 
methylate the free hydroxyl at C-7 before attempting the debenzylation/silyl 
ether cleavage step. Hence, the modified strategy, shown in scheme 3.13, 
consisted of methylation, then deprotection at O-5, O-8 and O-11, in the presence 
of MeOH and acid, to form the cyclic acetal 185, with undefined stereochemistry 
at C-7 and C-8. Subsequent oxidation at C-8, epimerisation at C-7 to give the 
desired equatorial position, and then reduction of the ketone with a large 
reducing agent such as L-selectride to give 186, with an axial hydroxyl as 
required at C-8, would set the required stereochemistry around the pyranose ring. 
  
BnO
O
OBn
7
OHO
OTBDPS
OMe
HO
HMeO
(S)-160
O
OMOM
OTBDPS
O
OTBDPS
OHOMeHO
MeO
178
OMOM
OTBDPSBnO
O OH
OBn
185
186
O
OTBDPS
OTESOMe
HO
MeO
1) Methylate
2) Remove Bn, MOM
2 diastereomers
2)
1) LDA, THF, -78oC
1) TESCl
2) Oxidise
3) epimerise e.g. NaOMe
4) Reduction
 
Scheme 3.13. Modified new strategy. 
 77 
 
3.4.2 Methylations 
 
Attempts to methylate the aldol product 178 were initiated by trying the 
standard Williamson ether synthesis (scheme 3.14). Monitoring the reaction by 
TLC revealed a product being formed with a higher Rf than the starting material, 
but unfortunately, upon workup and column chromatography, the methylated 
aldol product was not isolated. It appeared that, upon deprotonation, 178 had 
undergone a retro-aldol reaction. Ketone 7 was isolated from the crude reaction 
mixture in 58% yield, along with 32% of compound 187 as a by-product (scheme 
3.14).  
OMOM
OTBDPSBnO
O OH
OBn
178
THF
BnO
O
OBn BnO
O
OBn
NaH, MeI
2 x syn- diastereomers
+
7 58% 187 32%
+ OMOM
OTBDPSO
(S)-160 (not isolated)
 
Scheme 3.14. Attempted methylation of 178. 
 
The formation of the by-product 187 was attributed to nucleophilic attack 
of the enolate product of the retro-aldol reaction, on methyl iodide (as in scheme 
3.15). The retro-aldol reaction was observed even when only one equivalent of 
NaH was used. It was hoped that milder bases might reduce the tendency for the 
retro-aldol reaction to occur. However, the same products 7 and 187 were 
obtained from attempts to methylate 178 with KOH or KOtBu and methyl iodide 
in THF.  
178
NaH
OMOM
OTBDPS
BnO
O O-
OBn
BnO
O-
OBn
H3C
I BnO
O
OBn
Me
187
 
Scheme 3.15. Origin of byproduct 187. 
 
Alternative, mild methylation conditions were sought, but unfortunately 
no reaction was observed, and unmethylated aldol product was recovered after 
treatment of 178 with any of the following methylation conditions: K2CO3 and 
methyl iodide in THF; AgOTf, pyridine, and methyl iodide in dichloromethane;97  
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HC(OMe)2.BF4 in dichloromethane;98 or methyl trifluoromethanesulfonate in 
trimethyl phosphate (a mild procedure reported for the methylation of 
carbohydrates).99 It was concluded that methylation of the aldol product was not 
a viable strategy, and a different approach was required. One such alternative 
approach is described in the next section, 3.5. 
 
 
3.5 Fragment 188, a variant of gem-dimethyl ketone 7 
 
The use of a variant of the gem-dimethyl ketone fragment protected with 
two MOM groups (188, scheme 3.16) was briefly investigated. Use of 188 as the 
ketone would give rise to 189 after an aldol reaction with 160 (scheme 3.16). 
Subsequent global deprotection of the three MOM groups would give 191 and 
192 (scheme 3.17), which should be free to cyclise to give the pyranose ring 
fragment with syn- stereochemistry between C-7 and C-8. The oxidation-
epimerisation-reduction sequence described above would then be used to set the 
desired stereochemistry at those centres. 
 
3.5.1 Aldol reaction of 188 and subsequent protection of the hydroxyl group 
 
The gem-dimethyl ketone fragment 188 was prepared by Dr John Hoberg, 
following a procedure analogous to that used for the synthesis of 7. The aldol 
reaction between 188 and 160 proceeded in 38% yield, giving two diastereomers 
in 1:1 ratio. This yield is somewhat lower than the best yields obtained with 
fragment 7, however this reaction was only carried out once on a small scale. 
Due to the difficulties encountered previously with the methylation of 178, it was 
considered prudent not to attempt a methylation of the small supply of 189 in 
hand. Instead, 189 was acetylated in a 1:1 mixture of acetic anhydride:pyridine 
overnight at room temperature, to yield 190 in 80% yield. Fortuitously, the two 
resulting 7,8-syn- diastereomers were found to be separable on silica gel, and 
were independently characterised, although it was not possible to determine 
which of the isolated diastereomers was 190a and which was 190b.  
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Scheme 3.16. Aldol reaction of 188 and subsequent acetylation. 
 
3.5.2 Selective cleavage of the MOM ether 
 
In order to identify the best conditions for the cleavage of the MOM 
ethers of the aldol product, 189, alkene 158 was used as a model substrate. The 
objective was to cleave the MOM ether while retaining the silyl ether, hence to 
give alcohol B as the major product of the reaction (see table 3.2 overleaf). 
Surprisingly, removal of the MOM ether in preference to the TBDPS ether was 
not as straightforward as had been hoped. A wide range of both Brönsted and 
Lewis acidic conditions have been used for the cleavage of the MOM ether,76(d) 
and a number of these were tested, as summarised in table 3.2. 
 
The usual conditions for MOM ether removal, trace concentrated HCl in 
methanol, were found in this case to cause cleavage of the silyl ether even at 
room temperature. Although MOM ether cleavage with aqueous HCl has been 
reported at ice-cold temperatures,100 heating to 50 or 60 °C is often required for 
MOM ether cleavage under methanolic conditions. Hence it is not surprising that 
only traces of diol D (having lost both the TBDPS and MOM groups) were 
observed in the reaction mixtures at the point where all of the starting material 
was consumed (entries 1 and 2, table 3.2). Catalytic HCl in warmed iPrOH101 has 
been reported to cleave a MOM group in the presence of a secondary TIPS 
group. However in this case, although diol D was observed, the MOM ether was 
cleaved after the TBDPS had already been lost (entry 3). Using boron tribromide  
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Table 3.2. Attempts at selective cleavage of the MOM ether group of 158. 
TBDPSO
OMOM
TBDPSO
OH
HO
OMOM
+
A B C
HO
OH
D
A + +
(S)-158 (S)-12
  
 
 Entry                               Conditions      
 
 
Ratio of products 
A:B:C:D* 
1 0.05% HCl in MeOH, RT, 2 hr 0 : 0 : 1 : trace 
2 0.5% HCl in MeOH, RT, 0.5 hr 0 : 0 : 1 : trace 
3 0.05% HCl in iPrOH, 55 °C, 4 hr 0 : 0 : 1 : 1 
4 BBr3, CH2Cl2, -45 °C, 0.5 hr 1 : 0 : 1 : ? + other spots 
5 AcOH, cat. H2SO4, 10 °C, 0.5 hr 0 : 1 : 0 : 0 
6 AcOH, cat. H2SO4, 10 °C, 4 hr 0 : 1 : 0 : 10 
* Approximate ratios as determined by TLC analysis of the reaction mixtures.iv 
 
in CH2Cl2, conditions that are used for methyl ether cleavage (entry 4),76(e) the 
TBDPS ether was again cleaved, and significant other degradation also seemed 
to be taking place as evidenced by a number of unidentified spots appearing on 
the TLC. Again, the desired alcohol 12 was not observed. Finally, acetic acid 
with catalytic H2SO4102 was used to successfully cleave the MOM ether while 
retaining the TBDPS group (entry 5). Although extended reaction times did lead 
to the formation of the diol (entry 6), it was considered that TBDPS cleavage 
could be minimised by keeping the reaction cold, careful monitoring, and 
quenching after between 0.5 and 1 hours reaction time.  
 
3.5.3 Deprotection and Cyclisation of the tris-MOM-ether 190 
 
  Having established suitable conditions for the deprotection of the MOM 
ether, the cleavage of all three MOM groups of the acetylated aldol products 
190a and 190b was embarked upon. The planned synthesis involved deprotection 
of each diastereomer separately (scheme 3.17), followed by spontaneous 
cyclisation to give the pyranose ring systems 191 and 192. In the cyclic form, the 
                                                
iv
 Thanks go to Shivali Gulab for providing an authentic sample of alcohol C for TLC analysis. 
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configuration at C-7 and C-8 would be identifiable by NMR analysis, and hence 
191 could be identified and further elaborated as shown in scheme 3.17 to give 
193, which represents an analogue of the pyranose ring fragment 3 in the 
retrosynthesis presented in chapter one (page 14). Reduction of the ketone at C-8 
to the equatorial hydroxyl group would occur at a later stage in the synthesis. 
 
OTBDPS
OHOH
HO
O
AcO
OMOM
OTBDPSMOMO
O OAc
OMOM
OAcO
OTBDPS
OHOHHO
OMOM
OTBDPSMOMO
O OAc
OMOM
OAcO
OTBDPS
OOMeO
 Remove MOM
1) Methylate
2) Oxidise
+
Remove MOM
191 192
193
190b190a
 
Scheme 3.17. Deprotection of MOM ethers of 190, and further elaboration. 
 
However, when the compounds 190a and 190b were subjected to the 
conditions described above for the MOM ether cleavage, a higher Rf product was 
observed rather than the expected lower Rf product. The same product was 
observed in the reaction of both diastereomers, although in one case the spot was 
lost after workup (these reactions were only done on 12 and 14 mg scale). Hence, 
milder workup conditions were used after reaction of the second diastereomer, 
and in this case the product was isolated, albeit on small scale. Spectral analysis 
indicated that the three MOM ethers had certainly been cleaved, the acetyl group 
had been lost, and two molecules of water had been eliminated but the molecule 
had not cyclised in the desired manner. The likely identity of the high Rf product 
was 194 (scheme 3.18). As shown, one possible mechanism of formation of 194 
begins with loss of the primary MOM ether to give 195, subsequent nucleophilic 
attack at C-7 with acid-catalysed displacement of the OAc group to yield cyclic 
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molecule 196. Then, the remaining MOM ethers could also be cleaved to yield 
the diol 197, and finally one molecule of water eliminated as shown.  
 
OMOM
OTBDPSMOMO
O OAc
OMOM
190
OMOM
OTBDPS
OH
O
O
OMOM
O
H
195
H+
O
O
OTBDPS
OMOM
OMOM
196 197
O
O
OTBDPS
OH
O
O
OTBDPS
OH
O
H
H
H
AcOH, cat. H2SO4,
10 oC, 40 min
+
Loss of 1o 
MOM ether
+Loss of two 
2o MOM ethers
- H2O
-HOAc
194
 
Scheme 3.18. Unexpected product 194, and a possible mechanism of formation.
  
 
3.6 Discussion, conclusions and future work 
  
Although successful aldol reactions between ketone 8 and variants of 
aldehyde 7 have been achieved using LDA, as described in the previous sections, 
the resultant aldol product would lead to the undesired syn- relationship between 
C-7 and C-8 of peloruside A. Unfortunately, the aldol reaction conditions that 
were found to give anti- aldol products from reactions between ketone 8 and 
benzaldehyde did not give isolable aldol products when conducted with variants 
of aldehyde 7. 
 
The results obtained during this work have been echoed in the work of a 
post-doctoral fellow working in the same group on synthesis of analogues of 
peloruside A. A variety of aldol reactions were attempted between ketone 7 and 
an aldehyde similar to fragment 8. Again, only very limited success was 
obtained, and although the aldol reaction, to form 199, was successfully 
performed using LDA- and LiTMP- mediated aldol reaction conditions (scheme 
3.19), no other aldol reaction conditions were found to give satisfactory 
results.103 The aldol reaction conditions reported to give an anti aldol product 
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using similar substrates in Pagenkopf’s partial synthesis of peloruside A70 were 
found not to work here. 
.    
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Scheme 3.19. Aldol reactions between 7, 169 and aldehyde (S)-198. 
 
Why it should be that the aldol reaction with benzaldehyde and 7 
proceeds under a variety of conditions, while the aldol reaction between fragment 
8 and ketone 7 should be much less facile, may be explained by a combination of 
steric hindrance and -stacking. The generalised Z enolate of 7, 7a, is reasonably 
sterically crowded because of the gem-dimethyl groups and the benzyl group. 
Hence, approach of an aldehyde might be hindered. However, in the case of 
benzaldehyde, the incoming phenyl 
group could exhibit -stacking with 
the phenyl group of the benzyl moiety 
(figure 3.5), hence bringing the 
aldehyde into closer proximity. As the 
aldehyde also coordinates with the 
metal of the enolate, the aldol reaction 
can then take place. 
 
Even in the case of benzaldehyde, the sterically hindered nature of the 
system was suggested by the observation that the aldol reaction did not take 
place when the larger Ipc ligands (rather than Cy), were present. The O-B bond 
Figure 3.5. Enolate 7a with -stacking 
of two aromatic groups. 
BnO O
O
M
H
O
H
pi-stacking of 
phenyl rings
7a with benzaldehyde approaching
    (before transition state forms)
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distances are largely covalent in character, and shorter than the O-Li bond 
distance, leading to a more compact transition state for boron, which magnifies 
any steric interactions that may inhibit or control reactivity.88(c) Titanium enolates 
are intermediate in structural character between the largely ionic lithium enolates 
and the largely covalent boron enolates.88(d) This may be why the LDA aldol 
reaction of 7 with variants of fragment 8 was viable while the boron and 
titanium-mediated aldol reactions were not. 
 
It is worth noting at this point that Pagenkopf’s group had a great deal of 
difficulty finding suitable aldol reaction conditions for their formation of the C-7 
to C-8 bond (refer chapter one, page 40). They were happy to accept a modest 
diastereomeric ratio of 3.5:1 for the aldol reaction with their C-8 to C-12 ketone 
131 (scheme 1.36, chapter one). Comparing fragment 131 to fragment 7, the 
major difference is that 131 lacks the benzyloxy group - to the ketone as found 
in 7. The lack of reactivity of enolates of 7 observed in this work may partially 
result from coordination of metal of the enolate (7a) to the benzyloxy oxygen, to 
form a conformationally stable six-membered ring (figure 3.6). The gem-
dimethyl groups may be blocking the attack of the aldehyde onto the enolate, and 
the stability of the six-membered ring formation may to some degree reduce the 
tendency of the enolate to react with nucleophiles. Coordination of the metal to 
give the five membered ring shown in figure 3.6 is also possible, in which case 
the reactivity of the enolate would also be reduced by the increased electron 
density at C-8, due to the inductive effect. However this conformation is also 
available to 131 and hence does not specifically explain the lack of reactivity of 
the enolate of ketone 7. 
BnO OBn
O
OBn
O O
OBn
O
M
H
Ph
BnO
O
O M
H
Ph
131 7
Coordination of metal in enolate 7a
8
 
Figure 3.6. Pagenkopf’s C-12 to C-8 fragment, 131, fragment 7, enolate 7a. 
 
The overall conclusion of the work done towards the aldol reaction 
between 7 and 8, therefore, is that it is difficult to perform an aldol reaction with 
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ketone 7, and particularly that the likelihood of effecting a preparatively useful 
anti- aldol reaction using fragments 7 and 8 is slim. Although the alternative 
strategy for progressing the LDA aldol products may still yield a possible 
solution to the overall goal of forming the pyranose ring fragment, 3, and 
ultimately to completing the total synthesis of peloruside A, considerable 
difficulties have been experienced working with products from the LDA aldol 
reaction such as 28 and 178. Hence, a new strategy is now being pursued in the 
group for the preparation of the C-1 to C-11 portion of peloruside A, with the 
approach of using chiral auxiliaries such as Evan’s oxazolidinone (as proposed in 
chapter one for the introduction of the C-1 to C-2 fragment) to set the crucial 
stereochemistry in the C-5 to C-9 region.104 
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Chapter Four 
 
The Inositols; Isomers, Biology and Functionalisation 
 
 
This chapter is a prelude to the work described in the following chapters 
towards the functionalisation of inositols, as precursors to natural products and 
potentially bioactive compounds. Following an introduction to inositols, a brief 
overview of their biological significance and ubiquity will be given. This will 
establish the importance of synthetically useful and varied inositol precursors. 
The work presented in this thesis covers two broad areas of inositol chemistry: 
a) the use of quebrachitol as a synthetic precursor (chapter five); and b) the 
resolution of myo-inositol derivatives (chapters six and seven). A discussion of 
relevant literature in each of these areas will conclude this chapter. 
 
 
4.1 The Inositols  
 
When Scherer isolated an optically inactive cyclohexanehexol from 
muscle tissue extract in 1850,105 he gave it the name ‘inosit’. With the addition of 
the suffix –ol, this has become the generic term for the nine isomeric inositols, 
shown in figure 4.1. The naming and numbering of the inositols is a complex 
problem that has caused confusion in the past, although this has been ameliorated 
since the publication of the ‘IUPAC/IUB Tentative Rules for Cyclitols’ in 1967, 
and further by the ‘IUPAC Nomenclature of Cyclitols’ published in 1976.106 
Though classed as members of the carbohydrate family,i the inositols are 
significantly different from the more widely known sugars such as glucose, 
mannose, and galactose. This difference lies primarily in their six-membered all-
carbon ring structure, which necessarily precludes the presence of a carbonyl 
group, of an open-chain form, and therefore of anomeric reactions. All of the 
hydroxyl groups on the inositol ring are secondary.  
 
                                                
i
 Inositols are classed as carbohydrates because they conform to the general formula Cn(H2O)n. 
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Figure 4.1. The nine isomeric inositols. 
  
Six of the nine inositol isomers are present in nature: myo-, scyllo-, 
L-chiro-, D-chiro-, neo- and muco- (the latter two only in trace amounts). Myo-
inositol is found in the cells of almost all living organisms and hence is the most 
widely occurring of the nine inositols, and is also the cheapest at less than 50 
cents per gram.ii It is required by all animals for the synthesis of phospholipids, 
which play vital roles in intracellular signalling.107 It is also found in plants, for 
example as the methyl ethers sequoyitol (5-O-methyl-myo-inositol) and ononitol 
(1-D-4-O-methyl-myo-inositol, which is a biological precursor to D-pinitol). 
Phytic acid (myo-inositol hexaphosphate), is widely found in cereals and legumes 
and is associated with dietary fibre. Myo-inositol for sale and use is generally 
derived from the hexaphosphate, isolated from corn starch liquor or sugar cane 
liquor. Phytic acid and myo-inositol containing phospholipids from both plant 
and animal sources constitute the major sources of dietary myo-inositol, and are 
so ubiquitous that myo-inositol intake in the average diet is approximately one 
gram daily. Humans are also able to synthesise myo-inositol endogenously, from 
glucose.108 Myo-inositol is sometimes referred to as a vitamin, and although this 
is not the case, the levels of dietary myo-inositol can influence the levels of 
circulating and bound myo-inositol in the body. One of the deoxygenated 
                                                
ii
 At the time of this work, myo-inositol was available for $105 per 250 g from Scientific supplies 
in New Zealand. It was also available from Aldrich for AU$59.50 per 100 g (evidently not the 
cheapest source). For comparison, Aldrich prices for some other inositols and inositol derivatives 
follow: quebrachitol, AU$200.80 per 1 g; pinitol, AU$63.30 per 500 mg; D- or L-chiro-inositol, 
AU$276.20 per 1 g; allo-inositol, AU$227.70 per 100 mg; muco-inositol, AU$185.90 per 100 
mg; neo-inositol, AU$255.60 per 100 mg.   
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derivatives of myo-inositol, 1-D-3-deoxy-myo-inositol (D-viburnitol, figure 4.2) is 
also found in a number of plant species.  
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Figure 4.2. Some naturally occurring inositol derivatives. 
 
Scyllo-inositol has been isolated from mammals, plants, sharks and 
several species of insect. It occurs in mammalian urine, where it is thought to be 
a metabolite of myo-inositol. L-chiro- and D-chiro-inositols are found in plants 
both as the free inositols and as derivatives thereof, significantly as the methyl 
ethers L-quebrachitol and D-pinitol respectively (figure 4.2). Both are readily 
demethylated to give the parent inositols.109 Quebrachitol (2-O-methyl-L-chiro-
inositol) is extracted from rubber serum as a by-product of the rubber processing 
industry, and is available for sale from the Rubber Research Institute of 
Malaysia. Pinitol (3-O-methyl-D-chiro-inositol) is isolated in New Zealand from 
pine trees and may be purchased from New Zealand Pharmaceuticals. Epi-, allo-, 
and cis-inositols, not found in nature, have been synthetically prepared.110  
 
 
4.2 Biological Significance of the Inositols 
 
As is evident from the brief survey of the inositols given above, these 
molecules are ubiquitous in nature and important to all living organisms. Myo-
inositol, in particular, is a key component of many organisms. It is vital in cell 
signalling molecules (inositol phospholipids) in all eukaryotic cells, and is an 
important component of cell surface molecules essential to the function of many 
microorganisms. These biological functions will be introduced in the following 
sections. Recognition of the important role of the inositols has been the catalyst 
for synthetic chemists’ attention to the preparation of inositol derivatives. 
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4.2.1 Inositol phospholipids and cell signalling processes 
 
In order to place the importance of the inositol phospholipids in context, a 
brief overview of cell signalling processes will be presented here. Cells in 
multicellular organisms convey signals to each other by way of substances such 
as hormones and neurotransmitters. For signal transmission to occur, the 
‘message’ must cross the cell surface membrane, and this is done in a number of 
ways (see figure 4.3).111 Some of the signalling substances are able to pass 
through the lipid bilayer into the cell and bind directly to their target receptors. 
Many, however are too hydrophilic to cross the membrane. In this case, some 
form of signal transduction across the cell membrane is required. The chemical 
messengers are received by receptors located on the surface of the cell and their 
message passed into the cell by way of one of the following mechanisms: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Signal transduction mechanisms.111 
 
A. Receptors that are linked to an ion channel which spans the membrane. 
These receptors are specific for a particular ion. Stimulation of the receptor can 
trigger the influx or efflux of ions from the cell, and the resultant change of ion 
concentration in the cytosol activates enzymes within the cell. 
 
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B. Membrane-spanning enzymes called tyrosine kinases, which have 
receptor sites on the outside of the cell and an active site on the inner surface of 
the membrane. When the binding of a chemical messenger stimulates the 
receptor site, the enzyme phosphorylates tyrosine residues on target proteins 
within the cell. This mechanism is used by many growth factors and by 
hormones such as insulin. 
 
C. A receptor (which has no intrinsic membrane spanning function) is 
‘coupled’ to a membrane-bound GTP-binding protein (‘G-protein’). The family 
of G-proteins includes several members that regulate different intracellular 
pathways. Upon activation of the receptor, the G-protein releases guanosine 
diphosphate (GDP) from its  subunit and binds guanosine triphosphate (GTP) in 
its place. The  subunit is then released, which stimulates or inhibits the activity 
of the ion channel or enzyme that is the next ‘link’ in the chain. In the case of an 
enzyme, so-called ‘second messenger’ species are generated or released within 
the cell. The subsequent change in intracellular levels of second messengers 
produces an observed overall cellular response. Finally, the  subunit hydrolyses 
the GTP to GDP (it has intrinsic GTPase activity), the  subunit recombines 
with the  subunit, and the G-protein returns to its basal state. The classic 
example of this type of receptor system produces the second messenger cyclic 
adenosine monophosphate (cAMP) from adenosine triphosphate (ATP) via the 
G-protein regulated enzyme adenylate cyclase.  
  
It had long been known that inositol-containing phospholipids were 
present in mammalian tissues, and it was suggested that they played a role in 
stimulus-response coupling. In the late 1950’s emergent analytical techniques 
allowed the separation and elucidation of the structures of phosphatidylinositol 
(PtdIns), phosphatidylinositol-4-phosphate [PtdIns(4)P], and phosphatidyl-
inositol-4,5-bisphosphate [PtdIns(4,5)P2].112 However their physiological 
significance remained something of a mystery until in 1975 Michell suggested 
that the receptor-controlled hydrolysis of inositol phospholipids could be directly 
linked to the levels of Ca2+ (which had been identified as being linked to a variety 
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of cellular processes) within cells.113 In 1983, Berridge and co-workers identified 
the chemical link between these two events as the second messenger, myo-
inositol-1,4,5-triphosphate [Ins(1,4,5)P3].114 It is now known that the receptor-
stimulated hydrolysis of PtdIns(4,5)P2 occurs via a G-protein controlled enzyme, 
phospholipase C (PLC). Two second messengers are released, diacylglycerol 
(DAG) and Ins(1,4,5)P3. The former binds to and activates protein kinase C, and 
also acts as a precursor to the metabolites of the arachidonic acid cascade. The 
latter binds to receptors of Ca2+ channels on the endoplasmic reticulum resulting 
in the release of Ca2+ from an intracellular store.111 
 
Complex metabolic pathways exist for the conversion of Ins(1,4,5)P3 
back to free myo-inositol, which is used for the resynthesis of PtdIns(4,5)P2. 
Higher phosphates [Ins(1,3,4,5)P4,115 InsP6 and even the pyrophosphate-
containing InsP7 and InsP8] and lower phosphates [Ins(1,4)P2, Ins(1,3)P2, 
Ins(3,4)P2, Ins(4)P, and other inositol monophosphates] have been identified as 
part of these pathways. Other phospholipids have also been identified, for 
example PtdIns(3)P, PtdIns(3,4)P2, PtdIns(3,4,5)P3 and Ins(1,3,4,5)P4, which 
may be second messengers in their own right.107,111  
 
The complexity of the inositol-phosphate cycle, and the significance of 
these molecules to cellular processes, has generated intense interest in this area 
of biology in the last two decades. Hand in hand with this has been the synthesis 
of the inositol derivatives, and many laboratories have provided synthetic 
methodology to this end. Pharmacological intervention in the phosphoinositide 
signalling system seems a logical extension of this work, with potential targets 
for logical drug design being found in the receptors that bind the second 
messengers, in the complex metabolic pathways, and in the biosynthetic 
pathways that generate the functionalised inositol moieties. Hence, synthesis of 
modified inositol phosphates with new biological properties is also underway. 
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4.2.2 Glycosylphosphatidylinositol  
 
There are many proteins, with a myriad of functions, attached to 
biological membranes. Some are embedded directly into the lipid bilayer (via a 
hydrophobic portion of their structure), while many are attached to intermediary 
structures, which anchor them to the membrane. It has been shown that many of 
these proteins (and also glycoproteins) are covalently bonded (through the C-
terminal amino acid of the protein) to phosphatidylinositol anchors via an 
intervening glycan structure. These anchor structures are known as glycosylphos-
phatidylinositols (GPI’s). Ferguson et al. reported the first structure of a GPI in 
1988,116 that of the GPI anchor of the variant surface glycoprotein of the parasitic 
protozoan that causes sleeping sickness, Trypanosoma brucei (figure 4.4).  
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Figure 4.4. Structure of the GPI anchor of Trypanosoma brucei.116 
 
Shortly thereafter, the structures for the GPI anchors of rat-brain Thy-1 
glycoprotein117 and human erythrocyte acetylcholinesterase118 were reported. 
Based on these, and upon the many subsequent reports of GPI anchors from 
various eukaryotes, a general GPI structure has been elucidated, shown in figure 
4.5. The general structure appears to have been conserved in the evolutionary 
process, although there may be species-specific additional carbohydrate side 
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chains (at R1 and/or R2), and there are variations in the membrane-anchoring 
lipid structures depending on species and on cell type.  
 
  
 
 
 
 
Figure 4.5. General structure of a GPI. 
 
The GPI anchors of membrane proteins are found in all eukaryotes, 
although in higher eukaryotes only a minority of surface proteins are anchored in 
this manner. There is evidence however that GPI-anchored proteins are involved 
in specific tasks related to multicellular existence; they have been studied in their 
roles as enzymes, in interactions with bioactive factors, and in cell-cell 
recognition processes. More recently, there have been reports that metabolites 
derived from GPI anchors themselves, or from structurally related compounds, 
are mediators of regulatory processes. For instance, GPI fragments are thought to 
be involved in the signal transduction process triggered by insulin.119  
 
In the protozoa, GPI anchors are much more prevalent, and are the most 
common form of surface protein anchorage. The protozoan parasites that are 
responsible for certain devastating diseases exhibit unusually high levels of GPI-
anchored variant surface glycoproteins (VSG)’s on their surface. As well as 
Trypanosoma brucei (sleeping sickness) these include Plasmodium (malaria), 
Trypanosoma cruzi (Chagas disease) and Leishmania species (leishmaniasis). 
The VSG’s are arranged in tightly packed monolayers and form a barrier, 
protecting the parasite from lytic factors in the host serum. Thus, the integrity of 
their cell-surface coat is essential to the parasite for survival. By expressing 
different VSG’s at different times, the parasite is able to evade the host’s immune 
response, by making it difficult for the host to supply the matching antibodies at 
the right time. A consequence of this behaviour is that drugs targetted against 
specific VSG’s are rendered ineffectual. However, drugs that target the 
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biosynthesis of the GPI anchor, or drugs that target species-specific features of 
the GPI anchor (for example, in the case of the VSG GPI isolated from 
Trypanosoma brucei, the -galactose side chain seems to be parasite-specific) 
could prove successful.  
 
The treatments currently available for the diseases caused by the parasites 
mentioned above are far from satisfactory. Over the last decade work has been 
undertaken to elucidate the biosynthesis of the GPI anchors, and a biosynthetic 
pathway starting from phosphatidylinositol120,121 has been generally accepted. 
Much work is currently being undertaken focussing on the biosynthetic 
intermediates and enzymes involved, in particular focussing on any species 
dependent specificity that might reveal a possible drug target.  
 
Synthetic efforts towards the generalised GPI and related structures have 
been underway since the biological significance of these molecules was first 
discovered. The first total synthesis of the Trypanosoma brucei VSG GPI was 
reported in 1992122 by Murakata and Ogawa. Other total syntheses of this GPI,123 
and syntheses of other GPIs have appeared since, as well as syntheses of labelled 
GPI structures and of intermediates in the biosynthetic pathway. 
 
4.2.3 Lipoglycan cell surface structures related to GPIs 
 
A number of protein-free GPI structures, that are not involved in protein 
anchoring are also prevalent on the surface of protozoan parasites.120 These 
include the lipophosphoglycans (LPGs), and the glycoinositolphospholipids 
(GIPLs) isolated from Leishmania species. Interestingly, there is marked 
difference in the size of the LPGs and GIPLs, and in the nature of the side chains 
that are present, in the different developmental stages of the parasite. Certain 
LPG-deficient strains of Leishmania are unable to survive in the sandfly vector, 
or to infect the mammalian host, indicating that the LPG is essential to the 
virulence of the parasite.120  
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Another related class of lipoglycans are the lipoarabinomannan (LAM) 
structures. These are restricted to the mycobacteria, and are cell surface 
molecules that modulate the function of the immune system of the host.124 The 
LAM structure has a carbohydrate backbone, which consists of a D-mannan core 
and a D-arabinan domain. The mannan core is terminated at one end by a GPI 
anchor, and the arabinan domain is capped by mannosyl (the Man-LAMs) or 
phosphoinositide (the PI-LAMs) residues.124 The Man-LAM has been shown to 
bind to immature dendritic cells, which normally play a crucial role in the 
immune response against pathogens. The LAM allows the mycobacteria to 
interfere with the normal function of the dendritic cells and hence evade the 
immune response of the host, and it is therefore important to the bacteria’s 
survival. In the purification of lipoarabinomannans, three clear size classes of 
lipoglycan are seen, being the LAM, lipomannan (LM) and phosphatidylinositol 
manno-oligosaccharides (PIMs). The LAM and LM appear to be based on the 
PIM ‘core’ motif, and hence the PIM structures are important in gaining an 
understanding of the biosynthesis of LAMs. 
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Figure 4.6. PIM-6 isolated from Mycobacterium bovis and M. smegmatis.127 
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A series of glycerol phosphatidylinositol di-, tri- tetra- and penta-manno- 
oligosaccharides (PIM-2, PIM-3, PIM-4 and PIM-5 respectively) were the first 
PIM structures isolated, from Mycobacterium bovis strain BCG,125 M. 
tuberculosis, and M. phlei.126 An NMR-based method for the identification of the 
structure of PIM-6 (figure 4.6) was described by Severn et al.,127 who also 
reported a method for O-deacylation and isolation of the size classes (utilising 
size-exclusion chromatography) within PIM. Hence, the deacylated version of 
the PIM-6 molecule in figure 4.6, and also PIM-2, were isolated from M. bovis 
AN5 and Wag201, and from M. smegmatis mc2 155.127 In that report, it was not 
specified whether the myo-inositol core had the L- (as shown in structure 206, 
figure 4.6) or the D- (as shown in 207) configuration, although it was suggested 
that the L-configuration might be correct.128 However, it is notable that the 
inositol core of the related GPI structures such as that shown in figure 4.4 has a 
substitution pattern equivalent to a D- configured myo-inositol core in PIM. It is 
reasonable to presume that this would be conserved. More recent reports have 
established that the 1D-myo-inositol core is a basic structural feature of both 
LAM and PIM,129 with a biosynthetic pathway existing in which LAM is formed 
from PIM, which in turn is formed from PI (phospatidyl-myo-inositol).129(b)  
 
 
4.3 Synthetic Plan for the 1L-myo-Inositol Core of the PIM-6 Molecule  
 
The original driver for the work done towards the functionalisation of 
quebrachitol presented in this thesis, was a planned total synthesis of the PIM-6 
molecule shown in figure 4.6. It was decided to synthesise the PIM-6 molecule 
with the 1L-myo-inositol core as shown in figure 4.6, as even though at the time 
of planning it was not clear whether L- or D- was the natural configuration, 
having access to both structures would be useful in the evaluation of the 
biological roles of these molecules.  
 
The synthesis of the carbohydrate backbone was envisaged from just 
three building blocks, shown in the box in figure 4.6 – the C-2 acceptor 208, the 
C-6 acceptor 209, and the inositol core 210. The retrosynthetic plan incorporated 
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the unusual approach of using quebrachitol (rather than myo-inositol) as a 
starting point for the core inositol moiety. Unfortunately, this total synthesis 
project had to be discontinued approximately twelve months into the PhD 
program. Fortunately, the quebrachitol functionalisation work itself had given 
some interesting results, and several mono- and di- substituted L-chiro-inositol 
derivatives were prepared from quebrachitol, and tested against myo-inositol (the 
optimal substrate) in uptake assays of two micro-organisms, Candida albicans 
and Leishmania donovani. All of this work is described in chapter five, while the 
original synthetic plan for the preparation of suitably protected inositol core in 
the synthesis of PIM-6 is presented here. 
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Scheme 4.1. Planned synthesis of suitably protected inositol core for PIM-6. 
 
The triol 212 (scheme 4.1 above) was a key intermediate in the synthetic 
plan. According to literature reports, this molecule is available in three steps 
from quebrachitol; first, formation of the quebrachitol dicyclohexylidene 
acetal,130,131 subsequent protection of the free axial hydroxyl group to give 
211,132 and then a selective AlCl3-mediated dual cleavage of the trans-acetal and 
the methyl ether to yield the triol, in a reported yield of 75%.133,134 The three 
hydroxyl groups, which would become the three free hydroxyl groups of the 
inositol core of PIM-6, would then be protected with a suitable protecting group 
such as the benzyl ether. Then, the rest of the inositol core would be prepared. 
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Acid-catalysed cleavage of the cis-acetal reveals a differentiable pair of hydroxyl 
groups. Selective protection of the equatorial hydroxyl group should be possible 
because the axial position is sterically disfavoured by 1,3-diaxial interactions 
with the axial ring protons (if this is not successful, Sn-acetal mediated 
protection of one of the hydroxyl groups is another option). Inversion of the 
stereochemistry at the free hydroxyl of 214 is then required, which could be 
achieved via a Mitsunobu reaction (e.g. with EtOCON=NCOOEt, PPh3, and 
RCOOH) to give 215. Alternatively, conversion of the hydroxyl group in 214 to 
a good leaving group (triflate or mesylate) and subsequent SN2 displacement with 
a nucleophile,135 or an oxidation-reduction sequence, forming the more 
thermodynamically favourable equatorial hydroxyl135 could be used. Suitable 
protection of the resulting hydroxyl would give the target 210, orthogonally 
protected at O-2, O-3 and O-4, ready for deprotection at those positions and 
introduction of the single mannose residue (at O-2), the phospholipid (at O-3) 
and the mannose chain (at O-4).    
 
 The preparation of the mannose building blocks was envisaged from 
formation of allyl mannoside, then a combination of selective protecton of the 
primary (O-6) hydroxyl group with TBDMSCl, and protection at O-3 and O-4 
with the butane-bis acetal (BBA) protecting group to give the O-2 donor 208. 
Subsequent protection, for example benzyl ether formation, and removal of the 
TBDMS group would yield the C-6 donor 209. Imidate coupling methodology 
was planned both for coupling of the mannose residues, and their linkage to the 
inositol core. Due to the abandonment of this total synthesis project however, this 
work is not discussed further in this thesis. 
 
 
4.4 Quebrachitol as a Synthetic Precursor from the Chiral Pool 
 
4.4.1 Quebrachitol 
 
L-Quebrachitol (figure 4.2), a natural L-chiro-inositol derivative, occurs 
in eleven different families of dicotyledons. It was first reported in 1889 by 
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Tanret, who isolated it from the bark of Aspidosperma quebracho.136 Although it 
is found in many plant species, including in mistletoe (unusually, together with 
its isomer D-pinitol), it occurs in notably high concentrations in the rubber tree 
Hevea brasiliensis and therefore is isolated as a by-product from the rubber 
industry. Quebrachitol’s ready availability and unique carbon framework make it 
a useful addition to the chiral pool of starting materials for organic chemists to 
use, particularly in the synthesis of polyhydroxylated natural products. A 
laboratory method for the isolation of L-quebrachitol was published in 1951,137 
although patents for its isolation were held before that date. However 
L-quebrachitol did not find widespread synthetic use until several decades later. 
 
4.4.2 Quebrachitol as a synthetic precursor 
 
Many groups have contributed synthetic work using L-quebrachitol. The 
groups of Ogawa, Ozaki and Angyal have been particularly active in this area. 
The first reported synthesis of a natural product from L-quebrachitol was a short, 
practical route to L-mannitol, then unknown in nature, in 1963.138 Since then 
L-quebrachitol has been used as a starting point for the synthesis of other 
inositols and inositol derivatives (see below for examples), other carbohydrates, a 
number of inositol phosphates and related structures (see examples below), and 
numerous other natural and potentially bioactive products including 
(-)-conduritol F,139,140 (+)-conduritol B,140 cyclophellitol,140 and (-)-ovalicin.141 
The following examples are intended to give an idea of the range of related 
structures that have been prepared from L-quebrachitol, rather than a 
comprehensive overview. A review has been published covering the use of 
quebrachitol as a precursor to naturally occurring bioactive materials (other than 
other inositols and analogues thereof).142 
 
Inositols and inositol derivatives 
 
Some examples of inositols and inositol derivatives prepared from L-
quebrachitol (figure 4.7 overleaf) include muco-inositol,143 1D-2-deoxy-2-fluoro-
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chiro-inositol 216,144 the azido and amino derivatives 217 and 218,145 and 1L-
1,2-anhydro-myo-inositol 219.146  
muco-inositol
OH
OH
HO
OH OH
HO
216
F
OHHO
HO OH
OH
OH
OHN3
HO
OMe
N3 HO
OH
HO
OHO
OH
OH
RHN
HO
OMeOH
217 218 219
 
Figure 4.7. Some inositols and inositol derivatives prepared from L-quebrachitol 
 
Myo-inositol phosphates and related structures 
 
A number of examples of myo-inositol phosphates and analogues derived 
from L-quebrachitol are shown in figure 4.8. Akiyama’s group published one of 
the early syntheses of a myo-inositol phosphate, D-myo-inositol-1-phosphate 
(220).135,147 The L-chiro-inositol derivative 221, L-chiro-inositol-2,3,5-
trisphosphate, was synthesised by Potter’s group and shown to be an inhibitor of 
the enzymes of Ins(1,4,5)P3 metabolism. Similarly, the compound 3-deoxy-3-
fluoro-D-myo-inositol-1,4-bisphosphate-5-phosphorothioate (222), along with 
two isomers (synthesised by another group) were also shown to be inhibitors.149 
The trisphosphorothioate 223 has also been prepared.150 Deoxy-inositol 
analogues have also been prepared from L-quebrachitol; for example D-3-deoxy-
3-phosphonomethyl-myo-inositol 224,151 which was shown to inhibit the growth 
of NIH 3T3 cancer cells at millimolar concentration, and what was claimed to be 
the first novel PI analogue, 1D-3,4-dideoxy-phosphatidylinositol ether lipid 
(225)152 which was found to block a cellular signalling pathway that has the 
ability to repress apoptosis in cancer cells. 
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Figure 4.8. Examples of myo-inositol phosphates and analogues. 
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4.5 The Formation of Chiral Myo-inositol Derivatives 
 
4.5.1 Myo-inositol 
 
Being the most abundant inositol 
found in nature, myo-inositol is also the 
cheapest of the commercially available 
inositols, priced at less than 50 cents per 
gram. Hence it is also the logical starting 
point for syntheses of the various inositol 
phospholipids, GPI’s, and related structures. 
Myo-inositol has a single axial hydroxyl at O-
2 and a plane of symmetry between O-2 and O-5 (figure 4.9). Hence, myo-
inositol itself is an optically inactive, meso- compound. Substitution at O-2 
and/or O-5 leads to derivatives in which the plane of symmetry is retained. 
Substitution at O-1 (enantiotopic to O-3) and/or O-4 (enantiotopic to O-6) breaks 
the plane of symmetry and hence gives rise to a pair of enantiomers. Every 
example of naturally occurring myo-inositol derivatives (inositol phospholipids, 
GPI’s, and related structures), is optically active, and hence their preparation 
requires methods for the obtention of single enantiomer chiral derivatives of 
myo-inositol. 
 
4.5.2 The Preparation of Chiral Myo-inositol Derivatives  
 
The preparation of chiral myo-inositol derivatives, including the myo-
inositol phosphates and any number of other structures, is imperative for the 
study of the biological processes described above. It also represents a synthetic 
challenge in itself for the organic chemist. Chiral myo-inositol derivatives have 
been obtained by a variety of different methods, which are summarised in figure 
4.10 below. Illustrative examples of each of these routes are presented in the 
following sections. 
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Figure 4.9. Myo-inositol. 
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Figure 4.10. Sources of chiral myo-inositol derivatives. 
 
Synthesis from natural myo-inositol derivatives 
 
Phytic acid has been used as a starting material for the preparation of 
(+)-D-1,2-O-isopropylidene-myo-inositol (228) and (-)-D-3,4,5-tri-O-benzyl-myo-
inositol (229), two key intermediates in the synthesis of optically active myo-
inositol derivatives. Phytic acid was treated with Baker’s yeast (scheme 4.2) 
which contains phosphatases that selectively hydrolyse phosphates at O-3, O-4, 
and O-5 to give 226.153 Further elaboration gave the common intermediate 227, 
which was subsequently converted to either 228 or 229.153(b)  
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Scheme 4.2. Synthesis of 228 and 229 from naturally occurring phytic acid. 
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Synthesis from other carbohydrates using the Ferrier Rearrangement 
 
A number of groups have utilised Ferrier rearrangements as the basis for 
synthesis of all of the inositol isomers, including myo-inositol. This has been 
achieved from glucose, galactose and mannose substrates using a Pd(II)-
mediated Ferrier reaction,154(a),(b) or with an HgCl2 or Hg(OAc)2 mediated Ferrier 
reaction.154(c),(d) For example, the rearrangement of 231 (synthesised in four steps 
from methyl--D-galactopyranoside (230)), gave 232b (along with 232a) which 
was further elaborated to give 1D-6-deoxy-myo-inositol, 233 (scheme 4.3).154(c)  
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Scheme 4.3. Synthesis of 1D-6-deoxy-myo-inositol via Ferrier rearrangement. 
 
Synthesis from Bromobenzene (the Hudlicky route)  
 
Hudlicky et al. have prepared a range of inositols and inositol derivatives 
from bromocyclohexadiene cis-diol (235, scheme 4.4, overleaf), obtained by 
microbial oxidation of bromobenzene (234). These include syntheses of neo-
inositol,155(b) L-chiro- and muco-inositols,155(c) and allo-inositol.110(b) The 
synthesis of the myo-inositol derivative 5-deoxy-5-fluoro-myo-inositol, 239 
(along with a deoxyfluoro-L-chiro-inositol) has also been reported using this 
approach.155(a) As shown in scheme 4.4, the oxidation of bromobenzene was 
accomplished in this case using P. putida (39D) strain. The synthesis is fairly 
lengthy, but although the final product 239 is a meso-compound (like myo-
inositol itself), the precursor 238 is a chiral myo-inositol derivative and could be 
further elaborated before deprotection of the acetonide.  
 105 
O
OPO3H-HO
OPO3H-
-HO3PO OH
O
H2N
240
 
Br
234
TBPF-DF
238
O
OHO
OH
F
OH
235
Br
OH
OH
236
Br
O
OO
239
OH
OHHO
OH
F
OH HO
HO F
OH
OH
OH
237
O
OHO
O
OH
P. putida (39D) 3 steps2 steps
110 oC, 50%
HCl, H2O
quant.
 
Scheme 4.4. Synthesis of a myo-inositol derivative from bromobenzene. 
 
Chiral Chromatography 
 
In many cases, chiral chromatographic methods are used for separation of 
enantiomers of myo-inositol derivatives, often at the end of the synthesis. The 
chromatographic methods employed include chiral HPLC,156 chiral GC, and 
affinity chromatography. For example, Ozaki et al.157 
reported the successful separation of the enantiomers of 
240 (right) by affinity chromatography in 1992, as part of 
their studies of the synthesis and biological properties of 
2-substituted myo-inositol-1,4,5-trisphosphate analogues.  
 
Although it may sometimes be useful to prepare both enantiomers, 
usually only one is required and therefore 50% of the material is essentially 
wasted. Also, the practical difficulties (and the cost) of large-scale chiral 
chromatography make this an unfavourable method for the preparation of chiral 
myo-inositol derivatives on larger scale. 
 
Enzymatic Resolution 
 
Enzyme-mediated esterification and hydrolysis have both been used to 
resolve racemic mixtures of myo-inositol derivatives. Ling and Ozaki effected a 
kinetic resolution of 2,3-O-cyclohexylidene-myo-inositol (DL-241) by enzymatic 
esterification using the Pseudomonas lipases in organic solvent (scheme 4.5).132  
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L-241DL-241
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+
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Scheme 4.5. Example of enzyme-mediated esterification.  
 
The 1-acetylated product 242 and the optically pure L-241 were obtained 
in 49% yield each after separation by column chromatography. The enzyme 
could be reused after reactivation by hydration.  
 
Similarly, enzymatic hydrolysis is also used effectively to resolve myo-
inositol derivatives, as for example by Liu and Chen158 in their synthesis of 
optically active D-myo-inositol 1,4,5-triphosphate (scheme 4.6). They used 
cholesterol esterase to obtain 244 and 245, which were separated by flash 
chromatography. 
O
O
O
OAc
O OAc
DL-243
O
O
O
OH
O OAc
244 245
O
O
O
HO
OHO
Cholesterol esterase
1 g scale +
 
Scheme 4.6. Example of enzymatic hydrolysis. 
 
Formation and Separation of Diastereomers of Myo-inositol derivatives 
 
 A widely used method for the preparation of chiral myo-inositol 
derivatives is the formation and separation of diastereomers of racemic myo-
inositol derivatives with a chirally pure reagent (scheme 4.7). Usually a 
diastereomeric pair is formed in a 1:1 ratio. The two diastereomers are then 
separated by crystallisation or chromatography. In order to maximise the 
efficiency of the synthesis, this resolution step should take place as close to the 
beginning of the synthesis as possible i.e. a minimum number of synthetic steps 
from myo-inositol. In a few cases, which are discussed below, the derivatisation 
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favours the formation of one diastereomer over the other. The ideal case, in 
which only one diastereomer is formed in 100% yield from myo-inositol, has not 
yet been realised in practise. 
OH
(RO)5
X R* OR*
(RO)5
R*O
(OR)5
+
OR*
(RO)5
R*O
(OR)5
HO
(OR)5
OH
(RO)5
and
Separated 
enantiomeric 
myo-inositol 
derivatives
Racemic
myo-inositol 
derivative
Diastereomeric derivatives
R*=chiral group
remove R*
separate
Scheme 4.7. Resolution by formation and separation of diastereomers. 
 
Many different chiral groups (R* in scheme 4.7) have been used for the 
derivatisation, including menthyl, menthoxyacetyl, camphanate and mandelate 
esters, the bis-dihydropyran reagents, and camphanylide acetals. Examples of the 
use of different chiral (R*) groups will be given below.   
 
Schmidt et al. used a single diastereomer of a menthyl ester derivative of 
myo-inositol as a starting material in their 1992 synthesis159 of a GPI anchor of 
yeast. In another example, Liu and Chen158 successfully separated the two 
diastereomers of the di-L-menthyl carbonate 246 (scheme 4.8) by flash column 
chromatography. They obtained excellent yields of both diastereomers. 
O
O
O
OH
O OH
DL-245
O
O
O
Omenth
O Omenth
O
O
menth =
A pair of diastereomers
O
O
O
menthO
OmenthO
L-246D-246
 
Scheme 4.8. Use of a menthyl carbonate derivative. 
 
Camphanate esters have been often used to form separable diastereomers. 
For example, Desai et al.160 reported a resolution of 247 (scheme 4.9) by forming 
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the camphanate ester 248 and isolating one diastereomer by crystallisation. They 
were unable to isolate significant amounts of the other diastereomer from the 
mother liquors, and instead recovered their starting material by cleaving the ester 
and then repeating the process using the oppositely configured camphanate. 
O O
OBn
OH
OH
BnO
D-248
O O
OBn
Ocamph
Ocamph
BnO
O OBn
Ocamph
Ocamph
OBn
O
O
O
O
camph=(-)-w-camphanateDL-247
A pair of diastereomers
+
L-248
Scheme 4.9. Camphanate ester example.  
 
Another interesting example of camphanate ester use begins with racemic 
myo-inositol orthoacetate 249 (obtained in one step from myo-inositol in 65% 
yield).161 This is treated with (1S)-(-)-camphanoyl chloride and DMAP to give a 
mixture of diastereomers 250a and 250b (scheme 4.10), with 250b present in 
excess (although the actual ratio was not reported). Crystallisation gave the pure 
1D-2,6-diester 250b in 37% yield. Under different reaction conditions, with no 
DMAP present in the reaction mixture, the ratio of products changed to give an 
excess of the 2,4-diester 250a, which was then crystallised in 40% yield. 
O
OH
OH
O
O
OH
Me
DL-249
O
Ocamph
OH
O
O
Ocamph
Me
250a 250b
O
Ocamph
Ocamph
O
O
OH
Me
(1S)-(-)-camphanoyl chloride,
DMAP, CH2Cl2, 0 oC-RT
+
 
Scheme 4.10. Derivatisaton of myo-inositol orthoacetate as camphanate ester. 
 
Murakata and Ogawa, in their total synthesis of the Trypanosoma brucei 
VSG GPI,122(b) prepared the inositol core from racemic 1,2:5,6-di-O-
cyclohexylidene-myo-inositol (251, scheme 4.11 overleaf). Selective protection 
with para-methoxy-benzylchloride was followed by formation of separable 
diastereomers with (-)-camphanoyl chloride to give the mixture of diastereomers 
253a and 253b. Further protecting group manipulation of 253a gave their target 
molecule, 254. 
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PMBO
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PMBO
RO
OBnBnO
OBn
OBn Bn
BnO
OBnBnO
OR
OPMB
BnO
HO
OBnBnO
OBn
OBn
254
DL-251
DL-252 R=(-)-camphanoyl
+
253a 253b
Single enantiomer
 
Scheme 4.11. From the first total synthesis of the T. brucei VSG GPI. 
 
Ley and co-workers162 achieved a clever resolution by use of a chiral 
bis(dihydropyran) reagent (scheme 4.12). Racemic myo-inositol derivative 255 
(obtained in three steps from myo-inositol) was treated with the bis-dihydropyran 
reagent 256. Only one enantiomer (L-255) was able to react to give a single 
diastereomer 257, and unreacted D-255 was recovered. This was due to the 
congested nature of the system, where only the diastereomer that allows all the 6-
membered rings to adopt a chair conformation could be formed. 
O
O
OH
TBDPSO
OTBDPSHO
PPh3.HBr (cat.), CHCl3
DL-255 (racemate) 256
O O PhPh
257 35%
O
O
O
TBDPSO
OTBDPSO
O
O
Ph
Ph
D-255
O
O
OH
OTBDPS
TBDPSO OH
+
Scheme 4.12. Resolution using bis-dihydropyran reagent. 
 
The single diastereomer 257 was crystallised in 35% yield (based on the 
racemic starting material), and the other (unreacted) enantiomer was recovered 
from the residues and purified by column chromatography. Unfortunately, 
further reaction of 257 was hindered by the bulky TBDPS groups, which were 
replaced with benzyl groups before further reaction. Unfortunately, the 
ketalisation did not proceed when the benzyl groups were present from the start 
as the analogous material was not sufficiently soluble.  
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In a later publication of their total synthesis of the Trypanosoma brucei 
VSG GPI,123 the same group reported an improvement in their procedure, using 
the modified bis(dihydropyran) reagent 259 in the desymmetrisation of the meso- 
compounds 258a or 258b (scheme 4.13) both of which were obtained in three 
steps from myo-inositol, using butane-2,3-dione to selectively protect the pairs of 
trans-diequatorial diols. Although yields of 71% (for 260a) and 81% (for 260b) 
were obtained on small scale, the yield upon scale-up (277 mmol) was only 28%.   
OR
OH
OR
HO
OHHO
PPh3.HBr, CHCl3,
258a R=Bz
O OPhS
SPh
258b R=TBDPS
260a R=Bz 71% (de 98%)
OH
OHO
OR
OR
O
O
O
PhS
PhS
260b R=TBDPS 81% (de not reported)
reflux
259
 
Scheme 4.13. Resolution using an improved bis(dihydropyran) reagent. 
 
Another chiral reagent that has been used for myo-inositol diastereomer 
formation is acetyl mandelic acid. For example, Horne and Potter, in their 
synthesis of the enantiomers of 6-deoxy-myo-inositol-1,3,4,5-
tetrakisphosphate,163 obtained 261 in one step from myo-inositol164 and then 
further elaborated to give 262 (scheme 4.14). Subsequent treatment with acetyl 
mandelic acid and DCC gave 263a and 263b, which were separated by column 
chromatography.  
OH
OH
PMBO
PMBO
PMBO
PMBO
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HO
HO
HO
HO
DL-261
DL-262
HO
O
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PMBO
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O H
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OAc
OH
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OPMB
OPMB
O
O
Ph
H
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263a 263b
+
38% 40%
2 steps
 
Scheme 4.14. Formation of diastereomers with acetyl mandelic acid. 
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Menthoxyacetylchloride has also been used for diastereomer formation. 
In a 1986 publication,164 the racemic compound 264 (formed in five steps from 
myo-inositol) was treated with 1-menthoxyacetylchloride to give the 
diastereomers 265a and 265b. The former was isolated by crystallisation from 
hexanes (in 39% total yield) and the other, which was oily, was isolated by flash 
chromatography of the filtrate in 43% yield (scheme 4.15).  
OH
BnO O
O
OBnO
O
O
OH
OBnO
O
BnO O
O
O
265a   39% 265b  43%
O
O
ClOH
BnO OH
O
OBnO +
DL-264
 
Scheme 4.15. Use of menthoxyacetylchloride in diastereomer formation. 
 
A recent publication, claiming the first example where both diastereomers 
of a myo-inositol derivative could be obtained by sequential crystallisation, used 
acetylmandelic acid chloride to form diastereomers of the diketal 266 (scheme 
4.16).165 These were then separated by crystallisation, first from hexane-ethyl 
acetate to give 267a in 46% yield and then a second crystallisation from 
chloroform-hexane to yield 267b in 42% yield. The very good yields in this step 
are somewhat offset by the fact that 266 is obtained in three steps from myo-
inositol,166 in an overall yield of 22% (although all three steps involve 
purification by crystallisation).  Hence, the yields of 267a and 267b from myo-
inositol are only 10 and 9% respectively. 
O
OHO
O
OHO
DL-266
Me O Ph
O CH2OCl
267a
O
OMndAcO
O
OAcMndO
267b
O
O OAcMnd
O
MndAcO O
AcMnd = (s)-O-acetyl mandelic ester
(S)-(+)-O-acetyl mandelic 
acid chloride
Pyr, 0 oC, 2 hr
46% 42%
 
Scheme 4.16. Use of acetyl mandelic acid chloride in diastereomer formation. 
 
In 1989, Bruzik and Salamoczyk reported the use of D- or L-camphor for 
the formation of diastereomers directly from myo-inositol (scheme 4.17).167 
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Notably, the formation of ONE diastereomer as the major product (rather than a 
1:1 ratio of diastereomeric products) is observed in this reaction, and hence myo-
inositol can be directly and regioselectively protected and resolved in one step. 
The theoretical yield of the reaction is 100%, a vast improvement over the 50% 
maximum yield of many of the previous examples.  
 
OMeO OMe
L-268
HOOH
HO
OH
OH
OH
OO
HO
OH
OH
OH
(-)-269a
OMeMeO
D-268
O
OO
OH
HO
HO
HO
(+)-269a
1) DMSO, H2SO4, L-268
2) CHCl3, MeOH, H2O, 
pTsOH, RT overnight
myo-inositol
(-)-L-camphor
1D-myo-inositol-1,2-L-camphor acetal1D-myo-inositol-2,3-D-camphor acetal
1) DMSO, H2SO4, D-268
2) CHCl3, MeOH, H2O, 
pTsOH, RT overnight
(-)-D-camphor
 
Scheme 4.17. Formation of myo-inositol camphanylidene acetals. 
 
Use of L-camphor gives 1D-myo-inositol-1,2-camphanylidene acetal 
(-)-269a while use of D-camphor gives the opposite enantiomer, (+)-269a. There 
have been numerous slight variations on the original procedure,168,169,170,171 but 
essentially all involve the treatment of myo-inositol with > 2 equivalents of 
camphor dimethyl acetal (268).iii The crude product (a complex mixture of 
mono- and di-acetals) is then ‘equilibrated’ by stirring in an acidified solution of 
chloroform, methanol and water at room temperature overnight. The product 
(-)-269a (or (+)-269a) is isolated by filtration in between 65-75% yields, 
contaminated with small amounts of the other three possible diastereomers (see 
                                                
iii
 A further significant publication has appeared since submission of this thesis, which details a) a 
method for reworking the mother liquors which allows preparation of both enantiomers of tetra-
O-benzyl-myo-inositol via the myo-inositol camphanylidene acetal mixture prepared from 
cheaper D-camphor; b) a method for preparation of myo-inositol camphanylidene acetal that gives 
a low selectivity, so that a ca. 1:1 ratio of the two enantiomers of tetra-O-benzyl-myo-inositol 
may be obtained; c) an HPLC method for separation of the four diastereomers of myo-inositol 
camphanylidene acetal. The latter development appears to be the most useful element of this 
work. Wewers, W.; Gillandt, H.; Traub, H. S. Tetrahedon Asym., 2005, 16, 1723-1728. 
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figure 6.1, page 143 and accompanying discussion in chapter six). The major 
diastereomer is then isolated by recrystallisation from methanol or methanol-
water, in reported yields of 25-55% from myo-inositol.  
 
Demonstrating the utility of the new procedure, Salamoczyk and 
Pietrusiewicz used the acetal (+)-269a as a starting point for a short, elegant 
synthesis172 of D-Ins(1,4,5)P3 (scheme 4.18). (+)-269a was treated with five 
equivalents of pivaloyl chloride to give 270, which was then benzylated. 
Cleavage of the pivaloyl esters and phosphorylation of the resulting triol with 
reagent 272, and subsequent oxididation gave 273, which was finally deprotected 
to give the target molecule D-Ins(1,4,5)P3.  
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HO
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D-Ins(1,4,5)P3
(+)-269a 270 271
R =
Scheme 4.18. Synthesis of D-Ins(1,4,5)P3 from (+)-269a. 
 
4.6 Chapters Six and Seven of this Thesis  
 
The objective of the work described in chapters six and seven was to 
develop and perform a large-scale resolution of myo-inositol. The myo-inositol 
camphanylidene acetal procedure described above was chosen as an ideal basis 
for this objective. The reasons for this choice are elaborated in chapter six, which 
describes the process development work and investigation into analogues of the 
camphanylidene acetal, and in chapter seven, which describes the ensuing scale-
up campaign. As part of this work, previously unpublished X-ray crystal 
structures were obtained for the major product of the reaction, (-)-269a, and for 
two of the diastereomeric impurities. 
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Chapter Five 
 
Functionalisation of Quebrachitol 
 
 
5.1 Preparation of quebrachitol dicyclohexylidene acetal 
 
Quebrachitol dicyclohexylidene ketal 274 was a key precursor to all of 
the work described in this chapter, and hence the efficient and facile preparation 
of 274 was paramount. In the literature, 274 is prepared by treatment of 
quebrachitol with cyclohexanone in refluxing benzene under Dean-Stark 
conditions (scheme 5.1), followed by extraction with chloroform.130,131  
OH
OH
HO OH
OMeOH
O
Quebrachitol
O
O
O O
OMeOH
274 50 - 70%
     H+, benzene
Dean-Stark
 
Scheme 5.1. Preparation of 274 from quebrachitol under Dean-Stark conditions. 
 
The yields reported for this procedure are typically 50 – 70% (using 
recrystallised quebrachitol). In the course of this work yields below this range 
were obtained. In addition, a by-product, which was believed to be the product of 
an acid-catalysed aldol condensation of cyclohexanone, was formed in large 
amounts. Angyal and co-workers, who pioneered the use of the cyclohexylidene 
protecting groups with inositols, noted that ‘in larger concentration, pTsOH 
promotes the self-condensation of cyclohexanone, producing water which 
actually represses formation of the desired ketal’.131 The reaction was also 
attempted in neat refluxing cyclohexanone with catalytic pTsOH, however in this 
case 274 was isolated from the reaction in only 37% yield. 
 
Thus, a new, improved procedure, eliminating the toxic benzene and 
chloroform was designed that involved treatment of quebrachitol with 
1,1-dimethoxycyclohexane (275) under acidic conditions (scheme 5.2 overleaf). 
The reagent was easily prepared by heating cyclohexanone with 2.5 volumes of 
trimethylorthoformate and two volumes of methanol in the presence of catalytic 
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pTsOH. The workup is straightforward, involving quenching with triethylamine, 
removal of solvents and then an aqueous-diethyl ether partition. On small (2 mL 
of cyclohexanone) scale, the reaction proceeded to give essentially quantitative 
yield. When the reaction was scaled up to 400 mL of cyclohexanone, the crude 
product was of similar quality and yield to the product obtained on smaller scale. 
Unfortunately, accidental mechanical losses during distillation resulted in a yield 
of 77%, and the reaction was only performed once on this scale.  
 
The protection of quebrachitol using this reagent was based on a 
literature preparation173,174 for the protection of L-chiro-inositol in which the 
triacetonide derivative is prepared using acetone and 2,2-dimethoxypropane with 
catalytic acid. The diacetonide derivative of quebrachitol, analogous to the 
dicyclohexylidene derivative 274 was also prepared during the course of this 
work, in very satisfactory 85% yield. That reaction proceeded smoothly at RT, 
however for the preparation of 274 itself with 1,1-dimethoxycyclohexane it was 
necessary to heat the reaction mixture in order to drive the reaction forward. The 
conditions were also modified to reduce the total reaction volume; 
cyclohexanone was omitted as it was found that the reaction proceeded well with 
1,1-dimethoxycyclohexane only. The volume of DMF was also reduced to 
eight volumes of DMF to quebrachitol. Hence, 50 g of quebrachitol was heated 
overnight (to ca. 85 °C) in 400 mL DMF with reagent 275 (scheme 5.2) and 
pTsOH, and the reaction was quenched and worked up in the usual manner. 
From the residues of the first organic extracts, 64.8 g (71%) of crystalline 
product 274 was obtained. Additionally, when the aqueous fractions were 
concentrated and then re-extracted with ethyl acetate, 6.6 g (9%) of the mono-
cyclohexylidene derivative 276 was isolated as a by-product. 
 
OH
OH
HO OH
OMeOH
OMeMeO
Quebrachitol
O
O
O O
OMeOH
274 71%
OH
OH
O O
OMeOH
276 9%
+      pTsOH, DMF
85 oC, 18 h
275
Scheme 5.2. Synthesis of 1L-1,2:3,4-di-O-cyclohexylidene-5-O-methyl-chiro-
inositol (274) and 1L-1,2-O-cyclohexylidene-5-O-methyl-chiro-inositol (276). 
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The 1H NMR spectra of 274 and 276 were quite different. In the 
spectrum of 274, the signals for the inositol ring protons appeared as overlapping 
multiplets at 4.6 (3 H) and 3.6 (3 H) ppm. In the spectrum of 276 however, all of 
the ring proton signals were well-resolved and their coupling constants readily 
apparent. The signal attributed to the axial proton on the methoxy-bearing carbon 
(C-5) was furthest upfield at 3.38 ppm, and coupled to the neighbouring axial 
proton with J = 8.8 Hz and the neighbouring equatorial proton with J = 3.2 Hz.  
 
5.2 Further protection of quebrachitol dicyclohexylidene acetal 
 
 As described in chapter four, the synthetic plan for the inositol core 
involved protection at the free hydroxyl (at O-6) of 274, and subsequent 
deprotection at C-2, C-3 and C-4 to give a triol. Protection of the hydroxyl group 
to give the derivatives 277, 278 and 211 (scheme 5.3) was based on literature 
procedures. Benzoylation was achieved in excellent yields of up to 98% using 
the DMAP-catalysed procedure of Ozaki et al.135 The best yields were achieved 
with extended reaction times, rather than by increasing the amount of benzoyl 
chloride, which made purification of 278 more difficult.  
 
O
O
O O
OMeOBz
274
O
O
O O
OMeOTs
278 98%
O
O
O O
OMeOAc
211 79%
277 84%
BzCl, DMAP, Et3N,
CH2Cl2, RT, 5 days
TsCl, DMAP, Et3N,
CH2Cl2, reflux, 18 hr
Ac2O, py,
RT, 18 hr
 
Scheme 5.3. Preparation of derivatives 277, 278 and 211 from 274. 
 
Tosylation proved more troublesome; however, by heating to reflux in 
dichloromethane overnight, a 79% yield of 211 was achieved. Previously, 
vigorous tosylation conditions have been reported to be necessary for the 
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preparation of this derivative.130 Acetylation under standard conditions, using 
acetic anhydride in pyridine proceeded readily in yields > 80%.  
 
5.3 Demethylation of 278 and of 211 
 
In line with the planned strategy for the synthesis of the L-GPI core 
(scheme 4.1, page 98), the concurrent cleavage of the methyl ether and the trans-
cyclohexylidene groups of 278 or 211 was next attempted (scheme 5.4). Ozaki 
and co-workers report using AlCl3 and NaI in acetonitrile at RT to effect this 
cleavage.133 Triol 281 was obtained in 83% yield after overnight stirring.135,147,175 
Ozaki et al. also report that after three hours at RT, only 52% of 281 was 
isolated, along with 22% of 279, in which only the trans-cyclohexylidene group 
had been cleaved. When the reaction was performed at 0 °C for one hour, with 
half the amounts of AlCl3 and NaI, an 89% yield of 279 was reported. These 
results indicate that the cyclohexylidene moiety is lost first, with subsequent 
cleavage of the methyl ether assisted by the vicinal hydroxyl group. Synthesis of 
triol 212 under similar conditions has also been reported, in 75% yield.133,147  
 
O
O
O O
OMeOR
278 R=Bz
211 R=Ts 279 R=Bz
280 R=Ts
OH
OH
O O
OMeOR
OH
OH
O O
OHOR
281 R=Bz
212 R=Ts
+
AlCl3 (10 equiv),
NaI (10 equiv)
    MeCN
 
Scheme 5.4. Cleavage of trans-cyclohexylidene moiety and demethylation. 
 
Unfortunately the results of Ozaki et al. could not be repeated in the 
course of this work. The demethylation of both 278 and 211 was attempted, and 
although the trans-cyclohexylidene group was cleaved, the methyl ether was not, 
even under more forcing conditions (increased temperature or time). Some 
cleavage of the cis-cyclohexylidene group was also suspected. The results of 
relevant experiments are summarised in table 5.1 overleaf. 
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Table 5.1. Conditions and results of attempted demethylations.* 
 
Entry 
 
Start 
 
AlCl3 
 
Iodide 
source 
 
Time 
 
Temp 
 
Isolated yield (%) 
 mat. (equiv) (equiv) h  278/ 
211 
279/ 
280 
281/ 
212 
1 278 10 NaI (10) 18 RT 0 30 0 
2 278 10 NaI (10) 2 RT 11 75 0 
3 278 10 n-Bu4NI (10) 18 RT 0 24 0 
4 211 10 n-Bu4NI (10) 18 RT 0 35 0 
5 211 10 NaI (10) 16 RT 0 12 0 
6§ 211 5 NaI (5) 1 0 oC 10 57 0 
* 30 vols MeCN in all cases. Isolated yields. 
§
 Formation of 280 was the intent of this reaction. 
 
It is evident from a number of the reactions summarised in table 5.1 that 
material was being lost and this was attributed to the cleavage of both Cy groups 
and loss of the resultant tetra-ols in the aqueous washings. Concentration and 
subsequent analysis (1H NMR) of the aqueous washings confirmed these 
suspicions. The residues from the aqueous washings contained inositol with the 
methyl ether still present, clearly visible as a singlet at approximately 3.4 ppm.  
 
Material that had lost only the trans-cyclohexylidene group (280) was 
isolated (entry 6) and then subjected to demethylation with NaI (10 equiv) and 
nBu4NI (10 equiv), with 10 equivalents of pyridine added to suppress the 
cleavage of the cyclohexylidene group.139,140 The reaction was heated to 70 °C 
overnight, in line with demethylation conditions used successfully for the 
cleavage of the methyl ether of molecule 274 (which is vicinal to a cis- hydroxyl 
group, accelerating the cleavage135 - see discussion below). However, only 
starting material was recovered from this attempt. This suggests that under the 
conditions with pyridine present, the cleavage of a methyl ether vicinal to a 
trans- hydroxyl group will not proceed.  
 
Given the lack of success in the preparation of the triols 281 or 212, it 
was decided to attempt instead the formation of the diol 282, directly from 274 
(scheme 5.5). Ozaki and co-workers have reported133,139 that the methyl ether 
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with the vicinal cis- hydroxyl is cleaved chemoselectively, in preference to the 
normally very labile trans-cyclohexylidene moiety, by AlCl3-NaI or AlCl3-
nBu4NI in acetonitrile (the cleavage of methyl ethers with a vicinal trans 
hydroxyl group was reported to be much slower). The latter system, with nBu4NI 
as the iodide source, was found to be preferable139,140 because of a lesser 
tendency for the trans-cyclohexylidene moiety to be cleaved. Addition of 
pyridine to the reaction mixture also helps to suppress cleavage of the trans-
cyclohexylidene ketal.139,140 A number of reported attempts to optimise the 
reaction conditions have been made, with variations in the number of equivalents 
of AlCl3 and iodide reagent used (typically 10 equivalents of each are added), the 
nature of the base added to suppress cleavage of the trans-cyclohexylidene 
moiety, and reaction times. Optimal conditions for the preparation of 282 seem 
to be the use of 10 equivalents each of AlCl3, nBu4NI, and pyridine, in 
acetonitrile, at RT for 5 to 26 hours, but reported results do vary. It has also been 
observed133,140 that under acidic conditions, after demethylation, the trans-
cyclohexylidene can migrate to give 283, in which both cyclohexylidene groups 
protect a pair of vicinal cis hydroxyl groups. It was found that when the NaI-
AlCl3 system was used with no added pyridine, 283 was the sole isolated product 
in 40 – 60% yield.  
O
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O O
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py, MeCN, RT
 
Scheme 5.5. Formation of the diol 282 by demethylation of 274. 
 
 Hence, the dicyclohexylidene derivative 274 prepared as described 
above, was subjected to the demethylation conditions. Unfortunately, 
reproduction of the reported results was again not achieved. Stirring overnight at 
room temperature with either AlCl3-NaI or AlCl3-nBu4NI and pyridine in 
acetonitrile, gave largely unreacted starting material. Acetonitrile and pyridine 
were freshly distilled, and hence it was suspected that the AlCl3 being used was 
of poor quality, but only a small improvement was observed upon using fresh 
reagent. These results were therefore extremely puzzling. Fortunately, it was 
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found that heating the reaction mixture for a period of hours induced the desired 
methyl ether cleavage. A range of conditions was used with varying degrees of 
success, and the summary is presented in table 5.2. 
 
Table 5.2. Conditions and results of demethylations of 274.* 
 
Entry 
 
Equiv. 
 
Equiv. 
 
Time 
 
Temp 
 
Isolated yield (%) 
 AlCl3 nBu4NI h  274 282 283 
1 10 10 18 RT 78 0 0 
2 10 10 96 RT 38 0# 0 
3 10 10 26 RT 71 15 0 
4 10 10 72 RT 60 24 0 
5 10 10 48 40 oC 52 39 5 
6 10 10 18 60 oC 50 43 0 
7 10 10 18 reflux 5 23 55 
8 10 10 48 reflux 2 10 74 
9 10 7 18 62 oC 30 55 10 
10§ 8 5 18 62 oC 24 51 0 
* All reactions run in 30 volumes of MeCN and with 10 equiv of pyridine added.  
#
 TLC suggested ca. 50% conversion, but 282 was not isolated after workup. 
§
 Scaled up reaction, material was lost crystallising on the column. 
 
Although heating to 40 °C or over did induce the methyl ether cleavage, 
these more forcing reaction conditions also induced the rearrangement of 282, to 
give the isomeric product 283, via the Lewis-acid catalysed mechanism shown in 
scheme 5.6 overleaf. The identity of 283 was confirmed by comparison with 
literature NMR data for the same compound. This product possesses a rotational 
axis of symmetry and hence displays simple NMR spectra compared to 282. 
Three discrete signals appear for the inositol ring proton region of the 1H NMR 
spectrum (each equivalent to two protons), and nine signals appear in the 13C 
NMR spectrum (three for the symmetrical inositol ring and six for the equivalent 
cyclohexylidene moieties). 
 
 The isomerization to give 283 even in the presence of pyridine, was 
found to be aggravated both by prolonged reaction time (entries 5 and 8) and 
excessive heating (entries 7 and 8). Heating the reaction mixture to just over 
60 °C overnight was found to give the best yield of 282, so that although the 
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results were somewhat variable (entries 9 and 10), 282 could be isolated in 
useful quantities.  
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Scheme 5.6. Likely mechanism of migration of cyclohexylidene groups. 
 
The efficacy of the pyridine in suppressing the cleavage (rather than the 
migration) of the trans-cyclohexylidene moiety was demonstrated when the 
pyridine was accidentally added 10 minutes after all the other reagents had been 
stirring at RT. When this reaction was worked up after stirring overnight at RT, 
the crude product was found to contain 274 and 276 in an approximately 1:1 
ratio. Again, no demethylation was observed. It was assumed that the 
cyclohexylidene cleavage to give 276 had occurred in the first 10 minutes, before 
the addition of pyridine. 
 
Several attempts were made to cleave the methyl ether of either 278 or 
211 using either the AlCl3-NaI or the AlCl3-nBu4NI system in the presence of 
pyridine, in the hope that the methyl ether might be cleaved without loss of the 
trans-cyclohexylidene moiety (this had not been reported in the literature). At 
room temperature, in all cases no cleavage was observed. At 60 °C, 211 (Ts 
version) began to lose the trans- cyclohexylidene group, but retained the methyl 
ether. These results again demonstrate the need for a vicinal cis- hydroxyl group 
for a successful demethylation using this procedure. 
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5.4 Mono-acetylation of diol 282 
 
As part of a project being undertaken by G. S. Cousins in the same 
laboratory, the mono-esterification of certain symmetrical inositol derivatives 
containing vicinal di-equatorial diols was achieved174,176 using the method of 
Clarke and co-workers (scheme 5.7).177 Clarke’s group reported that mono-
acetylation of a C-2 symmetric diol was readily achieved in good yield in a 
simple one-step procedure using acetic anhydride and a Lanthanide salt catalyst. 
Best results were obtained with CeCl3 and YbCl3 in either THF or 
dichloromethane, with reported yields in excess of 90%. When these conditions 
were applied to the inositol derivative 284, similarly good yields of the mono-
esters such as 285 (scheme 5.7) were achieved with no trace of any diester 
products being formed. It was found that for the inositol substrate, the catalyst 
loading could be reduced to 5 mol% without loss of yield. A variety of other 
anhydrides were also successfully used; chloroacetic, propionic, crotonic, 
benzoic and pivalic monoesters were prepared. Monoesters of the 
dicyclohexylidene analogue of 284 were also successfully prepared. 
HO
HO
OO
O O
284
AcO
HO
OO
O O
285
      Ac2O, THF,
10 mol % LnCl3.xH2O
Ln=Yb, 4h RT                                78%
Ln=Ce, 2.5 h RT                            83%
 
Scheme 5.7. Monoacetylation of inositol derivative 284. 
 
Two different mechanisms have been proposed to explain the 
selectivity.176,177 The first (I, scheme 5.8) proposes that the metal coordinates to 
one of the diol hydroxyl groups and one carbonyl from the anhydride, leaving 
the uncoordinated hydroxyl group free to attack the activated anhydride 
carbonyl. Alternatively (II, scheme 5.8), both the diol and the anhydride could 
chelate to the metal centre to give 287. Acyl transfer from the anhydride to the 
diol then occurs, resulting in the seven-membered chelate 288, which, being less 
energetically stable than the five-membered chelated diol (287), is released and a 
new diol chelated to continue the reaction.  
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Scheme 5.8. Proposed transition states for the monoacetylation reaction. 
 
This method had not been applied to non-symmetrical inositol 
derivatives. It was thought that this reaction might show some selectivity in a 
vicinal axial-equatorial diol such as 1L-1,2:3,4-di-O-cyclohexylidene-chiro-
inositol (282), because in I above, it could be favourable to coordinate the metal 
in an equatorial or axial position, and in II, steric effects or ring strain effects 
could favour acetylation at only one of the available positions.i Hence, 75 mg 
(0.22 mmol) of diol 282 were treated with CeCl3.7H2O (0.02 mmol) and Ac2O 
(1.10 mmol) and stirred in THF at RT overnight (scheme 5.9). After this time, 1H 
NMR and TLC analysis indicated that no starting material remained, and one 
major product spot was evident. After workup, 1H NMR analysis demonstrated 
that these reaction conditions had indeed given a mono-acetylated product in 
good yield of 78%. Analysis by HRMS (ESI) found a signal at m/z 383.2051; the 
calculated m/z for the protonated mono-acetylated product (C20H31O7 [M + H+]) 
being 383.2064. No signal was observed that could be attributed to a di-
acetylated product.  
 
O
O
O O
OHOH
282
O
O
O O
OHOAc
289
O
O
O O
OAcOH
290
+
CeCl3.7H2O, Ac2O,
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Scheme 5.9. Monoacetylation reaction applied to non-symmetrical diol 282. 
 
                                                
i
 Literature reports suggest that acylation of sugars is often selective for equatorial hydroxyl 
groups, whereas alkylation tends to be selective for axial hydroxyl groups; this has been 
rationalised on the basis of transition state bulk: Bert Fraser-Reid et al. Aust. J. Chem. 2002, 55, 
123-130, and references therein. 
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However, examination of the 1H NMR spectrum revealed that acetylation 
had occurred at both the O-5 and O-6 position of 282 to give 289 and 290 in an 
approximately 1.3:1 ratio. The 1H NMR of the mixture of products showed a 
doublet of doublets at 5.55 ppm (Jeq-eq = 3.2, Jax-eq = 2.6 Hz), which was 
attributed to the equatorial proton vicinal to the acetyloxy group in 289, and a 
doublet of doublets at 5.05 ppm (Jax-ax = 8.1, Jax-eq = 2.5 Hz) attributed to the 
axial proton vicinal to the acetyloxy group in 290. To further confirm the 
presence of two products, gCOSY analysis was done and showed no correlation 
between the two protons at 5.55 and 5.05 ppm. The relative integration for these 
two protons was used to determine the product ratio, and the relative integration 
of the other inositol ring protons (signals between 3.5 – 4.4 ppm) were correct 
for a monoacetylated product. The methyl signals for the acetyl groups of the 
two products appeared as singlets at 2.16 and 2.13 ppm.  
 
The reaction mechanism evidently does not significantly favour the 
esterification of either the axial or the equatorial hydroxyl of this vicinal axial-
equatorial diol, under these conditions. However, the slight excess of axial 
product 289 may be explained by invoking transition state I as discussed above. 
Co-ordination of the equatorial hydroxyl group to the metal centre would form 
transition state I as shown in scheme 5.10.  
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Scheme 5.10. Formation of the axial acetyl product 289 via transition state I. 
 
This would be the thermodynamically favoured transition state, and lead 
to the formation of the axial acetyl product 289. It is conceivable that modified 
reaction conditions might be able to enhance the selectivity of this reaction. 
Preferentially forming the equatorial acetyl product 290 might be possible by 
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using conditions that might favour the kinetically favoured transition state, such 
as running the reaction at lower temperatures.  
 
5.5 Butane diacetal derivatives 
 
 The butane diacetal (BDA) protecting group is a useful and widely used 
protecting group that is specific for trans-diequatorial diols. It is reasonably 
inexpensive and simple to introduce, the products are often crystalline, and the 
NMR spectra simple, displaying four diagnostic singlets per BDA group.    
 
Its introduction, using the reagent 2,2,3,3-tetramethoxybutane (TMB) 
was first reported 178 in 1996.ii The TMB reagent was prepared by refluxing a 
methanol solution of trimethyl orthoformate and 2,3-butanedione with catalytic 
sulphuric acid, followed by distillation to purify the crude product. Reaction of 
TMB with the diol was again done in refluxing methanolic solution and in the 
presence of trimethyl orthoformate, but catalysed by camphor sulphonic acid. A 
variety of carbohydrates were successfully derivatised using this procedure. 
Soon after this, a paper appeared evaluating a range of cyclic and open chain 1,2-
diketones as potential protecting groups, in-situ generation of the TMB reagent, 
and use of BF3.OEt2 as an (not necessarily better) alternative to CSA.179 In the 
one-step procedure, butanedione, trimethyl orthoformate, and CSA are all added 
to a methanolic solution of the diol and after refluxing for a period of hours the 
resultant BDA derivative is often able to be isolated by crystallisation. 
 
 In the course of this work, the BDA group was used for the protection of 
O-3 and O-4 of mannose, as part of the strategy for the synthesis of the GPI 
presented in chapter four. Upon isolation of the mono-cyclohexylidene protected 
quebrachitol derivative 276, it was decided to attempt the protection of the free 
vicinal diequatorial diols of 276 using BDA (scheme 5.11). Thus, 276 was 
treated with butanedione, trimethyl orthoformate and CSA in refluxing methanol 
overnight.180 Upon workup, product was isolated as a fine white solid that 
crystallised from the crude reaction product by addition of a small amount of 
                                                
ii
 In this first report, the term ‘butane bis-acetal’ (BBA) was used to denote these derivatives, 
however the term butane diacetal has now been widely adopted. 
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acetone. This product was initially presumed to be 292, in which the free 
hydroxyl pair had been protected with the BDA moiety, and the cis-
cyclohexylidene group had then been lost. However, 293 could also be a possible 
structure for the product. It could be formed if the cyclohexylidene group was 
lost first, and the BDA protection occurred next. It was found that essentially 
identical results were obtained if the reaction was only refluxed for three hours.  
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Scheme 5.11. Attempted protection of the vicinal diequatorial diol of 276 with 
BDA. Reagents and conditions, a) Butanedione, MeOH, HC(OMe)3, CSA, 
reflux, 18 h; b) butanedione, MeOH, HC(OMe)3, CSA, reflux, 3 h. 
  
It was not clear whether any of the expected product 291, retaining the 
cis-cyclohexylidene group, had been formed in the reaction. Careful TLC 
monitoring was inconclusive and column chromatography of the evaporated 
filtrate from the product filtration failed to isolate any 291. Assuming then that 
the product was 292, it was postulated that the loss of the cis-cyclohexylidene 
group was accelerated by the formation of the fused inositol-dioxane ring system 
of the BDA group. The rigidity imposed by the BDA group invokes some 
conformational restriction and possibly also strain in the five-membered ring of 
the cyclohexylidene acetal, thus destabilising it. Although it is much more stable 
than the trans-cyclohexylidene group, the cis-cyclohexylidene could also be lost. 
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 Presuming that the product was 292, protection of the pair of cis-
hydroxyl groups as a cyclic acetal was also attempted (scheme 5.12). When 292 
was treated with 1,1-dimethoxy-cyclohexane and pTsOH in DMF at 85 °C (the 
procedure which had been used very successfully for the protection of 
quebrachitol), there was no sign of 291 being formed in the reaction. Even after 
heating for several days, no likely-looking spots were seen in TLC analysis and 
1H NMR analysis showed that starting material was the only significant inositol 
component present in the reaction mixture. It was postulated that the 
isopropylidene derivative 294 might form more readily, since it is acyclic and 
hence has less inherent conformational restrictions. However, similarly no sign 
of product was seen when literature methods173 were applied. 
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Scheme 5.12. Attempts to protect O-3 and O-4 of (presumed) 292 as a cyclic 
acetal. Reagents and conditions: a) Dimethoxycyclohexane, pTsOH, DMF, 
85 °C, 3 days; b) Acetone, 2,2-dimethoxypropane, pTsOH, RT, several days. 
 
Having still not conclusively identified the structure of the BDA product 
as either 292 or 293, the white solid was subjected to per-methylation and the 
BDA moiety then removed with methanolic HCl. The two possible structures of 
the tetra-methylated product are shown in scheme 5.13. The deprotection was 
achieved by warming to 50 °C for two days, and did not proceed at RT. The 
tetra-methoxy derivative was readily synthesised, with the methylation 
proceeding in 70% yield and the deprotection in 82% yield.  
 
The NMR spectra of the tetra-methoxy derivative were revealing. Had 
the product been the symmetrical molecule 296, the 13C NMR spectrum would 
have been a simple spectrum showing only five signals.iii However, there were  
 
                                                
iii
 Authentic NMR spectra of the enantiomer of 296 (the D-chiro tetra-methoxy derivative) were 
kindly supplied for comparison by Dr. Andy Falshaw, Industrial Research Limited. 
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Scheme 5.13. Per-methylation and deprotection of the BDA product, 292 or 293. 
 
ten signals in the spectrum, six in the region where signals for inositol ring 
carbons are usually found (70 – 85 ppm), and four discrete methoxy carbon 
signals (around 60 ppm). This indicated that the product that had been formed 
was 298, and hence that the original product from the BDA reaction of 
quebrachitol cyclohexylidene acetal was 293. This was further confirmed by 
acetylation of the product, now presumed to be 293 (scheme 5.14). NMR 
analysis of the acetylated product (including gCOSY analysis) confirmed the 
structure to be 299. The inositol ring protons next to the three acetyl groups were 
shifted downfield to 5.43, 5.26 and 5.20 ppm, and hence the proton couplings 
around the ring could be identified.  
OH
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Scheme 5.14. Acetylation of the BDA derivative 293.  
 
The 1H NMR spectrum of the product 293 is shown in figure 5.1 on the 
following page. The distinctive pattern of four singlets of the BDA group is 
clearly discernible - the two singlets attributed to the methyl groups at 1.32 and 
1.33 ppm and the two attributed to the methoxyl groups at 3.28 and 3.25 ppm. 
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Figure 5.1. 1H NMR spectrum of 293. 
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The reason for the preferential formation of 293 over 292 may be 
attributed to increased stability of 293 due to extra hydrogen-bonding available 
within the structure. The five-membered rings formed by hydrogen bonds 
between the ring oxygens of the BDA moiety and the vicinal inositol ring 
hydroxyl protons are shown in scheme 5.11 (page 126). In 292, only one 
hydrogen bond is possible, either as shown or between the equatorial alcohol and 
the neighbouring axial alcohol, whereas in 293, two such five-membered rings 
are available. 
 
It was postulated that 274 could also serve as a substrate for the 
formation of 293, via in-situ generation of 276 by cleavage of the more labile 
trans-cyclohexylidene group under the acidic reaction conditions. Indeed, upon 
subjecting 274 to analogous reaction conditions, the same product was isolated 
in comparable yield (scheme 5.15). Reaction of 278 and 211 under the same 
conditions was also performed. In both cases, product was again crystallised out 
of the crude reaction mixture, after removal of solvents, by the addition of a 
small amount of acetone. These products were identified as 300 and 301 by 
analogy with the triol product 293. The acetate derivative 277 was also subjected 
to the reaction conditions, but the analogous product was not isolated. A very 
small amount (approx. 5%) of 293, having lost the acetyl group, was obtained, 
but since this reaction was only done on a small scale it was not clear whether 
any of the desired product had been formed.  
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Scheme 5.15. Preparation of a trimethoxy derivative. Reagents and conditions, 
a) Butanedione, MeOH, HC(OMe)3, CSA, reflux, overnight; b) butanedione, 
MeOH, HC(OMe)3, CSA, reflux, 3 hours. 
 
The trimethoxy derivative 302, would also be readily available using a 
similar methodology to that used for the preparation of the tetra-methoxy 
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derivative, but starting with the benzoyl or tosyl-containing molecules 278 or 
211 (scheme 5.15).    
 
Due to the harsh conditions normally required for the cleavage of a 
methyl ether, the BDA derivatives formed from quebrachitol without 
demethylation may have only limited usefulness in many cases (unless a methyl 
ether is present in the target molecule at the equivalent position). Hence, it would 
be useful to demethylate the dicyclohexylidene derivative 274 (for example, as 
above) and then proceed to protect both hydroxyls of the resulting diol 282, with 
either the same or different protecting groups before effecting the simultaneous 
introduction of BDA moiety and cleavage of both cyclohexylidene groups. This 
has been achieved using TBDPS to protect the equatorial hydroxyl of 282 
(scheme 5.16). This reaction was selective for the equatorial hydroxyl, giving an 
approximately 5:1 ratio of equatorial:axial OTBDPS products that could be 
separated by flash column chromatography (the selectivity of this reaction is 
discussed further later in this chapter). Material contaminated with a small 
amount of the regioisomer was carried through the subsequent benzoylation to 
give 303 and then subjected to the conditions for the introduction of the BDA 
moiety. The major product 304 was isolated by flash column chromatography 
(rather than by the crystallisation method used for the other BDA derivatives). 
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Scheme 5.16. BDA derivative from demethylated compound. 
 
The 1H NMR spectrum of 304 is shown in figure 5.2 overleaf, and the 
13C NMR spectrum on page 133. Note the distinctive pattern of the BDA group 
in the 1H spectrum, of two methyl and two methoxy groups which appear at 1.32 
and 1.27 ppm, and at 3.22 and 3.15 ppm respectively. The ring proton next to the 
benzoyl protecting group appears at 5.28 as a doublet of doublets (see the 
expansion box in figure 5.2), with coupling constants Jeq-eq = 3.5 Hz and Jax-eq =  
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Figure 5.2. 1H NMR spectrum of 304. 
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Figure 5.3. 13C NMR spectrum of 304. 
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3.4 Hz. The observed couplings of this proton allowed the two regioisomers to 
be differentiated and quantified in compound 303, as is discussed further in the 
next section. In the 13C NMR spectrum the two phenyl groups of the TBDPS 
group are differentiable. This indicates that the two are not equivalent, due to the 
rigid structure and steric interactions precluding free rotation of the large TBDPS 
group. The distinctive pattern of the BDA moiety is again visible, with the two 
methoxy carbon signals appearing at 47.9 and 48.0 ppm, and the two methyl 
signals at 17.5 and 17.2 ppm.    
 
 
5.6 Synthesis of quebrachitol derivatives for uptake inhibition assays 
 
 The work described here was done in order to extend the usefulness of 
quebrachitol and its derivatives as potential inhibitors of the biosynthesis of 
inositol-containing cell surface molecules. These are important to the function of 
certain bacterial species (eg Mycobacterium tuberculosis), as discussed in 
chapter four. The four derivatives shown in scheme 5.17 were prepared and 
tested, with biological activity results discussed at the end of this section.  
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Scheme 5.17. The derivatives prepared for the enzyme inhibition study. 
 
Preparation of the dimethyl derivative 1L-1,2-di-O-methyl-chiro-inositol 
(305) was achieved readily in two steps from the dicyclohexylidene derivative 
274 (scheme 5.18). Methylation of the free hydroxyl group with sodium hydride 
and methyl iodide in DMF proceeded to give 308 in 94% yield (this reaction has 
also been reported181 using silver oxide and methyl iodide in DMF). Subsequent 
cleavage of the two cyclohexylidene groups was accomplished upon stirring in 
10% HCl in methanol at room temperature overnight. This deprotection was also 
attempted using 80% acetic acid in water, but after stirring for 18 hours, TLC 
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analysis of the reaction mixture revealed that a significant amount of mono-
cyclohexylidene protected material was still present.  
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Scheme 5.18. Synthesis of 1L-1,2-di-O-methyl-chiro-inositol, 305. 
 
The dimethyl derivative 305, was not soluble in CDCl3 or deuterated 
acetone, and thus its NMR spectra were run in deuterated DMSO. In this solvent, 
the hydroxyl protons are essentially non-exchangeable and the four hydroxyl 
signals were clearly visible as doublets at 4.86, 4.60, 4.55, and 4.45 ppm. The 
signal attributed to the one equatorial proton on a hydroxyl-bearing carbon, at C-
6, was significantly downfield of the other ring protons, appearing at 3.80 ppm. 
The other three ring protons (identified by HSQC, and by coupling to three of the 
hydroxyl protons in the gCOSY spectrum) on hydroxyl-bearing carbons C-3 to 
C-5 gave signals that were indistinguishable from each other as overlapping 
multiplets at 3.26 ppm.  
 
The preparation of 1L-1-O-benzoyl-2-O-methyl-chiro-inositol (306) was 
also effected in two steps from 274 (scheme 5.19). Benzoylation as discussed 
earlier in this chapter and subsequent cleavage of the cyclohexylidene groups 
gave the tetra-ol 306. As shown in scheme 5.19, a catalytic amount of para-
toluene sulfonic acid in acetone was used to remove both groups in acceptable 
yield after three days. The same conditions, but stirring for a much shorter time 
were also used to cleave only the trans- acetal, allowing the isolation of diol 279. 
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Scheme 5.19. Synthesis of 1L-1-O-benzoyl-2-O-methyl-chiro-inositol. 
 136 
 
The NMR spectra of the tetra-ol 306 were run in deuterated acetone 
(although 306 was sparingly soluble in CDCl3). In the 1H NMR spectrum, 
although signals for all of the hydroxyl protons could be seen, only the signal 
attributed to the proton of the axial hydroxyl on C-6 was coupled to the nearest 
inositol ring proton, appearing as a doublet at 4.65 ppm. It was also significantly 
downfield of the other three hydroxyl proton signals, which appeared as broad 
singlets at 4.32, 4.24, and 4.15 ppm. Similarly, the equatorial ring proton on C-6 
appeared at 4.06 ppm, downfield of the three axial protons on hydroxyl-bearing 
carbons (C-3 to C-5), which were indistinguishable from each other as 
overlapping multiplets at 3.66 ppm.  
 
By contrast, in the 1H NMR spectrum of the diol 279, run in CDCl3, all of 
the inositol ring proton signals were well resolved. The signal for the proton on 
the methoxy-bearing carbon (C-2) appeared furthest upfield at 3.53 ppm, as a 
distinct doublet of doublets, with coupling constants Jax-ax = 9.3 Hz and Jax-eq 2.9 
Hz. The C-1 ring proton signal appeared at 6.00 ppm, the furthest downfield of 
the ring proton signals in the 1H NMR spectrum. In the 13C NMR spectrum of 
306 (shown overleaf in figure 5.4), the C-1 signal appeared at 70.6 ppm, well 
upfield amongst the six inositol ring carbons. These observations are consistent 
with the benzoyl substituent on C-1, and gCOSY and HSQC analyses supported 
the assignment of these signals. There is one previous report of compound 
306,182 which reports an optical rotation of []D = +50.1° (c 1.01, MeOH). 
However, repeated measurements of the optical rotation of compound 306 
prepared during this work gave []D = -48° (c 0.06, MeOH or acetone). This data 
suggests that the sign of the optical rotation may have been incorrectly reported 
in the literature.182  
 
The third derivative was prepared from diol 282, which was prepared as 
described in section 5.3 of this chapter. Selective protection of the equatorial 
hydroxyl group of 282 is possible because the protection at the axial hydroxyl is 
disfavoured by 1,3-diaxial interactions with the axial ring protons. The diol was 
initially protected as the tert-butyldimethylsilyl ether by treatment with tert-  
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Figure 5.4. 13C NMR spectrum of 306. 
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butyldimethylsilyl chloride and imidazole in DMF (scheme 5.20). Mono- 
protected product was isolated in 75% yield, but silylation had occurred at both 
O-5 and O-6 of 282 to give a mixture of 309 and 310, with 309 as the major 
product. The two methyl groups of the TBDMS moiety were found to give 
unique signals in both the 1H and 13C NMR spectra, indicating that the bulky 
tert-butyl group also attached to the silicon restricted rotation about the Si-C 
bond. Benzoylation of a portion of the product to give a mixture of 313 and 314 
simplified the determination of the regioisomeric ratio due to the downfield shift 
of the signal attributed to the proton vicinal to the OBz group. The 1H NMR of 
the crude product, a doublet of doublets at 5.58 ppm (Jeq-eq = 4.9, Jax-eq = 3.5 Hz) 
which was attributed to the equatorial proton vicinal to the OBz group in the 
major product 313, and a doublet of doublets at 5.41 ppm (Jax-ax = 9.6, Jax-eq = 4.4 
Hz) attributed to the axial proton vicinal to the OBz group in the regioisomeric 
product 314. The ratio of 313:314 (and hence of 309:310) was obtained from the 
ratio of the integrals of those two signals, and was approximately 2:1.  
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Scheme 5.20. Preparation of 1L-1-O-methyl-chiro-inositol. 
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Despite this poor regioselectivity, compound 309 was progressed to the 
methyl ether 316, via a Williamson ether synthesis. The yield of this reaction 
was moderate, but upon purification by column chromatography, it was found 
that essentially pure 316 could be obtained in 45% yield. Subsequent 
simultaneous acid hydrolysis of the silyl ether and both of the cyclohexylidene 
groups, followed by workup and purification by flash column chromatography in 
CH2Cl2:methanol, gave the target penta-ol 307 in 89% yield, with an optical 
rotation []D = -57° (c 0.05, D2O), equivalent but opposite in sign to that reported 
for the enantiomer, 1D-1-O-methyl-chiro-inositol; []D = +59° (c 1.3, D2O).183  
 
Since the selectivity of the above silylation is based on steric bulk of the 
silyl group, the tert-butyl diphenyl silyl ether 311 was also prepared, in the hope 
that the larger group would enhance the regioselectivity. When the monosilylated 
product was benzoylated (as discussed previously), the 1H NMR spectrum of the 
product showed a doublet of doublets at 5.45 ppm (Jeq-eq = 3.9, Jax-eq = 3.8 Hz) 
which was attributed to the equatorial proton vicinal to the OBz group in the 
major product 303, and a doublet of doublets at 5.36 ppm (Jax-ax = 10.2, Jax-eq = 
3.9 Hz) attributed to the axial proton vicinal to the OBz group in 315. The ratio 
of products 303 and 315 (and hence of 311 and 312) was found to be 
approximately 5:1; significantly better than the analogous TBDMS analogue. It 
was found that 311 could be separated from the regioisomer by careful flash 
column chromatography. However, as the desired L-chiro-inositol derivative 307 
had already been prepared, the TBDPS protected compound was not progressed 
further. A potential disadvantage of using TBDPS over TBDMS is that harsher 
reaction conditions would be required for its removal.  
 
5.7 Biological testing of the derivatives 
 
The testing of these derivatives was carried out in the Department of 
Biochemistry and Molecular Biology, Medical College of Georgia. All four 
compounds were tested in uptake assays of two microorganisms, Candida 
albicans184 and Leishmania donovani.185 The former is an opportunistic fungus 
that is a normal part of the human endogenous microflora. However it is one of 
 140 
the most common human pathogens, and can cause a variety of infections from 
unpleasant mucosal infections in generally healthy people, to potentially life-
threatening systemic infections in already compromised individuals such as 
cancer patients. The second microorganism, Leishmania donovani is a parasitic 
protozoan flagellate that is responsible for the most severe form of leishmaniasis, 
known as visceral leishmaniasis or kala-azar. An estimated twelve million people 
worldwide are infected with this chronic disease, which is fatal if left untreated. 
 
Myo-inositol is an important component of these parasitic organisms. In 
C. albicans (yeast cells) it is an essential precursor for phospholipomannan, a 
GPI-anchored glycolipid that is involved in the cell’s pathogenic nature, binding 
to and stimulating human macrophages.184 In L. donovani, myo-inositol is 
essential for the formation of the GPI-anchors that form most of the surface 
molecules.185 As in all eukaryotic cells, myo-inositol is also important for the 
cell-cycle regulating phosphatidylinositol signal transduction pathways in both 
microorganisms. Hence, inhibition of GPI-anchor biosynthesis or of myo-inositol 
transport in these organisms are attractive drug targets.184,185 
 
In the uptake assays, the uptake of radiolabelled myo-inositol by the 
microorganisms was measured in the presence of the four L-chiro-inositol 
derivatives, and the inhibition of uptake of labelled myo-inositol was compared 
against the inhibition observed with unlabelled myo-inositol, as the optimal 
competitor. The concentration of radiolabelled myo-inositol was 100 M and of 
the unlabelled compounds was 10 mM. For both microorganisms, the mono- and  
 
Table 5.3. Results of the uptake assays in C. albicans and L. donovani.*  
 C. albicans L. donovani 
Control 100 ± 6.3% 100 ± 3.4% 
Myo-Inositol 5.4 ± 1.7% (P < 0.001) 5.4 ± 1.7% (P < 0.001) 
Quebrachitol 72.5 ± 6.8% (P < 0.001) 75.9 ± 3.1% (P < 0.001) 
307 73.7 ± 3.1% (P < 0.001) 91.2 ± 5.1% (P < 0.02) 
305 69.9 ± 3.5% (P < 0.0001) 88.4 ± 7.8% (P < 0.05) 
306 107.7 ± 8.8% (P < 0.20, n.s.) 96.1 ± 4.6% (P < 0.20, n.s.) 
* Results presented as percentage of (radiolabelled) myo-inositol uptake compared to control, as 
mean ± S.D. of 4-5 uptake assays, each. Statistical analysis performed by paired sample t-test. 
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Figure 5.5. Graphical presentation of the results of the uptake assays in C. 
albicans and L. donovani (the data shown in table 5.3), as mean ± S.D. of 4-5 
uptake assays, each. Statistical analysis performed by paired sample t-test (*** P 
< 0.001, * P < 0.05, al others P < 0.20/not significant). 
 
di-O-methylated L-chiro-inositol derivatives 307 and 305, as well as 
quebrachitol, gave significant inhibition results, with P values from P < 0.001 to 
P < 0.05 for paired-sample t-test analyses, i.e. 99.9% to 95% confidence for 
significant inhibition, respectively.186 The benzoylated derivative 306 did not 
induce any inhibition of myo-inositol uptake, indicating that the substrates 
showed no recognition for 306.186 This could be due either to the bulkiness of the 
benzoyl group, or perhaps that the benzoyl group, with its -electron system, has 
higher affinity for other amino acid side groups outside the binding site involved 
in the uptake assay, and hence does not compete with the myo-inositol uptake 
The results are presented in table 5.3, and also graphically in figure 5.5. 
 
Although none of the compounds showed inhibition as high as for myo-
inositol (i.e. the substrate specificity was highest for myo-inositol) these results 
show that the L-chiro inositol derivatives are recognised by the microorganisms. 
Hence, this work could form the starting point for further work on the effects of 
these compounds on the growth rate of the microorganisms, or for the synthesis 
and testing of other derivatives.  
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Chapter Six 
 
Variations and Improvements on the Preparation of 
myo-Inositol Camphanylidene Acetal  
 
 
The resolution of myo-inositol via the formation of a camphanylidene 
acetal, (-)-269a (with L-camphor, or (+)-269a with D-camphor, see scheme 4.17) 
was considered one of the most promising methods for large-scale preparation of 
enantiomerically pure myo-inositol derivatives.  
 
The work described in this chapter had the dual aims of a) gaining a 
better understanding of, and hence possibly improving the diastereoselectivity of, 
the procedure by using analogues of camphor in the acetal formation (section 
6.1), and b) process development to improve the procedure with a view to 
scaleup (section 6.2). A campaign to prepare 1.2 kg of (-)-269a was subsequently 
conducted, and is presented in chapter seven.  
 
 
6.1 Myo-inositol camphanylidene acetal and variations thereof 
 
6.1.1 Introduction  
 
The procedure for the preparation of myo-inositol camphanylidene acetal, 
which is discussed in detail in section 6.2, involves reaction of myo-inositol with 
camphor dimethyl acetal and catalytic sulphuric acid in DMSO at 70 °C. The 
product of this reaction, a complex mixture of acetals, is then ‘equilibrated’ in a 
mixture of chloroform, methanol and water acidified with pTsOH. It is unclear 
whether this equilibration step serves only to cleave the trans-acetals that also 
form in the initial reaction, or whether there is also interconversion between the 
four possible diastereomeric cis-acetals. Bruzik et al.168,171 report an increase in 
the level of desired diastereomer present from 47% to 65% during the 
equilibration. During the equilibration step, a slurry forms, and filtration of the 
slurry gives the crude product ((-)-269a or (+)-269a) in typically 75% yield. As 
discussed in chapter four, the major product is the 1,2- acetal (-)-269a shown in 
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scheme 6.1, when L-camphor is used, and the enantiomer (+)-269a when D-
camphor is used.  
MeO OMe
OO
HO
OH
OH
OH
1) DMSO, H2SO4
2) CHCl3, MeOH, H2O, 
pTsOH, RT overnightL-268 (-)-269a
HOOH
HO
OH
OH
OH+
Myo-inositol
 
 
Scheme 6.1. Formation of (-)-269a. 
 
The product is contaminated with the other three possible diastereomers, 
269b, 269c, and 269d (when L-camphor is used as the starting material) shown 
in figure 6.1, and is purified further by recrystallisation. Although the reaction 
works well, recovered yields of purified product vary from 25% - 65% in the 
literature. There appears to be a lack of understanding of why the selectivity for 
(-)-269a is so marked, or how the selectivity may be increased. The major yield 
loss seems to be in the recrystallisation, and if cleaner crude product could be 
obtained, this could potentially be improved.  
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Figure 6.1. The four possible diastereomers of myo-inositol L-camphanylidene 
acetal, and the major steric interactions found in (-)-269a. 
 
Analysis of the structures of (-)-269a, 269b 269c and 269d (using 
molecular models) shows that both the methyl group and the methylene H’s α to 
the acetal centre are responsible for the steric interactions within the molecule 
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(figure 6.1 shows those for (-)-269a). The interactions in each of the four 
diastereomers appear to be similar, with no interaction evident (from the 
molecular models) in the structure of 269b, 269c, or 269d that is significantly 
larger than those in (-)-269a. It was postulated that changing the steric bulk of 
the camphanylidene moiety at either the methylene or the methyl positions might 
enhance or decrease one of the interactions and thus increase the selectivity of 
the reaction. Several analogues of camphor (figure 6.2) were identified as 
candidates for acetal formation. Fenchone and norcamphor are commercially 
available, while the synthesis of C-10 substituted camphor derivatives is reported 
in the literature.187 
O
Nor-camphor
  (L- shown)
O
OO
E
L-camphor FenchoneC-10 substituted
     camphor, 318
 
Figure 6.2. Analogues of camphor for preparation of myo-inositol 
camphanylidene acetal analogues. 
 
 
6.1.2 Synthesis of a C-10 substituted camphor analogue 
 
The planned synthesis of a camphor analogue substituted at the C-10 
(methyl group - to the carbonyl) is shown in scheme 6.2 overleaf. Treatment of 
camphor with trifluoromethane sulfonic anhydride gives the triflate 319 by 
means of a Wagner-Meerwein rearrangement.187,188 Subsequent treatment with 
LAH or KOH gives the alcohol 320, then nucleophilic attack of the carbon-
carbon-double bond on  an electrophile (E+) to give a tertiary carbocation, 
followed by a second Wagner-Meerwein rearrangement gives the C-10 C-
substituted camphor analogues, 318. A variety of electrophiles have been used to 
give 10-dimethyl-aminomethylcamphor,187(b) 10-hydroxycamphor,187(c) and 
10-bromo-camphor,187(d) among other examples. The possibility of introducing a 
hydrogen bond was appealing, as this could introduce different interactions, 
which again might favour one diastereomer. 
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Treatment of camphor with trifluoromethane sulfonic anhydride was 
found to give product that appeared to contain two products by NMR analysis. 
Camphor was completely consumed during the reaction, but the two products 
could not be separated by TLC or column chromatography and further progress 
with this synthesis was limited. Unfortunately reaction of the mixed product 
could not be effected with LAH, or with KOH in diethyl ether.  
 
O
(Tf)2O TfO
EO
Base
LAH E
+
Camphor 319 320 318
H2C
HO
H2C
 
 
Scheme 6.2. Planned synthesis of a camphor analogue. 
 
6.1.3 Fenchone 
 
The preparation of the di-methyl acetal 321 of fenchone proved to be 
difficult, with low yields obtained using a variety of conditions (table 6.1). Using 
the analogous procedure to that used for the preparation of the dimethyl acetal of 
camphor (trimethyl orthoformate, methanol and pTsOH at RT for two days), 
only 5 - 10% conversion was obtained (by 1H NMR). Heating the reaction 
mixture gave somewhat improved conversion, but the reaction mixture began to 
discolour over time. Extending the reaction time to six days gave approximately 
30% conversion.  
 
Table 6.1. Formation of dimethyl acetal 321 from fenchone. 
O MeO OMe
321Fenchone
.
 
entry conditions temp time conversion* 
1 HC(OMe)3, MeOH, H2SO4 RT 2 days 5 – 10% 
2 HC(OMe)3, MeOH, H2SO4 60 oC 2 days 10% 
3 HC(OMe)3, MeOH, H2SO4 RT 6 days 30% 
4 MeOH, TMSCl RT 3 days < 5% 
*Starting material to product ratio was determined by inspection of the crude 1H NMR spectrum. 
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Literature reports echo this difficulty. The preparation of 321, as one of a 
range of acetals, was reported by treatment of fenchone with an excess of TMSCl 
in methanol, at RT for one hour.189 This was on a small scale for GC analysis of 
the products, and yields for individual reactions were not reported. Preparation of 
321 in this manner was attempted (table 6.1, entry 4), but after three days stirring 
at RT only traces of the product were detected in the reaction mixture. The 
acetalisation of fenchone at high pressure (15 mbar) with ethylene glycol in 
benzene with triethyl orthoformate and pTsOH has also been reported.190 At 
20 °C and 15 mbar for 48 h, the yield of the acetal was still only 22%, while at 
40 °C at that pressure a yield of 90% was reported.190(b) The authors mention190(a) 
that this acetalisation ‘failed to undergo reaction effectively with heating at 
atmospheric pressure’. 
 
It was decided to use the procedure in entry 3, table 6.1 to prepare 321, 
and purify the product by column chromatography (in petroleum ether) to free it 
from the unreacted fenchone. Approximately 5 g of 321 were thus obtained. The 
acetal was found to be a white solid that was volatile under hi-vacuum.  
  
With the reagent prepared, attempts to prepare the fenchone acetal of 
myo-inositol were conducted. Attempts to use the crude (30%) dimethyl acetal 
were unsuccessful - the myo-inositol never dissolved (indicating it was not 
reacting) and quantitative amounts of myo-inositol were recovered, even after 
several days of heating at 70 °C. However, when the purified reagent was used, a 
clear solution was obtained, suggesting that the myo-inositol was reacting. 
Unfortunately, the acetal products could not be isolated from the mixture. When 
the ‘equilibration’ was attempted on the crude material, myo-inositol was again 
recovered, indicating that the fenchone acetal (had it been present) had been 
cleaved. Direct reaction of fenchone with myo-inositol was also attempted 
(scheme 6.3), but again the myo-inositol did not dissolve and was recovered 
quantitatively. These results suggest that the increase in steric bulk obtained by 
replacing the protons of the methylene group  to the acetal centre (in the 
camphanylidene case) with a gem-dimethyl group, as in fenchone, precludes the 
formation of the analogous myo-inositol acetal. 
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Scheme 6.3. Attempts to prepare a fenchone acetal of myo-inositol. 
 
6.1.4 Norcamphor 
   
The second commercially available camphor analogue that was 
investigated was (racemic) norcamphor. Using the original acetalisation 
procedure that worked well with camphor, conversion of norcamphor to the 
dimethyl acetal 322 was achieved (scheme 6.5). However, some hydrolysis back 
to the ketone was observed upon workup. It was found to be preferable to use 
pTsOH as the acid catalyst, and quench the reaction with solid sodium carbonate 
before workup to give crude 322 in essentially quantitative yield. If water was 
added to quench the reaction, rapid hydrolysis of product to the ketone was 
observed. The crude acetal was purified by short-path distillation to give a clear, 
colourless liquid. 
O MeO OMe
322Norcamphor
.
+
OH
OH
HO
HO
HO HO
myo-inositol
323
 
Scheme 6.5. Formation of myo-inositol norcamphanylidene acetal. 
 
Subsequent reaction of the norcamphor dimethyl acetal with myo-inositol 
was much more successful than the analogous fenchone reaction had been. 
Reaction in DMSO with catalytic H2SO4 led to rapid disappearance of the solid 
myo-inositol to give a clear, very pale yellow solution. After neutralisation and 
concentration as in the camphanylidene acetal procedure described in the next 
section (section 6.2), two different workup procedures were employed. Firstly, 
the normal ‘equilibration step’ was conducted, stirring overnight in an acidic 
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mixture of CHCl3, MeOH, and water. This treatment gave a thick precipitate 
which, when filtered, gave an 80% yield of crude myo-inositol norcamphor 
acetals. In the second case, after neutralisation, more volatile components of the 
reaction mixture were removed in-vacuo, and then DMSO, any unreacted myo-
inositol and salts were removed by dissolving in toluene and washing with water 
and brine. The toluene was then concentrated and the residues subjected to the 
equilibration step as normal. It was thought that this might be a less harsh 
method to remove DMSO, avoiding the need to heat the product to 80 °C for 
what would become extended periods on scale. However, only a 30% yield of the 
norcamphor acetals was obtained from the equilibration step using this method, 
suggesting a significant amount of the product had been lost to the aqueous 
washes despite the fact that at that point each myo-inositol should, in theory, 
have had two norcamphor acetal moieties. 
 
The composition of the products from the two workups described above 
was very similar. Although the product of the toluene workup was cleaner, 
containing less myo-inositol and other (unidentified) impurities, both contained 
two major products. These were two diastereomers of myo-inositol nor-
camphanylidene acetal (the four possible diastereomers are shown in figure 6.3). 
Since the norcamphor that was used was racemic, each would be present as an 
enantiomeric pair. The two diastereomers could not be separated, and hence were 
not identified, but it may be proposed that either 323a and 323b OR 323c and 
323d were present. This is based on the fact that the methyl group, which, in the 
camphanylidene acetal, provides one of the two major steric interactions with 
myo-inositol, had been removed. Hence, steric interaction with the protons of the 
methylene group  to the acetal centre provides the major steric interaction in the 
nor-camphanylidene acetal. In 323a and 323b, interaction with the axial protons 
on the ‘top’ face of the inositol ring is minimised. In 323c and 323d, interaction 
with the equatorial inositol proton at C-2 is minimised.  
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Figure 6.3. The four diastereomeric myo-inositol norcamphanylidene acetals that 
are possible from one of the enantiomers of norcamphor. 
 
Recrystallisation of the crude myo-inositol norcamphanylidene acetals did 
result in enrichment in one of the products, but isolation of a sample of a single 
isomer proved elusive. Per-acetylation of the crude product was also carried out, 
in the hope that the products could be chromatographically separated, but the 
products still appeared as one spot on TLC.  
 
 
6.2 Process development for myo-inositol camphanylidene acetal  
 
The formation of myo-inositol camphanylidene acetal was chosen for 
further development with a view to scale up. To summarise the advantages of the 
procedure that led to this decision: 
• Resolution occurs early in the synthesis (minimum number of steps).  
• Use of L-camphor gives 1D-1,2-myo-inositol-camphanylidene acetal, 
while use of D-camphor gives 1D-2,3-myo-inositol-camphanylidene 
acetal. Hence access to both enantiomers is easy.  
• Both D- and L-camphor are commercially available. 
• The starting materials are readily available and not expensive (although 
L-camphor is significantly more costly than D-camphor, L-camphor may 
be prepared from the more reasonably priced (-)-borneol).  
• The reaction is performed at reasonable temperature of 70 °C (easy to 
achieve in the scale up equipment). 
• The product is isolable by crystallisation (this is far preferable to 
chromatography when considering scale up). 
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• When overall yield is considered, the method is superior to most of the 
other methods in the literature, with theoretical yield of 100%. 
• 1,2-protected D-myo-inositol was required by chemists in the 
carbohydrate team at IRL as part of their research program and for the 
synthesis of a target molecule requested by a client. The procedure had 
already been carried out in-house to give high quality product but in low 
yields (on several gram scale). 
 
The procedure published by Lindberg et al.169 was the basis of the work 
presented in this chapter, along with a published oxidation of (-)-borneol191 to 
give L-camphor. The complete synthesis that was intended to be scaled up is 
shown in scheme 6.6. In Lindberg’s procedure, the camphor dimethyl acetal 
reagent is prepared in-situ, avoiding the need for a purification step. This was a 
reason for choosing this procedure as a basis. Subsequent reaction of the crude 
camphor dimethyl acetal with myo-inositol and sulphuric acid in DMSO gives a 
complex mixture of acetals, which after removal of the DMSO (likely to be a 
difficulty on larger scale) is ‘equilibrated’ overnight in the solvent mixture 
shown (scheme 6.6) with pTsOH. The crude product precipitates from this 
mixture, and is collected by filtration in reported yields of typically 60 – 70%. 
Recrystallisation of the crude material from unspecified volumes of methanol or 
methanol: water to give pure (-)-269a in 39% is reported in the literature. These 
crystallisations were found to be unsatisfactory for potential scale up, primarily 
due to the large volumes required (discussed in section 6.3.4).  
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Scheme 6.6. The synthesis of 1D-1,2-myo-inositol-L-camphanylidene acetal, 
proposed for process development and scale up. 
 
One of the important considerations upon scale-up of a procedure is the 
total volume of the reaction or workup being considered. In the large-scale 
 151 
laboratory, the size of the reactor and receiver vessels is fixed. Hence, the 
procedure must be scaled so that the largest volume step of the synthesis will fit 
in the available equipment. Generally, the lower the volume the better (assuming 
product quality and yield are not compromised), both for reasons of cost and 
efficiency, and simply because smaller volumes are easier to handle and take less 
time to process (eg a filtration that needs to be done with the 24 cm Buchner 
filters and 10 L Buchner flasks that are available will take twice the time if there 
are 20 L of filtrate versus 10 L of filtrate). Significant changes were made to the 
crystallisation procedure (discussed in section 6.2.4). In the following sections 
(6.2.1, 6.2.2 and 6.2.3), each step of the synthesis is considered and the process 
development that was done to address the likely scale-up issues is described.  
 
6.2.1 Oxidation of (-)-borneol to give L-camphor  
 
Naturally occurring (1R)-(+)-camphor, (D-camphor), is available at a cost 
of $209.70 for 500g.i The unnatural enantiomer, (1S)-(-)-camphor (L-camphor), 
is available commercially but for the much higher price of $109.90 for 10 g (95% 
purity) or $104.00 for 5 g (99% purity). Unfortunately, the latter was the isomer 
required for the derivatisation of myo-inositol described in chapter seven. 
Approximately 5.7 kg of (-)-camphor were required for the planned synthesis, 
which at the price quoted would cost $62,643.00, which far exceeded the 
available budget! Fortunately, (-)-borneol is available at a much more reasonable 
cost and a synthesis of camphor via the oxidation of borneol that was reported to 
be suitable for large-scale work has been reported.191 The synthesis involves 
treating camphor with aqueous sodium hypochlorite in glacial acetic acid, 
followed by a quench with sodium bisulfite, precipitation of the product in 
ice/brine, and then a petroleum ether:water partition. This procedure should be 
able to be completed in three days in the scale-up laboratory. A conservative 
estimated total cost of preparing the L-camphor in-house using this method is 
presented in table 6.2. Searching different suppliers would almost certainly 
identify cheaper sources of the reagents, and bulk order rates usually apply on 
                                                
i
 Prices quoted in this section are all from the Aldrich Chemical Company 2003-04 catalogue. 
Prices quoted are in Australian dollars. In chapter seven, different prices may be quoted because 
different suppliers were used for some items, and bulk order rates applied.  
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this scale. Two scientists are required at all times in the scale up laboratory for 
safety reasons, and the figure shown in the table is for two IRL scientists. 
However in this case, this cost, usually one of the biggest costs of scale-up 
synthesis, was mitigated because one of the two scientists would be the student. 
 
This analysis demonstrated that it would be far preferable to prepare the 
camphor in-house. However, in order to demonstrate that the highly exothermic 
oxidation could be carried out safely with the available equipment, a calorimetric 
analysis of the exotherm was required. 
 
Table 6.2. Estimated cost of in-house synthesis of ca. 5.6 kg of L-camphor. 
Item Unit cost # required Total cost 
(-)-Borneol $312.30/500 g 12 $3,747.60 
Glacial acetic acid $393.40/19 kg 1 $393.40 
15% aq. NaOCl $12/5 L 4 $48 
Sodium bisulfite $58.20/500 g 1 $58.20 
NaCl (for 60 L brine) $256.70/12 kg 1 $256.70 
Petroleum ether $345.70/20L 1 $345.70 
LT9 facility charge $250/day 3 $750 
2 Scientist’s time $120/hour 2 x (3 x 7.5 h days) $5,400 
TOTAL   $10,999.60 
 
 
Calorimetric analysis of the oxidation 
 
Two pieces of information were required to confirm the safety of the 
oxidation procedure; the magnitude of reaction exotherm, and the heat transfer 
capacity of the reactor, together with the power available from the heater/cooler 
unit. These two pieces of data were necessary in order to determine whether there 
was enough cooling power available to control the exotherm of the oxidation, 
even in a worst-case scenario (i.e. all reagent added at once and cooling failure). 
 
Dr Graham Caygill (IRL) calibrated the then new 50 L reactor (which 
was commissioned during the scaleup synthesis of 1,2-D-myo-inositol-L-
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camphanylidene acetal, see chapter seven) in order to obtain the second piece of 
information listed avove. A known volume of methanol was heated to 40 °C in 
the reactor and the temperature change of both the jacket and the reactor contents 
were logged for 50 minutes after the jacket setpoint was changed from 40 °C to 
5 °C. Although it took only 8 minutes for the jacket temperature to reach the new 
setpoint, the reactor contents temperature lagged far behind. After 50 minutes the 
contents temperature was 9.5 °C. From this data, the rate of heat transfer between 
the jacket and the contents could be calculated. This value changes somewhat 
with the volume and composition of the reactor contents, but it is reasonably low 
(as evident from the slow rate of methanol cooling) because the thick glass walls 
do not transfer heat very well. The result of this calibration was deemed a good 
approximation for the borneol oxidation. Having this figure, and knowing the 
theoretical output of the heating/cooling unit and the physical dimensions of the 
system, the cooling power that would be available for the oxidation reaction on 
the planned scale of 38 L was calculated to be approximately 2 kW.  
 
To determine the magnitude of the reaction exotherm, the calorimetery 
equipment available at Industrial Research Limited was used, with the help of Dr 
Graham Caygill (IRL). The reaction was run in a 1 L glass vessel on the scale of 
65 g (0.42 mol) of borneol, 200 mL of glacial acetic acid and 215 mL of 15% 
aqueous NaOCl. During the course of the experiment, a range of parameters were 
logged, including oil temperature going into and coming out of the 
heating/cooling jacket, heater power, and reactor contents temperature. Four key 
reaction steps were undertaken: 
1. After stabilisation of the reactor contents (borneol and acetic acid) at 
15 °C with the heater set at a ‘baseline’ low level (5%), an initial 
calibration step was done. Thus, the heater power was increased to a fixed 
power of 30%, and a new steady state established. On reaching the new 
jacket temperature required to maintain the contents at 15 °C, and after a 
steady state had been maintained for 20 minutes, the heater power was 
reduced back to the original 5%. The data collected allowed calculation 
of the UA (heat transfer rate) of the system. 
2. The original baseline steady state was re-established. 
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3. The NaOCl solution was added at a constant feed rate over a period of 
two hours. This was the planned rate of addition in the 50 L reactor. The 
heater was kept at a fixed power of 5% to provide a ‘background’, and 
the reactor contents were held isothermally at 15 °C. A slight increase in 
reactor contents temperature to 17 °C was observed before the jacket 
temperature dropped to allow for the reaction exotherm, and a slight drop 
was observed when the reaction was essentially complete and when the 
NaOCl feed was complete. After the end of the addition, the reaction was 
allowed to stir until a steady state had been maintained for 30 minutes. 
4. A second calibration step was done in the same way as in step 2.  
 
The specific reaction power calculated for the AcOH/NaOCl oxidation of 
65 g of borneol from the data collected above was 20 W. Since the volume of 
this reaction was 415 mL, the reaction power was calculated to be 20/0.415 = 
48 WL-1. The planned scale of the reaction on scale-up was 5.9 kg of borneol, 
with a total reaction volume of 37 L. Hence, the reaction power on that scale was 
calculated to be 48 x 37 = 1776 W (1.78 kW). Given that the cooling power of 
the equipment at the planned reaction temperature (15 °C) was ca. 2 kW based 
on the calibration discussed above, this indicates that the cooling power should 
be sufficient to control the exotherm. 
 
Also calculated as part of this analysis was the maximum temperature 
that would be reached (maximum temperature of the synthesis reaction, MTSR) 
if the NaOCl solution were to be dumped into the reactor (in this case the 
calorimeter) in one portion, and cooling should fail. The MTSR is the adiabatic 
temperature rise (ATR) plus the reaction temperature (Treaction, 15 °C), and: 
 
ATR = - H/mcp   
where  H = - 128 kJ (the total energy output of this reaction) 
m = mass of each component of the reaction mixture  
cp = specific heat capacity at constant P of each component 
 
The mass of borneol in the reactor is small relative to the amounts of AcOH and 
aqueous NaOCl, hence the borneol component was ignored (this was allowable 
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since it would give a more conservative estimate of the ATR). The 15% NaOCl 
solution, for the purposes of this calculation was assumed to have the properties 
of water. Hence: 
 
 mcp for HOAc = 0.20 L * 1.05 kgL-1 * 2.04 kJkg-1K-1 
 mcp for NaOCl = 0.215 kg * 1.00 kgL-1 * 4.18 kJkg-1K-1 
 
mcp for borneol = negligible (may be ignored) 
      
therefore,  ATR = 128 kJ / (0.428 kJK-1 + 0.899 kJK-1) = + 96 K 
   
and   MTSR = ATR + Treaction = 96 + 15 = 111 °C 
 
The MTSR is above the boiling point of the lowest boiling component of the 
mixture, water (b.p. 100 °C), and hence this indicates that in the worst case, the 
reaction mixture could be caused to boil, or even to suddenly volatilise and 
explode out of the reaction vessel. However, it was decided that the reaction 
would be safe to run in the available equipment, given that the calculation was a 
conservative one, and that in this case it would be easy to avoid addition of the 
entire amount of NaOCl solution at once. In fact, adding all the solution at once 
would be impossible, since it was to be added slowly from the header vessel, 
which holds only 5 L, while 19.6 L would be required. 
 
Unfortunately, when the oxidation was carried out in the calorimeter, the 
HCl evolved from the aqueous NaOCl solution corroded the stainless steel probe, 
discolouring the reaction to a brown colour. This did not appear to affect product 
quality or yield, which were comparable to other laboratory scale runs. However, 
corrosion of stainless steel is a major issue in scaleup, as stainless steel is 
commonly present in plant-scale equipment. The available 50 L reactor that was 
planned to be used was made of glass, with no stainless steel fittings that 
normally come into contact with the reaction mixture, but the framing and some 
fittings that support the reactor were made of stainless steel. Therefore, it was 
decided to use a positive flow of air through the reactor and away from the 
stainless steel fittings at the top of the condenser when it was run on scale, as 
well as running the fume hood on ‘boost’ and washing everything down with 
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water as soon as possible after the reaction was complete, to avoid corrosion by 
chlorine gas as much as possible.  
 
The workup of this oxidation involves quenching the reaction with 
saturated aqueous sodium bisulfite solution (approximately 25 mL was required 
for the 65 g of borneol scale run in the calorimeter), and then pouring the entire 
contents of the reactor into ice/brine to precipitate the product. In the literature 
procedure, 20 volumes (relative to the mass of the borneol used) of ice/brine 
were used. The planned scale of 5.9 kg of borneol would equate to 120 L, which 
added to the reaction volume would have been in excess of 150 L. This was too 
large a volume to reasonably manage. Fortunately, it was found that using only 
8-10 volumes of ice/brine had no apparent negative effects on yield or quality of 
product. The reaction mixture from the calorimetry experiment discussed above 
was quenched with sodium bisulfite as in the literature and then poured onto 
650 mL (10 volumes) of ice/brine. The solid product was collected by filtration 
and then dissolved in petroleum ether. The solution was then washed with water, 
dried with brine, and subsequently evaporated to give 60.2 g (94%) of L-
camphor. This yield was comparable to those achieved on laboratory scale during 
this work and also to the literature yield of 95.8%. 1H and 13C NMR spectra were 
analogous to those obtained on smaller scale, and to those from an authentic 
sample of camphor. 
 
6.2.2 Preparation of (-)-L-camphor dimethyl acetal ((-)-268) 
 
This step, as reported by Lindberg et al.,169 involves treatment of 
camphor with trimethyl orthoformate, methanol and sulphuric acid, and stirring 
at RT for 48 hours. The mixture is then neutralised with solid sodium methoxide, 
and the solvent and excess trimethyl orthoformate removed under vacuum. The 
residues are dissolved in toluene, and Na2SO4 salts precipitated out. These are 
removed by filtration, and the toluene removed under vacuum to give crude 
camphor dimethyl acetal, suitable for use in the next step.  
 
Since every operation (e.g. separation, filtration etc.) takes an extended 
time on scale, the ‘in-situ’ preparation of the camphor dimethyl acetal reagent 
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was very desirable. The drawback of the reported procedure was that the reaction 
was run for 48 hours. This equates to inefficient use of time on large scale, since 
the equipment cannot be used for any other process while the 48 h stir takes 
place, and the facility charges (and scientist’s time) must still to be paid for. 
Fortunately, monitoring of the reaction (by workup of a small aliquot of the 
reaction mixture and subsequent 1H NMR analysis) showed that after 20 h the 
reaction was essentially complete. Stirring for the full 48 h did not detectibly 
change the composition of the reaction mixture. 
 
Also, a significant reduction in the amount of trimethyl orthoformate used 
in this step was effected. Although the total volume of this reaction, at seven 
volumes, was not excessive, the cost of the trimethyl orthoformate reagent 
(A$217.90 for 2 Lii) made any reduction of the amount required worthwhile. 
Lindberg’s procedure used seven equivalents (five volumes) of trimethyl 
orthoformate. It was found that this could be reduced to five equivalents (3.5 
volumes) without detectable (1H NMR) loss of product quality or yield. 
Reducing the amount of trimethyl orthoformate further to two equivalents did 
result in a lower conversion of camphor to product (ca. 10% camphor was still 
present after 20 hr). Since there is no purification step at this stage, the product 
quality needs to be high, and it was decided to use no less than five equivalents.  
 
The precipitation of salts with toluene and subsequent filtration was not 
expected to cause any particular issues on scale up. The use of a toluene 
azeotrope is an effective method for drying materials on large scale because it is 
efficient and requires a minimum amount of manual handling.  
 
6.2.3 Myo-inositol camphanylidene acetal formation 
 
The formation of myo-inositol camphanylidene acetal is a two-step 
procedure. In the first step, the crude camphor dimethyl acetal is dissolved in 
DMSO and then myo-inositol and catalytic sulphuric acid are added. Then, the 
mixture is heated to 70 °C for three hours, during which time the suspension 
                                                
ii
 Aldrich Chemical Company 2003-2004 catalogue price. 
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changes to a clear solution as the myo-inositol reacts (myo-inositol itself is not 
readily soluble in DMSO). Workup of the reaction involves neutralisation with 
triethylamine and then concentration of the mixture to give a viscous crude 
product, which is a complex mixture of acetals. It is likely that each molecule of 
myo-inositol has two camphanylidene acetal substituents at this point; one 
cis-acetal (i.e. the desired product, at the 1,2- position, or one of the three other 
isomeric possibilities), and one less stable trans-acetal. The equilibration step 
then involves dissolving the crude product in a 50:5:1 mixture of 
chloroform:methanol:water, adding catalytic pTsOH and stirring at ambient 
temperature overnight. In this process, cleavage of the trans-acetals occurs, and 
there may also be some interconversion between the four possible diastereomeric 
cis-acetal products. This would be an equilibrium-type process favouring the 
major product for a combination of solubility and steric reasons. The desired 
diastereomer precipitates out as the major product during the equilibration and 
the crude product is collected by filtration, in yields 65 – 75% (typically 
containing 10-20% of the other three diastereomers). The crude product is then 
recrystallised (discussed in section 6.3 below). 
 
A number of issues were identified that would be likely to cause 
difficulty with the scale-up of this procedure: 
• The boiling point of DMSO is 182-3 °C. In the lab, removal of DMSO 
was done at 1-2 mm Hg with a hi-vacuum pump attached to a rotovap 
with the water bath at 80-90 °C; on large scale these conditions will be 
difficult to reproduce. The available 50 L rotovap is connected to house 
vacuum and a typically the best vacuum obtainable is 12 mm; 
• Chloroform is a toxic and undesirable solvent; 
• Large volumes (22 volumes) of solvent are required for the equilibration.  
 
Reaction solvent 
 
Ideally, replacement of DMSO with another solvent was envisaged, 
thereby completely eliminating the problem of DMSO removal. DMF and 
dioxane were both tried as alternatives, however neither was satisfactory. With 
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dioxane as the solvent, after heating to 95 °C overnight (c.f. the three hours at 
70°C in DMSO) nearly quantitative amounts of myo-inositol were recovered. In 
DMF, after stirring for two days at 85 °C there was still solid myo-inositol 
present. Even after further heating to 110 °C for ten hours, 80% of the myo-
inositol was recovered after quenching and filtering. 
  
 As replacing the DMSO was clearly not viable, the focus turned to 
reducing the total volume of DMSO in order to minimise the difficulties of 
removing it in the workup. Lindberg et al. had noted that a small amount of 
DMSO present in the equilibration increased the yield and quality of product. 
Hence, it was thought that if the reaction could be performed in a minimal 
volume, the removal of the DMSO might be avoided altogether. It was found that 
with one volume of DMSO a biphasic mixture formed and incomplete reaction of 
myo-inositol was observed. With two volumes, the reaction did proceed, and was 
carried through the equilibration step as usual to give crude product in 70% yield. 
However, the quality of the product was not satisfactory, with increased amounts 
(compared to the crude product made following the literature procedure) of the 
undesired diastereomers present in the product. Using three volumes of DMSO, a 
similar crude yield was obtained but the quality of the crude product was now 
comparable (by 1H and 13C NMR) to the crude product mixtures obtained using 
the original literature procedure. Three volumes of DMSO were preferable to the 
original ten, as the time required to remove the solvent would be much shorter.iii 
In the worst case scenario, the reaction mixture from a large scale run with three 
volumes of DMSO could be portioned up and concentrated in the laboratory. 
 
Equilibration step 
 
The solvent system for the equilibration step, 20 volumes (relative to the 
amount of myo-inositol used) of 50:5:1 chloroform:methanol:water, was reported 
in the original procedure (Bruzik et al.)167,168 and is repeated in the subsequent 
literature with little change. Evidently this solvent system was arrived at with a 
significant amount of experimentation, since efforts during this work to modify 
                                                
iii
 In fact, as reported in chapter seven, the removal of four litres (of the 7.5 that were used) of 
DMSO from the reaction mixture on large scale took 7 h at 15-20 mbar and 95±5 °C. 
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the system had limited success. Replacement of toxic chloroform with 
dichloromethane led to somewhat lower yields of crude product (50-55%). 
Although (-)-269a was still the major product, significantly more of the 
diastereomeric impurities were also present. Whether this was because the 
solvent system was less preferential for precipitation of the major product, or 
because the different system was affecting the equilibration/interconversion 
between the diastereomers was not clear. The subsequent crystallisation step was 
attempted, but purifying the crude product proved to be very difficult. After two 
crystallisations (with the new acetone:water procedure described in the next 
section), with a loss of approximately 20% of the mass each time, the product 
still contained significant amounts of the undesired diastereomers. 
 
Reducing the volume of the equilibration step also proved tricky. With 20 
volumes of the specified solvent mixture, after the precipitation a reasonably 
mobile slurry is formed that filters readily. When ten volumesiv of the solvent 
mixture were used, the result was an essentially immobile slurry which required 
a large amount of solvent (at least another ten volumes on the laboratory scale) to 
a) mobilise the slurry so it could be poured from the flask and b) rinse the flask 
effectively to get all of the product out. Use of 15 volumes of solvent gave 
slightly better results, but extra solvent was still required to get all the material 
onto the filter. On large scale, very thick mixtures are undesirable for two 
reasons. Firstly, if a mixture is not stirred consistently, loss of control of the 
process may occur, and secondly, the thicker the mixture, the more likely it is 
that lines or valves will block as the mixture is being transferred from vessel to 
vessel. It was decided to avoid these risks and therefore to use the full 20 
volumes of solvent upon scale-up of this process.   
 
6.2.4 Improved Crystallisation Procedure 
 
The crude myo-inositol camphanylidene acetal obtained from the 
equilibration step described above requires recrystallisation to remove the other 
three diastereomers, which are invariably also precipitated. In the literature, 
                                                
iv
 Upon scale-up of a reaction, 10 volumes is generally considered an acceptable volume, any 
more than 10 volumes becomes too inefficient and is less than ideal. 
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recrystallisation from unspecified volumes of methanol or methanol-water are 
reported. However, these solvents were found to be far from ideal, with 
extremely large solvent volumes (up to 300 volumes) required to effect complete 
dissolution of the crude myo-inositol camphanylidene acetal. Often, the solution 
would not clarify, and hot filtration was done. The solids thus removed were 
shown to be fairly clean product. Both the quality and the recovered yield of the 
product was variable, with yields typically well below 40%. In the literature, the 
initial report168 quotes a 65% crude yield of ‘sufficiently high purity for direct 
synthetic use’, but does mention that spectrally (NMR) detectable amounts of 
diastereomers are present, and also that difficulty was experienced in preparing 
completely transparent solutions of (-)-269a and (+)-269a. Other reports describe 
two, three or more crystallisations to obtain material ‘essentially free of other 
isomers’ in typically 25 - 30% yield,171 or use unspecified ‘modified procedures’ 
and report yields in the low 30%’s.170  
 
Crystallisation is always the preferred method for purification on scale 
(far preferable to column chromatography for example). However it was clear 
that the literature method for recrystallising (-)-269a was far from satisfactory. 
Therefore, a series of alternative crystallisations were tried on a small scale, with 
selected results presented in table 6.3. In each case, the crude camphanylidene 
acetal was dissolved hot in the indicated solvent and then allowed to cool slowly 
(by standing on a warm hotplate that had just been turned off), to better 
approximate the slower rate of cooling that occurs in a larger volume of solution.   
 
The crude myo-inositol camphanylidene acetal was essentially insoluble 
in any solvent other than acetone:water or methanol/ethanol:water mixtures. 
Attempts to use co-solvents (such as diethyl ether or ethyl acetate) to precipitate 
out the product invariably caused all of the diastereomers to crash out of solution. 
In the acetone:water case, approximately 1:1 mixtures allowed dissolution of the 
material in the lowest volume of solvent (30-50 volumes depending on the 
quality of the starting material; less clean material required less solvent); using 
1:4 or 4:1 mixtures of acetone:water both required larger volumes (ca. 
100 volumes) for complete dissolution. Additionally, the camphanylidene acetal 
was very difficult to dissolve in either acetone or water alone.  
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Table 6.3. Alternative crystallisation procedure – small scale trials. 
* Quality of the crystals assessed by a combination of 1H and 13C NMR analysis, physical 
appearance and ease of filtration of the crystals, and optical rotation. 
  
Based on these results, the acetone:water procedure was chosen for 
further investigation. This was due in large part to the nature of the crystals 
obtained - fine platelet-like crystals that filtered rapidly. Such crystalline material 
had never been obtained from methanol, which gave white amorphous material. 
Hence, the acetone:water procedures were scaled up to the several gram scale 
(selected results, table 6.4). On this slightly larger scale the solutions were stirred 
as they cooled, which is the usual crystallisation procedure in a kilo-scale 
laboratory due to better control with a stirred solution. Heat transfer upon cooling 
is better (a homogeneous mixture is more easily maintained), especially 
important if a ramp cooling of a jacketed vessel is used.  
 
In this case, the stirred 1:1 acetone:water solution gave a relatively 
impure (though still much cleaner than the crude material) white powdery instead 
of the crystals previously observed; this was probably due to the stirring of the 
solution causing a change in the way nucleation occurred. Generally, larger 
crystals seemed to form when solutions were not stirred as they cooled. Also, the 
best recovered yield obtained for the 3:2 acetone:water procedure was obtained 
for a crystallisation that was not stirred. Attempts to prepare a second crop of  
Amount 
of crude 
material 
Crystallisation 
solvent 
Volume Yield 
(% recovery) 
Comments* 
300 mg MeOH 100 mL 90 mg (30%) Hot filtration required 
to clarify the solution 
350 mg MeOH:H2O:Acetone 
1:1:1 
40 mL 117 mg (33%) Good quality 
300 mg Acetone:water 1:2 25 mL 113 mg (39%) Good quality 
300 mg EtOH:water 1:1 30 mL 117 mg (39%) Good quality but 
somewhat slow to 
filter 
200 mg EtOAc - - Wouldn’t dissolve 
even upon MeOH 
and/or acetone 
addition 
300 mg Acetone:H2O 3:2 17 mL 120 mg (40%) Excellent quality 
360 mg Acetone:H2O 1:1 23 mL 142 mg (39%) Excellent quality 
360 mg Acetone:H2O 4:1 42 mL 124 mg (34%) Excellent quality 
360 mg Acetone:H2O 1:4 37 mL 155 mg (43%) Fine crystals – lower 
quality – slow to filter 
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Table 6.4. Alternative crystallisation procedure – larger scale trials. 
* Quality of the crystals assessed by a combination of 1H and 13C NMR analysis, physical 
appearance and ease of filtration of the crystals, and optical rotation. 
 
 
crystals from the filtrate of these larger scale trials were of limited use. Solid 
product could be obtained from the filtrate in reasonable yield (40 - 50%), but 
this was invariably contaminated with significant amounts of diastereomeric 
acetals. 
 
The modified crystallisation procedure using 3:2 acetone:water at a rate 
of 30-50 volumes (mL g-1) was soon adopted as the preferred purification method 
in the preparation of the myo-inositol camphanylidene acetal. This method 
consistently gave 35-40% recovery of product from the crude material, which 
equates to more than 25% yield (from myo-inositol) of good quality crystalline 
product. This is comparable to reported literature yields, while the method is less 
problematic than the published crystallisation procedure. Very good quality 
crystals could now be obtained, and a single crystal X-ray structure (figure 6.4) 
was obtained. This crystal structure had not been previously published. 
 
The crystal structure confirmed the orientation of the camphor moiety in 
the major camphanylidene acetal (-)-269a. The gem-dimethyl group does not 
interact with the inositol ring but is well away. The methyl group (labelled as 
C 13 in figure 6.4) is oriented over the plane of the inositol ring. The potential 
for steric interaction between the C-13 protons and the axial inositol ring protons 
is evident in the structure, as well as that between the equatorial C-2 inositol ring 
Amount 
of crude 
material 
Crystallisation 
solvent 
Volume Yield 
(% recovery) 
Comments* 
2.8 g Acetone:H2O 1:1 
stirred 
170 mL 1.2 g (43%) Fine white powder – 
slow to filter, 
containing some 
diastereomeric 
impurities 
2.8 g Acetone:H2O 3:2 
stirred 
140 mL 1.1 g (38%) Good quality 
2 g Acetone:H2O 3:2 
not stirred 
80 mL 0.9 g (47%) Excellent quality 
12 g Acetone:H2O 3:2 
stirred 
450 mL 5.1 g (43%) Excellent quality 
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proton and the methylene protons of C-12 (in figure 6.4) of the camphor moiety. 
The balance between these two interactions, and with the analogous interactions 
in the other three isomers, along with solubility effects during the equilibration, 
must form the basis of the selectivity seen in this reaction. 
 
 
Figure 6.4. X-ray crystal structure of 1D-(6-S)-1,2-O-(L-1,7,7-
trimethyl[2,2,1] bicyclohept-6-ylidene)-myo-inositol, (-)-269a.v 
 
6.2.5 Summary and Conclusions 
 
The process development work described in the previous sections is 
partially summarised in table 6.5. The significant volumes of reagents used in 
Lindberg’s procedure are shown, alongside the volumes that were arrived at after 
the process development described in the previous sections. The reaction volume 
required for the formation of (-)-L-camphor dimethyl acetal ((-)-268) has been 
reduced, which is beneficial because the trimethyl orthoformate used in that step 
is relatively expensive. Also, the volume of DMSO used in the reaction with 
myo-inositol was significantly reduced. This was important because removal of 
DMSO was forecast to be one of the major problems with the procedure on 
                                                
v
 Numbering of the atoms in the X-ray structure is not equivalent to the IUPAC numbering. 
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7 8
13
914
16
12
11
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scaleup (DMSO could not be replaced with another solvent, see section 6.2.3). 
Reducing the volume of the equilibration step was not possible, and 
unfortunately this is the ‘limiting’ volume step in this synthesis. 
 
Table 6.5. Volumes (mL/g) used in the myo-inositol camphanylidene acetal 
preparation before§ and after process development.** 
 Reagent Before After  
Borneol  (-)-L-camphor 1 1 
oxidation Trimethyl orthoformate 5 3.5 
 Methanol 1 1 
 TOTAL REACTION VOLUME 7 5.5 
 Toluene 4.8 4.8 
 WORKUP VOLUME 5.8 5.8 
Reaction of Myo-inositol 1 1 
myo-inositol (-)-L-camphor dimethyl acetal (from step 1) 2.6 2.6 
 DMSO 10 3 
 TOTAL REACTION VOLUME 13.6 7.6 
Equilibration Chloroform 17 17 
 Methanol 1 1 
 Water 0.4 0.4 
 EQUILIBRATION VOLUME* 22 22 
§ i.e.volumes used in the procedure published by Lindberg.169 
* Includes volumes of myo-inositol and (-)-L-camphor dimethyl acetal from step 2. 
** Relatively small-volume reagents such as catalytic sulphuric acid are omitted for clarity. 
 
 The crystallisation step is not included in the table because the volumes 
required were not reported in the literature. However the crystallisation step was 
significantly improved, as changing to an acetone:water mixed solvent allowed a 
smaller crystallisation volume to be used and excellent quality final product to be 
obtained. 
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Chapter Seven 
 
Myo-Inositol Camphanylidene Acetal Scaleup Campaign 
 
In December 2003, the opportunity arose to perform a larger scale 
synthesis of 1,2-D-myo-inositol-L-camphanylidene acetal, (-)-269a. The scale up 
laboratory (Light Technology Laboratory Number 9 (LT9)) at Industrial 
Research Ltd, Gracefield, Lower Hutt, became available for this project, and the 
objectives of the work were as follows: 
1) To perform a commissioning run on the (then) new 50 L reactor 
ideally demonstrating that all of the following operations could be 
performed successfully: heat a solvent to reflux, add reagents (solids 
and liquids), cool, distil, distil under vacuum, perform vacuum 
transfers, clean in place. 
2) To provide quantities of (-)-269a to chemists in the 
carbohydrate team, as starting material for the 
synthesis of a target requested by a commercial 
client, and for research use.  
 
 
7.1 Work and Procedure in the scaleup laboratory 
 
Equipment available in LT9  
 
The equipment available in LT9 and used in this campaign included:  
• the new 50 L, glass, jacketed reactor (see figure 7.4), fitted with 
a heating/cooling unit. The reactor is capable of reflux and 
distillation, is able to be placed under vacuum, and is fitted with a 
header vessel for the addition of liquids to the reactor.   
• a large scale Buchi rotary evaporator with 50 L and 20 L flasks.  
• two 20 L sealed glass vessels (known as the 20 L transfer skids, 
see figure 7.2) mounted on a trolley that could be placed under 
O
OHO
OH
OHHO
(-)-269a
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vacuum or pumped into/out of, used for transferring solutions or 
liquids without operator.  
• a benchtop suction filter (for typically > 5 kg of solid) called a 
Table top Buchner (pictured in figure 7.1). Mother liquors are 
sucked through the filter into 20 L transfer skids. 
• several 24 cm Buchner funnels and 10 L Buchner flasks for 
filtration of 1-5 kg of solids. 
• a range of associated glassware and equipment (including a large 
number of extremely useful 20 L yellow buckets!).   
 
The myo-inositol camphor acetal campaign 
 
The synthetic scheme that was used to prepare (-)-269a (as discussed in 
chapter six) is shown in scheme 7.1, with the planned amounts and expected 
yields of each product. (-)-L-camphor was to be prepared from the oxidation of 
5.9 kg of (-)-borneol, followed by conversion to the dimethyl acetal (-)-268. 
Then, reaction of (-)-268 with myo-inositol, after the equilibration and 
crystallisation steps also discussed in chapter six, would give 1.35 kg of (-)-269a.  
 
MeO
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O
H2SO4, HC(OMe)3
MeOH
(-)-L-borneol
HO
glacial AcOH, 
NaOCl (15 % aq.)
OH
OHHO
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OHHO
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Myo-inositol
O
OHO
OH
OHHO
(-)-269a
1) H2SO4, DMSO
2) pTsOH, H2O,
MeOH, CHCl3
3) Crystallisation
+
Stage One Stage Two
Stage Three
5.9 kg 5.0 kg (86%)
1.35 kg (30%)
2.6 kg
'6.5 kg' (100% assumed)
(from stage 2)
 
 
Scheme 7.1. Planned scale up campaign, showing the expected yields. 
 
As part of the preparation for the scaleup synthesis, a large amount of 
paperwork was required. Most importantly, the required amounts of each solvent, 
reagent, etc were calculated and ordered. For this campaign, a balance was struck 
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between using the maximum capacity of the reactor, and preparing a quantity of 
material that would be manageable in the work-up stages. For example, the 
borneol oxidation step involves pouring the reaction mixture onto almost three 
times the reaction volume of ice-water before isolating the resultant precipitate 
by filtration. The oxidation was done on smaller scale than the maximum reactor 
volume, to make this filtration manageable.  
 
The limiting step volume-wise for this campaign, based on the maximum 
volume of the reactor and on obtaining yields equal to those obtained in the 
laboratory, is the equilibration step of stage three. As detailed in chapter six, it 
was not possible to reduce the volume of this step significantly. The amounts of 
each material that were required based on these considerations and on the process 
development described in chapter six, are presented in table 7.1. 
 
A ‘batch process record’ and a ‘reaction scaleup assessment’ were also 
required for each step of the campaign before work could begin in LT9. The 
batch process record is a step-by-step description of what will be done. This 
includes all additions of reagents (amounts and addition times), reaction times, 
temperatures, and all the details of the workup and cleaning procedures. The 
planned/required values are entered before the process begins, and the actual 
values entered during the process. Every step is signed off as complete by the 
chemist carrying out the work, and verified by another (two chemists are always 
present for safety reasons). This procedure ensures an accurate record of what 
actually happened, and is particularly useful for tracking errors, or for improving 
a procedure if it is to be repeated at a later date.  
 
The ‘reaction scaleup assessment’ is a questionnaire that allows an 
overall assessment of whether the reaction (as written) is safe and suitable for 
scale-up using the equipment and facilities that are available in LT9. It focuses 
on potential hazards and requires the chemist to plan mitigations for potential 
problems (e.g how will a runaway reaction be brought under control; how will 
spills of toxic or hazardous chemicals be contained; are the reagents/solvents 
compatible with the reactor vessel and other equipment they will come in contact 
with). The head process chemist must sign off the document before work begins.   
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Table 7.1. Materials required and ordered for the scaleup preparation of (-)-269a. 
 
 
 
 
 
* Materials used from stock not included in this total.  
Material Amount 
required Cost/unit 
Amount 
ordered Cost 
1(S)-endo-borneol 5.9 kg $213/500 g 6 kg $2,556 
NaOCl 15% 19.65 L $12/5 L 20 L $48 
Acetic acid glacial 17.7 L $62/5L 20 L $248 
Aq.sat. sodium bisulphite 2.35 L    
Ice/brine 60 L    
Reaction volume 45.6 L 
Workup volume 105.6 L 
 
L-Camphor (ex step 1) 5 kg - - - 
Trimethyl orthoformate 17.5 L $264.50/2.5 L 20 L $2,116 
Methanol 5 L    
Sulphuric acid conc. 47 mL    
NaOMe 105 g    
Toluene 24 L    
Reaction volume 27.5 L 
Workup volume 51.5 L 
 
di-Me acetal (ex step 2) 5 kg - - - 
Myo-inositol 2.58 kg $105/250 g 3 kg $1,260 
DMSO 7.5 L $89/2.5 L 7.5 L $267 
Sulphuric acid conc. 145 ml    
Triethylamine 970 ml    
Chloroform (AR) 42.5 L $402.50/20 L 40 L $805 
Methanol 4.25 L    
Water 850 ml    
pTsOH.H2O 9.75 g    
Triethylamine 323 ml    
Chloroform (wash) 30 L $390/20 L 40 L $780 
Reaction volume 16.2 L 
Equilibration volume 63.0 L 
Expected yield 1350 g 
 
TOTAL* materials cost    $8,080 
St
ag
e 
1 
St
ag
e
 
2 
St
ag
e
 
3 
 
Materials used from stock 
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7.2 Stage 1 – Oxidation of (-)-Borneol 
 
The oxidation of (-)-borneoli to L-camphor was conducted according to 
the literature procedure191 that was deemed suitable for scale up based on the 
work described in chapter six. This step proceeded smoothly on scale, with little 
deviation from the procedure laid out in the batch record. Five kgii of (-)-borneol 
were dissolved in 15 L of glacial acetic acid (breathing masks were worn during 
the charging of the reactor) and subsequently 16.7 L of 15% aqueous sodium 
hypochlorite was added over 2.5 hours. The addition time was longer than the 
planned two hours, due to the temperature increase observed, resulting from the 
reaction exotherm. The desired 
reaction temperature of 15 °C 
could not be maintained with 
the available cooling; in fact, 
the reaction was run at about 
25 °C for most of the addition. 
This was with the jacket of the 
50 L reactor set to –20 °C (for 
most of the duration of the 
addition). Although cooling the 
jacket further would have 
resulted in a lower reaction 
temperature, it may also have 
caused a layer of glacial acetic 
acid to freeze to the internal 
glass wall of the reactor. Should 
this have happened, heat transfer would have become even less efficient, and this 
risk was considered to be too great to warrant cooling the jacket further.  
                                                
i
 (-)-Borneol = endo-(1S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol. 
ii
 Although it was planned to run the reaction on a slightly larger scale starting with 5.9 kg of (-)-
borneol, as indicated in table 7.1, a decision was later made to start with only 5 kg of (-)-borneol. 
Figure 7.1. The author with the L-camphor 
filter cake, in the tabletop Buchner filter. 
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The workup of the reaction involved pouring the entire contents of the 
reactor (ca. 38 L) into a further 40 L of ice/brine to precipitate a white solid. This 
was the most challenging part of the reaction in a practical sense. A series of 
20 L buckets were used for this step, with the resulting white solid being 
collected by filtration using the ‘table-top buchner’ unit (pictured in figure 7.1, 
previous page, and figure 7.2, above), and washed with aqueous sodium 
bicarbonate (to neutralise the residual acetic acid) and water. A large volume of 
solvent waste was produced in this step, and careful management thereof was 
required. For example, the aqueous sodium bicarbonate was collected into a 20 L 
transfer skid that was empty of any acidic filtrate. This precaution avoided any 
effervescence and foaming that could lead to material being sucked into the 
house vacuum system. Acidic wastes were collected into 20 L plastic drums for 
disposal, while the neutral aqueous wastes were collected into normal (stainless 
steel) waste drums for the same. The wet filter cake was then returned to the 50 L 
reactor, dissolved in 20 L of petroleum ether, and the resulting solution washed 
with water and brine. Solvents were then removed in the 50 L rotary evaporator 
(figure 7.3).  
Figure 7.2. The table-top Buchner filter (in fume hood) and 20 L transfer skids 
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The crude product was dried by use of a toluene azeotrope. The solid 
residue was dissolved in toluene, which was subsequently removed under 
reduced pressure. This was somewhat troublesome, as the camphor began to 
sublime before all of the toluene was removed. Fortunately, the slightly toluene-
wet camphor was successfully carried through the next step. The experimental 
procedure for the 50 L reactor run of this step is contained in the experimental 
section. The total yield for stage 2 was approximately 4.55 kg (92%) – including 
300 g of material that was recovered from the base plate of the table-top buchner 
filtration unit. The yield allows for the retained toluene, which was quantified by 
1H NMR and by the mass loss after removal of the toluene from a portion of the 
bulk material in the laboratory. 
 
 
7.3 Stage 2 - Camphor di-methyl acetal 
 
Formation of (-)-L-camphor dimethyl acetal, (-)-268, from the stage 1 
product was the most straightforward of the three stages in the scaleup campaign. 
Figure 7.3. The (-)-L-camphor in the 50 L flask of the Buchi rotary evaporator.  
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The (-)-L-camphor from stage 1 was carried through to stage 2 while still slightly 
toluene-wet. This was done to minimise loss of camphor, as it had begun to 
sublime in the 50 L rotary evaporator. A lab-scale run of the dimethyl acetal 
formation using the toluene-wet material proceeded without apparent loss of 
yield or quality. The reaction was therefore run in the 50 L reactor on the full 
4.55 kg of crude (-)-L-camphor. The modified literature procedure discussed in 
chapter six was followed (experimental details of the scaleup may be found in 
chapter eight).  
 
The acidified mixture of (-)-L-camphor, trimethyl orthoformate and 
methanol was stirred at 20 °C for a full 24 hours, after which time 1H NMR 
analysis showed essentially complete conversion to the dimethyl acetal. After 
neutralisation with solid sodium methoxide,iii the entire 26 L reaction mixture 
was vacuum transferred to the 50 L Buchi. Subsequent removal of the solvents 
took approximately four hours, and salts began to precipitate out during the 
concentration. In order to further precipitate the salts formed during the reaction, 
the residues in the 50 L Buchi were dissolved in a further 12 Liv of toluene (in 
two 20 L vessels). The mixture was allowed to stand overnight to allow 
maximum precipitation and the solids were removed by filtration the next day. 
There appeared to be efficient removal of salts, as a clear solution was obtained. 
After evaporation of most of the toluene, 6.40 kg of crude (-)-L-camphor 
dimethyl acetal was obtained as a clear, pale yellow liquid. The theoretical yield 
of this reaction was 5.92 kg, so there was clearly residual toluene present, but it 
was decided to proceed to the third the third stage with the toluene present for the 
following reasons: 
a) Evaporation of the product (as well as toluene) was occurring – 
as evidenced when the flask was removed from the Buchi for weighing, 
and the characteristic greasiness and smell of the product was noted 
around the neck of the 50 L Buchi flask; 
b) material containing residual toluene had been used successfully 
in stage three in laboratory scale experiments; and  
                                                
iii
 The pH of the reaction mixture was determined by removing a small sample from the reactor, 
diluting it with distilled water, and testing using pH paper to confirm that pH 7 had been reached. 
iv
 This was less then the 20 L of toluene that would have represented a proportional scaleup of the 
laboratory procedure, but physical constraints in LT9 precluded the use of 20 L in this case. 
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c) time constraints due to another campaign being scheduled in 
LT9. Effecting complete toluene removal would have added a day to the 
processing time since stage three needed to begin early in the day (in 
order to reach a point at which it was safe to leave the product overnight). 
The mass of 6.40 kg had been achieved at the end of a day.  
 
 
7.4 Stage 3 - 1,2-D-Myo-inositol-L-camphanylidene acetal, (-)-269a 
 
The amounts of myo-inositol and other reagents used in this stage were 
based on a 100% yield in stage 2 (i.e, 5.92 kg of (-)-268 going into the reaction). 
Hence, 2.40 kg of myo-inositol were charged to the 50 L reactor and to this was 
added all of the L-camphor dimethyl acetal from stage 2, dissolved in 7.5 L of 
DMSO. The mixture was acidified with concentrated sulphuric acid, and then 
heated to 70 °C.  
 
At this point, the reaction began to behave differently from the laboratory 
scale reactions. Whereas in the laboratory, the myo-inositol reacted and dissolved 
(generally within 30 minutes of reaching 70 °C) to give a clear, essentially 
colourless solution, the mixture in the 50 L reactor began to go orange within one 
hour, and after the prescribed three hours of heating, the colour was red-brown. 
In addition, there were still significant amounts of solid material not dissolved. It 
was noted at this point that fine air bubbles were being entrained into the viscous 
solution by the powerful stirring mechanism in the 50 L reactor. This had not 
been apparent at the beginning of the reaction time, because the bubbles 
resembled particulate matter when being vigorously stirred, and their presence 
was masked by the large amount of solid myo-inositol initially present. Inert 
atmosphere was not available in the 50 L reactor at the time this work was 
carried out, so the reaction was carried out under air, which had previously been 
successfully carried out in the laboratory. 
 
Although in the laboratory, the reaction would normally be heated until 
all the solids had dissolved (indicating complete reaction of the myo-inositol, 
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which is not significantly soluble in DMSO), it was decided in view of the 
unpleasant and unusual colour change to quench the reaction at this point. The 
mixture was cooled and triethylamine added, which resulted in a disturbing 
darkening of the colour to dark red-brown. 
 
Undissolved solids were removed from the reaction mixture by filtration 
(using the 10 L Buchi flasks / 24 cm filters) to give 30 g of white material, which 
was insoluble in chloroform or DMSO. The red-brown filtrates were then 
transferred to the 50 L Buchi for removal of solvents. Residual toluene, and the 
petroleum ether and methanol that had been used to rinse reactor and lines, were 
removed rapidly. Not unexpectedly, removal of the 7.5 L of DMSO was 
significantly more troublesome. Seven hours of distilling at 15-20 mbar, with the 
bath temperature maintained at 95±5 °C, resulted in the recovery of only 4 L of 
DMSO. At that point the evaporation was stopped, because the flask contents 
had dropped below the ‘critical weight’ of 4.9 times the mass of myo-inositol 
used.v Although the flask was too heavy to be removed physically from the 
rotary evaporator and weighed, contents of the 50 L flask after 4 L of DMSO had 
been removed were calculated to be:  
 
  7.5 – 4 = 3.5 L DMSO (d=1.102)     3.86 kg 
plus   the mass of salts [(Et3NH)2SO4] from 132 mL H2SO4  0.75 kg 
plus   13.32 mol myo-inositol bis-camphor acetal (MW 448.6)  5.98 kg 
       EQUALS A TOTAL OF 10.59 kg 
minus  the solids filtered out       0.30 kg 
     A FINAL TOTAL OF  10.29 kg 
 
This total is less than the 11.76 kg that represent the ‘critical mass’. 
Concern about the stability of the product over extended periods of time at 
temperatures over 90 °C also prompted the end of the distillation. Hence, the 
mixture was cooled, dissolved in 20 L of CHCl3, and transferred back to the 50 L 
reactor. Gratifyingly, the material was largely soluble in the CHCl3, indicating 
                                                
v
 Lindberg et al.169 removed the solvents from their crude product and then added DMSO back to 
the flask to 4.9 times the weight of the myo-inositol used. They found this amount of DMSO to 
be important for the success of the subsequent equilibration step; this was not the case in our 
hands but the extra DMSO was not found to be detrimental. 
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that the major component was camphanylidene acetals of myo-inositol (rather 
than unreacted myo-inositol!). To the reactor was then added the CHCl3, 
methanol, water, and catalytic pTsOH required for the equilibration step, and the 
mixture (still red-brown, and much less inclined to form a thick precipitate than 
had previous laboratory scale reactions) was left to stir for three days.  
 
The slurry that had formed after this time (figure 7.4) was drained from 
the reactor into buckets and filtered using two 10 L Buchi/24 cm filters. After 
washing with CHCl3, each cake was blended with 4 L of CHCl3 to give a slurry 
(which had the consistency of paint) and filtered again. This process was 
repeated once more to yield a pale tan coloured solid, which upon air-drying for 
three days gave 2.26 kg of product. Had this solid been clean (-)-269a, this 
would represent a yield of 54%. However, 1H NMR analysis quickly revealed 
that this solid had a significantly different composition than had been expected. 
The desired product (-)-269a had been formed, but in conjunction with the other 
three possible diastereomers, 269b, 269c and 269d (see figure 7.5).   
 
Although signal overlap in the 1H NMR spectrum suggested the presence 
of only three diastereomers, 13C NMR and single crystal XRD analysis 
Figure 7.4. The 50 L reactor containing the myo-inositol camphanylidene 
acetal in CHCl3, MeOH and H2O at the end of the equilibration step. 
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demonstrated that all four had been formed. Substantial amounts of myo-inositol 
were also present in the crude product (approximately 19% by 1H NMR 
analysis). It was not clear whether the myo-inositol present was due to 
incomplete conversion during the reaction, or to the hydrolysis of the product 
during the workup or equilibration.  
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Figure 7.5. The four diastereomers of camphanylidene acetal 269. 
 
In the analysis of this unexpected result, it was clear that the major 
problem lay in the reaction, rather than the workup or the equilibration. The 
observations made during the reaction were dramatically different to those made 
during laboratory-scale runs. The deep red-brown colour and the failure of all of 
the solids to dissolve were key indicators that the problem had occurred during 
the reaction. The possible reasons for the unusual behaviour, and consequent 
reduced diastereoselectivity of the reaction include: 
 
• The quality of the DMSO;  
• The lack of inert atmosphere in the 50 L reactor. Although the reaction 
had been carried out in the laboratory under air (using anhydrous 
solvents), in the 50 L reactor the stirring action was very powerful and air 
bubbles were entrained very effectively into the viscous reaction mixture. 
A much higher degree of aeration of the reaction was obtained on scale; 
• Contamination of the (-)-L-camphor dimethyl acetal with inorganic salts 
due, potentially, to the salts removal in stage 2 being less efficient on 
scale - not a likely scenario (as discussed in section 7.3); 
• Overheating. In the laboratory, reactions were normally run with the flask 
immersed in an oil bath at 70 °C (so contents of the flask were probably 
several degrees cooler), whereas in the reactor, the temperature was set to 
hold the reactor contents at 70 °C. However, the reaction has previously 
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been carried out at 90 °C, in this work and in the literature,171 so this is 
unlikely to be the cause of the problem;  
• That, having reduced the volume of DMSO used in the process 
development, we were already pushing the limits of the reaction’s 
selectivity, and that combined with one or more of the above factors this 
reduced the selectively of the reaction much more dramatically. 
 
Although the major problem evidently lay in the reaction, the workup 
may well have exacerbated the troubles. In particular, the lengthy (compared to 
laboratory scale) period of heating for the DMSO removal could have aggravated 
the low yield by causing further hydrolysis, perhaps of the desired product in 
favour of one of the other diastereomers. Interconversion between the 
diastereomers is also possible, if traces of acid remained in the mixture (and even 
if the sulphuric acid had been neutralised, the resulting triethyl ammonium salt 
can act as a weak acid). Unfortunately, no analysis was done on the crude 
reaction mixture before DMSO removal. The complex mixture of products at this 
stage and the presence of DMSO solvent makes TLC analysis extremely 
difficult. The NMR spectrum is similarly difficult to interpret. Ideally, an HPLC 
method could be developed to monitor the mixture at this stage (and during the 
equilibration). This should be a definite focus of any future work.   
 
 
7.5 Crystallisation of myo-inositol camphanylidene acetals 
 
The 13C NMR spectrum of the expected major product from this reaction, 
(-)-269a, is shown in figure 7.6 overleaf, and that of the crude product from stage 
three in figure 7.7 on page 180. It is clear from inspection of these that although 
the (-)-269a was present, this was in conjunction with three other products 269b, 
269c and 269d, which were identified by single crystal XRD as described later in 
this section. This is particularly clear upon inspection of the 115-118 ppm 
portion of the spectra; the signal attributed to the acetal carbon of (-)-269a 
appears at 116.3 ppm, and in the crude product, three other acetal peaks are 
present. Myo-inositol was also present in the crude product, and was able to be  
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Figure 7.6. 13C NMR spectrum of the desired camphanylidene acetal, (-)-269a. 
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Figure 7.7. 13C NMR spectrum of the crude product, containing (-)-269a, 
269b-d, and myo-inositol.  
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quantified because the myo-inositol hydroxyl protons are well-resolved and 
upfield of the myo-inositol camphanylidene hydroxyl protons (see figure 7.11).  
 
It was decided to attempt purification of the crude material via a series of 
crystallisations. Laboratory-scale (5-10 g) trial crystallisations of the crude 
material from stage 3 were encouraging; an initial crystallisation from 
approximately 10 volumes of 3:2 acetone:water efficiently removed the myo-
inositol. This was a much smaller volume of solvent than would dissolve the 
crude product from laboratory reactions (which contained (-)-269a as the major 
diastereomer), indicating that 269b is more soluble than (-)-269a in the 3:2 
acetone:water system. A subsequent series of crystallisations from 30-40 
volumes of the same solvent were shown by NMR analysis to give material that 
was progressively richer in the desired (-)-269a. Unfortunately, the most 
successful crystallisations were slow – several days – and with commercial 
projects due to begin in LT9, there was limited time available for large-scale 
recrystallisations. It was decided to attempt a partial purification of the crude 
material on large scale. Further crystallisations of smaller portions could be more 
easily carried out in the laboratory.   
 
The series of crystallisations that were done in LT9 are summarised in the 
flow chart shown in figure 7.8. The first step was to dissolve all 2.21 kg of the 
crude material in acetone:water (3:2), in the 50 L reactor. The jacket temperature 
was set to 75 °C until the acetone was refluxing, and then reduced to 65 °C for 
two hours, during which time the solids all dissolved. The temperature was then 
ramped down to 16 °C over 2.5 h during which time a cloudiness developed; 
stirring overnight at that temperature resulted in a thick white precipitate. This 
was filtered and washed with acetone:water to yield 2.53 kg (wet weight) of a 
white solid. Unfortunately, 1H NMR analysis of the solidvi showed that this first 
recrystallisation had not changed the composition of the material significantly; it 
                                                
vi
 The ratio of myo-inositol to the four diastereomers was calculated from the integrals of the 
hydroxyl protons in the 1H NMR spectrum. This analysis is fairly crude but is adequate for this 
analysis. It was facilitated by the fact that the myo-inositol hydroxyl signals do not overlap at all 
with the camphor acetal hydroxyl signals, which appear further downfield. See figure 7.11. The 
camphanylidene acetals would not dissolve satisfactorily in any common NMR solvent other than 
DMSO.    
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appeared that everything had simply precipitated out again. If anything, there 
was more myo-inositol present (ca. 32% rather than the original 19%) in the first 
crystallisation product, as is clear in figure 7.9. 
 
Figure 7.9. Comparison of the percentage composition of the crude product, the 
first crystallisation product, and the first mother liquors. 
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This suggested that hydrolysis of one or more of the diastereomers of 
myo-inositol camphanylidene acetal had occurred; this was confirmed when the 
mother liquors from this initial crystallisation were reduced in-vacuo, and 
significant quantities of camphor were seen to sublime. In addition, the overall 
mass balance (see table 7.2) reveals a loss of ca. 185 g, approximately equivalent 
to the amount of camphor that would need be lost to cause the observed increase 
in the mass of myo-inositol. 
  
The significant hydrolysis observed during the first crystallisation was 
not seen in subsequent crystallisations. This suggests that an acidic impurity, 
which catalysed the hydrolysis, was present in the crude material and was largely 
removed during the first crystallisation. If the hydrolysis of myo-inositol 
camphanylidene acetal had been due to prolonged heating in the acetone:water 
solvent system, the usefulness of this crystallisation method would have been 
called into question. Gratifyingly, this was not the case, since in subsequent 
crystallisations the solution was heated for much longer in the same solvent 
system, and further significant hydrolysis was not observed. 
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The second crystallisation was performed at a much higher volume:solid 
ratio than the first in the hope that the camphanylidene acetal products would 
precipitate and leave the myo-inositol in solution. The entire first crystallisation 
product was submitted to the second crystallisation, and readily dissolved in 20 
volumes (45 L) of solvent, but in this case, when the solution was cooled, no 
precipitate formed. Some of the solution was removed from the 50 L reactor and 
allowed to stand without stirring (as laboratory trials had suggested that this gave 
a more crystalline product), while the remaining solution was stirred slowly in 
the 50 L reactor. All parts of the solution were seeded with crystals of the desired 
(-)-269a, but after leaving for 18 hours none of the solutions had developed any 
precipitate. With limited time in hand the solution in the reactor was heated and 
approximately 8 L of solvent was distilled out under vacuum at ca. 40 °C. When 
the concentrated solution was cooled, a white solid precipitated out, and was 
isolated by filtration. Although the second crystallisation product (yield 550 g) 
now contained only about 5% myo-inositol, it was also enriched in 269b rather 
than the desired (-)-269a. Only approximately 20% of the desired diastereomer 
(-)-269a was present, while approximately 75% of the mass was attributed to 
269b and 269c (based on integrals in the 1H NMR spectrum). 
 
Analysis of the Products of the Crystallisation Sequence 
 
In the 1H NMR spectrum, peaks attributed to single inositol ring protons 
of (-)-269a and of 269d are well resolved in the region 3.8-4.2 ppm (see figure 
7.10 overleaf and 7.11 on the following page). However, the equivalent peaks for 
269b and 269c overlap, and hence it is impossible to determine the relative 
proportions of these two diastereomers from the 1H NMR spectrum. They have 
been analysed together in the mass balance, which follows. It is a fair 
assumption, based on the 13C NMR and other observations, that the actual 
amount of 269c is similar to that of 269d (i.e. (-)-269a and 269b are the major 
and 269c and 269d the minor diastereomers).  
 
It has also been observed that 269b and 269c co-crystallise. Very good-
looking, plate-like crystals were obtained when attempts were made to obtain a  
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Figure 7.10. 1H NMR spectra of (-)-269a, and of the co-crystals of 269b and 
269c, in d6-DMSO. 
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Figure 7.11. 1H NMR spectra of myo-inositol, and of a sample that contains all 
four diastereomers including 269d, and myo-inositol, in d6-DMSO. 
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pure, crystalline sample of the major impurity 269b. These crystals were sent for 
single crystal XRD analysis, and it was found that a mixture of 269b and 269c 
was present. XRD was able to resolve the crystal structures of the two 
diastereomers (figures 7.12 and 7.13 respectively), which had formed a crystal 
structure in a 2:1 ratio together with three water molecules. Indeed, 13C NMR 
analysis of the crystals revealed two diastereomers present in an approximately 
2:1 ratio, allowing assignment of the spectral peaks. The major component of the 
crystals sent for XRD was also the major impurity seen in the 13C NMR 
spectrum of the crude product (see figure 7.7), and hence it was possible to 
assign the major and one of the minor diastereomeric impurities as 269b and 
269c. Having therefore identified three of the diastereomers by their X-ray 
structures, the fourth could also be assigned by the process of elimination 
(spectral data are presented in chapter eight).   
 
Figure 7.12. X-ray crystal structure of 1D-(6-S)-2,3-O-(L-1,7,7-
trimethyl[2,2,1]bicyclohept-6-ylidene)-myo-inositol, 269b.vii 
 
 The crystal structure of 269b, the major impurity, revealed it to be the 
2,3-D-myo-inositol-L-camphanylidene acetal, with the camphanylidene moiety 
                                                
vii
 Numbering of the atoms in the X-ray structure is not equivalent to the IUPAC numbering. 
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oriented so that the methyl group is away from the inositol ring. This is 
interesting in that (-)-269a, the favoured diastereomer, has the configuration with 
the methyl group over the inositol ring. The structure of 269c, the minor impurity 
that co-crystallised with 269b, had the methyl group over the ring as in (-)-269a. 
The selectivity that is normally observed with this reaction is attributed to steric 
factors favouring (-)-269a, but evidently the selectivity observed cannot be 
attributed to steric interaction with just one part of the camphanylidene moiety. 
These results suggest that the steric difference between the conformations, 
particularly between (-)-269a and 269b, is not large.  
 
Figure 7.13. X-ray crystal structure of 1D-(6-R)-2,3-O-(L-1,7,7-
trimethyl[2,2,1]bicyclohept-6-ylidene)-myo-inositol, 269c.viii 
 
Back to the crystallisation story 
 
Preferential crystallisation of 269b,ix as was observed in the second 
crystallisation of the crude myo-inositol camphor acetal on large scale, had never 
                                                
viii
 Numbering of the atoms in the X-ray structure is not equivalent to the IUPAC numbering. 
ix
 It was assumed that when 269b crystallised, 269c always co-crystallised, because of the 
observed XRD spectrum and also because the 1H NMR spectrum always gave ‘messy’ signals in 
the 3.8-4.2 ppm region for the 269b/269c inositol ring protons. As opposed to the ‘tidy’ signals 
seen in that region for (-)-269a and 269d (figure 7.10 and 7.11). 
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been observed in the laboratory. However, it was hoped that if levels of 269b 
could be reduced, the proportion of (-)-269a might increase to a point where it 
would crystallise preferentially instead. The mother liquors were therefore 
returned to the 50 L reactor, and distillation of solvent out of the vessel was 
continued. The solution was allowed to cool and stir overnight and a third crop of 
crystals, yield 273 g, were isolated and found to be of a similar composition to 
the second crystallisation. A fourth cycle of heating the mother liquors and 
removing solvent, cooling and precipitating gave a fourth crop of 139 g, which 
now contained no myo-inositol at all (the composition of the mother liquors 
being almost 100% water by this stage, and myo-inositol being extremely soluble 
in water) but a mixture of (-)-269a, 269b, 269c, and somewhat more of 269d 
than had been obtained in the previous crystallisations. This would be expected, 
as the previous crystallisations favoured 269b and 269c, and to a lesser degree 
(-)-269a, and hence 269d had become more concentrated in the mother liquors. 
Since 269d did not precipitate out when the solvent was richer in acetone, this 
could also indicate that it is more soluble in acetone than (-)-269a, 269b and 
269c.  
 
After the fourth crystallisation, the time available in LT9 was almost 
complete. Thus the final mother liquors were concentrated from about 20 L to a 
slurry of about 5 L volume. The same was done with the first mother liquors 
(which had been set aside), in order to make the material more manageable on 
the laboratory scale. All further work was carried out in the laboratory.  
 
Figure 7.14. Composition of the slurry of the fourth mother liquors. 
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When a portion of the final slurry of the fourth mother liquors was 
filtered, it was found that the solids contained a small amount of myo-inositol 
and all four diastereomers (-)-269a and 269b-d (figure 7.14 above). The mother 
liquors from this filtration, when reduced to dryness, contained nearly 100% 
myo-inositol, which is very soluble in water. In effect, a fifth 
precipitation/crystallisation had been conducted, in which all of the camphor 
acetal diastereomers (-)-269a and 269b-d precipitated due to the fact that they 
are essentially insoluble in water. The compositional analysis of this portion was 
extrapolated to give the total mass composition of the fourth mother liquor 
slurry; this is presented in figure 7.14. The total dry weight of the fourth mother 
liquors was 321 g. 
 
Mass Balance Analysis for the Crystallisation Sequence 
 
As may be apparent from the previous discussion, none of the parts 
collected during the series of crystallisations was significantly enriched in the 
desired diastereomer, (-)-269a. In an attempt to understand the fate of (-)-269a, 
an overall mass balance analysis was done. This mass balance is presented in 
table 7.2. Included are the main crystallisation products, and two portions that 
were removed during the sequence (the test solution removed from the second  
 
Table 7.2. Mass balance over all parts of the crystallisation sequence. 
 Myo- (g) (-)-269a (g) 269b/c (g) 269d (g) Total mass (g) 
1st ml slurry* 334 43 156 85 618 
Sols from 1st ml** 0 3 31 0 34 
Test 2nd cryst 22 27 33 10 92 
2nd cryst 17 112 411 10 550 
3rd cryst 11 58 194 10 273 
4th cryst 3 5 90 41 139 
4th ml slurry 247 24 29 21 321 
Total isolated 633 271 945 177 2026 
Crude product 
composition 287 729 941 250 2210 
* The composition of the dry material when all solvents removed from the 1st mother liquor 
under reduced pressure.  
**Crystalline solids removed by filtration from the first mother liquors after they had been set 
aside for several days (and before the reduction to a slurry). 
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crystallisation, and the solids that were filtered from the first mother liquor after 
it had been standing for several days but before it was reduced to a slurry). All 
the figures in the table represent dry weights. 
 
Analysis of the crude product indicated that before the crystallisations, 
there had been approximately 730 g of (-)-269a present. However, the total 
amount of (-)-269a over all of the parts after the crystallisation sequence was 
only ca. 270 g. This represents a loss of 460 g!! Losses of the other 
diastereomers were less dramatic. The combined mass of 269b + 269c did not 
change, while that of 269d dropped from ca. 250 g to ca. 175 g. Thus, the loss of 
(-)-269a is certainly significant. There are two possible explanations for this loss; 
a) preferential hydrolysis of (-)-269a, to give myo-inositol, and b) that some 
interconversion between diastereomers was taking place. These two scenarios are 
discussed further below.  
 
Figure 7.15. Percentage composition of each of the parts of the mass balance. 
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The percentage composition of each of the parts of the mass balance is 
shown in figure 7.15 on the previous page. This emphasises that none of the parts 
were enriched in the desired diastereomer, (-)-269a. Indeed, none of the four 
diastereomers were cleanly isolated in this crystallisation sequence. 
 
Hydrolysis of the camphanylidene acetals 
 
The total mass of crude product that went into the first crystallisation was 
2210 g, while the total mass of the parts collected after the crystallisations was 
2027 g. this represents an overall loss of 183 g. Some of this may be accounted 
for by mechanical losses during the filtrations. However, some must also be due 
to loss of camphor by hydrolysis of the camphor acetals. Camphor was observed 
subliming in the condenser of the 50 L Buchi rotary evaporator, particularly 
during the concentration of the first mother liquors to a slurry. The loss of 
camphor in this manner was not quantified. However, this observation is in 
agreement with the apparent significant hydrolysis during the first crystallisation 
discussed earlier in this section.  
 
Figure 7.16. Composition of the slurry of the first mother liquors. 
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The composition of the first mother liquor slurry, analysed as the solids 
filtered out and the mother liquors therefrom, is shown in figure 7.16 above. It is 
worth noting at this point that the first mother liquors may have initially 
contained less myo-inositol and more of (-)-269a and 269b-d than the analysis 
presented here indicates. Although the 1H NMR taken on the day of the filtration 
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indicates that no significant change had occurred, a rigorous analysis of the 
composition of the first mother liquors was not done until after the solution had 
been concentrated. It is, however unlikely that hydrolysis occurred during the 
concentration. No further sublimation of camphor was observed when a portion 
of the slurry was later reduced to dryness for the mass balance analysis.  
 
The amount of myo-inositol present in the crude was 420 g, which 
increased by 312 g over the course of the crystallisations according to this mass 
balance analysis. If formed from the hydrolysis of myo-inositol camphanylidene 
acetal, 312 g (1.73 moles) of myo-inositol would liberate 264 g of camphor. 
Therefore camphor loss by hydrolysis and sublimation could account for a large 
part of the 183 g of mass lost in the overall mass balance analysis. The amount of 
all the camphanylidene acetals ((-)-269a and 269b-d) lost from the total mass is 
529 g (1.68 moles). This is in good agreement with the increase in the number of 
moles of myo-inositol present. 
 
Why (-)-269a might be hydrolysed in preference to the other camphor 
acetals is not clear. However it is likely that if hydrolysis did occur, it would be 
while the acetal was dissolved. Since 269b/269c were being precipitated out 
preferentially, they spent less time in solution (and a smaller proportion of their 
mass was resubmitted to the next cycle of crystallisation each time). This means 
that (-)-269a (and 269d, which also suffered a mass loss) simply spent more time 
in conditions that might cause hydrolysis. Alternatively, if the hydrolysis of 
(-)-269a was occurring more rapidly than hydrolysis of the other diastereomers 
under these conditions, then even if it was relatively slow, it would keep the 
proportion of (-)-269a relative to the other diastereomers down and hence inhibit 
the crystallisation of (-)-269a. 
 
Interconversion of diastereomers 
 
Although the mass balance supports an overall loss of (-)-269a by 
hydrolysis, it is notable that the major impurity 269b is the diastereomer that is 
available from an acetal migration of (-)-269a, as shown in scheme 7.2 (of 
course, all of the diastereomers (-)-269a and 269b-d may be interconverted by 
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this type of mechanism). It is possible that, as 269b precipitated out of solution, 
some (-)-269a was converted to 269b by this mechanism, with the equilibrium 
being driven by the decrease in concentration of 269b as it precipitated out. 
Better data about the levels of 269b would be necessary to prove this, as from the 
available data it is not possible to determine whether the total amount of 269b 
has increased. If hydrolysis of 269b was also occurring during the crystallisation 
sequence, this would further complicate the situation.  
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Scheme 7.2. Acid-catalysed interconversion between 269a and 269b. 
 
 
7.6 Conclusions 
 
Although a successful large-scale preparation of (-)-269a was not 
achieved during the course of the work presented in this chapter, several positive 
outcomes of the work were identified: 
• The 50 L reactor was considered ‘commissioned’ at the end of the work. 
It had been demonstrated to perform well and to be suitable for carrying 
out the requisite operations. 
• The preparation of the L-camphor dimethyl acetal reagent in two steps 
from borneol was successfully carried out. Of particular note, it was 
demonstrated that the cooling available in the 50 L reactor was sufficient 
to control the exotherm of the borneol oxidation step. 
• The single crystal XRD structures of (-)-269a, 269b and 269c were all 
obtained. None of these had been previously published. This also allowed 
definitive assignment of the NMR spectra of the diastereomeric 
impurities that are seen in the preparation of 269a.    
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 The results obtained in the attempt to prepare 1D-myo-inositol-1,2-L-
camphanylidene acetal were probably related to the quality of the DMSO, and 
the lack of inert atmosphere in the reactor. Some time after this work was 
completed, the synthesis of (-)-269a was repeated at Industrial Research, using a 
slightly higher quality DMSO from a different supplier for the third stage and 
conducting the reaction under inert atmosphere. With these modifications, 600 g 
of (-)-269a were successfully prepared, and subsequently used in the production 
of a target compound requested by a client. This confirms the usefulness of the 
process development work described here, particularly the crystallisation 
procedure, which performed very well on scale. A yield of slightly less than 30% 
of good quality pure crystalline product was obtained from myo-inositol, equal to 
the best yields typically obtained on laboratory scale. 
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Chapter Eight 
 
Experimental Section 
 
 
8.1 General 
 
Unless otherwise stated, the following conditions apply: All reactions 
were performed under argon in oven-dried glassware using standard syringe 
techniques. Diethyl ether and THF were distilled from sodium and 
benzophenone. Dichloromethane, triethylamine, acetonitrile and methanol were 
distilled from calcium hydride. Diisopropylamine and pyridine were distilled 
from sodium hydroxide. Toluene was distilled from sodium. Anhydrous N,N-
dimethylformamide (DMF) and dimethylsulfoxide (DMSO) were purchased 
from Aldrich Chemical company and used without further purification. All other 
reagents were of commercial quality and distilled prior to use if necessary. 
Reaction progress was monitored using aluminium backed t.l.c. plates pre-coated 
with silica UV254 and visualised by either UV radiation (254 nm), ceric 
ammonium molybdate dip, anisaldehyde dip, or an iodine tank. Purification of 
products via flash column chromatography was conducted using a column 
packed with silica gel 60 (220-240 mesh) with the solvent systems as indicated. 
Optical rotations were measured using a Perkin-Elmer 241 polarimeter. 1H and 
13C spectra were recorded on either a Varian Inova NMR spectrometer or a 
Bruker Advance NMR spectrometer, at 300 and 75 MHz respectively. Spectra 
were referenced to solvent peaks (1H – residual CHCl3 or DMSO or acetone, 13C 
– CDCl3 or d6-DMSO or d6-acetone). Infrared spectra were obtained on a Biorad 
FTS-7 or a Bruker Tensor 27 FTIR spectrometer. High-resolution mass spectra 
were recorded using a Mariner electrospray time of flight spectrometer.  
 
8.2 Experimental for Chapter Two 
 
3-(tert-Butyldimethylsilyloxy)-propionitrile (137): 3-Hydroxy-
propionitrile (960 L, 1.00 g, 14 mmol) and imidazole (1.43 g, 21 mmol) were 
dissolved in DMF (5 mL) and then cooled to 0 °C. TBDMSCl (2.32 g, 15 mmol) 
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was then added, and the mixture allowed to warm to RT and stirred overnight. 
The mixture was then diluted with diethyl ether (80 mL), washed with sat. aq. 
NaHCO3 (20 mL), water (20 mL), and brine (20 mL), dried over anhydrous 
MgSO4, and the solvent removed under reduced pressure. Flash column 
chromatography (1:10 EtOAc:petroleumether) gave the TBDMS-protected nitrile 
137 as a colourless oil, 2.50 g (97%). 1H NMR (300 MHz, CDCl3)  3.84 (t, 2 H, 
J = 6.2 Hz), 2.54 (t, 2 H, J = 6.2 Hz), 0.90 (s, 9 H), 0.10 (s, 6 H) ppm. 13C NMR 
(75 MHz, CDCl3)  118.1, 58.5, 25.7, 21.7, 18.1, -5.5 ppm. IR (neat) 2956, 2931, 
2859, 2253, 1427, 1256, 1116, 914, 838, 779, 722 cm-1. HRMS (ESI) calcd. for 
C9H20NOSi [M + H+] 186.1314, found 186.1543.  
 
3-(tert-Butyldiphenylsilyloxy)-propionitrile (14): 3-Hydroxy-
propionitrile (868 L, 904 mg, 12.7 mmol) and imidazole (1.96 g, 28.8 mmol) 
were dissolved in DMF (4.5 mL) and then cooled to 0 °C. TBDPSCl (3.0 mL, 
3.17 g, 11.5 mmol) was then added and the mixture allowed to warm slowly to 
RT. After stirring at RT for two days, the mixture was diluted with diethyl ether 
(80 mL), washed with sat. aq. NaHCO3 (30 mL), water (30 mL), and brine 
(20 mL), and then dried over anhydrous MgSO4. The solvent was removed under 
reduced pressure to yield a colourless oil. Purification by flash column 
chromatography (1:20 EtOAc:petroleumether) gave the nitrile 14 as a colourless 
oil, 3.21 g (90%, based on the limiting reagent TBDPSCl). 1H NMR (300 MHz, 
CDCl3)  7.68 (m, 4 H), 7.44 (m, 6 H), 3.85 (t, 2 H, J = 6.4 Hz), 2.55 (t, 2 H, J = 
6.4 Hz), 1.09 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3)  135.5, 132.6, 130.0, 
127.9, 117.9, 59.0, 26.6, 21.4, 19.1 ppm. IR (neat) 3071, 2931, 2857, 2252, 1427, 
1104, 914, 821, 733, 700 cm-1. HRMS (ESI) calcd. for C19H27N2OSi [M + NH4+] 
327.1887, found 327.1904.  
 
3-Tetrahydropyranyloxy-propionitrile (146): A mixture of 3-hydroxy-
propionitrile (1 mL, 1.04 g, 14.6 mmol) and 3,4-dihydro-2-H-pyran (1.47 mL, 
1.36 g, 16.1 mmol) was stirred at 30 °C. AlCl3.6H2O was then added and stirring 
continued at 30 °C for 2 h, after which time the mixture was filtered through a 
short silica plug which was then washed with 1:5 EtOAc:petroleum ether 
(100 mL). The solvent was removed under reduced pressure to yield the crude 
product. 1HNMR indicated 80% conversion to the product. Flash column 
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chromatography (1:10 EtOAc:petroleumether) gave the tetrahydropyranyl ether 
146 as a colourless oil, 1.48 g (an isolated yield of 65%). 1H NMR (300 MHz, 
CDCl3)  4.67 (m, 1 H), 3.97-3.82 (m, 2 H), 3.69-3.61 (m, 1 H), 3.58-3.50 (m, 1 
H), 2.64 (m, 2 H), 1.87-1.50 (m, 6 H) ppm. 13C NMR (75 MHz, CDCl3)  117.9, 
98.6, 61.9, 61.8, 30.1, 25.1, 18.8 (2 C) ppm. IR (neat) 2942, 2873, 2251, 1352, 
1122, 1065, 1032, 917, 847, 813 cm-1. HRMS (ESI) calcd. for C18H17O2N2 [M + 
NH4+] 173.1285, found 173.1285. 
 
3-(para-Methoxybenzyloxy)-propionitrile (147): A solution of 
3-hydroxypropionitrile (150 L, 156 mg, 2.21 mmol) and KOtBu (1 M in THF, 
1.63 mL, 1.63 mmol) in DMF was cooled to 0 °C. PMBCl (200 L, 231 mg, 
1.48 mmol) was then added and the mixture stirred for 1 h at that temperature, 
then warmed to RT and stirred for a further 4 h. The mixture was quenched with 
5% aq. HCl, and extracted with diethyl ether (three times 50 mL). The combined 
organic portions were washed with water (50 mL) and brine (50 mL) and then 
dried over anhydrous MgSO4. The solvent was removed under reduced pressure 
to yield a colourless oil. Purification by flash column chromatography (1:20 
EtOAc:petroleumether) gave para-methoxybenzyl ether 147 as a colourless oil, 
110 mg (40%). 1H NMR (300 MHz, CDCl3)  7.29 (d, 2 H, J = 8.5 Hz), 6.90 (d, 
2 H, J = 8.6 Hz), 4.52 (s, 2 H), 3.82 (s, 3 H), 3.66 (t, 2 H, J = 6.4 Hz), 2.61 (t, 2 
H, J = 6.5 Hz) ppm. 13C NMR (75 MHz, CDCl3)  159.5, 129.4, 129.2, 117.8, 
114.1, 73.0, 64.2, 55.3, 18.9 ppm. IR (neat) 3000.4, 2859, 2252, 1611, 1512, 
1245, 1172, 1102, 1006, 908, 818, 730 cm-1. HRMS (ESI) calcd. for C11H17O2N 
[M + NH4+] 209.1285, found 209.1285. 
 
6-(tert-Butyldimethylsilyloxy)-hex-1-en-4-one (138): The nitrile 137 
(500 mg, 2.7 mmol) was dissolved in THF (60 mL) under argon and then 
allylmagnesium chloride (2 M solution in Et2O, 4.05 mL, 8.1 mmol) was added 
dropwise. The mixture was stirred overnight at RT, and then poured onto an 
ice/water mixture (50 mL) to which had been added 5 drops of glacial acetic 
acid. This was stirred for 0.5 h, after which time the aqueous mixture was 
extracted with diethyl ether (three times 50 mL). The combined organic fractions 
were then washed with 5% aq. NaHCO3 (20 mL) and brine (20 mL), and then 
dried over anhydrous MgSO4. The solvent was removed under reduced pressure 
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to yield an orange oil which was promptly purified by gradient flash column 
chromatography (petroleum ether – 1:20 EtOAc:petroleum ether) to yield 138 as 
a colourless oil, 230 mg (38%). 1H NMR (300 MHz, CDCl3)  6.01-5.87 (m, 
1 H), 5.22-5.11 (m, 2 H), 3.90 (t, 2 H, J = 6 Hz), 3.24 (d, 2 H, J = 7 Hz), 2.67 (t, 
2 H, J = 6 Hz), 0.91 (s, 9 H), 0.08 (s, 6 H) ppm. 13C NMR (75 MHz, CDCl3)  
207.7, 130.4, 118.8, 58.8, 48.6, 45.1, 25.8, 18.2, -5.5 ppm. IR (neat) 2956, 2930, 
2858, 1716, 1472, 1256, 1097, 836, 778 cm-1. HRMS (ESI) calcd. for 
C12H25O2Si [M + H+] 229.1624, found 229.1728. 
E-6-(tert-Butyldimethylsilyloxy)-hex-2-en-4-one (143). Isolated as a 
byproduct in the preparation of 138 in yields of 5 – 40%. 1H NMR (300 MHz, 
CDCl3)  6.89 (dq, 1 H, J = 14, 7 Hz), 6.70 (d, 1 H J = 14 Hz), 3.96 (t, 2 H, J = 6 
Hz), 2.78 (t, 2 H, J = 6 Hz), 1.93 (d, 3 H, J = 7 Hz), 1.89 (s, 9 H), 0.08 (s, 6 H) 
ppm. 13C NMR (75 MHz, CDCl3)  199.2, 143.3, 135.6, 133.5, 132.5, 129.7, 
127.7, 60.0, 42.6, 26.7, 19.1, 18.3 ppm. IR (neat) 2955, 2930, 2858, 1673, 1633, 
1471, 1390, 1255, 1095, 971, 834, 778 cm-1.  
 
6-(tert-Butyldiphenylsilyloxy)-hex-1-en-4-one (16): The nitrile 14 
(1.57 g, 5.07 mmol) was dissolved in THF (60 mL) under argon and then 
allylmagnesium chloride (2 M solution in Et2O, 7.6 mL, 15.2 mmol) was added 
dropwise. The mixture was heated to reflux for 3 h. The mixture was then cooled 
and poured onto an ice/water mixture (100 mL) to which had been added 10 
drops of glacial acetic acid. This was stirred for 1 h, after which time the aqueous 
mixture was extracted with diethyl ether (three times 100 mL). The combined 
organic fractions were then washed with 5% aq. NaHCO3 (50 mL) and brine 
(50 mL), and then dried over anhydrous MgSO4. The solvents were removed 
under reduced pressure to yield an orange oil which was promptly filtered 
through a short silica plug to give the crude product. Purification by flash column 
chromatography (1:50 EtOAc:petroleum ether) gave 16 as a colourless oil, 
943 mg (53%). 1H NMR (300 MHz, CDCl3)  7.69 (m, 4 H), 7.4 (m, 6 H), 6.04-
5.88 (m, 1 H), 5.25-5.12 (m, 2 H), 3.97 (t, 2 H, J = 6.2 Hz), 3.27 (d, 2 H, J = 6.8 
Hz), 2.69 (t, 2 H, J = 6.2 Hz), 1.07 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3)  
207.6, 135.5, 133.3, 130.4, 129.7, 127.7, 118.9, 59.6, 48.5, 44.9, 26.7, 19.1 ppm. 
HRMS (ESI) calcd. for C22H28NaO2Si [M + Na+] 375.1756, found 375.2170. 
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The isomeric product 144 was also isolated, as a colourless oil, 350 mg 
(20%): E-6-(tert-Butyldiphenylsilyloxy)-hex-2-en-4-one (144). 1H NMR (300 
MHz, CDCl3)  7.68-7.63 (m, 4 H), 7.44-7.34 (m, 6 H), 6.82 (dq, 1 H, J = 15.9, 
6.8 Hz), 6.14 (dq, 1 H J = 15.9, 1.7 Hz), 3.97 (t, 2 H, J = 6.4 Hz), 2.77 (t, 2 H, J 
= 6.4 Hz), 1.89 (dd, 3 H, J = 6.6, 1.5 Hz), 1.05 (s, 9 H) ppm. 13C NMR (75 MHz, 
CDCl3)  199.2, 143.3, 135.6, 133.5, 132.5, 129.7, 127.7, 60.0, 42.6, 26.7, 19.1, 
18.3 ppm. IR (neat) 3050, 2930, 2857 1670, 1631, 1428, 1108, 735, 702 cm-1.  
 
Representative procedure for the conversion of ketones 138 and 16 
into the alcohols 139 and 12, respectively: The ketone (1 eq.) was dissolved in 
THF (3.5 mL/mmol ketone). Lithium borohydride (2 M solution in Et2O, 1.2 eq.) 
was then added dropwise at 0 °C. The mixture was allowed to warm slowly to 
RT over 3 h, and was then quenched by the addition of Na2SO4.10H2O (and 
sometimes drops of water) until effervescence was no longer observed. 
Anhydrous MgSO4 was then added, and the salts filtered off, rinsing well with 
diethyl ether. The solvents were then removed under reduced pressure to yield an 
oil which was purified by flash column chromatography (1:10 or 1:20 
(depending on the levels of impurities present) EtOAc:petroleum ether) to yield 
the alcohol as a colourless oil. 
6-(tert-Butyldimethylsilyloxy)-4-hydroxy-hex-1-ene (139) was 
prepared from 138 (230 mg, 1.01 mmol) to yield 139 (225 mg, 97%). 1H NMR 
(300 MHz, CDCl3)  5.86 (m, 1 H), 5.23 (m, 2 H), 3.93 (m, 2 H), 3.86 (m, 1 H), 
2.26 (m, 2 H), 1.68 (m, 2 H), 0.92 (s, 9 H), 0.10 (s, 6 H) ppm. 13C NMR (75 
MHz, CDCl3)  135.0, 117.3, 71.3, 56.3, 42.0, 37.7, 25.8, 18.1, -5.6 ppm. IR 
(neat) 3397, 3081, 2946, 2859, 1642, 1472, 1257, 1097, 1005, 913, 836, 776, 667 
cm-1. HRMS (ESI) calcd. for C12H27O2Si [M + H+] 231.1780, found 231.1812.  
6-(tert-Butyldiphenylsilyloxy)-4-hydroxy-hex-1-ene (12) was prepared 
from 16 (857 mg, 2.43 mmol) to yield 12 (694 mg, 84%). 1H NMR (300 MHz, 
CDCl3)  7.70 (m, 4 H), 7.41 (m, 6 H), 5.86 (m, 1 H), 5.18 (m, 1 H), 5.12 (m, 
1 H), 4.00 (m, 1 H), 3.88 (m, 2 H), 3.26 (broad s, 1 H), 2.28 (m, 2 H), 1.72 (m, 
2 H), 1.08 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3)  135.8, 135.2, 133.3, 133.2 
130.1, 128.1, 117.7, 71.2, 63.6, 42.2, 38.0, 27.1, 19.3 ppm. IR (neat) 3385, 3071, 
2930, 2857, 1734, 1638, 1471, 1427, 1275, 1108, 1038, 914, 764, 748, 701 cm-1. 
HRMS (ESI) calcd. for C22H31O2Si [M + H+] 355.2088, found 355.2086.  
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6-para-Methoxybenzyloxy-4-hydroxy-hex-1-ene (72): Nitrile 147 
(100 mg, 0.52 mmol) was dissolved in THF (6 mL) under argon and then 
allylmagnesium chloride (2 M solution in Et2O, 910 L, 1.82 mmol) was added 
dropwise at 0 °C. The mixture was stirred overnight at RT, and then poured onto 
an ice/water mixture (10 mL) to which had been added 1 drop glacial acetic acid. 
This was stirred for 0.5 h, after which time the aqueous layer was separated and 
extracted three times with diethyl ether. The combined organic fractions were 
dried over anhydrous MgSO4, and the solvent was removed under reduced 
pressure to yield an orange oil. This was passed through a plug of silica with 
1:100 EtOAc:petroleum ether to yield 42 mg of an oil. This material was 
dissolved in THF (1 mL) and cooled to 0 °C. A solution of LiBH4 (2 M in THF, 
180 L, 0.36 mmol) was then added dropwise and the solution allowed to warm 
to RT over 3 h. The reaction was quenched by the addition of drops of water till 
effervescence was no longer observed, then dried with anhydrous MgSO4, 
filtered, and solvents removed under reduced pressure. The resulting oil was 
purified by flash column chromatography (1:10 EtOAc:petroleum ether) to yield 
72 as a colourless oil, 37 mg (30% over 2 steps from 147). 1H NMR (300 MHz, 
CDCl3)  7.24 (d, 2 H, J = 8.3 Hz), 6.87 (d, 2 H, J = 8.8 Hz), 5.83 (m, 1 H), 5.10 
(m, 2 H), 4.45 (s, 2 H), 3.86 (m, 1 H), 3.80 (s, 3 H), 3.65 (m, 2 H), 2.24 (t, 2 H, J 
= 6.1 Hz), 1.72 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3)  159.2, 134.9, 130.0, 
129.3, 117.5, 113.8, 72.9, 70.4, 68.6, 55.3, 41.9, 35.8 ppm. IR (neat) 3074, 2932, 
2858, 1640, 1512, 1246, 1088, 1030, 913, 820 cm-1. HRMS (ESI) calcd. for 
C14H21O3 [M + H+] 237.1491, found 237.1477.  
 
Representative procedure for the conversion of alcohols 139, 12 and 
72 into the TES-protected alcohols 140, 148 and 73, respectively: The alcohol 
(1 eq.) and imidazole (2.2 eq.) were dissolved in DMF (ca. 1 mL/mmol alcohol) 
and then cooled to 0 °C. TESCl (1.1 eq.) was then added and the mixture allowed 
to warm to RT and stir at RT overnight. The mixture was then diluted with 
diethyl ether (ca. 50 mL/mmol alcohol), washed with sat. aq. NaHCO3, water, 
and brine, dried over anhydrous MgSO4, and the solvent removed under reduced 
pressure. Flash column chromatography (1:50 EtOAc:petroleum ether) gave the 
protected alcohol as a colourless oil in yields typically > 80%.  
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6-(tert-Butyldimethylsilyloxy)-4-(triethylsilyloxy)-hex-1-ene (140) was 
prepared from 139 (190 mg, 0.83 mmol) to yield 140 (240 mg, 86%).1H NMR 
(300 MHz, CDCl3)  5.85 (m, 1 H), 5.17 (m, 2 H), 3.92 (m, 1 H), 3.71 (t, 2 H, J 
= 6.6 Hz), 2.25 (m, 2 H), 1.66 (m, 2 H), 0.98 (t, 9 H, J = 7.6 Hz), 0.91 (s, 9 H), 
0.62 (q, 6 H, J = 7.6 Hz), 0.07 (s, 6 H) ppm. 13C NMR (75 MHz, CDCl3)  135.1, 
116.8, 68.8, 59.8, 42.2, 39.9, 25.9, 18.2, 6.9, 5.0, -5.3 ppm. IR (neat) 3073, 2954, 
2877, 1651, 1464, 1255, 1096, 1006, 911, 835, 774, 741 cm-1. HRMS (ESI) 
calcd. for C18H41O2Si2 [M + H+] 345.2645, found 345.2703.  
6-(tert-Butyldiphenylsilyloxy)-4-(triethylsilyloxy)-hex-1-ene (148) was 
prepared from 12 (410 mg, 1.16 mmol) to yield 148 (460 mg, 85%). 1H NMR 
(300 MHz, CDCl3)  7.65-7.63 (m, 4 H), 7.42-7.34 (m, 6 H), 5.81 (m, 1 H), 5.12 
(m, 2 H), 3.97 (m, 1 H), 3.72 (m, 2 H), 2.22 (m, 2 H), 1.69 (m, 2 H), 1.05 (s, 9 
H), 0.93 (t, 9 H, J = 7.9 Hz), 0.59 (q, 6 H, J = 7.9 Hz) ppm. 13C NMR (75 MHz, 
CDCl3)  135.8, 135.4, 134.2, 129.8, 129.7, 127.8, 117.1, 69.1, 61.0, 42.4, 39.9, 
27.1, 19.4, 7.2, 5.2 ppm. IR (neat) 3071, 2953, 2875, 1461, 1423, 1108, 1085, 
1005, 909 cm-1. HRMS (ESI) calcd. for C28H45O2Si2 [M + H+] 469.2953, found 
469.2973.  
6-(para-Methoxybenzyloxy)-4-(triethylsilyloxy)-hex-1-ene (73) was 
prepared from 72 (30 mg, 0.13 mmol) to yield 73 (35 mg, 80%). 1H NMR (300 
MHz, CDCl3)  7.26 (d, 2 H, J = 8.9 Hz), 6.88 (d, 2 H, J = 8.9 Hz), 5.84 (m, 1 
H), 5.05 (m, 2 H), 4.46 (d, 1 H, J = 10.9 Hz), 4.41 (d, 1 H, J = 10.9 Hz), 3.94 (m, 
1 H), 3.83 (s, 3 H), 3.57 (t, 2 H, J = 6.8 Hz), 2.26 (m, 2 H), 1.78 (m, 2 H), 0.97 (t, 
6 H, J = 7.8 Hz), 0.63 (q, 9 H, J = 7.8 Hz) ppm. 13C NMR (75 MHz, CDCl3)  
159.1, 134.9, 130.6, 129.3, 117.0, 113.7, 72.6, 69.0, 66.7, 55.2, 42.4, 36.8, 6.9, 
5.0 ppm.i 
 
5-(tert-Butyldimethylsilyloxy)-3-(triethylsilyloxy)-pentanal (141) - 
ozonolysis using the IRL ozonolysis machine: Alkene 140 (175 mg, 
0.51 mmol) was dissolved in CH2Cl2 (4 mL) and anhydrous MeOH (0.4 mL) and 
one drop of Sudan (III) solution (0.1% in CH2Cl2) was added. The solution was 
cooled to –78 °C, purged with argon, and then ozone was bubbled through the 
solution until the pink colour disappeared (ca. 15 min). The flask was then 
                                                
i
 HRMS and IR data were not obtained for this compound when it was initially prepared, and 
since it was not useful to the progress of the synthesis it was not re-made.  
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purged with argon, and DMS (200 L, 169 mg, 2.72 mmol) was added. The 
stirred solution was kept at- 78 °C for 1 h, 0 °C for 30 min, and RT for 1 h, and 
the solvents then removed under reduced pressure. The residue was purified by 
gradient flash column chromatography (1:100-1:40 EtOAc:petroleum ether) to 
give the aldehyde 141 as a colourless oil, 95 mg (54%). 1H NMR (300 MHz, 
CDCl3)  9.81 (t, 1 H, J = 2 Hz), 4.38 (m, 1 H), 3.68 (t, 2 H, J = 7.7 Hz), 2.59 
(m, 2 H), 1.80 (m, 2 H), 0.98 (t, 9 H, J = 7.6 Hz), 0.91 (s, 9 H), 0.63 (q, 6 H, J = 
7.6 Hz), 0.07 (s, 6 H) ppm. HRMS (ESI) calcd. for C17H39O3Si2 [M + H+] 
347.2432, found 347.2453.  
 
Note: The optimised ozonolysis procedure using the VUW ozonolysis 
machine is presented later in this chapter on page 208).  
 
Data for the byproducts of the ozonolysis (152a and 152b) discussed 
in section 2.1.2 of chapter 2 follows. Data for 152a as a mixture of two 
diastereomers: 1H NMR (300 MHz, CDCl3)  7.66 (m, 8 H), 7.40 (m, 12 H), 
5.34 (m, 2 H), 5.19 (s, 1 H), 5.16 (s, 1 H), 5.08 (s, 1 H), 5.06 (s, 1 H), 4.18 (m, 2 
H), 3.72 (m, 4 H), 1.90 (m, 4 H), 1.79 (m, 4 H), 1.08 (s, 18 H), 0.96 (t, 18 H, J = 
7.8 Hz), 0.62 (q, 12 H, J = 7.8 Hz) ppm. HRMS (ESI) calcd. for the carboxylic 
acid derivative (153a) C27H42O4Si2Na [M + Na+] 509.2519, found 509.2496. 
Data for 152b: 1H NMR (300 MHz, CDCl3)  7.64 (m, 8 H), 7.60 (m, 8 H), 7.40 
(m, 24 H), 5.35 (m, 2 H), 5.12 (s, 1 H), 5.11 (s, 1 H), 4.98 (s, 1 H), 4.95 (s, 1 H), 
4.24 (m, 2 H), 3.62 (m, 4 H), 2.03 – 1.66 (m, 8 H), 1.09 (s, 9 H), 1.08 (s, 9 H), 
1.02 (s, 9 H), 1.01 (s, 9 H) ppm. 13C NMRii (75 MHz, CDCl3)  136.2, 135.8, 
134.3, 134.2, 134.0, 133.9, 130.0, 129.9, 129.8, 127.9, 127.8, 102.0, 101.8, 94.0, 
93.9, 68.0, 67.9, 60.7, 39.9, 39.8, 38.6, 38.5, 27.3, 27.0, 19.7, 19.6, 19.3 ppm. 
HRMS (ESI) calcd. for the carboxylic acid derivative (153b) C37H46O4Si2Na [M 
+ Na+] 633.2832, found 633.2919.  
 
3-(tert-Butyldiphenylsilyloxy)-propanal (10): Oxalyl chloride (89 L, 
1.02 mmol) was dissolved in CH2Cl2 (7 mL). Upon cooling to –78 °C, DMSO 
                                                
ii
 In the 13C NMR spectrum of the two diastereomers of 152b, most of the signals show different 
values for the two diastereomers. Those that do not (i.e. where the signals for the two 
diastereomers overlap) are at 60.7 pm, three of the t-butyl signals at 27.3, 27.0, and 19.3 ppm, 
and the phenyl signals at 136.2, 135.8, 127.9, and 127.8 ppm. 
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(145 L, 2.04 mmol) was added dropwise via syringe. Gas evolution was 
observed. After 15 min, a solution of 3-(tert-butyldiphenylsilyloxy)-propan-1-ol 
(synthesis follows) in CH2Cl2 was slowly added. The cloudy solution was stirred 
at -78 °C for 30 min, and then Et3N (460 L, 3.30 mmol) was added dropwise. 
The resultant clear solution was stirred at -78 °C for 1.25 h, and was then 
warmed to 0 °C and stirred for an additional 5 min. The mixture was quenched at 
0 °C with sat. aq. NaHCO3 (4.5 mL), extracted twice with CH2Cl2, and the 
combined extracts then washed twice with 1 M sodium bisulfite, once with brine, 
dried over anhydrous MgSO4, and the solvent removed under reduced pressure. 
Flash column chromatography (1:10 EtOAc:petroleum ether) gave the aldehyde 
10 as a colourless oil, 215 mg (84%). 1H NMR (300 MHz, CDCl3)  9.82 (t, 1 H, 
J = 2.1 Hz), 7.67-7.62 (m, 4 H), 7.45-7.36 (m, 6 H), 4.03 (t, 2 H, J = 6.0 Hz), 
2.61 (dt, 2 H, J = 2.1, 6.0 Hz) ppm. 13C NMR (75 MHz, CDCl3)  202.0, 135.5, 
133.2, 129.8, 127.7, 58.2, 46.3, 26.7, 19.1ppm. IR (neat) 3071, 2930, 2857, 1726, 
1612, 1472, 1427, 1389, 1105, 822, 737, 700 cm-1. HRMS (ESI) calcd. for 
C19H28O2NSi [M + NH4+] 330.1884, found 330.1879.  
 
3-(tert-butyldiphenylsilyloxy)-propan-1-ol: 1,3-propane diol (140 L, 
147 mg, 1.92 mmol) and imidazole (288 mg, 4.22 mmol) were dissolved in DMF 
(5 mL) and then cooled to 0 °C. TBDPSCl (500 L, 528 mg, 1.92 mmol) was 
then added and the mixture allowed to warm slowly to RT. After stirring at RT 
overnight, the mixture was diluted with Et2O (100 mL), washed with sat. aq. 
NaHCO3 (40 mL), water (40 mL), and brine (40 mL), dried over anhydrous 
MgSO4, and the solvent removed under reduced pressure. Gradient flash column 
chromatography (1:20-1:10 EtOAc:petroleum ether) gave the title compound as a 
colourless oil, 376 mg (61%). 1H NMR (300 MHz, CDCl3)  7.70-7.66 (m, 4 H), 
7.42-7.36 (m, 6 H), 3.85 (t, 4 H, J = 5.9 Hz), 2.08 (broad s, 1 H), 1.81 (m, 2 H), 
1.06 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3)  135.5, 133.2, 129.8, 127.8, 
63.4, 62.1, 34.1, 26.8, 19.0 ppm. IR (neat) 3366, 3070, 2930, 2857, 1472, 1427, 
1275, 1260, 1106, 1086, 822, 745, 700, 689 cm-1. HRMS (ESI) calcd. for 
C19H27O2Si [M + H+] 315.1775, found 315.1791. Also isolated was di-protected 
product 1,3-di-(tert-butyldiphenylsilyloxy)-propane, as a white solid, 370 mg 
(35%, based on the diol). 1H NMR (300 MHz, CDCl3)  7.68-7.62 (m, 8 H), 
7.42-7.32 (m, 12 H), 3.82 (t, 4 H, J = 5.9 Hz), 1.60 (m, 2 H), 1.03 (s, 18 H) ppm. 
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13C NMR (75 MHz, CDCl3)  135.5, 134.0, 129.5, 127.6, 60.5, 35.5, 26.8, 19.2 
ppm. IR (neat) 3070, 2929, 2856, 1471, 1427, 1104, 1084, 978, 821, 698 cm-1. 
HRMS (ESI) calcd. for C35H45O2Si2 [M + H+] 533.2958, found 533.3019.  
 
(+)-B-allyldiisopinocampheylborane ((+)-11): A dry 250 mL 3-neck 
round bottomed flask (fitted with a large magnetic stir bar and a Schlenk 
filtration unit) was charged with BH3.SMe2 (2 M in Et2O, 25 mL, 50 mmol). The 
solution was cooled to 0 °C, and (-)--pinene (15.9 mL, 13.6 g, 100 mmol) was 
added dropwise via syringe. The mixture was stirred at 0 °C for 3 h, during 
which time a white solid precipitated. Anhydrous THF (10 mL) was then added 
to the flask, and DMS and Et2O subsequently removed under vacuum (ca. 20 
mm) with vigorous stirring. When a solid white mass remained, the flask was 
returned to atmospheric pressure by flushing with argon. A further 10 mL THF, 
and 2.4 mL (2.04 g, 15 mmol) of (-)--pinene were then added to the flask, the 
slurry stirred to homogeneity and then left to stand (without stirring) at 0 °C for 
3 days. MeOH (4 mL, 3.2 g, 100 mmol) was then added at 0 °C (H2 gas was 
evolved). The reaction mixture was then stirred at RT for 1 h, the solvents 
removed under vacuum (20 mm Hg, 1 h, then 0.2 mm, 2 h), then the flask was 
returned to atmospheric pressure by flushing with argon. The resulting viscous 
oil was dissolved in anhydrous Et2O and cooled to -78 °C to yield a clear pale 
yellow solution. Allylmagnesium bromide (2 M in Et2O, 25 mL, 50 mmol) was 
then slowly added and the mixture allowed to stir for 15 min at -78 °C. The flask 
was removed from the cold bath and allowed to warm slowly to RT, and stirred 
for an additional 30 min after reaching that temperature. White solids began to 
precipitate soon after warming. Solvents were removed under reduced pressure, 
and the residues treated with anhydrous pentane (ca. 60 mL). The precipitated 
magnesium salts were removed by filtration (under argon), and rinsed with a 
further ca. 40 mL pentane. The solvent was removed under reduced pressure to 
yield the B-allyldiisopinocampheylborane, 14.72 g (90%), which was stored neat 
in a freezer under argon until required for use. The viscous material was then 
dissolved in anhydrous Et2O (165 mL, to give a 0.27 mmol/mL solution), and 
stored as a solution under argon for a period of weeks without apparent detriment 
to the subsequent allylation reaction. (-)-11 was prepared in an analogous manner 
using (+)--pinene. 
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(4-R)-6-(tert-Butyldiphenylsilyloxy)-4-hydroxy-hex-1-ene ((R)-12): A 
solution of reagent (+)-11 in Et2O (0.27 mmol/mL, 4.6mL, 1.25 mmol) was 
cooled to -78 °C and aldehyde 10 (280 mg, 0.90 mmol) then slowly added as a 
solution in anhydrous Et2O. The mixture was stirred at -78 °C for 45 min, and 
then quenched by the addition of MeOH (0.7 mL). The reaction mixture was then 
allowed to warm to RT before the addition of 2M aq. NaOH (0.7 mL) and 30% 
aq. H2O2 (0.6 mL). After stirring for 1 h, the mixture was extracted three times 
with Et2O (three times 20 mL). The combined organic fractions were then 
washed with brine (30 mL), and dried over anhydrous MgSO4. The solvent was 
removed under reduced pressure to yield an oil which was purified by flash 
column chromatography (1:20 EtOAc:petroleum ether) to yield pure (R)-12 as a 
colourless oil, 161 mg (51%), and a further 65 mg (ca. 20%) of product which 
was not pure. 1H NMR, 13C NMR, IR, and HRMS data were equivalent to those 
obtained for the racemic alcohol 12.  
 
(4-S)-6-(tert-Butyldiphenylsilyloxy)-4-hydroxy-hex-1-ene ((S)-12): 
Was prepared in an analogous manner to (R)-12 but using reagent (-)-11. 1H 
NMR, 13C NMR, IR, and HRMS data were equivalent to those obtained for 
racemic 12.  
 
Note: The following series of reactions to yield aldehydes (R)-13 and 
(R)-160 from (R)-12, also applies for the preparation (S)-13 and (S)-160 from 
(S)-12. Spectral data for the (S)-enantiomers were analogous to those obtained 
for the (R)-enantiomers. 
 
(4-R)-6-(tert-Butyldiphenylsilyloxy)-4-triethylsilyloxy-hex-1-ene 
((R)-148): The representative procedure given above for the preparation of 140 
and 148 was followed. Hence, (R)-12 (580 mg, 1.64 mmol) was converted into 
silyl ether (R)-148 (580 mg, 75%). 1H NMR, 13C NMR, IR, and HRMS data 
were equivalent to those obtained for the racemic silyl ether 148.  
  
(4-R)-6-(tert-Butyldiphenylsilyloxy)-4-(methoxymethyloxy)-1-hexene 
((R)-158): Alcohol (R)-12 (232 mg, 0.65 mmol) and N,N-diisopropylethylamine 
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(230 L, 170 mg, 1.31 mmol) were cooled to 0 °C. MOMCl (60 L, 64 mg, 
0.78 mmol) was then added and the mixture allowed to warm slowly to RT. 
After stirring at RT overnight, the mixture was quenched with water (10 mL) and 
diluted with Et2O (50 mL). The aqueous layer was separated and extracted once 
with Et2O (50 mL), and the combined organic fractions then washed with brine 
(40 mL), dried over anhydrous MgSO4, and the solvent removed under reduced 
pressure. Gradient flash column chromatography (1:20-1:10 EtOAc:petroleum 
ether) gave the methoxymethyl ether (R)-158 as a colourless oil, 150 mg (60%). 
1H NMR (300 MHz, CDCl3)  7.71-7.66 (m, 4 H), 7.44-7.36 (m, 6 H), 5.83 (m, 
1 H), 5.10 (m, 1 H), 5.06 (m, 1 H), 4.65 (s, 2 H), 3.87 (m, 1 H), 3.78 (m, 2 H), 
3.34 (s, 3 H), 2.32 (t, 2 H, J = 6.5 Hz), 1.80 (m, 2 H), 1.07 (s, 9 H) ppm. 
13C NMR (75 MHz, CDCl3)  135.5, 134.6, 133.8, 129.6, 127.6, 117.2, 95.7, 
74.0, 60.4, 55.4, 39.2, 37.1, 26.8, 19.1 ppm. IR (neat) 3071, 2930, 2886, 2857, 
1640, 1472, 1427, 1152, 1106, 1036, 915, 822, 740, 701 cm-1. HRMS (ESI) 
calcd. for C24H35O3Si [M + H+] 399.2355, found 399.2343.  
 
Representative procedure for ozonolysis of alkenes 148, 158, and 159 
(using the Envirozone V.T-2A ozonolysis machine): Alkene (1 equivalent) 
was dissolved in CH2Cl2 (10 mL/mmol) and anhydrous MeOH (1 mL/mmol) and 
cooled to -78 °C under argon. Then, ozone was bubbled through the solution for 
a brief period (see under individual compounds below). The flask was then 
purged with argon, and PPh3 (1.5 equivalents) was added. The stirred solution 
was kept at - 78 °C for 30 min, and than at RT for 1 h. Solvents were then 
removed under reduced pressure. The residue was purified by flash column 
chromatography (usually 1:20 EtOAc:petroleum ether), loading the residue onto 
the column with 1:50 EtOAc:petroleum ether in order to precipitate the by-
product, triphenylphosphine oxide (which otherwise elutes on the column close 
to the desired product). The aldehydes were obtained as clear oils that were 
reasonably stable (for a period of days) if kept under argon in the freezer.  
(3-R)-5-(tert-Butyldiphenylsilyloxy)-3-triethylsilyloxy-pentanal 
((R)-13) was prepared from (R)-148 (164 mg, 0.35 mmol), with ozone bubbling 
for 150 seconds, to yield (R)-13 (136 mg, 84%). 1H NMR (300 MHz, CDCl3)  
9.80 (t, 1 H, J = 2.4 Hz), 7.66 (m, 4 H), 7.42 (m, 6 H), 4.46 (m, 1 H), 3.74 (m, 
2 H), 2.54 (m, 2 H), 1.79 (m, 2 H), 1.07 (s, 9 H), 0.94 (t, 9 H, J = 8 Hz), 0.60 (q, 
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6 H, J = 8 Hz) ppm. 13C NMR (75 MHz, CDCl3)  202.2, 135.6, 135.5, 133.6, 
133.5, 129.7, 129.6, 127.7, 127.6, 65.4, 60.2, 50.9, 40.4, 26.8, 19.1, 6.8, 4.8 ppm. 
IR (neat) 2953, 1725, 1427, 1238, 1086, 1005, 731, 700 cm-1. HRMS (ESI) 
calcd. for C27H42O3Si2Na [M + Na+] 493.2565, found 493.2571.  
(3-R)-5-(tert-Butyldiphenylsilyloxy)-3-(methoxymethyloxy)-pentanal 
((R)-160) was prepared from (R)-158 (120 mg, 0.31 mmol), ozone bubbling for 
90 seconds, to yield (R)-160 (100 mg, 83%). 1H NMR (300 MHz, CDCl3)  9.77 
(t, 1 H, J = 2.0 Hz), 7.68-7.62 (m, 4 H), 7.45-7.32 (m, 6 H), 4.67 (d, 1 H, J = 7.1 
Hz), 4.61 (d, 1 H, J = 7.1 Hz), 4.32 (m, 1 H), 3.76 (m, 2 H), 3.30 (s, 3 H), 2.62 
(m, 2 H), 1.82 (m, 2 H), 1.05 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3)  201.4, 
135.5, 133.5, 129.7, 127.7, 96.1, 70.7, 60.0, 55.5, 49.0, 37.6, 26.8, 19.1 ppm. 
HRMS (ESI) calcd. for C23H32O4SiNa [M + Na+] 423.1968, found 423.1972.  
 
 
8.3 Experimental for Chapter Three 
 
Dihydro-3-allyloxy-4,4-dimethyl-2(3H)-furanone (165): To a solution 
of pantolactone 25 (10 g, 76.8 mmol) in DMF (80 mL) at 0 °C was slowly added 
a solution of KOtBu (8.62 g, 76.8 mmol) in THF (80 mL). The solution was 
stirred at 0 °C for 30 min before the addition, over 40 min, of allyl bromide (6.98 
mL, 9.75 g 80.6 mmol) in THF (7 mL). The reaction mixture was warmed to RT 
and stirred overnight, and then quenched with water (50 mL), extracted with 
Et2O (4 x 100 mL). The combined organic extracts were then washed twice with 
sat. aq. NaHCO3 solution (100 mL), water (100 mL), and brine (100 mL), dried 
over MgSO4 and solvents removed under reduced pressure. Purification by 
gradient flash column chromatography (1:20 – 1:5 EtOAc:petroleum ether) gave 
the allyl pantolactone 165 as a colourless oil, 11.62 g (88%). Spectral data 
matched those reported by Stocker.48 
 
2,2-Dimethyl-3-(allyloxy)butane-1,4-diol (166): LAH (3.86 g, 
101.85 mmol) was suspended in THF (130 mL) and a solution of allyl 
pantolactone 165 (11.62 g, 67.9 mmol) in THF (65 mL) was added cautiously 
dropwise over 20 min. The resulting solution was then refluxed for 3 h before 
being cooled to 0 °C and being quenched by portionwise addition of hydrated 
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sodium sulphate and drops of water until effervescence was no longer apparent. 
Anhydrous MgSO4 was added, and the mixture diluted with ethanol (200 mL), 
divided into portions, and filtered through several celite/silica gel plugs with 
ethanol. The solvents were removed under reduced pressure to yield 10.5 g of 
crude product which was purified by flash column chromatography (1:1 
EtOAc:petroleum ether) to yield 8.73 g (74%) of the diol 166. Spectral data 
matched those reported by Stocker.48 
 
1,4-Dibenzyloxy-2,2-dimethyl-3-(allyloxy)butane (167): A solution of 
diol 166 (8.73 g, 50 mmol) in DMF (65 mL) was added to a rapidly stirred 
solution of NaH (5.4 g, 225 mmol) in DMF (80 mL) at 0 °C. The mixture was 
stirred at that temperature for 30 min and then benzyl bromide (12.15 mL, 
17.47 g, 102 mmol) was added over 30 min. The reaction mixture was then 
warmed to room temperature and stirred overnight before being quenched with 
water (200 mL) and extracted three times with Et2O (three times 200 mL). The 
combined organic fractions were then washed with sat. aq. NaHCO3 solution 
(200 mL), water (100 mL), and brine (150 mL), dried over MgSO4 and the 
solvents removed under reduced pressure. 1H NMR analysis of the crude product 
revealed the presence of the dibenzyl ether 167 and also the mono-benzylated 
product, which were readily separated by flash column chromatography 
(petroleum ether - 1:10 EtOAc:petroleum ether) to yield 167, 10.1 g (57%) and 
5.0 g (38%) of the monobenzylated product. The latter (4.98 g, 18.8 mmol) was 
resubmitted to the benzylation procedure described above (NaH 1.35 g, 56.4 
mmol; DMF 85 mL (total); benzyl bromide 2.34 mL, 19.7 mmol; workup and 
flash column chromatography as above) to yield 6.42 g (96%) of 167. The total 
yield of 167 was therefore 16.52 g (93%). Spectral data matched those reported 
by Stocker.48 
 
1,4-Dibenzyloxy-3,3-dimethylbutan-2-ol (168): To a solution of 167 
(5 g, 14 mmol), in THF (75 mL) were added para-toluenesulfinic acid as its HCl 
salt (2.6 g, 16.8 mmol) and Pd(PPh3)4 (1 g, 0.98 mmol). After stirring for 18 h at 
RT, 1H NMR analysis of an aliquot showed a significant amount of starting 
material was still present. A further 2 g of para-toluenesulfinic acid as its HCl 
salt and 1 g of Pd(PPh3)4 from a freshly opened bottle were added and stirring 
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was continued for a further 24 h. At this point the reaction was judged to be 
essentially complete by 1H NMR, and so was quenched by addition of Et3N 
(1 mL). Solvents were then removed under reduced pressure and the residues 
purified by gradient flash column chromatography (1:50 - 1:10 EtOAc:petroleum 
ether) to yield 168, 3.23 g (73%). Spectral data matched those reported by 
Stocker.48 
 
1,4-Dibenzyloxy-3,3-dimethylbutan-2-one (7): To a solution of 168 
(2.87 g, 9.11 mmol) in CH2Cl2 (46 mL) was added PDC (5.14 g, 13.6 mmol), 
freshly activated 3 Å molecular sieves (7.5 g) and anhydrous AcOH (0.90 mL, 
15.8 mmol). The mixture was stirred at RT for 3 h and then filtered through a 
short celite-silica plug (washing the plug thoroughly with CH2Cl2). The filtrate 
was washed with water and brine and then dried over MgSO4, and solvents then 
removed under reduced pressure. Purification of the crude material by flash 
column chromatography (1:10 EtOAc:petroleum ether) gave the ketone 7 as a 
colourless oil, 2.34 g (82%). Spectral data matched those reported by Stocker.48  
 
(Z)-1,4-Dibenzyloxy-3,3-dimethyl-2-(trimethylsilyloxy)-1-butene 
(169): A stirred solution of diisopropylamine (395 L, 2.79 mmol) in THF 
(5 mL) was cooled to 0 °C and n-BuLi (1.74 mL of a 1.6 M solution in hexane, 
2.79 mmol) then added. The mixture was stirred at 0 °C for 20 min and then 
cooled to –78 °C, at which temperature 7 (580 mg, 1.86 mmol) was added as a 
solution in THF (5 mL). Stirring was continued at –78 °C for 30 min during 
which time the solution developed a bright yellow colour. TMSCl (375 L, 321 
mg, 2.79 mmol) was added and the mixture was stirred at –78 °C for 30 min and 
then warmed to RT for 1 h. The reaction was quenched by the addition of water 
(2 mL) and then extracted 3 times with hexanes (three times 10 mL). The 
combined organic fractions were washed with water (5 mL) and brine (10 mL), 
dried over MgSO4, and the solvents removed under reduced pressure. Only one 
isomer was detectable in the 1H NMR of the crude product, determined to be the 
Z- isomer by NOE experiments (see discussion in chapter three). Purification by 
flash column chromatography (1:50 EtOAc:petroleum ether, neutralised with a 
few drops of Et3N) gave the silyl enol ether 169 as a colourless oil, 680 mg 
(95%). 1H NMR (300 MHz, CDCl3)  7.35-7.25 (m, 10 H), 5.67 (s, 1 H), 4.70 (s, 
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2 H), 4.51 (s, 2 H), 3.26 (s, 2 H), 1.02 (s, 6 H), 0.12 (s, 9 H) ppm. 13C NMR (75 
MHz, CDCl3)  140.5, 139.0, 137.5, 128.3, 128.2, 127.9, 127.7, 127.4, 127.2, 
76.7, 73.7, 73.1, 38.8, 23.0, 0.7 ppm. IR (neat) 2958, 2863, 1679, 1496, 1247, 
1205, 1098, 1027, 843, 731 cm-1.  
 
1,4-Di(methoxymethyl)oxy-3,3-dimethylbutan-2-one (188), was 
prepared by Dr John Hoberg by an analogous synthesis (using MOMCl in place 
of BnCl) to that used for the preparation of ketone 7: 1H NMR (300 MHz, 
CDCl3)  4.68 (s, 2 H), 4.58 (s, 2 H), 4.52 (s, 2 H), 3.51 (s, 2 H), 3.38 (s, 3 H), 
3.33 (s, 3 H), 1.18 (s, 6 H) ppm. 13C NMR (75 MHz, CDCl3)  209.8, 96.6, 96.3, 
74.4, 69.1, 55.6, 55.4, 46.9, 21.7 (2 C) ppm. IR (neat) 2933, 1723, 1466, 1149, 
1111, 1048, 912, 730 cm-1. HRMS (ESI) calcd. for C10H24O5N [M + NH4+] 
238.1649, found 238.1661. 
 
(1S*, 2R*)-2,5-Di(benzyloxy)-4,4-dimethyl-1-hydroxy-1-phenyl-3-
pentanone ((±)-170a) and (1S*, 2S*)-2,5-Di(benzyloxy)-4,4-dimethyl-1-
hydroxy-1-phenyl-3-pentanone ((±)-170b) were prepared by the following 
methods A-F: 
 
A. LDA. A stirred solution of diisopropylamine (40 L, 29 mg, 
0.30 mmol) in THF (1 mL) was cooled to –78 °C and n-BuLi (150 L of a 1.6 M 
solution in hexane, 0.30 mmol) then added. The mixture was stirred at  –78 °C 
for 15 min and then 7 (80 mg, 0.25 mmol) was added as a solution in THF (ca. 1 
mL). Stirring was continued at –78 °C for 50 min during which time the solution 
developed a bright yellow colour. Then, benzaldehyde (60 L, 63 mg, 0.50 
mmol) was added. After 70 minutes stirring at –78 °C, although TLC analysis 
did not indicate complete conversion, it appeared that by-products were 
beginning to form and so the reaction was quenched by the addition of aq. NH4Cl 
and diluted with Et2O (20 mL). The phases were separated and the aqueous phase 
extracted a further two times with Et2O (two times 10 mL). The combined 
organic fractions were then washed with water (10 mL) and brine (10 mL), dried 
over MgSO4, and the solvents removed under reduced pressure. Purification of 
the crude material by flash column chromatography (1:10 – 1:5 
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EtOAc:petroleum ether) gave a mixture of (±)-170a and (±)-170b as a colourless 
oil, 68 mg (65%), syn:anti ratio 14:1. 
 
B. LiTMP. A stirred solution of LiTMP (101 L, 0.60 mmol) in THF 
(1.5 mL) was cooled to –78 °C and n-BuLi (300 L of a 2 M solution in hexane, 
0.60 mmol) then added. The mixture was stirred at  –78 °C for 15 min and then 7 
(170 mg, 0.54 mmol) was added as a solution in THF (ca. 1 mL). Stirring was 
continued at –78 °C for 1 h during which time the solution developed a bright 
yellow colour. Then, benzaldehyde (110 L, 115 mg, 1.08 mmol) was added. 
After 90 minutes stirring at –78 °C, the reaction was quenched by the addition of 
aq. NH4Cl (10 mL) and diluted with Et2O (20 mL). The phases were separated 
and the aqueous phase extracted a further two times with Et2O (two times 10 
mL). The combined organic fractions were then washed with water (10 mL) and 
brine (10 mL), dried over MgSO4, and the solvents removed under reduced 
pressure. Purification of the crude material by gradient flash column 
chromatography (1:10 – 1:5 EtOAc:petroleum ether) gave a mixture of (±)-170a 
and (±)-170b as a colourless oil, 125 mg (55%), syn:anti ratio 13:1. 
 
C. Cy2BOTf. A solution of 7 (210 mg, 0.67 mmol) and Et3N (224 L, 
1.61 mmol) in CH2Cl2 (3.5 mL) was cooled to –78 °C. A solution of Cy2BOTf in 
hexane (3 mL of a 0.5 M solution, 1.48 mmol) was then slowly added. The 
resultant solution was stirred at –78 °C for 30 min before the addition of 
benzaldehyde (81 L, 85 mg, 0.80 mmol). After stirring at –78 °C for 30 min, the 
solution was warmed to RT and stirred for a further h before being quenched by 
the addition of pH 7 buffer solution (2 mL), 30% aq. H2O2 (2 mL) and MeOH 
(2.5 mL). The mixture was stirred at RT overnight, after which time water 
(15 mL) was added and the solution then extracted three times with CH2Cl2 
(three times 20 mL). The combined organic fractions were then washed with 
water (20 mL) and brine (20 mL), dried over MgSO4, and the solvents removed 
under reduced pressure. Purification of the crude material by gradient flash 
column chromatography (1:10 – 1:5 EtOAc:petroleum ether) gave a mixture of 
(±)-170a and (±)-170b as a colourless oil, 168 mg (60%), syn:anti ratio > 20:1. 
Several columns were required to free the product from the cyclohexanol by-
product, which has an Rf very close to that of 170. 
 214 
 
D. LDA then Ti(OiPr)4. A stirred solution of diisopropylamine (90 L, 
0.62 mmol) in THF (1 mL) was cooled to 0 °C and n-BuLi (375 L of a 1.6 M 
solution in hexane, 0.60 mmol) then added. The mixture was stirred at 0 °C for 
10 min and then cooled to –78 °C, at which temperature 7 (170 mg, 0.54 mmol) 
was added as a solution in THF (ca. 1 mL). Stirring was continued at –78 °C for 
30 min and then freshly distilled Ti(OiPr)4 (180 L, 173 mg, 0.60 mmol) was 
added. The temperature was increased to –40 °C for 30 min. Then, benzaldehyde 
(82 L, 86 mg, 0.81 mmol) was added and the solution allowed to warm slowly 
to RT over 2.5 h. The reaction was quenched by the addition of aq. NH4Cl (2 
mL) and diluted with Et2O (10 mL). The phases were separated and the aqueous 
phase extracted two times with Et2O (two times 10 mL). The combined organic 
fractions were then washed with water (5 mL) and brine (10 mL), dried over 
MgSO4, and the solvents removed under reduced pressure. Purification of the 
crude material by gradient flash column chromatography (1:20 – 1:10 
EtOAc:petroleum ether) gave a mixture of (±)-170a and (±)-170b as a colourless 
oil, 132 mg (59%), syn:anti ratio 4:1.  
 
E. Cy2BCl. A solution of Cy2BCl (230 mg, 0.93 mmol) in Et2O (5 mL) 
was cooled to 0 °C and then treated with Et3N (138 L, 100 mg, 0.99 mmol), 
followed by addition of a solution of the ketone 7 (192 mg, 0.62 mmol) in Et2O 
(2 mL). The mixture was stirred for 20 min at 0 °C, after which time the white 
suspension was cooled to –78 °C. Benzaldehyde (126 L, 132 mg, 1.24 mmol) 
was then added and the mixture stirred at –78 °C for 5 h. The reaction was then 
quenched by the addition of 2 mL of a 6:1 mixture of MeOH : pH 7 buffer 
solution, and then 30% aq. H2O2 (0.6 mL). The mixture was stirred at RT 
overnight, and then water (10 mL) was added and the solution extracted 3 times 
with Et2O (three times 20 mL). The combined organic fractions were then 
washed with water (20 mL) and brine (20 mL), dried over MgSO4, and the 
solvents removed under reduced pressure. Purification of the crude material by 
gradient flash column chromatography (1:10 – 1:5 EtOAc:petroleum ether) and 
removal of the last traces of the cyclohexanol by-product using a hi-vacuum 
pump gave a mixture of (±)-170a and (±)-170b as a colourless oil, 110 mg 
(42%), syn:anti ratio 1:4. 
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F. TiCl4. To a solution of benzaldehyde (52 L, 54 mg, 0.51 mmol) in 
CH2Cl2 (1 mL) at –78 °C was added freshly distilled TiCl4 (56 L, 97 mg, 
0.51 mmol). The resultant mobile slurry was stirred for 10 min before the 
addition of enol silane 169 (197 mg, 0.51 mmol) as a solution in CH2Cl2 (1 mL). 
The reaction was then stirred at –78 °C for 1 h, at which time TLC analysis 
showed that no more 169 was present. The reaction was then quenched by the 
addition of aq. NH4Cl (5 mL) and diluted with CH2Cl2 (10 mL). The phases were 
separated and the aqueous phase extracted a further two times with CH2Cl2 (two 
times 10 mL). The combined organic fractions were then washed with water (5 
mL) and brine (5 mL), dried over MgSO4, and the solvents removed under 
reduced pressure. Purification by flash column chromatography (1:10 – 1:5 
EtOAc:petroleum ether) gave a mixture of (±)-170a and (±)-170b as a colourless 
oil, 70 mg (33%), syn:anti ratio 1:3, plus 95 mg (60% recovery) of the ketone 7. 
 
(1S*, 2R*)-2,5-Di(benzyloxy)-4,4-dimethyl-1-hydroxy-1-phenyl-3-
pentanone ((±)-170a): 1H NMR (300 MHz, CDCl3)  7.35-7.22 and 7.08-7.02 
(m, 10 H), 5.06 (dd, 1 H, J = 4.2, 5.4 Hz), 4.58 (d, 1 H, J = 4.2 Hz), 4.51 (d, 1 H, 
J = 11.7 Hz), 4.46 (s, 2 H), 4.23 (d, 1 H, J = 11.7 Hz), 3.47 (d, 1 H, J = 8.8 Hz), 
3.40 (d, 1 H, J = 8.8 Hz), 3.22 (d, 1 H, J = 5.4 Hz, OH), 1.10 (s, 3 H), 1.04 (s, 
3 H) ppm. 13C NMR (75 MHz, CDCl3)  213.1, 140.4, 138.0, 137.6, 128.7, 
128.6, 128.5 (2 C), 128.3, 128.1, 128.0 127.5, 127.0, 83.3, 77.5, 73.8, 73.5, 72.4, 
48.7, 22.2, 22.1 ppm. IR (neat) 3444, 2859, 1701, 1495, 1360, 1095, 1027, 910, 
697 cm-1. HRMS (ESI) calcd. for C27H30O4Na [M + Na+] 441.2036, found 
441.2041.  
 
(1S*, 2S*)-2,5-Di(benzyloxy)-4,4-dimethyl-1-hydroxy-1-phenyl-3-
pentanone ((±)-170b): 1H NMR (300 MHz, CDCl3)  7.40-7.20 and 7.01-6.85 
(m, 10 H), 4.97 (d, 1 H, J = 7.3 Hz), 4.48 (s, 2 H), 4.43 (d, 1 H, J = 7.3 Hz), 4.29 
(d, 1 H, J = 11.5 Hz), 4.07 (d, 1 H, J = 11.5 Hz), 3.49 (d, 2 H, J = 1.0 Hz), 1.15 
(s, 3 H), 1.14 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3)  214.9, 140.9, 137.5, 
137.2, 128.4, 128.2, 128.0, 127.8 (2 C), 127.7, 127.2, 82.3, 77.4, 74.6, 73.5, 72.3, 
48.7, 22.1, 22.0 ppm. IR (neat) 3445, 3063, 3031, 2860, 1703, 1602, 1495, 1362, 
 216 
1205, 1093, 1026, 909, 712, 695 cm-1. HRMS (ESI) calcd. for C27H30O4Na 
[M + Na+] 441.2036, found 441.2047.  
 
Representative procedure for LDA aldol reactions between ketone 7 
or 188 and aldehydes 13, 140, or 160: A stirred solution of diisopropylamine 
(1.1 eq) in THF (3 mL per mmol of ketone) was cooled to –78 °C and n-BuLi 
(2 M solution in hexane, 1.1 eq) then added. The mixture was stirred at  –78 °C 
for 5 min, at 0 °C for 15 min, and then cooled back to –78 °C before addition of 
the ketone (1 eq.) as a solution in THF (ca. 1 mL per mmol). Stirring was 
continued at –78 °C for 50 min, during which time the solution developed a 
bright yellow colour. Then the aldehyde (0.5-1.5 eq.) was added as a solution in 
THF (ca. 1 mL per mmol). After 60 minutes stirring at –78 °C, the reaction was 
quenched by the addition of aq. NH4Cl and diluted with Et2O. The phases were 
separated and the aqueous phase extracted a further two times with Et2O. The 
combined organic fractions were then washed with water and brine, dried over 
MgSO4, and the solvents removed under reduced pressure. Products were 
purified by column chromatography using the solvent systems indicated.  
 
(4S*,5R*)-1,4-Di(benzyloxy)-9-(tert-butyldiphenylsilyloxy)-5-
hydroxy-7-(triethylsilyloxy)-2,2-dimethyl-nonan-3-one (28c/28d): An aldol 
reaction was performed using the representative aldol procedure, between ketone 
7 (150 mg, 0.48 mmol) and aldehyde (±)-13 (180 mg, 0.38 mmol).  Purification 
of the crude material by flash column chromatography (1:10 EtOAc:petroleum 
ether) gave an unidentified diastereomer of 28 (28c or 28d) as a colourless oil, 60 
mg (20%). Only one diastereomer was isolated, but retrospective inspection of 
the crude 1H NMR suggested that other diastereomers had also been formed (the 
other diastereomers were not isolated cleanly and, due to the inexperience of the 
author at the time, inadvertently discarded!). Also isolated were the elimination 
product 176, 30 mg (23%), and unreacted 13 20 mg (11%). Data for the isolated 
diastereomer of 28: 1H NMR (300 MHz, CDCl3)  7.67 (m, 4 H), 7.42-7.20 (m, 
16 H), 4.60 (d, 1 H, J = 11.7 Hz), 4.47 (s, 2 H), 4.31 (m, 1 H), 4.26 (d, 1 H, J = 
11.7 Hz), 4.20 (m, 2 H), 3.69 (m, 2 H), 3.57 (d, 1 H, J = 9.0 Hz), 3.47 (d, 1 H, J 
= 9.0 Hz), 2.72 (broad s, 1 H), 1.90-1.65 (m, 3 H), 1.43 (m, 1 H), 1.23 (s, 3 H), 
1.19 (s, 3 H), 1.05 (s, 9 H), 0.93 (t, 9 H, J = 7.9 Hz), 0.59 (q, 6 H, J = 7.9 Hz) 
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ppm. 13C NMR (75 MHz, CDCl3)  213.0, 138.2, 138.0, 135.8, 134.1, 134.0, 
129.9, 129.8, 128.6, 128.5, 128.3, 127.8, 127.9, 83.0, 78.3, 73.7, 72.1, 68.1, 67.2, 
60.8, 48.3, 40.8, 40.7, 27.1, 22.6, 22.4, 19.4, 7.2, 5.2 ppm. HRMS (ESI) calcd. 
for C47H67O6Si2 [M + H+] 783.4471, found 783.4503.  
Data for 5-(tert-Butyldiphenylsilyloxy)-pent-2-en-1-al (176): 1H NMR 
(300 MHz, CDCl3)  9.48 (d, 1 H, J = 8.1 Hz), 7.65 (m, 4 H), 7.40 (m, 6 H), 6.85 
(dt, 1 H, J = 15.6, 6.9 Hz), 6.15 (m, 1 H), 3.83 (t, 2 H, J = 6.1 Hz), 2.55 (m, 2 H), 
1.05 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3)  194.1, 155.6, 135.5, 134.4, 
133.4, 129.8, 127.7, 61.9, 35.9, 26.8, 19.2 ppm. IR (neat) 1691, 1471, 1427, 
1389, 1104, 1007, 822, 733, 700 cm-1. HRMS (ESI) calcd. for C21H30NO2Si [M 
+ NH4+] 356.2046, found 356.2072.  
 
(4S*,5R*)-1,4-Di(benzyloxy)-9-(tert-butyldiphenylsilyloxy)-5,7-
di(hydroxy)-2,2-dimethyl-nonan-3-one (181): A solution of 28 (one 
diastereomer, 50 mg, 0.06 mmol) in MeOH (2 mL) was cooled to 0 °C and 
catalytic pTsOH (5 mg, 0.02 mmol) was then added. The mixture was stirred for 
20 min at 0 °C and then solid NaHCO3 (50 mg, 0.60 mmol) was added. The 
mixture was concentrated under reduced pressure and the residue purified by 
column chromatography (1:10-1:1 EtOAc:petroleum ether) to yield the diol 181 
(32 mg, 82%). 1H NMR (300 MHz, CDCl3)  7.66-7.22 (m, 20 H), 4.64 (d, 1 H, 
J = 11.7 Hz), 4.49 (s, 2 H), 4.47 (d, 1 H, J = 3.2 Hz), 4.28 (d, 1 H, J = 11.7 Hz), 
4.24 (m, 1 H), 3.83 (m, 2 H), 3.68 (m, 1 H), 3.49 (d, 1 H, J = 8.8 Hz), 3.54 (d, 1 
H, J = 8.8 Hz), 3.24 (broad s, 1 H), 2.95 (broad s, 1 H), 1.86-1.46 (m, 4 H), 1.27 
(s, 3 H), 1.22 (s, 3 h), 1.06 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3)  213.4, 
135.8, 135.7, 130.1, 128.7, 128.6, 128.4, 128.1 (2 C), 128.0, 127.9, 81.6, 78.1, 
73.7, 72.1, 71.3, 71.2, 63.3, 48.5, 40.1, 38.9, 27.0, 22.7, 22.5, 19.3 ppm. HRMS 
(ESI) calcd. for C41H52NaO6Si [M + Na+] 691.3425, found 691.3453.   
 
(4S*,5R*,7S)-1,4-Di(benzyloxy)-9-(tert-butyldiphenylsilyloxy)-5-
hydroxy-7-(methoxymethyloxy)-2,2-dimethyl-nonan-3-one (178a/b): An 
aldol reaction was performed using the representative aldol procedure above, 
between ketone 7 (110 mg, 0.35 mmol) and aldehyde (S)-160 (50 mg, 0.12 
mmol).  Purification of the crude material by flash column chromatography 
(1:10-1:5 EtOAc:petroleum ether) gave the title compound (Rf  0.35, 1:5 
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EtOAc:petroleum ether), as a 1:1 mixture of two diastereomeric syn- aldol 
products, as a colourless oil, 50 mg (56%). Data for the mixed diastereomers: 
1H NMR (300 MHz, CDCl3)  7.70 (m, 8 H), 7.45-7.22 (m, 32 H), 4.66-4.56 (m, 
6 H), 4.48 (s, 2 H), 4.47 (s, 2 H), 4.39 (d, 1 H, J = 3.2 Hz), 4.34 (d, 1 H, J = 2.7 
Hz), 4.30 (d, 1 H, J = 4.4 Hz), 4.26 (d, 1 H, J = 4.6 Hz), 4.23 (m, 1 H), 4.14 (m, 1 
H), 4.01 (m, 1 H), 3.90 (m, 1 H), 3.75 (m, 4 H), 3.60-3.48 (m, 4 H), 3.31 (s, 3 H), 
3.30 (s, 3 H), 2.83 (d, 1 H, J = 6.6 Hz, OH), 2.72 (d, 1 H, J = 7.1 Hz, OH), 1.90-
1.70 (m, 7 H), 1.54 (m, 1 H), 1.26 (s, 3 H), 1.24 (s, 3 H), 1.21 (s, 6 H), 1.07 (s, 
18 H) ppm. 13C NMR (75 MHz, CDCl3)  213.1, 212.8, 138.1, 137.9, 135.8, 
134.1, 134.0, 129.9, 128.7, 128.6, 128.3, 128.2, 128.1, 128.0, 127.9, 96.9, 95.9, 
82.9, 82.3, 78.2, 78.1, 73.8, 73.7, 73.6, 72.2, 72.1, 69.4, 67.9, 60.7, 60.6, 55.9, 
55.8, 48.4, 48.3, 39.7, 38.7, 38.4, 37.7, 27.1, 22.6 (2 C),iii 22.5, 22.4, 19.4 ppm. 
HRMS (ESI) calcd. for C43H57O7Si [M + H+] 713.3874, found 713.3871. 
 
(7S)-1,4-Di(benzyloxy)-7,9-di(tert-butyldiphenylsilyloxy)-2,2-dimethyl 
-non-4-en-3-one (179): A stirred solution of diisopropylamine (65 L, 47 mg, 
0.46 mmol) in THF (1 mL) was cooled to 0 °C and n-BuLi (275 L of a 1.6 M 
solution in hexane, 0.44 mmol) then added. The mixture was stirred at 0 °C for 
10 min and then cooled to –78 °C, at which temperature ketone 7 (125 mg, 0.40 
mmol) was added as a solution in THF (ca. 1 mL). Stirring was continued at 
- 78 °C for 30 min and then freshly distilled Ti(OiPr)4 (130 L, 125 mg, 0.44 
mmol) was added. The temperature was increased to –40 °C for 30 min. Then, 
aldehyde (S)-161 (160 mg, 0.27 mmol) was added and the solution warmed 
slowly to RT over 2.5 h. The reaction was quenched by the addition of aq. 
NH4Cl (2 mL) and diluted with Et2O (10 mL). The phases were separated and the 
aqueous phase extracted with Et2O (two times 10 mL). The combined organic 
fractions were then washed with water (5 mL) and brine (10 mL), dried over 
MgSO4, and the solvents removed under reduced pressure. Purification of the 
crude material by flash column chromatography (1:20 – 1:10 EtOAc:petroleum 
ether) gave the eliminated aldol product 179 (98 mg, 40%), along with ketone 7 
                                                
iii
 The signal at 22.6 ppm is attributed to the overlapping gem-dimethyl groups of one 
diastereomer of 178, whereas for the other diastereomer the gem-dimethyl groups are not 
equivalent and their signals appear at 22.5 and 22.4 ppm. Overlapping peaks also occur for the 
TBDPS and Bn groups of the two diastereomers of 178; however these are not noted in the peak 
listing. 
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(70 mg, 56%) and the eliminated aldehyde 176 (45 mg, 50%). Data for 179: 1H 
NMR (300 MHz, CDCl3)  7.65-7.20 (m, 30 H), 5.92 (t, 1 H, J = 9 Hz), 4.55 (s, 
2 H), 4.41 (s, 2 H), 4.10 (m, 1 H), 3.62 (m, 2 H), 3.53 (s, 2 H), 2.32 (m, 2 H), 
1.78 (m, 1 H), 1.61 (m, 1 H), 1.19 (s, 6 H), 0.99 (s, 9 H), 0.93 (s, 9 H) ppm. 
HRMS (ESI) calcd. for C57H69O2Si2 [M + H+] 782.4187, found 782.4182. 
 
(4S*,5R*,7S)-1,4,7-Tri(methoxymethyloxy)-9-(tert-butyldiphenylsilyl 
oxy)-5-acetyloxy-2,2-dimethyl-nonan-3-one (190a and 190b): An aldol 
reaction between ketone 7 (60 mg, 0.24 mmol) and aldehyde (S)-160 (65 mg, 
0.16 mmol) was performed using the representative LDA aldol procedure above. 
The crude aldol product was purified by column chromatography (1:3-1:1 
EtOAc:petroleum ether) to yield 38 mg (0.06 mmol, 38%) of 189 as a mixture of 
diastereomers. The mixture was dissolved in pyridine (0.2 mL) and acetic 
anhydride (0.2 mL) was then added at 0 °C. The solution was warmed to RT and 
stirred overnight, and then quenched with water (5 mL). The mixture was 
extracted with diethyl ether (two times 20 mL), and the combined organic 
portions then washed with brine (5 mL), dried over anhydrous MgSO4, and 
evaporated under reduced pressure. Column chromatography (1:10-1:3 
EtOAc:petroleum ether) allowed the separation of two diastereomers of 190, the 
first eluting (in 1:3 EtOAc:petroleum ether) at Rf 0.31 (17 mg, 43%). 1H NMR 
(300 MHz, CDCl3)  7.68 (m, 4 H), 7.40 (m, 6 H), 5.49 (m, 1 H), 4.68 (m, 1 H), 
4.62-4.49 (m, 6 H), 3.75 (m, 3 H), 3.51 (s, 2 H), 3.34 (s, 3 H), 3.31 (s, 3 H), 3.30 
(s, 3 H), 2.18-1.62 (m, 4 H), 2.03 (s, 3 H), 1.28 (s, 3 H), 1.19 (s, 3 H), 1.04 (s, 
9 H) ppm. 13C NMR (75 MHz, CDCl3)  210.5, 170.7, 135.5 (4 C), 133.6 (2 C), 
129.6 (2 C), 127.7 (4 C), 96.6, 96.4, 95.9, 77.6, 74.6, 72.1, 69.3, 60.1, 56.0, 55.8, 
55.3, 48.1, 38.0, 37.3, 26.7 (3 C), 21.5, 21.4, 20.9, 19.1 ppm. IR (neat) 2931, 
2889, 1739, 1715, 1472, 1371, 1238, 1150, 1108, 1034, 918, 734, 703 cm-1. The 
second diastereomer, eluting at Rf 0.25 (15 mg, 37%). 1H NMR (300 MHz, 
CDCl3)  7.64 (m, 4 H), 7.39 (m, 6 H), 5.46 (dt, 1 H, J = 2.2, 6.5 Hz), 4.73 (d, 
1 H, J = 2.2 Hz), 4.63-4.50 (m, 6 H), 3.85 (m, 1 H), 3.74 (m, 2 H), 3.51 (s, 2 H), 
3.33 (s, 3 H), 3.32 (s, 3 H), 3.31 (s, 3 H), 2.18-1.92 (m, 2 H), 2.02 (s, 3 H), 1.88-
1.65 (m, 2 H), 1.27 (s, 3 H), 1.19 (s, 3 H), 1.04 (s, 9 H) ppm. 13C NMR (75 MHz, 
CDCl3)  210.4, 170.3, 135.5 (4 C), 133.7 (2 C), 129.6 (2 C), 127.7 (4 C), 96.6, 
96.1, 95.8, 77.2, 74.7, 71.9, 69.2, 60.1, 56.2, 55.6, 55.3, 48.1, 37.2, 36.1, 26.8 (3 
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C), 21.6 (2 C), 21.0, 19.1 ppm. IR (neat) 2931, 2888, 1738, 1715, 1472, 1237, 
1149, 1108, 1030, 916, 733, 702 cm-1. HRMS (ESI) calcd. for C35H58NO10Si [M 
+ NH+] 680.3830, found 680.3800. 
 
(S)-6-(4-(Tert-butyldiphenylsilyloxy)-2-hydroxybutyl)-3,3-dimethyl-
2,3-dihydropyran-4-one (194): A solution of 190 (one diastereomer, 14 mg, 
0.02 mmol) in 0.2 mL of 0.5% (v/v) H2SO4 in AcOH was stirred for 30 minutes 
at RT. The solution was diluted with toluene and solid NaHCO3 (50 mg) was 
added and stirred for 15 minutes. Then the solvents were removed under reduced 
pressure and the residue subjected to column chromatography (1:10-1:3 
EtOAc:petroleum ether) to yield 3 mg (35%) of 194. IR (neat) 3450, 2958, 2929, 
1767, 1436, 1428, 1111, 1006, 740, 702 cm-1. HRMS (ESI) calcd. for 
C27H37O4Si [M + H+] 453.2461, found 453.2465. 
 
 
Experimental for Chapter Five 
 
 Cyclohexanone dimethyl acetal (275): A solution of cyclohexanone 
(20 mL, 18.9 g, 193 mmol), HC(OMe)3 (52 mL, 466 mmol), and pTsOH.H2O 
(670 mg, 3.22 mmol) in MeOH (50 mL) was stirred at RT overnight, after which 
time 1HNMR analysis showed > 95% conversion to the acetal product. The 
reaction was then diluted with Et2O (200 mL), and quenched with 5% NaHCO3. 
The layers were separated and the aqueous portion extracted once with Et2O 
(200 mL), then the combined organic fractions were washed with water and brine 
(100 mL each), dried with anhydrous MgSO4, and the solvents and by-products 
removed in-vacuo to yield a pale yellow liquid. This crude product was distilled 
under vacuum (approximately 20 mbar, 35 °C) to yield 27 mL (27.8 g, 92%) of 
the product 275 as a clear colourless liquid, used directly in the next reaction.    
 
1L-1,2:3,4-di-O-cyclohexylidene-5-O-methyl-chiro-inositol (274) and 
1L-1,2-O-cyclohexylidene-5-O-methyl-chiro-inositol (276): To a stirred 
suspension of quebrachitol (50 g, 0.25 mol) in DMF (400 mL) and 
dimethoxycyclohexane (320 mL, 2.06 mol), under argon, was added pTsOH.H2O 
(8.0 g, 0.04 mol) at room temperature. The mixture was then heated to 85 °C and 
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stirred for 18 h, after which time 1H NMR analysis of an aliquot of the reaction 
mixture showed a 70:30 ratio of 274 to 276. Heating to 105°C for 4.5 h increased 
this to a steady 75:25 ratio. The reaction was then cooled, treated with Et3N 
(7 mL; 0.05 mol), and diluted with EtOAc (1 L). The solution was washed with 
three times 500 mL H2O, and the combined H2O washings were extracted with 
ether (two times 300 mL). The combined organic fractions were washed with 
brine (100 mL), dried with anhydrous MgSO4, and the solvents removed in-
vacuo to yield a yellow solid, which was recrystallised from petroleum ether (ca. 
500 mL) to yield 274 as white crystals (45.5 g, 50%). Two further 
crystallisations from petroleum ether gave a total yield of 64.8 g (71%). m.p. 
117-119 °C, lit.130 117-119 °C. []D= -18 (c 0.1, CH2Cl2), lit.130 -18 (c 0.1, 
CH2Cl2). 1H NMR (300 MHz, CDCl3)  3.80-4.24 (m, 3 H), 3.71-3.56 (m, 3 H), 
3.56 (s, 3 H), 2.80 (broad s, 1 H) 1.76-1.32 (m, 20 H) ppm. 13C NMR (75 MHz, 
CDCl3)  112.7, 110.6, 79.3, 79.0, 78.3, 76.4, 75.9, 69.5, 58.2, 38.0, 36.7, 34.9, 
25.2, 24.1, 23.9, 23.8, 23.7 ppm. IR (neat) 3499, 2940, 1468, 1336, 1098, 1040, 
973, 902, 769, 648 cm-1. HRMS (ESI) calcd. for C19H31O6 [M + H+] 355.2115, 
found 355.2106.  
The aqueous washings from the extraction of 274 were reduced under 
high vacuum to yield 34 g of an orange oil, which was dissolved in a minimum 
amount of H2O and then extracted with EtOAc (three times 200 mL). The 
combined EtOAc portions were dried with anhydrous MgSO4, and the solvent 
volume reduced under vacuum (water aspirator) to ca. 35 mL. Standing 
overnight gave one crop of crystals which were washed with petroleum ether to 
yield 276 as pale yellow crystals, 6.6 g (9%). 1H NMR (300 MHz, CDCl3)  4.4 
(dd, 1 H, J = 3.0, 3.2 Hz), 4.3 (dd, 1 H, J = 5.4, 2.9 Hz), 4.16 (dd, 1 H, J = 7.3, 
5.9 Hz), 3.75 (dd, 1 H, J = 9.0, 8.8 Hz), 3.63 (dd, 1 H, J = 9.6, 7.6 Hz), 3.38 (dd, 
1 H, J = 8.8, 3.2 Hz), 3.53 (s, 3 H), 2.70 (broad s, 3 H), 1.72-1.32 (m, 10 H) ppm. 
13C NMR (75 MHz, CDCl3)  110.3, 81.8, 78.3, 76.5, 76.3, 70.7, 66.6, 58.4, 
38.1, 35.1, 25.2, 24.2, 23.9 ppm. IR (neat) 3498, 2935, 2861, 1276, 1148, 1098, 
1040, 940, 647 cm-1. HRMS (ESI) calcd. for C13H23O6 [M + H+] 275.1495, found 
275.1499.  
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1L-1,2:3,4-Di-O-cyclohexylidene-chiro-inositol (282): Dicyclohexyl-
idene quebrachitol (274, 1.00 g, 2.82 mmol) was dissolved in anhydrous MeCN 
(25 mL) and cooled to 0°C. Pyridine (2.3 mL, 28.2 mmol), n-Bu4NI (7.0 g, 19.0 
mmol) and AlCl3 (3.8 g, 28.2 mmol) were then added in that order. The mixture 
was heated to 62°C overnight, cooled to RT, quenched by careful addition of 
water (60 mL) and extracted with CH2Cl2 (three times 60 mL). The organic 
fractions were combined and washed with brine, dried over MgSO4 and the 
solvents removed under reduced pressure to yield a white solid which was 
subsequently re-dissolved in a minimum amount of CH2Cl2. Diethyl ether (ca. 
100 mL) was added to the solution and the resulting white precipitate removed 
by vacuum filtration. The filtrate was reduced in-vacuo to yield an oil which was 
purified by flash chromatography (EtOAc:petroleum ether, 1:10 – 1:3) to give 
624 mg (65%) of 282 as a white solid. 1H NMR (300 MHz, CDCl3)  4.39 (m, 
2 H), 4.19 (m, 1 H), 4.13 (m, 1 H), 3.78 – 3.63 (m, 2 H), 2.77 (d, 1 H, J = 2.9 
Hz), 2.73 (d, 1 H, J = 2.4 Hz), 1.85 – 1.36 (m, 20 H) ppm. 13C NMR (75 MHz, 
CDCl3)  113.1, 110.9, 78.7, 78.1, 77.3, 75.9, 71.0, 70.1, 38.0, 36.7 (2 C), 34.8, 
25.2, 25.1, 24.2, 23.9, 23.8, 23.7 ppm. []D = -18 (c 0.1, CH2Cl2). IR (neat) 3460, 
2937, 2857, 1368, 1270, 1095, 1046, 909, 730 cm-1. HRMS (ESI) calcd. for 
C18H29O6 [M + H+] 341.1959, found 341.1973.  
Data for the isomer of 282, 1L-1,2:5,6-Di-O-cyclohexylidene-chiro-
inositol (283): 1H NMR (300 MHz, CDCl3)  4.41 (dd, 2 H, J = 4.9, 2.0 Hz), 
4.17 (dd, 2 H, J = 7.1, 2.7 Hz), 3.55 (dd, 2 H, J = 5.2, 2.5 Hz), 2.87 (broad s, 
2 H), 1.84 – 1.36 (m, 20 H) ppm. 13C NMR (75 MHz, CDCl3)  110.4, 78.4, 
75.9, 72.9, 37.8, 34.7, 25.2, 24.2, 23.8 ppm. IR (neat) 3450, 3400, 2937, 2856, 
1363, 1231, 1089, 1042, 931, 909, 730 cm-1. HRMS (ESI) calcd. for C18H29O6 
[M + H+] 341.1959, found 341.1960.  
 
1L-1-O-Benzoyl-3,4:5,6-di-O-cyclohexylidene-2-O-methyl-chiro-
inositol (278): Benzoyl chloride (260 µL, 2.32 mmol) and DMAP (7 mg, 0.06 
mmol) were added to a solution of 274 (412 mg, 1.16 mmol) in CH2Cl2 (5.5 mL) 
and Et3N (645 µL, 4.66 mmol) at 0 °C under argon, and then stirred for 5 days at 
RT. Water (10 mL) was then added and the mixture extracted three times with 
CH2Cl2 (50 mL each). The combined organic fractions were washed with brine 
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(20 mL), dried over MgSO4 and the solvents removed under reduced pressure to 
yield an orange oil which was purified by flash chromatography 
(EtOAc:petroleum ether 1:15) to yield 278 as a white solid, 522 mg (98%). m.p. 
79-81 °C. []D = -8.3° (c 0.1, CH2Cl2). 1H NMR (300 MHz, CDCl3)  8.04 (m, 
2 H), 7.59 (m, 1 H), 7.46 (m, 2 H), 5.82 (dd, 1 H, J = 3.7, 3.2 Hz), 4.42 (m, 2 H), 
3.90-3.68 (m, 3 H), 3.46 (s, 3 H), 1.85-1.35 (m, 20 H) ppm. 13C NMR (75 MHz, 
CDCl3)  165.5, 133.3, 129.9, 129.5, 128.4, 112.6, 111.0, 79.2, 77.9, 76.4, 76.0, 
75.7, 70.0, 58.2, 37.9, 36.5, 36.3, 34.8, 25.0, 24.9, 23.9, 23.6 (2 C), 23.5 ppm. IR 
(neat) 2936, 2860, 1724, 1450, 1269, 1107, 1070, 908, 731 cm-1. HRMS (ESI) 
calcd. for C26H35O7 [M + H+] 459.2377, found 459.2383.  
 
1L-1-O-para-toluenesulfonyl-3,4:5,6-di-O-cyclohexylidene-2-O-
methyl-chiro-inositol (211): para-Toluenesulfonyl chloride (285 mg, 1.50 
mmol) and DMAP (2 mg, 0.01 mmol) were added to a stirred solution of 274 
(105 mg, 0.30 mmol) in CH2Cl2 (1 mL) and Et3N (1 mL) at RT under argon, and 
then heated to reflux overnight. The reaction mixture was diluted with EtOAc 
(30 mL), washed with 5% aqueous HCl (10 mL), water (10 mL) and brine (10 
mL), dried over MgSO4, and reduced in-vacuo. The resulting red coloured 
residue was purified by flash column chromatography (EtOAc:petroleum ether 
1:15) to yield 211 as a white solid, 120 mg (79%). m.p. 126-128 °C, lit.130 128-
129 °C. []D = -13° (c 0.1, CH2Cl2), lit.130 -12° (c 0.73, CHCl3).  1H NMR (300 
MHz, CDCl3)  7.83 (d, 2 H, J = 8.8 Hz), 7.42 (d, 2 H, J = 8.8 Hz), 4.97 (dd, 1 
H, J = 3.8, 3.6 Hz), 4.35 (m, 2 H), 3.68-3.50 (m, 3 H), 3.27 (s, 3 H), 2.41 (s, 
3 H), 1.82-1.30 (m, 20 H) ppm.  
 
Representative procedure for the conversion of 276, 274, 278, 211, 
and 303 into the butane diacetal derivatives 293, 293, 300, 301, and 304 
respectively: To a stirred solution of the starting material (1 eq) and camphor-
sulfonic acid (2.5 mol%) in MeOH under argon were added HC(OMe)3 (3.7 eq.) 
and butanedione (1.2 eq.). The resulting clear yellow solution was heated to 
reflux for 5 h, cooled to RT, treated with 1 drop Et3N per mmol of starting 
material, and reduced in-vacuo to yield a gelatinous material. Unless otherwise 
indicated, addition of a small amount of acetone induced the formation of fine 
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white needle-like crystals, which were collected by filtration to yield the BDA 
derivatives in yields of 10 to 45%.  
 
1L-(2S,3S)-2-O-Methyl-4,5-O-(2,3-dimethoxybutane-2,3-diyl)-
chiro-inositol (293) was prepared from both quebrachitol monocyclohexylidene 
acetal (276) (2.85 g, 10.4 mmol) to yield 1.21 g (38%) of 293, and from 
quebrachitol dicyclohexylidene acetal (274) (645 mg, 1.82 mmol) to yield 250 
mg (45%) of 293. m. p. 188-190 °C. []D = +135° (c 0.1, CH2Cl2). 1H NMR (300 
MHz, CDCl3)  4.23 (dd, 1 H, J = 3.2, 3.0 Hz), 4.12 (m, 1 H), 3.94 – 3.86 (m, 
3 H), 3.53 (s, 3 H), 3.47 (m, 1 H), 3.28 (s, 3 H), 3.25 (s, 3 H), 2.42 (broad s, 3 H), 
1.33 (s, 3 H), 1.32 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3)  99.9, 99.2, 81.6, 
70.1, 70.0, 68.1, 67.9, 67.5, 58.2, 48.1, 48.0, 17.7, 17.6 ppm. IR (neat) 3468, 
3347, 2928, 1463, 1376, 1212, 1129, 1049, 1031, 925, 670 cm-1. HRMS (ESI) 
calcd. for C13H28O8N [M + NH4+] 326.1809, found 326.1813.  
 
1L-(2S,3S)-1-O-Benzoyl-2-O-methyl-4,5-O-(2,3-dimethoxybutane-
2,3-diyl)-chiro-inositol (300) was prepared from 278 (42 mg, 0.09 mmol) to 
yield 300 (17 mg, 44%). 1H NMR (300 MHz, CDCl3)  8.04 – 8.00 (m, 2 H), 
7.62 – 7.53 (m, 1 H), 7.48 – 7.42 (m, 2 H), 5.79 (dd, 1 H, J = 3.5, 3.2 Hz), 4.12 
(m, 1 H), 4.06 – 4.01 (m, 3 H), 3.95 (m, 1 H), 3.65 (dd, 1 H, J = 5.0 Hz), 3.45 (s, 
3 H), 3.34, (s, 3 H), 3.24 (s, 3 H), 2.86 (broad s, 1 H), 2.70 (broad s, 1 H), 1.40 
(s, 3 H), 1.35 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3)  165.2, 133.3, 129.8, 
129.4, 128.5, 100.1, 99.3, 80.0, 70.1, 68.9, 68.3, 68.1, 68.0, 58.1, 48.1, 48.0, 
17.7, 17.5 ppm. IR (neat) 3446, 2930, 1707, 1267, 1108, 1128, 923, 881, 844, 
711 cm-1. HRMS (ESI) calcd. for C20H32O9N [M + NH4+] 430.2096, found 
430.2072.  
 
1L-(2S,3S)-1-O-para-toluenesulfonyl-2-O-methyl-4,5-O-(2,3-
dimethoxybutane-2,3-diyl)-chiro-inositol (301) was prepared from 211 (115 
mg, 0.23 mmol) to yield 40 mg (38%) of 301 as a white solid. m.p. 187-189 °C. 
1H NMR (300 MHz, CDCl3)  7.82 (d, 2 H, J = 8.3 Hz), 7.33 (d, 2 H, J = 8.3 
Hz), 4.96 (dd, 1 H, J = 3.4, 3.1 Hz), 4.96 (dd, 1 H, J = 3.6, 2.5 Hz), 3.89 – 3.78 
(m, 3 H), 3.44 (dd, 1 H, J = 9.1, 3.1 Hz), 3.27 (s, 3 H), 3.23 (s, 3 H), 3.13 (s, 
3 H). 2.45 (s, 3 H), 1.32 (s, 3 H), 1.31 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3) 
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 145.3, 133.3, 129.6, 128.0, 100.1, 99.3, 79.1, 74.9, 69.4, 69.0, 68.0, 67.1, 57.8, 
48.0, 47.9, 21.6, 17.6, 17.5 ppm. IR (neat) 3464, 2952, 1367, 1177, 1136, 1113, 
1035, 891, 683, 556 cm-1. HRMS (ESI) calcd. for C24H34O10SN [M + NH4+] 
480.1903, found 480.1944. 
 
1L-(2S,3S)-1-O-Benzoyl-2-O-tert-butyldiphenylsilyloxy-4,5-O-(2,3-
dimethoxybutane-2,3-diyl)-chiro-inositol (304) was prepared from 303 (see 
below), (250 mg, 0.37 mmol, containing 20% of the isomer 315) to yield 304 (60 
mg, 30% from 303) isolated by flash column chromatography (EtOAc:petroleum 
ether 1:5) as an oil. 1H NMR (300 MHz, CDCl3)  8.18 (m, 2 H), 7.64-7.22 (m, 
13 H), 5.28 (dd, 1 H, J = 3.4, 3.5 Hz), 4.22-4.08 (m, 2 H), 3.99 (m, 1 H), 3.80 (m, 
2 H), 3.22 (s, 3 H), 3.15 (s, 3 H), 1.32 (s, 3 H), 1.27 (s, 3 H), 0.97 (s, 9 H) ppm. 
13C NMR (75 MHz, CDCl3)  165.3, 136.0, 135.6, 133.8, 133.3, 132.8, 129.8, 
129.7, 128.5, 127.7, 127.6, 99.9, 99.2, 73.3, 72.5, 71.6, 68.6, 68.0, 67.9, 48.0, 
47.9, 26.7, 19.3, 17.7, 17.5 ppm. IR (neat) 3481, 3071, 2932, 2857, 1723, 1266, 
1132, 1108, 1029, 735, 701 cm-1. HRMS (ESI) calcd. for C35H48O9SiN [M + 
NH4+] 654.3093, found 654.3066. 
 
1L-(2S,3S)-1,2,3,6-Tetra-O-methyl-4,5-O-(2,3-dimethoxybutane-
2,3-diyl)-chiro-inositol (297): To a solution of 293 (320 mg, 1.04 mmol) in 
DMF (4.5 mL) at 0 °C was added NaH (80% in mineral oil, 140 mg, 4.68 mmol). 
After stirring the suspension for 10 min, MeI (970 L, 2.21 g, 15.6 mmol) was 
added and the solution allowed to warm to RT. After stirring at RT for 18 h, the 
reaction was quenched with water (5 mL), and then extracted 3 times with Et2O 
(three times 10 mL). The combined organic fractions were washed with sat. aq. 
NaHCO3 (10 mL) and brine (10 mL), dried over MgSO4 and the solvents 
removed under reduced pressure. The residues were purified by flash column 
chromatography (EtOAc:petroleum ether 1:3 – 1:1) to yield 297 as a colourless 
oil, 254 mg (70%). 1H NMR (300 MHz, CDCl3)  3.88 – 3.84 (m, 2 H), 3.2 (dd, 
1 H, J = 3.7, 3.0 Hz), 3.62 (s, 3 H), 3.61 (m, 1 H), 3.50 (s, 3 H), 3.47 (s, 3 H), 
3.44 (m, 1 H), 3.43 (s, 3 H), 3.33 (dd, 1 H, J = 9.5, 3.0 Hz), 3.28 (s, 3 H), 3.24 (s, 
3 H), 1.30 (s, 6 H) ppm. 13C NMR (75 MHz, CDCl3)  99.5, 98.7, 81.0, 80.4, 
76.4, 76.3, 69.8, 67.9, 60.9, 59.1, 59.0, 58.6, 47.7, 47.6, 17.8, 17.6 ppm. IR (neat) 
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2932, 2831, 1445, 1372, 1110, 1093, 1038, 967, 882, 729 cm-1. HRMS (ESI) 
calcd. for C16H34O8N [M + NH4+] 368.2279, found 368.2293.  
 
1L-1,2,3,6-Tetra-O-methyl-chiro-inositol (298): A solution of 297 (150 
mg) in 3 mL of MeOH and 0.3 mL of conc. HCl was heated to 50 °C for 48 h, 
during which time a yellow colour developed. The solution was then cooled to 
RT and diluted with MeOH before solid NaHCO3 was added until effervescence 
was no longer observed. Solvents were then removed under reduced pressure and 
the residues purified by gradient flash column chromatography (MeOH:CH2Cl2, 
1:50 – 1:10) to yield 298 as an oil, 83 mg (82%). 1H NMR (300 MHz, CDCl3)  
3.77 – 3.72 (m, 2 H), 3.67 (dd, 1 H, J = 3.7, 3.2), 3.60 (s, 3 H), 3.55 (dd, 1 H, J = 
9.2, 1.5 Hz), 3.48 (s, 3 H), 3.47 (s, 3 H), 3.46 (s, 3 H), 3.38 – 3.27 (m, 2 H), 2.78 
(broad s, 2 H) ppm. 13C NMR (75 MHz, CDCl3)  82.2, 81.2, 77.9, 75.4, 73.4, 
71.2, 60.8, 59.2, 59.0, 58.4 ppm. IR (neat) 3443, 2930, 2828, 1445, 1369, 1191, 
1135, 1090, 1048, 957 cm-1. HRMS (ESI) calcd. for C10H21O6 [M + H+] 
237.1333, found 237.1341.  
 
1L-(2S,3S)-1,3,6-Tri-O-acetyl-2-O-methyl-4,5-O-(2,3-
dimethoxybutane-2,3-diyl)-chiro-inositol (299): A solution of 293 (83 mg) in 
0.85 mL of pyridine was cooled 0 °C and acetic anhydride (152 L, 1.62 mmol) 
was added. The solution was then warmed to RT and stirred for 18 h. Water 
(5 mL) was then added, and the mixture extracted with Et2O (three times 40 mL). 
The combined organic fractions were washed with water and brine, dried over 
MgSO4, solvents removed under reduced pressure and the residues purified by 
flash column chromatography (EtOAc:petroleum ether 1:3) to yield 299 as an oil, 
92 mg (78%). []D = +82.0° (c 0.12, CH2Cl2).  1H NMR (300 MHz, CDCl3)  
5.43 (dd, 1 H, J = 3.7, 2.8 Hz), 5.26 (dd, 1 H, J = 9.8, 9.5 Hz), 5.20 (dd, 1 H, J = 
3.4, 3.4 Hz), 4.20 – 3.88 (m, 2 H), 3.44 (dd, 1 H, J = 9.8, 3.4 Hz), 3.34 (s, 3 H), 
3.22 (s, 3 H), 3.21 (s, 3 H), 2.14 (s, 3 H), 2.11 (s, 3 H), 2.10 (s, 3 H), 1.25 (s, 
3 H), 1.23 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3)  169.7, 169.2, 169.1, 99.8, 
99.1, 78.3, 70.7, 68.4, 66.8, 65.9 (2 C), 58.4, 47.9, 47.4, 20.9 (3 C), 17.5, 17.4 
ppm. IR (neat) 2949, 2834, 1751, 1370, 1132, 1112, 1035, 915, 730 cm-1. HRMS 
(ESI) calcd. for C19H34O11N [M + NH4+] 452.2126, found 452.2114.  
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1L-3,4:5,6-Di-O-cyclohexylidene-1,2-di-O-methyl-chiro-inositol (308): 
To a solution of 274 (460 mg, 1.30 mmol) in anhydrous DMF (6 mL) at 0 °C was 
added NaH (80% in mineral oil, 60 mg, 1.95 mmol). The resulting suspension 
was stirred for 30 min after which time methyl iodide (405 µL, 923 mg, 6.5 
mmol) was added. The solution was then warmed to RT and allowed to stir 
overnight. Water (10 mL) was then added to quench the reaction, and the mixture 
was extracted twice with Et2O (two times 20 mL). The combined organic 
fractions were then washed with 5% NaHCO3 (5 mL), water (5 mL), and brine (5 
mL), dried over MgSO4 and the solvents removed under reduced pressure. The 
residues were purified by flash column chromatography (EtOAc:petroleum ether 
1:10 - 1:5) to yield 308 as an oil which solidified upon standing, 450 mg (94%). 
[]D = -50° (c 0.18, CH2Cl2). 1H NMR (300 MHz, CDCl3)  4.39 – 4.26 (m, 2 H), 
3.83 (dd, 1 H, J  = 4.1, 3.8 Hz), 3.74 – 3.68 (m, 2 H), 3.59 (dd, 1 H, J = 8.0, 1.5 
Hz), 3.54 (s, 3 H), 3.52 (s, 3 H), 1.84 – 1.32 (m, 20 H) ppm. 13C NMR (75 MHz, 
CDCl3)  112.0, 110.4, 79.0, 78.6, 78.2, 76.2, 76.1, 75.6, 59.5, 57.8, 37.6, 36.3, 
36.2, 34.5, 24.8 (2 C), 23.7, 23.5, 23.4, 23.3 ppm. []D = -50 (c 0.18, CH2Cl2). IR 
(neat) 2934, 2860, 1449, 1279, 1100, 907, 830, 727 cm-1. HRMS (ESI) calcd. for 
C20H33O6 [M + H+] 369.2272, found 369.2267.  
 
1L-1,2-Di-O-methyl-chiro-inositol (305): A solution of 308 (250 mg, 
0.68 mmol) was stirred overnight at RT under air in 3 mL 10% aq. HCl in 
MeOH. After this time, solid NaHCO3 was added until effervescence was no 
longer observed, and the solvents then removed under reduced pressure. The 
residues were purified by flash column chromatography (MeOH:CH2Cl2 1:6) to 
yield 305, 120 mg (71%), as an oil which crystallised upon standing. m.p. 
138-140 °C, lit.181 141.5-142.5 °C. []D = -56° (c 0.06, MeOH), lit.181 -52.1° 
(c 0.98, MeOH). 1H NMR (300 MHz, DMSO)  4.86 (d, 1 H, J = 3.9 Hz), 4.60 
(d, 1 H, J = 4.2 Hz), 4.55 (d, 1 H, J = 3.7 Hz), 4.45 (d, 1 H, J = 4.7 Hz), 3.80 (m, 
1 H), 3.53 (m, 1 H), 3.30 (s, 3 H), 3.29 (s, 3 H), 3.26 (m, 3 H), 3.15 (dd, 1 H, J = 
9.3, 2.7 Hz) ppm. 13C NMR (75 MHz, DMSO)  81.3, 78.6, 73.5, 72.7, 71.0, 
69.1, 58.9, 57.7 ppm. IR (neat) 1340, 2932, 2854, 1448, 1365, 1278, 1105, 1026, 
927, 907 cm-1. HRMS (ESI) calcd. for C8H17O6 [M + H+] 209.1019, found 
209.1009.  
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1L-1-O-Benzoyl-5,6-O-cyclohexylidene-2-O-methyl-chiro-inositol 
(279): To a solution of 278 (30 mg, 0.07 mmol) in acetone (1 mL) at RT under 
air was added pTsOH (1 mg, 0.005 mmol). The solution was stirred for 2 h at 
RT, after which time solid NaHCO3 (10 mg) was added, and the solvents 
removed under reduced pressure. The residues were purified by flash column 
chromatography (EtOAc:petroleum ether 1:1) to yield 279, 18 mg (72%) as an 
oil. 1H NMR (300 MHz, CDCl3)  8.02 (m, 2 H), 7.59 (m, 1 H), 7.46 (m, 2 H), 
6.00 (m, 1 H), 4.31 (dd, 1 H, J = 5.3, 2.9 Hz), 4.26 (m, 1 H), 3.89 (m, 1 H), 3.77 
(dd, 1 H, J = 7.1, 7.8 Hz), 3.53 (dd, 1 H, J = 9.3, 2.9 Hz), 3.48 (s, 3 H), 1.80-1.30 
(m, 10 H) ppm. 13C NMR (75 MHz, CDCl3)  165.2, 133.5, 129.8, 129.3, 128.5, 
110.8, 79.4, 78.3, 76.1, 74.6, 70.7, 66.7, 58.2, 37.9, 35.1, 24.8, 23.9, 23.6 ppm. 
IR (neat) 3335, 2934, 1721, 1451, 1265, 1249, 1093, 1068, 1023, 707 cm-1. 
HRMS (ESI) calcd. for C20H27O7 [M + H+] 379.1757, found 379.1762. 
 
1L-1-O-Benzoyl-2-O-methyl-chiro-inositol (306): To a solution of 278 
(80 mg, 0.18 mmol) in acetone (1 mL) at RT under air was added a catalytic 
amount of pTsOH (3.5 mg, 0.02 mmol). The solution was stirred at RT for 3 
days, after which time TLC analysis showed approximately equal amounts of 
279 and 306 present. Two drops of aqueous HCl were added and the reaction 
stirred for a further 2 days, after which time TLC analysis showed essentially 
complete conversion to 306. Solid NaHCO3 (50 mg) was added, and the solvents 
removed under reduced pressure. The residues were purified by flash column 
chromatography (MeOH:CH2Cl2 1:10) to yield 306, 46 mg (88%) as a crystalline 
solid. m.p. 144-149 °C, lit.182 143-144 °C. []D = -48° (c 0.06, MeOH or acetone), 
lit.182 +50.1° (c 1.01, MeOH). 1H NMR (300 MHz, (CD3)2CO)  8.00 (m, 2 H), 
7.64 (m, 1 H), 7.51 (m, 2 H), 5.63 (m, 1 H), 4.65 (d, 1 H, J = 3.4 Hz), 4.32 
(broad s, 1 H), 4.24 (broad s, 1 H), 4.15 (broad s, 1 H), 4.06 (m, 1 H), 3.66 (m, 3 
H), 3.47 (dd, 1 H, J = 9.5, 3.2 Hz), 3.38 (s, 3 H) ppm. 13C NMR (75 MHz, 
(CD3)2CO)  165.6, 133.9, 130.8, 130.2, 129.3, 80.5, 74.1, 73.8, 72.4, 70.6, 70.5, 
58.1 ppm. IR (neat) 3336, 2928, 1699, 1450, 1178, 1096, 1070, 1025, 751, 708 
cm-1. HRMS (ESI) calcd. for C14H19O7 [M + H+] 299.1125, found 299.1133. 
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1L-1,2:3,4-Di-O-cyclohexylidene-5-O-(tert-butyldimethylsilyloxy)-
chiro-inositol (309) and 1L-1,2:3,4-Di-O-cyclohexylidene-6-O-(tert-
butyldimethylsilyloxy)-chiro-inositol (310): To a solution of the diol 282 (130 
mg, 0.38 mmol) in DMF (650 L) at 0 °C were added imidazole (52 mg, 0.76 
mmol) and TBDMSCl (63 mg, 0.42 mmol). The solution was then allowed to 
warm to RT and stir overnight, after which it was diluted with Et2O (50 mL), 
washed with sat. aq. NaHCO3 (10 mL), water (10 mL) and brine (10 mL), dried 
over MgSO4, and the solvents removed under reduced pressure. The product was 
isolated by flash column chromatography (EtOAc:petroleum ether 1:5) as an oil, 
130 mg (75%, as a mixture of 309 and 310 in a 2:1 ratio).iv The mixture was used 
directly in the next reaction without further purification.  
 
 1L-1-O-methyl-3,4:5,6-di-O-cyclohexylidene-2-O-(tert-
butyldimethylsilyloxy)-chiro-inositol (316): To a solution of a mixture of 309 
and 310 from the above reaction (220 mg, 0.48 mmol) in DMF (2 mL) was 
added NaH (80% in mineral oil, 25 mg, 0.72 mmol). The suspension was stirred 
for 10 min, after which time methyl iodide (150 µL, 342 mg, 2.40 mmol) was 
added. The solution was warmed to RT and allowed to stir for 20 h. Water 
(10 mL) was then added to quench the reaction, and the mixture was extracted 
three times with Et2O (three times 20 mL). The combined organic fractions were 
washed with 5% NaHCO3 (20 mL), water (10 mL), and brine (20 mL), dried over 
MgSO4 and the solvents removed under reduced pressure. The residues were 
purified by flash column chromatography (EtOAc:petroleum ether 1:20) to yield 
101 mg (45%) of 316 as an oil. 1H NMR (300 MHz, CDCl3)  4.32 – 4.25 (m, 2 
H), 4.60 (dd, 1 H J = 9.0, 4.2 Hz), 3.68 – 3.60 (m, 2 H), 3.53 (s, 3 H), 3.49 (m, 1 
H), 1.70 – 1.30 (m, 20 H), 0.93 (s, 9 H), 0.17 (s, 3 H), 0.14 (s, 3 H) ppm. 13C 
NMR (75 MHz, CDCl3)  111.6, 110.3, 81.3, 79.3, 77.1, 76.9, 76.4, 75.9, 71.6, 
60.6, 37.9, 36.8, 36.0, 34.9, 25.8 (3 C), 25.1, 25.0, 23.9, 23.8, 23.6, 23.5, 18.4, -
                                                
iv
 Benzoylation of a portion of the product mixture to give a mixture of 313 and 314 simplified 
the determination of the regioisomeric ratio. Downfield shift of the signal attributed to the proton 
next to the OBz group was observed. In the 1H NMR of the product mixture, a doublet of 
doublets at 5.58 ppm (Jeq-eq = 4.9, Jax-eq = 3.5 Hz) was attributed to the equatorial proton vicinal to 
the OBz group in the major product 313, and a doublet of doublets at 5.41 ppm (Jax-ax = 9.6, Jax-eq 
= 4.4 Hz) was attributed to the axial proton vicinal to the OBz group in the regioisomeric product 
(314). The 2:1 ratio of 313:314 (and hence 2:1 ratio of 309:310) was obtained from the ratio of 
the integrals of those two signals.   
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4.5, -5.0 ppm. IR (neat) 2933, 2856, 1449, 1366, 1252, 1104, 907, 837, 778, 731 
cm-1. HRMS (ESI) calcd. for C25H45O6Si [M + H+] 469.2979, found 469.2973.  
 
1L-1-O-Methyl-chiro-inositol (307): The fully protected chiro-inositol 
derivative 316 (45 mg, 0.1 mmol) was dissolved in 2 mL of 10% HCl in 
methanol and stirred at RT for 4 h. Solvents were then removed under reduced 
pressure and the residue purified by gradient flash column chromatography 
(MeOH:CH2Cl2 1:3 – 1:2) to yield 307 (17 mg, 89%). []D = -57° (c 0.05, D2O), 
lit.183 for the enantiomer, 1D-1-O-methyl-chiro-inositol: []D = +59° (c 1.3, D2O). 
1H NMR (300 MHz, DMSO)  4.76 (d, 1 H, J = 3.9 Hz), 4.49 (d, 1 H, J = 4.1 
Hz), 4.47 (d, 1 H, J = 3.9 Hz), 4.41 (d, 1 H, J = 3.9 Hz), 4.39 (d, 1 H, J = 3.4 
Hz), 3.77 (dd, 1 H, J = 6.7, 3.4 Hz), 3.53 – 3.43 (m, 1 H), 3.33 – 3.16 (m, 4 H), 
3.32 (s, 3 H) ppm. 13C NMR (75 MHz, DMSO)  82.9, 73.5, 73.3, 71.2, 70.8, 
69.4, 59.2 ppm. HRMS (ESI) calcd. for C7H18O6N [M + NH4+] 212.1129, found 
212.1126.  
 
1L-1,2:3,4-Di-O-cyclohexylidene-5-O-(tert-butyldiphenylsilyloxy)-
chiro-inositol (311) and 1L-1,2:3,4-di-O-cyclohexylidene-6-O-(tert-
butyldiphenylsilyloxy)-chiro-inositol (312): To a solution of the diol 282 (110 
mg, 0.35 mmol) in DMF (2 mL) at 0 °C were added imidazole (70 mg, 0.77 
mmol) and TBDPSCl (100 L, 0.39 mmol). The solution was then allowed to 
warm to RT and stir overnight, after which it was diluted with Et2O, washed with 
sat. aq. NaHCO3, water and brine, dried over MgSO4, and the solvents removed 
under reduced pressure. The product was isolated by flash column 
chromatography (EtOAc:petroleum ether 1:10) as an oil, 165 mg (88% as a 
mixture of 311 and 312 in a 5:1 ratio).v Further column chromatography 
(EtOAc:petroleum ether 1:50-1:10)  isolated 66 mg (35%) of essentially pure 311 
as an oil. 1H NMR (300 MHz, CDCl3)  7.74-7.69 (m, 4 H), 7.48-7.36 (m, 6 H), 
4.37-4.27 (m, 2 H), 4.11 (dd, 1 H, J = 9.3, 4.6 Hz), 4.02 (dd, 1 H, J = 4.4, 2.9 
                                                
v
 Benzoylation of a portion of the product mixture to give a mixture of 303 and 315, again was 
used to simplify determination of the regioisomeric ratio. The 1H NMR spectrum of the 
benzoylated product mixture showed a doublet of doublets at 5.45 ppm (Jeq-eq = 3.9, Jax-eq = 3.8 
Hz) which was attributed to the equatorial proton vicinal to the OBz group in the major product 
303, and a doublet of doublets at 5.36 ppm (Jax-ax = 10.2, Jax-eq = 3.9 Hz) attributed to the axial 
proton vicinal to the OBz group in 315. The ratio of products 303 and 315 (and hence of 311 and 
312) was found to be ca. 5:1; significantly better than the analogous TBDMS analogue.  
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Hz), 3.78 (dd, 1 H, J = 9.8, 9.7 Hz), 3.38 (dd, 1 H, J = 10.2, 8.4 Hz), 3.01 (broad 
s, 1 H), 1.64-1.26 (m, 20 H), 1.12 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3)  
136.2, 135.7, 133.1, 132.5, 130.0, 129.9, 127.8, 127.4, 111.9, 110.0, 79.1, 78.1, 
76.0, 75.7, 72.6, 71.1, 37.8, 36.6, 36.0, 34.7, 26.9, 25.0, 24.9, 23.8, 23.7, 23.5 
(2 C), 19.4 ppm. IR (neat) 3071, 2932, 2857, 1730, 1448, 1104, 934, 820, 737 
cm-1. HRMS (ESI) calcd. for C34H47O6Si [M + H+] 579.3136, found 579.3116.  
 
 
Experimental for Chapter Six  
 
(-)-1,3,3-trimethyl-2-norbornanone dimethyl acetal (321): 
(-)-Fenchone ((-)-1,3,3-trimethyl-2-norbornanone) (10 g, 0.066 mol) was 
dissolved in MeOH (10 mL) and trimethyl orthoformate (30 mL, 29 g, 0.274 
mol) at RT under an inert atmosphere. To the solution was added pTsOH.H2O 
(680 mg, 0.003 mol), and the reaction was then stirred at RT for 3 days. Solid 
NaHCO3 (820 mg, 0.009 mol) was added and the mixture stirred for 30 min. 
Diethyl ether (200 mL) and water (80 mL) were then added, and after vigorous 
stirring the layers were separated. The ether part was washed with brine, dried 
over anhydrous MgSO4 and concentrated under vacuum. The residue was 
purified by flash column chromatography (petroleum ether) to yield the product 
321 as an oil which solidified upon standing, 3.62 g (28%). m. p. 107-109 °C. 
[]D = +20° (c 0.15, CH2Cl2). 1H NMR (300 MHz, CDCl3)  3.25 (s, 3 H), 3.23 
(s, 3 H), 1.83 (m, 2 H), 1.67 (m, 2 H), 1.60 (m, 1 H), 1.38 (m, 2 H), 1.19 (s, 3 H), 
1.10 (s, 3 H), 0.97 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3)  108.4, 51.9, 51.8, 
51.6, 49.8, 48.0, 42.8, 30.2, 26.0, 25.1, 23.1, 18.7 ppm. IR (neat) 2931, 2831, 
1468, 1267, 1171, 1139, 1123, 1056, 1011, 739 cm-1. HRMS (ESI) calcd. for 
C12H23O2 [M + H+] 199.1698, found 199.1695. 
 
(±)-2-Norbornanone dimethyl acetal (322): To a solution of 
(±)-norcamphor ((±)-2-norbornanone) (21.8 g, 0.20 mol) in anhydrous MeOH 
(44 mL) were added trimethyl orthoformate (66 mL, 64.02 g, 0.60 mol) and 
pTsOH.H2O (2.07 g, 0.01 mol), at RT under argon. The mixture was stirred for 
18 h during which time a deep purple colour developed. Solid NaHCO3 (4 g) was 
added and the mixture stirred for 10 min, during which time the colour changed 
 232 
to a pale brown. The mixture was then diluted with diethyl ether (150 mL) and 
water (100 mL), vigorously mixed, and the aqueous and organic parts separated. 
The aqueous layer was extracted with further diethyl ether (two times 50 mL) 
and the combined organic fractions then washed with water and brine, dried over 
MgSO4, and reduced in-vacuo. The crude product was purified by kugelroh 
short-path distillation to yield 25.06 g (82%) of 322 as a clear, colourless liquid. 
1H NMR (300 MHz, CDCl3)  3.15 (s, 3 H), 3.12 (s, 3 H), 2.32 (m, 1 H), 2.21 
(m, 1 H), 1.73 (m, 1 H), 1.62 (m, 1 H), 1.58 – 1.48 (m, 2 H), 1.36 (m, 1 H), 1.25 
(m, 1 H), 1.22 – 1.12 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3)  110.5, 50.0, 
47.5, 43.1, 41.2, 37.2, 35.9, 28.5, 21.9 ppm. IR (neat) 2945, 2828, 1453, 1331, 
1174, 1133, 1103, 1048, 965, 871, 847 cm-1. HRMS (ESI) calcd. for C9H12O2 
[M + H+] 157.1229, found 157.1232.  
 
(±)-1,2-O-((±)-2-norbornylidene)-myo-inositol (323). Method A: To a 
suspension of myo-inositol (4.0 g, 22.2 mmol) in anhydrous DMSO (44 mL) 
were added 322 (7.86 g, 50 mmol) and sulphuric acid (0.22 mL, 0.40 g, 4.1 
mmol). The mixture was heated to 70 °C for 3 h, to give a clear, very pale yellow 
solution. This solution was cooled and neutralised with triethylamine (1.5 mL) 
and then concentrated under vacuum (< 5 mbar) to a weight of ca. 13 g. The 
residue was dissolved in CHCl3 (51 mL) and then MeOH (5.1 mL), H2O (1.0 
mL) and pTsOH (15 mg) were added. The resulting slurry was stirred at RT 
overnight and then filtered. The solid was washed with CHCl3 (three times 5 mL) 
and air-dried to yield 4.86 g (80%) of mixed diastereomers of 323.     
Method B: To a suspension of myo-inositol (2.7 g, 14.7 mmol) in 
anhydrous DMSO (29 mL) were added 322 (5.2 g, 33 mmol) and sulphuric acid 
(0.16 mL, 0.26 g, 2.7 mmol). The mixture was heated to 70 °C for 3 h, to give a 
clear, very pale yellow solution. This solution was cooled and neutralised with 
triethylamine (1.0 mL) and then concentrated under vacuum (ca. 20 mbar) to 
remove the volatile solvents, to a weight of ca. 40 g. The residue was dissolved 
in toluene (130 mL) and then washed with water (10 mL) and brine (20 mL). The 
combined aqueous fractions were then extracted with toluene (two times 20 mL), 
and all the toluene parts finally combined and washed with brine (30 mL), dried 
over anhydrous MgSO4 and concentrated under vacuum to a weight of 4.1 g. The 
residue was dissolved in CHCl3 (33 mL), MeOH (3.3 mL), H2O (0.66 mL) and 
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pTsOH (10 mg). The resulting solution was stirred at RT overnight, during 
which time a precipitate developed. The solid was filtered off, washed with 
CHCl3 (three times 5 mL) and air-dried to yield 4.04 g (30%) of mixed 
diastereomers of 323.     
Data for the mixed diastereomers of 323 (see discussion): 1H NMR 
(300 MHz, d6-DMSO)vi  4.93-4.65 (m, 4 H), 3.94 (m, 1 H), 3.72 (m, 1 H), 3.45 
(m, 1 H), 3.25 (m, 1 H), 3.20 (m, 1 H), 2.90 (m, 1 H), 2.20, 2.14, 2.02, and 1.78-
1.15 (multiplets, total 10 H) ppm. 13C NMR (75 MHz, d6-DMSO)vii  116.6, 
116.0, 79.9, 79.5, 78.2, 77.8, 75.1, 74.7, 74.6, 74.5, 73.4, 72.9, 70.5, 70.4, 45.4, 
45.0, 44.9, 44.2, 37.5, 37.2, 35.4, 35.3, 28.2, 28.0, 21.6, 21.2 ppm. HRMS (ESI) 
calcd. for C13H21O6 [M + H+] 273.1333, found 273.1331.  
 
(±)-1,2-O-((±)-2-norbornylidene)-3,4,5,6-tetra-O-acetyl-myo-inositol 
(per-acetylated 323): Recrystallised 323 (24 mg, 0.09 mmol of a ca. 2:1 ratio of 
two diastereomers) was dissolved in pyridine (100 L) and acetic anhydride 
(100 L) and stirred at RT for 18 h. The reaction mixture was then diluted with 
diethyl ether and water and agitated vigorously. The layers were then separated 
and the organic part washed with brine, dried over anhydrous MgSO4 and 
concentrated under vacuum, and then azeotroped with toluene to remove residual 
pyridine. The product was purified by flash column chromatography 
(EtOAc:petroleum ether 1:3) to yield the tetra-acetylated products as an oil, 28 
mg (72%), containing two inseparable diastereomers in a ca. 2:1 ratio. 1H NMR 
(300 MHz, CDCl3)viii  5.51 (m, 1 H), 5.20 (m, 2 H), 5.03 (m, 1 H), 4.32 (m, 1 
H), 4.14 (m, 1 H), 2.27 (m, 1 H), 2.14, (s, 3 H), 2.09 (s, 3 H), 2.08 (s, 3 H), 2.03 
(s, 3 H), 2.02, (s, 3 H), 2.01 (s, 3 H), 1.70-1.20 (m, 6 H) ppm. 13C NMR (75 
                                                
vi
 Signals for the two diastereomers of 323 present in the mixture overlap; integrals are reported 
as if for ONE diastereomer/molecule. 
vii
 Signals for the two diastereomers are reported together; it was not possible to assign signals to 
the separate diastereomers. Molecule 323 contains 13 carbons; 26 signals are reported. 
 
viii
 Signals from the two diastereomers overlap in the inositol and nor-camphor regions. 
Integrations are given for ONE molecule of per-acetylated 323. The signals for the acetate methyl 
groups partially overlap; six acetate signals are reported, although each molecule of per-
acetylated 323 has only four acetate groups.  
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MHz, CDCl3)ix  170.5, 170.1, 169.8, 119.3(A), 118.9(B), 76.3(B), 75.8(A), 
74.3(A), 73.9(B), 72.8(A), 72.4(B), 71.5, 70.0, 69.6(A), 69.5(B), 45.3(A), 
44.7(B), 44.5(A), 44.3(B), 38.1(B), 37.9(A), 36.0(A), 35.9(B), 28.4(A), 28.2(B), 
22.2(A), 21.7(B), 21.2, 21.1, 21.0, 20.9 ppm.  
  
 
Experimental for Chapter Seven  
 
Scaleup campaign stage 1; preparation of (1S)-(-)-camphor: 
(-)-Borneol (5.02 kg, 32.54 mol) and glacial acetic acid (15.0 L) were charged to 
the 50 L reactor and stirred at 15 °C until the borneol was completely dissolved. 
Aqueous sodium hypochlorite (16.66 L of a 15% solution) was then slowly 
added over 2.5 h (this is equivalent to an addition rate of ca. 30 mL per minute). 
The temperature of the solution was maintained at 25 °C (± 5 °C) during the 
addition period, and the solution was stirred at 15 °C for a further h after 
completion of the addition. At this time a positive potassium iodide-starch test 
was obtained. Saturated aqueous sodium bisulfite solution (2.0 L) was then 
added, after which addition the solution colour changed from yellow to white and 
the starch test was negative. The mixture was removed from the reaction vessel 
and poured over an ice-brine mixture (50 L). The resulting white solid was 
isolated by filtration (10 L Buchi flasks / 24 cm filters) and washed with 
saturated aqueous sodium carbonate and water (ca. 10 L each). The solid product 
was pressed dry and then charged manually to the 50 L reactor and dissolved in 
petroleum ether (20 L). The aqueous layer was removed and the organic layer 
washed with brine in the 50 L reactor. The petroleum ether was evaporated under 
reduced pressure in the 50 L Buchi to yield a white solid, which was dissolved in 
toluene (5 L) and the toluene then removed under reduced pressure to yield the 
product, 4.55 kg (92%). 1H and 13C NMR were analogous to the previously 
reported values and to those obtained for an authentic sample. 
  
                                                
ix
 Signals for two diastereomers are listed together, denoted A and B (the configuration of the 
diastereomers A and B was not determined). Signals for A were approximately two times 
stronger than those for B. Where neither A or B is indicated, signals were overlapping. 
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Scaleup campaign stage 2; preparation of (1S)-(-)-camphor dimethyl 
acetal ((-)-268): The (-)-camphor (4.55 kg, 29.89 mol) from stage 1, trimethyl 
orthoformate (17.5 L, 16.98 kg, 159.84 mol) and methanol (4.5 L) were charged 
to the 50 L reactor and stirred at 20 °C under an inert atmosphere until the 
camphor was dissolved (ca. 10 min). Concentrated sulphuric acid (44 mL, 81 g, 
0.83 mol) was then added and the mixture stirred at 20 °C overnight. Solid 
sodium methoxide (110 g, 2.11 mol) was then charged to the reactor (pH paper 
used to check the solution is neutral) and the mixture reduced in the 50 L Buchi 
to a volume of approximately 6 L. Toluene (12 L) was then added to the solution 
and the resulting precipitate removed by filtration (10 L Buchi/24 cm filter). The 
filtrate was transferred to a clean 50 L Buchi flask and the majority of the toluene 
removed under vacuum to give crude (-)-268, 6.40 kg (1H and 13C NMR matched 
previously reported values). The product, still containing toluene, was used 
directly in stage 3.   
 
Scaleup campaign stage 3; preparation of 1D-(6-S)-1,2-O-(L-1,7,7-
trimethyl[2,2,1]bicyclohept-6-ylidene)-myo-inositol ((-)-269a): Myo-
inositol (2.40 kg, 13.32 mol) was charged to the 50 L reactor. The crude (-)-268 
(5.92 kg, 29.86 mol, based on 100% yield in stage 2) was then dissolved in 
DMSO (7.5 L) and transferred to the reactor. The mixture was stirred rapidly and 
sulphuric acid (131 mL, 241 g, 2.46 mol) added. Then the mixture was heated to 
70 °C for 3 h, during which time the solution turned an unexpected and 
unpleasant brown-black colour. The mixture was cooled, triethylamine (885 mL, 
643 g, 6.33 mol) added, and the solution removed from the reactor (using ca. 2 L 
of methanol to rinse the vessel). Undissolved solids (ca. 300 g) were filtered out, 
and the solution then transferred to the 50 L Buchi, where the excess methanol 
and trimethyl orthoformate and finally ca. 4 L of DMSO were removed under 
vacuum at 90 °C (± 5 °C) (this brought the weight down to less than the critical 
12.6 kg – see discussion in chapter seven). The residue was largely dissolved in 
CHCl3 (38.5 L) and transferred back to the 50 L reactor (some undissolved 
material was present). After the transfer, methanol (3.90 L), water (775 mL) and 
pTsOH.H2O (8.9 g) were added to the reactor and the mixture stirred over the 
weekend at 20 °C. A mobile slurry formed, which was neutralised with 
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triethylamine (290 mL) and the precipitate filtered off in two portions (using two 
10 L Buchi/24 cm filters). Approximately 10 L of CHCl3 was used to rinse the 
slurry out of the reactor and wash the filter cakes, and then each cake was 
slurried with 4 L of CHCl3 and refiltered. This was repeated and the product was 
air-dried for 3 days to give 2.26 kg (54%) of a pale tan coloured solid. The 
composition of this solid was an unexpected mixture of the diastereomers (-)-
269a, 269b, 269c, 269d, and unreacted myo-inositol, which were partially 
separated by successive crystallisations (see the discussion in chapter seven). 
Data for (-)-269a: m.p. 244-47 °C; lit.171 231-232 °C and lit.169 260-
262 °C. []D = - 38 ° (c 0.2, acetone:water 1:1); []D = - 44.2° (c 1.0, py); lit.169 - 
44.0° (c 1.0, py). 1H NMR (300 MHz, d6-DMSO)x  4.84-4.68 (m, 4 H), 4.06 (m, 
1 H), 3.64 (m, 1 H), 3.48 (m, 1 H), 3.30-3.18 (m, 2 H), 2.90 (m, 1 H), 1.98-1.82 
(m, 2 H), 1.64 (m, 2 H), 1.38 (m, 1 H), 1.29 (m, 1 H), 1.11 (m, 1 H), 0.94 (s, 3 
H), 0.80 (s, 3 H), 0.74 (s, 3 H) ppm. 13C NMR (75 MHz, d6-DMSO)  116.3, 
77.0, 76.4, 75.9, 74.1, 72.1, 70.0, 51.1, 47.6, 45.3, 44.6, 29.2, 26.9, 20.6, 20.4, 
9.8 ppm. IR (KBr disc) 3370, 2952, 1453, 1359, 1375, 1317, 1148, 1122, 1106, 
1024, 986, 893, 727 cm-1. Anal. calcd. for C16H26O6: C, 61.13; H, 8.34; O, 30.54; 
found: C, 61.22; H, 8.41. 
Data for the co-crystals of 1D-(6-S)-2,3-O-(L-1,7,7-
trimethyl[2,2,1]bicyclohept-6-ylidene)-myo-inositol (269b) and 1D-(6-R)-
2,3-O-(L-1,7,7-trimethyl[2,2,1]bicyclohept-6-ylidene)-myo-inositol 
(269c): m.p. 238-241 °C. []D = + 40 ° (c 0.1, acetone:water 1:1);. 1H NMR (300 
MHz, d6-DMSO)xi  4.96-4.68 (m, 4 H), 3.94 (m, 1 H), 3.76 (m, 1 H), 3.84 (m, 1 
H), 3.26 (m, 2 H), 2.87 (1 H), 1.97 (m, 1 H), 1.82 (m, 1 H), 1.68-1.48 and 1.34-
1.04 (multiplets, 5 H), 0.94 (s, 3 H), 0.79 (s, 3 H, 269b only), 0.78 (s, 3 H), 0.72 
(s, 3 H, 269c only) ppm. IR (KBr disc) 3444, 2947, 1451, 1390, 1370, 1311, 
1121, 1023, 968, 887, 848, 725 cm-1. Anal. calcd. for C16H26O6 + 3H2O: C, 
52.16; H, 8.75; O, 39.08; found: C, 52.54; H, 8.71. 
Data for 269b: 13C NMR (75 MHz, d6-DMSO)  116.3, 78.6, 78.0, 73.7, 
73.0, 71.9, 70.1, 53.1, 47.3, 46.4, 44.5, 28.2, 26.6, 20.4, 20.3, 9.8 ppm.  
                                                
x
 Literature NMR data169 was reported in D2O. 
xi
 Signals in the 1H NMR spectrum overlap for 269b and 269c in all cases except for one of the 
methyl singlets, which were assigned based on their relative integrals. 
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Data for 269c: 13C NMR (75 MHz, d6-DMSO)  116.7, 78.5, 75.6, 74.7, 
74.0, 72.1 69.9, 51.0, 47.7, 45.6, 44.5, 29.2, 26.5, 20.6, 20.2, 10.8 ppm.  
Data for 1D-(6-R)-1,2-O-(L-1,7,7-trimethyl[2,2,1]bicyclohept-6-
ylidene)-myo-inositol (269d): 1H NMR (300 MHz, d6-DMSO): Inositol ring 
proton signals, differentiable from the other three isomers appear at  4.01 and 
3.82 ppm. 13C NMR (75 MHz, d6-DMSO): The acetal C appears at  116.8 ppm.  
 
Recovery of (-)-L-camphor: The CHCl3, MeOH, and H2O filtrates from 
the initial crude product filtration were returned to the 50 L reactor and washed 
with water (20 L) and 10% brine (20 L) and the organic part then reduced in the 
50 L Buchi to yield 1.80 kg of a brown solid. Water (10 L) was added to the 
solid and left for 3 days, and the resulting pale tan solid was collected by 
filtration, washed with distilled water, air-dried for 48 h and then dried in a 
desiccator to yield approximately 1.20 kg of crude L-camphor as a pale tan solid. 
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